Pharmaceutical preparations comprising acid-stabilised insulin

Abstract

Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.

Description

FIELD OF THE INVENTION

The present invention discloses pharmaceutical preparations comprising ligands for the HisB10 Zn²⁺ sites of the R-state insulin hexamer and acid-stabilsed insulin analogues. The compositions release insulin slowly following subcutaneous injection.

BACKGROUND OF THE INVENTION

Insulin Allostery. The insulin hexamer is an allosteric protein that exhibits both positive and negative cooperativity and half-of-the-sites reactivity in ligand binding. This allosteric behaviour consists of two interrelated allosteric transitions designated L^A₀ and L^B₀, three interconverting allosteric conformation states (eq. 1), designated T₆, T₃R₃, and R₆ and two classes of allosteric ligand binding sites designated as the phenolic pockets and the His^B10 anion sites. These allosteric sites are associated only with insulin subunits in the R conformation.

Insulin Hexamer Structures and Ligand Binding. The T- to R-transition of the insulin hexamer involves transformation of the first nine residues of the B chain from an extended conformation in the T-state to an α-helical conformation in the R-state. This coil-to-helix transition causes the N-terminal residue, Phe^B1, to undergo an ˜30 Å change in position. This conformational change creates hydrophobic pockets (the phenolic pockets) at the subunit interfaces (three in T₃R₃, and six in R₆), and the new B-chain helices form 3-helix bundles (one in T₃R₃ and two in R₆) with the bundle axis aligned along the hexamer three-fold symmetry axis. The His^B10 Zn²⁺ in each R₃ unit is forced to change coordination geometry from octahedral to either tetrahedral (monodentate ligands) or pentahedral (bidentate ligands). Formation of the helix bundle creates a narrow hydrophobic tunnel in each R₃ unit that extends from the surface ˜12 Å down to the His^B10 metal ion. This tunnel and the His^B10 Zn²⁺ ion form the anion binding site.

Hexamer Ligand Binding and Stability of Insulin Formulations. The in vivo role of the T to R transition is unknown. However, the addition of allosteric ligands (e.g. phenol and chloride ion) to insulin preparations is widely used. Hexamerization is driven by coordination of Zn²⁺ at the His^B10 sites to give T₆, and the subsequent ligand-mediated transition of T₆ to T₃R₃ and to R₆ is known to greatly enhance the physical and chemical stability of the resulting formulations.

Ligand Binding and Long Acting Insulin Formulations. Although the conversion of T₆ to T₃R₃ and R₆ improves the stability of the preparation, the rate of absorption following subcutaneous injection of a soluble hexameric preparation is not much affected by the addition of phenol and cloride.

Putative events following injection of a soluble hexameric preparation. The small molecule ligands initially diffuse away from the protein. The affinity of the ligands for insulin may help to slow this process. On the other hand, the affinity of Zn²⁺ for e.g. albumin and the large effective space available for diffusion of the lipophilic phenol will tend to speed up the separation. In about 10-15 minutes after injection, the distribution of insulin species in the subcutaneous tissue will roughly correspond to that of a zinc-free insulin preparation at the same dilution. Then, the equilibrium distribution of species at this point will determine the observed absorption rate. In this regimen, absorption rates vary between about 1 hour (for rapid-acting insulin analogues, such as Asp^B28 human insulin) and about 4 hours (Co³⁺-hexamer).

Current Approaches Toward Slow Acting Insulins. The inherent limitation of the absorption half-life to about 4 hours for a soluble human insulin hexamer necessitates further modifications to obtain the desired protraction. Traditionally, this has been achieved by the use of preparations wherein the constituent insulin is in the form of a crystalline and/or amorphous precipitate. In this type of formulation, the dissolution of the precipitate in the subcutaneous depot becomes rate-limiting for the absorption. NPH and Ultralente belong to this category of insulin preparations where crystallization/precipitation is effected by the addition of protamine and excessive zinc ion, respectively.

Another approach involves the use of insulin derivatives where the net charge is increased to shift the isoelectric point, and hence the pH of minimum solubility, from about 5.5 to the physiological range. Such preparations may be injected as clear solutions at slightly acidic pH. The subsequent adjustment of the pH to neutral induces crystallization/precipitation in the subcutaneous depot and dissolution again becomes rate-limiting for the absorption. Gly^A21Arg^B31Arg^B32 human insulin belongs to this category of insulin analogues.

Most recently, a series of soluble insulin derivatives with a hydrophobic moiety covalently attached to the side chain of Lys^B29 have been synthesized. These derivatives may show prolonged action profile due to various mechanisms including albumin binding (e.g. B29-N^ε-myristoyl-des(B30) human insulin), extensive protein self-association and/or stickiness (e.g. B29-N^ε-(N-lithocholyl-γ-glutamyl)-des(B30) human insulin) induced by the attached hydrophobic group.

SUMMARY OF THE INVENTION

The present invention provides a pharmaceutical preparation comprising ligands for the His^B10 Zn²⁺ sites of the R-state insulin hexamer, zinc ions and acid-stabilised insulin analogs. The preparations form clear solutions at slightly acidic pH. When the pH is adjusted towards neutral upon subcutaneous injection, the ligands work to stabilize hexamers and modify solubility in the neutral pH range. As a result, the preparations release insulin slowly following subcutaneous injection.

The invention furthermore provides a method of preparing ligands for the His^B10Zn²⁺ sites of the R-state insulin hexamer comprising the steps of

• • Identifying a starter compound that binds to the R-state His^B10-Zn²⁺ site
  • optionally attaching a fragment consisting of 0 to 5 neutral α- or β-amino acids
  • attaching a fragment comprising 1 to 20 positively charged groups independently selected from amino or guanidino groups.

The invention also provides a method of prolonging the action of an acid-stabilised insulin preparation which comprises adding a zinc-binding ligand of the invention to the acid-stabilised insulin preparation.

The invention finally provides a method of treating type 1 or type 2 diabetes comprising administering to a patient in need thereof a theraputically effective amount of a pharmaceutical preparation of the invention.

Definitions

The following is a detailed definition of the terms used to describe the invention:

“Halogen” designates an atom selected from the group consisting of F, Cl, Br and I.

The term “C₁-C₆-alkyl” as used herein represents a saturated, branched or straight hydrocarbon group having from 1 to 6 carbon atoms. Representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-hexyl, isohexyl and the like.

The term “C₁-C₆-alkylene” as used herein represents a saturated, branched or straight bivalent hydrocarbon group having from 1 to 6 carbon atoms. Representative examples include, but are not limited to, methylene, 1,2-ethylene, 1,3-propylene, 1,2-propylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene, and the like.

The term “C₂-C₆-alkenyl” as used herein represents a branched or straight hydrocarbon group having from 2 to 6 carbon atoms and at least one double bond. Examples of such groups include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, iso-propenyl, 1,3-butadienyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 3-methyl-2-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 2,4-hexadienyl, 5-hexenyl and the like.

The term “C₂-C₆-alkynyl” as used herein represents a branched or straight hydrocarbon group having from 2 to 6 carbon atoms and at least one triple bond. Examples of such groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 2,4-hexadiynyl and the like.

The term “C₁-C₆-alkoxy” as used herein refers to the radical —O-C₁-C₆-alkyl, wherein C₁-C₆-alkyl is as defined above. Representative examples are methoxy, ethoxy, n-propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy and the like.

The term “C₃-C₈-cycloalkyl” as used herein represents a saturated, carbocyclic group having from 3 to 8 carbon atoms. Representative examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.

The term “C_4-8-cycloalkenyl” as used herein represents a non-aromatic, carbocyclic group having from 4 to 8 carbon atoms containing one or two double bonds. Representative examples are 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 2-cycloheptenyl, 3-cycloheptenyl, 2-cyclooctenyl, 1,4-cyclooctadienyl and the like.

The term “heterocyclyl” as used herein represents a non-aromatic 3 to 10 membered ring containing one or more heteroatoms selected from nitrogen, oxygen and sulphur and optionally containing one or two double bonds. Representative examples are pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, aziridinyl, tetrahydrofuranyl and the like.

The term “aryl” as used herein is intended to include carbocyclic, aromatic ring systems such as 6 membered monocyclic and 9 to 14 membered bi- and tricyclic, carbocyclic, aromatic ring systems. Representative examples are phenyl, biphenylyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, indenyl, azulenyl and the like. Aryl is also intended to include the partially hydrogenated derivatives of the ring systems enumerated above. Non-limiting examples of such partially hydrogenated derivatives are 1,2,3,4-tetrahydronaphthyl, 1,4-dihydronaphthyl and the like.

The term “arylene” as used herein is intended to include divalent, carbocyclic, aromatic ring systems such as 6 membered monocyclic and 9 to 14 membered bi- and tricyclic, divalent, carbocyclic, aromatic ring systems. Representative examples are phenylene, biphenylylene, naphthylene, anthracenylene, phenanthrenylene, fluorenylene, indenylene, azulenylene and the like. Arylene is also intended to include the partially hydrogenated derivatives of the ring systems enumerated above. Non-limiting examples of such partially hydrogenated derivatives are 1,2,3,4-tetrahydronaphthylene, 1,4-dihydronaphthylene and the like.

The term “aryloxy” as used herein denotes a group —O-aryl, wherein aryl is as defined above.

The term “aroyl” as used herein denotes a group —C(O)-aryl, wherein aryl is as defined above.

The term “heteroaryl” as used herein is intended to include aromatic, heterocyclic ring systems containing one or more heteroatoms selected from nitrogen, oxygen and sulphur such as 5 to 7 membered monocyclic and 8 to 14 membered bi- and tricyclic aromatic, heterocyclic ring systems containing one or more heteroatoms selected from nitrogen, oxygen and sulphur. Representative examples are furyl, thienyl, pyrrolyl, pyrazolyl, 3-oxopyrazolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, tetrazolyl, thiadiazinyl, indolyl, isoindolyl, benzofuryl, benzothienyl, indazolyl, benzimidazolyl, benzthiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, purinyl, quinazolinyl, quinolizinyl, quinolinyl, isoquinolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, azepinyl, diazepinyl, acridinyl, thiazolidinyl, 2-thiooxothiazolidinyl and the like. Heteroaryl is also intended to include the partially hydrogenated derivatives of the ring systems enumerated above. Non-limiting examples of such partially hydrogenated derivatives are 2,3-dihydrobenzofuranyl, pyrrolinyl, pyrazolinyl, indolinyl, oxazolidinyl, oxazolinyl, oxazepinyl and the like.

The term “heteroarylene” as used herein is intended to include divalent, aromatic, heterocyclic ring systems containing one or more heteroatoms selected from nitrogen, oxygen and sulphur such as 5 to 7 membered monocyclic and 8 to 14 membered bi- and tricyclic aromatic, heterocyclic ring systems containing one or more heteroatoms selected from nitrogen, oxygen and sulphur. Representative examples are furylene, thienylene, pyrrolylene, oxazolylene, thiazolylene, imidazolylene, isoxazolylene, isothiazolylene, 1,2,3-triazolylene, 1,2,4-triazolylene, pyranylene, pyridylene, pyridazinylene, pyrimidinylene, pyrazinylene, 1,2,3-triazinylene, 1,2,4-triazinylene, 1,3,5-triazinylene, 1,2,3-oxadiazolylene, 1,2,4-oxadiazolylene, 1,2,5-oxadiazolylene, 1,3,4-oxadiazolylene, 1,2,3-thiadiazolylene, 1,2,4-thiadiazolylene, 1,2,5-thiadiazolylene, 1,3,4-thiadiazolylene, tetrazolylene, thiadiazinylene, indolylene, isoindolylene, benzofurylene, benzothienylene, indazolylene, benzimidazolylene, benzthiazolylene, benzisothiazolylene, benzoxazolylene, benzisoxazolylene, purinylene, quinazolinylene, quinolizinylene, quinolinylene, isoquinolinylene, quinoxalinylene, naphthyridinylene, pteridinylene, carbazolylene, azepinylene, diazepinylene, acridinylene and the like. Heteroaryl is also intended to include the partially hydrogenated derivatives of the ring systems enumerated above. Non-limiting examples of such partially hydrogenated derivatives are 2,3-dihydrobenzofuranylene, pyrrolinylene, pyrazolinylene, indolinylene, oxazolidinylene, oxazolinylene, oxazepinylene and the like.

The term “ArG1” as used herein is intended to include an aryl or arylene radical as applicable, where aryl or arylene are as defined above but limited to phenyl, biphenylyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, indenyl, and azulenyl as well as the corrresponding divalent radicals.

The term “ArG2” as used herein is intended to include an aryl or arylene radical as applicable, where aryl or arylene are as defined above but limited to phenyl, biphenylyl, naphthyl, fluorenyl, and indenyl, as well as the corrresponding divalent radicals.

The term “Het1” as used herein is intended to include a heteroaryl or heteroarylene radical as applicable, where heteroaryl or heteroarylene are as defined above but limited to furyl, thienyl, pyrrolyl, pyrazolyl, 3-oxopyrazolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, tetrazolyl, thiadiazinyl, indolyl, isoindolyl, benzofuryl, benzothienyl, indazolyl, benzimidazolyl, benzthiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, purinyl, quinazolinyl, quinolizinyl, quinolinyl, isoquinolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, azepinyl, diazepinyl, acridinyl, thiazolidinyl, 2-thiooxothiazolidinyl, as well as the corrresponding divalent radicals.

The term “Het2” as used herein is intended to include a heteroaryl or heteroarylene radical as applicable, where heteroaryl or heteroarylene are as defined above but limited to furyl, thienyl, pyrrolyl, pyrazolyl, 3-oxopyrazolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, tetrazolyl, thiadiazinyl, indolyl, isoindolyl, benzofuryl, benzothienyl, benzimidazolyl, benzthiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, carbazolyl, thiazolidinyl, 2-thiooxothiazolidinyl, as well as the corrresponding divalent radicals.

The term “Het3” as used herein is intended to include a heteroaryl or heteroarylene radical as applicable, where heteroaryl or heteroarylene are as defined above but limited to furyl, thienyl, pyrrolyl, pyrazolyl, 3-oxopyrazolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyridyl, tetrazolyl, indolyl, isoindolyl, benzofuryl, benzothienyl, benzimidazolyl, benzthiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, quinolyl, isoquinolyl, quinoxalinyl, carbazolyl, thiazolidinyl, 2-thiooxothiazolidinyl, as well as the corrresponding divalent radicals.

“Aryl-C₁-C₆-alkyl”, “heteroaryl-C₁-C₆-alkyl”, “aryl-C₂-C₆-alkenyl” etc. is intended to mean C₁-C₆-alkyl or C₂-C₆-alkenyl as defined above, substituted by an aryl or heteroaryl as defined above, for example:

The term “optionally substituted” as used herein means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified. When the groups in question are substituted with more than one substituent the substituents may be the same or different.

Certain of the above defined terms may occur more than once in the structural formulae, and upon such occurrence each term shall be defined independently of the other.

Furthermore, when using the terms “independently are” and “independently selected from” it should be understood that the groups in question may be the same or different.

The terms “treatment” and “treating” as used herein means the management and care of a patient for the purpose of combating a disease, disorder or condition. The term is intended to include the delaying of the progression of the disease, disorder or condition, the alleviation or relief of symptoms and complications, and/or the cure or elimination of the disease, disorder or condition. The patient to be treated is preferably a mammal, in particular a human being.

The term “fragment” as used herein is intended to mean a bivalent chemical group

The term “Neutral amino acid” as used herein is intended to mean any natural (codable) and non-natural amino acid, including α- or β-aminocarboxylic acids, including D-isomers of these (when applicable) without charges at physiologically relevant pH in the side chain, such as glycine, alanine, β-alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, aspargine, glutamine, cysteine, methionine, 3-aminobenzoic acid, 4-aminobenzoic acid or the like. The term “positively charged group” as used herein is intended to mean any pharmaceutically acceptable group that contains a positive charge at physiologically relevant pH, such as amino (primary, secondary and tertiary), ammonium and guanidino groups.

The term “α amino acid” as used herein is intended to mean mean any natural (codable) and non-natural α-aminocarboxylic acid, including D-isomers of these.

The term “β amino acid” as used herein is intended to mean any β-aminocarboxylic acid, such as β-alanine, isoserine or the like.

The term “desB30” as used herein is intended to mean meant a natural insulin B chain or an analogue thereof lacking the B30 amino acid residue.

The amino acid residues are indicated in the three letter amino acid code or the one letter amino code.

The terms “B1”, “A1” and the like as used herein is intended to mean the amino acid residue in position 1 in the B chain of insulin or analogue thereof (counted from the N-terminal end) and the amino acid residue in position 1 in the A chain of insulin or analogue thereof (counted from the N-terminal end), respectively.

When in the specification or claims mention is made of groups of compounds such as carboxylates, dithiocarboxylates, phenolates, thiophenolates, alkylthiolates, sulfonamides, imidazoles, triazoles, 4-cyano-1,2,3-triazoles, benzimidazoles, benzotriazoles, purines, thiazolidinediones, tetrazoles, 5-mercaptotetrazoles, rhodanines, N-hydroxyazoles, hydantoines, thiohydantoines, naphthoic acids and salicylic acids, these groups of compounds are intended to include also derivatives of the compounds from which the groups take their name.

The term acid-stabilised insulin as used herein refers to an insulin analog that does not deamidate or dimerize at pH values below 7. Specifically, the analog cannot have Asn or Asp as a C-terminal residue.

The term human insulin as used herein refers to naturally produced insulin or recombinantly produced insulin. Recombinant human insulin may be produced in any suitable host cell, for example the host cells may be bacterial, fungal (including yeast), insect, animal or plant cells.

The expression “insulin derivative” as used herein (and related expressions) refers to human insulin or an analogue thereof in which at least one organic substituent is bound to one or more of the amino acids.

By “analogue of human insulin” as used herein (and related expressions) is meant human insulin in which one or more amino acids have been deleted and/or replaced by other amino acids, including non-codeable amino acids, or human insulin comprising additional amino acids, i.e. more than 51 amino acids, such that the resulting analogue possesses insulin activity.

The term “phenolic compound” or similar expressions as used herein refers to a chemical compound in which a hydroxyl group is bound directly to a benzene or substituted benzene ring. Examples of such compounds include, but are not limited to, phenol, o-cresol, m-cresol and p-cresol.

The term “physiologically relevant pH” as used herein is intended to mean a pH of about 7.1 to 7.9.

Abbreviations:

• 4H₃N 4-hydroxy-3-nitrobenzoic acid
• AcOH acetic acid
• BT Benzotriazol-5-oyl
• DMF N,N-Dimethylformamide
• DMSO Dimethylsulfoxide
• DIC Diisopropylcarbodiimide
• EDAC 1-ethyl-3-(3′-dimethylamino-propyl)carbodiimide, hydrochloride
• Fmoc 9H-Fluorene-9-ylmethoxycarbonyl
• G, Gly Glycine
• HOAt 1-hydroxy-7-azabenzotriazole
• HOBT 1-Hydroxybenzotriazole
• L, Lys Lysine
• NMP N-methyl-2-pyrrolidone
• Pbf 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl
• Pmc 2,2,5,7,8-pentamethylchroman-6-sulfonyl
• R, Arg Arginine
• TFA Trifluoroacetic acid

Abbreviations for non-natural amino acid residues:

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1: The effect of various concentrations of the ligand 4-[3-(2H-tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₂-NH₂ on the pH-dependence of Gly^A21, Asp^B28 insulin solubility.

FIG. 2: The effect of a high concentrations of the ligand 4-[3-(2H-tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₂-NH₂ on the pH-dependence of Gly^A21 insulin solubility.

FIG. 3: Disappearance from the subcutaneous depot (pig model) of insulin preparations.

Curves a)-c) are Gly^A21, Asp^B28 human insulin formulated with an excess concentration compared to Zn²⁺ of a) 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₃-NH₂, b) 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₅-NH₂ and c) 4-(2H-Tetrazol-5-yl)benzoyl-Abz-Gly₂-Arg₅-NH₂. Curve d) is B29-N′-myristoyldes(B30) human insulin. Curves e) and f) are Gly^A21 human insulin formulated with two different excess concentrations compared to Zn²⁺ of 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₂-NH₂.

FIG. 4: 4H₃N-assay. UV/vis spectra resulting from a titration of hexameric insulin with the compound 3-hydroxy-2-naphthoic acid in the presence of 4-hydroxy-3-nitrobenzoic acid (4H₃N). Inserted in the upper right corner is the absorbance at 444 nm vs. the concentration of ligand

FIG. 5: TZD-assay. Fluorescence spectra resulting from a titration of hexameric insulin with 5-(3-methoxybenzylidene)thiazolidine-2,4-dione in the presence of 5-(4-dimethylaminobenzylidene)thiazolidine-2,4-dione (TZD). Inserted in the upper right corner is the fluorescence at 460 nm vs. the concentration of ligand

DESCRIPTION OF THE INVENTION

The present invention is based on the discovery that the His^B10 Zn⁺⁺ ligand binding sites of the R-state insulin hexamer can be used to obtain an insulin preparation having prolonged action designed for flexible injection regimes including once-daily, based on acid-stabillised insulins.

The basic concept underlying the present invention involves reversible attachment of a ligand to the His^B10 Zn²⁺ site of the R-state hexamer. A suitable ligand binds to the hexamer metal site with one end while other moieties are covalently attachment to the other end. On this basis, prolonged action via modification of preparation solubility may be obtained in a number of ways. However, all cases involve the same point of protein-ligand attachment and the delivery of human insulin (or analogues or derivatives thereof) as the active species. Use of a acid-stabilized analog allows a stable, clear solution with ligand to be formulated at slightly acidic pH. Following subcutaneous injection, the pH is gradually adjusted towards neutral. As a result the ligand binds to and precipitates insulin in the subcutaneous tissue. The release of insulin analog into the blood stream is then limited by the rate of redissolution of the precipitate. Of particular advantage is the possibility of adjusting the amount of added ligand as well as the charge and affinity of the ligand. Variation of these parameters allows adjustment of the rate of dissolution following precipitation in the subcutis and hence the proportion of slow and fast acting analog in the formulationon. Hence formulations covering a wide range of release rates may be prepared by this principle.

The anions currently used in insulin formulations as allosteric ligands for the R-state hexamers (notably chloride ion) bind only weakly to the His^B10 anion site. The present invention, which is based on the discovery of suitable higher affinity ligands for these anion sites, provides ligands which are extended to modify timing via changes in hexamer solubility as outlined above.

Most ligand binding sites in proteins are highly asymmetric. Because the His^B10 Zn²⁺ sites reside on the three-fold symmetry axis, these sites posses a symmetry that is unusual, but not unique. Several other proteins have highly symmetric ligand binding sites.

The His^B10 Zn²⁺ site consists of a tunnel or cavity with a triangular-shaped cross-section that extends ˜12 Å from the surface of the hexamer down to the His^B10 Zn²⁺ ion. The diameter of the tunnel varies along its length and, depending on the nature of the ligand occupying the site, the opening can be capped over by the Asn^B3 and Phe^B1 side chains. The walls of the tunnel are made up of the side chains of the amino acid residues along one face each of the three α-helices. The side chains from each helix that make up the lining of the tunnel are Phe^B1, Asn^B3, and Leu^B6. Therefore, except for the zinc ion, which is coordinated to three His^B10 residues and is positioned at the bottom of the tunnel, the site is principally hydrophobic. Depending on the ligand structure, it may be possible for substituents on the ligand to make H-bonding interactions with Asn^B3 and with the peptide linkage to Cys^B7.

The present invention originates from a search for compounds with suitable binding properties by using UV-visible and fluorescence based competition assays described herein which are based on the displacement of chromophoric ligands from the R-state His^B10-Zn²⁺ site by the incoming ligand in question. These compounds will be referred to as “starter compounds” in the following. These assays are easily transformed into a high-throughput format capable of handling libraries constructed around hits from the initial search of compound databases.

These starter compounds provide the starting point for the task of constructing a chemical handle that allows for attachment of the positively charged fragment Frg2 (see below).

Thus, from the structure-activity relationship (SAR) information obtained from the binding assay(s) it will be apparent for those skilled in the art to modify the starter compounds in question by introduction of a chemical group that will allow for coupling to a peptide containing e.g. one or more arginine or lysine residues. These chemical groups include carboxylic acid (amide bond formation with the peptide), carbaldehyde (reductive alkylation of the peptide), sulfonyl chloride (sulphonamide formation with the peptide) or the like.

The decision where and how to introduce this chemical group can be made in various ways. For example: From the SAR of a series of closely related starter compounds, a suitable position in the starter compound can be identified and the chemical group can be attached to this position, optionally using a spacer group, using synthesis procedures known to those skilled in the art.

Alternatively, this chemical group can be attached (optionally using a spacer group using and synthesis procedures known to those skilled in the art) to a position on the starter compound remote from the Zn²⁺-binding functionality.

The invention thus provides pharmaceutical preparation comprising

• • 1. Acid-stabilised insulin
  • 2. Zinc ions
  • 3. A zinc-binding ligand of the following general formula (I) CGr-Lnk-Frg1-Frg2-X  (I) wherein:
• CGr is a chemical group which reversibly binds to a HisBio Zn²⁺ site of an insulin hexamer;
• Lnk is a linker selected from
  • a valence bond
  • a chemical group G^B of the formula —B¹—B²—C(O)—, —B¹—B²—SO₂—, —B¹—B²—CH₂—, or —B¹—B²-NH—; wherein B¹ is a valence bond, —O—, —S—, or —NR⁶—,
  • B² is a valence bond, C₁-C₁₈-alkylene, C₂-C₁₈-alkenylene, C₂-C₁₈-alkynylene, arylene, heteroarylene, -C₁-C₁₈-alkyl-aryl-, —C₂-C₁₈-alkenyl-aryl-, —C₂-C₁₈-alkynyl-aryl-, —C(═O)-C₁-C₁₈-alkyl-C(═O)—, —C(═O)-C₁-C₁₈-alkenyl-C(═O)—, —C(═O)-C₁-C₁₈-alkyl-O-C₁-C₁₈-alkyl-C(═O)—, —C(═O)-C₁-C₁₈-alkyl-S-C₁-C₁₈-alkyl-C(═O)—, —C(═O)-C₁-C₁₈-alkyl-NR⁶-C₁-C₁₈-alkyl-C(═O)—, —C(═O)-aryl-C(═O)—, —C(═O)-heteroaryl-C(═O)—;
  • wherein the alkylene, alkenylene, and alkynylene moieties are optionally substituted by —CN, —CF₃, —OCF₃, —OR⁶, or —NR⁶R⁷ and the arylene and heteroarylene moieties are optionally substituted by halogen, —C(O)OR⁶, —C(O)H, OCOR⁶, —SO₂, —CN, —CF₃, —OCF₃, —NO₂, —OR⁶, —NR⁶R⁷, C₁-C₁₈-alkyl, or C₁-C₁₈-alkanoyl;
  • R⁶ and R⁷ are independently H, C₁-C₄-alkyl;
• Frg1 is a fragment consisting of 0 to 5 neutral α- or β-amino acids
• Frg2 is a fragment comprising 1 to 20 positively charged groups independently selected from amino or guanidino groups; and
• X is —OH, —NH₂ or a diamino group,
• or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.

In one embodiment CGr is a chemical structure selected from the group consisting of carboxylates, dithiocarboxylates, phenolates, thiophenolates, alkylthiolates, sulfonamides, imidazoles, triazoles, 4-cyano-1,2,3-triazoles, benzimidazoles, benzotriazoles, purines, thiazolidinediones, tetrazoles, 5-mercaptotetrazoles, rhodanines, N-hydroxyazoles, hydantoines, thiohydantoines, barbiturates, naphthoic acids and salicylic acids.

In another embodiment CGr is a chemical structure selected from the group consisting of benzotriazoles, 3-hydroxy 2-napthoic acids, salicylic acids, tetrazoles, thiazolidinediones, 5-mercaptotetrazoles, or 4-cyano-1,2,3-triazoles.

In another embodiment CGr is wherein

• X is ═O, ═S or ═NH
• Y is —S—, —O— or —NH—
• R¹ and R⁴ are independently selected from hydrogen or C₁-C₆-alkyl,
• R² is hydrogen or C₁-C₆-alkyl or aryl, R¹ and R² may optionally be combined to form a double bond,
• R³ and R⁵ are independently selected from hydrogen, halogen, aryl, C₁-C₆-alkyl, or —C(O)NR¹¹R¹²,
• A and B are independently selected from C₁-C₆-alkylene, arylene, aryl-C₁-C₆-alkyl-, aryl-C₂-C₆-alkenyl- or heteroarylene, wherein the alkylene or alkenylene is optionally substituted with one or more substituents independently selected from R⁶ and the arylene or heteroarylene is optionally substituted with up to four substituents R⁷, R⁸, R⁹, and R¹⁰,
• A and R³ may be connected through one or two valence bonds, B and R⁵ may be connected through one or two valence bonds,
• R⁶ is independently selected from halogen, —CN, —CF₃, —OCF₃, aryl, —COOH and —NH₂,
• R⁷, R⁸, R⁹ and R¹⁰ are independently selected from
  • hydrogen, halogen, —CN, —CH₂CN, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —S(O)₂CF₃, —OS(O)₂CF₃, —SCF₃, —NO₂, —OR¹¹, —NR¹¹R¹², —SR¹¹, —NR¹¹S(O)₂R¹², —S(O)₂NR¹¹R¹², —S(O)NR¹¹R¹², —S(O)R¹¹, —S(O)₂R¹¹, —OS(O)₂ R¹¹, —C(O)NR¹¹R¹², —OC(O)NR¹¹R¹², —NR¹¹C(O)R¹², —CH₂C(O)NR¹¹R¹², —OC₁-C₆-alkyl-C(O)NR¹¹R¹², —CH₂OR¹¹, —CH₂OC(O)R¹¹, —CH₂NR¹¹R¹², —OC(O)R¹¹, —OC₁-C₁₅-alkyl-C(O)OR¹¹, —OC₁-C₆-alkyl-OR¹¹, —SC₁-C₆-alkyl-C(O)OR¹¹-C₂-C₆-alkenyl-C(═O)OR¹¹, —NR¹¹—C(═O)-C₁-C₆-alkyl-C(═O)OR¹¹, —NR¹¹—C(═O)-C₁-C₆-alkenyl-C(═O)OR¹¹, —C(O)OR¹¹, C(O)R¹¹, or —C₂-C₆-alkenyl-C(═O)R¹¹, ═O, or —C₂-C₆-alkenyl-C(═O)—NR¹¹R¹²,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, each of which may optionally be substituted with one or more substituents independently selected from R¹³,
  • aryl, aryloxy, aryloxycarbonyl, aroyl, arylsulfanyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aroyl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl, heteroaryl-C₂-C₆-alkynyl, or C₃-C₆ cycloalkyl,
  • of which each cyclic moiety may optionally be substituted with one or more substituents independently selected from R¹⁴,
• R¹¹ and R¹² are independently selected from hydrogen, OH, C₁-C₂₀-alkyl, aryl-C₁-C₆-alkyl or aryl, wherein the alkyl groups may optionally be substituted with one or more substituents independently selected from R¹⁵, and the aryl groups may optionally be substituted one or more substituents independently selected from R¹⁶; R¹¹ and R¹² when attached to the same nitrogen atom may form a 3 to 8 membered heterocyclic ring with the said nitrogen atom, the heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulphur, and optionally containing one or two double bonds,
• R¹³ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OR¹¹, —C(O)OR¹¹, —NR¹¹R¹², and —C(O)NR¹¹R¹²,
• R¹⁴ is independently selected from halogen, —C(O)OR¹¹, —CH₂C(O)OR¹¹, —CH₂OR¹¹, —CN, —CF₃, —OCF₃, —NO₂, —OR¹¹, —NR¹¹R¹², S(O)₂R¹¹, aryl and C₁-C₆-alkyl,
• R¹⁵ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OC₁-C₆-alkyl, —C(O)OC₁-C₆-alkyl, —COOH and —NH₂,
• R¹⁶ is independently selected from halogen, —C(O)OC₁-C₆-alkyl, —COOH, —CN, —CF₃, —OCF₃, —NO₂, —OH, —OC₁-C₆-alkyl, —NH₂, C(═O) or C₁-C₆-alkyl, or any enantiomer, diastereomer, including a racemic mixture, tautomer as well as a salt thereof with a pharmaceutically acceptable acid or base.

In another embodiment X is ═O or ═S.

In another embodiment X is ═O.

In another embodiment X is ═S.

In another embodiment Y is —O— or —S—.

In another embodiment Y is —O—.

In another embodiment wherein Y is —S—.

In another embodiment Crg is arylene optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

In another embodiment A is selected from ArG1 optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

In another embodiment A is phenylene or naphtylene optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

In another embodiment A is

In another embodiment A is phenylene.

In another embodiment A is heteroarylene optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

In another embodiment A is selected from Het1 optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

In another embodiment A is selected from Het2 optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

In another embodiment A is selected from Het3 optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

In another embodiment A is selected from the group consisting of indolylene, benzofuranylidene, quinolylene, furylene, thienylene, or pyrrolylene, wherein each heteroaryl may optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

In another embodiment A is benzofuranylene optionally substituted with up to four substituents R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different. In another embodiment A is

In another embodiment A is carbazolylidene optionally substituted with up to four substituents R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

In another embodiment A is

In another embodiment A is quinolylidene optionally substituted with up to four substituents R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different. In another embodiment A is

In another embodiment A is indolylene optionally substituted with up to four substituents R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different. In another embodiment A is

In another embodiment R¹ is hydrogen.

In another embodiment R² is hydrogen.

In another embodiment R¹ and R² are combined to form a double bond.

In another embodiment R³ is C₁-C₆-alkyl, halogen, or C(O)NR¹⁶R¹⁷.

In another embodiment R³ is C₁-C₆-alkyl or C(O)NR¹⁶R¹⁷.

In another embodiment R³ is methyl.

In another embodiment B is phenylene optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

In another embodiment R⁴ is hydrogen.

In another embodiment R⁵ is hydrogen.

In another embodiment R⁶ is aryl.

In another embodiment R⁶ is phenyl.

In another embodiment R⁷, R⁸, R⁹ and R¹⁰ are independently selected from

• • hydrogen, halogen, —NO₂, —OR¹¹, —NR¹¹R¹², —SR¹¹, —NR¹¹S(O)₂R², —S(O)₂NR¹¹R¹², —S(O)NR¹¹R¹², —S(O)R¹¹, —S(O)₂R¹¹, —OS(O)₂ R¹¹, —NR¹¹C(O)R¹², —CH₂OR¹¹, —CH₂OC(O)R¹¹, —CH₂NR¹¹R¹², —OC(O)R¹¹, —OC₁-C₆-alkyl-C(O)OR¹¹, —OC₁-C₆-alkyl-C(O)NR¹¹R¹², —OC₁-C₆-alkyl-OR¹¹, —SC₁-C₆-alkyl-C(O)O R¹¹, —C₂-C₆-alkenyl-C(═O)OR¹¹, —C(O)OR¹¹, or —C₂-C₆-alkenyl-C(═O)R¹¹,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, which may each optionally be substituted with one or more substituents independently selected from R¹³
  • aryl, aryloxy, aroyl, arylsulfanyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aroyl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, wherein each of the cyclic moieties optionally may be substituted with one or more substituents independently selected from R¹⁴

In another embodiment R⁷, R⁸, R⁹ and R¹⁰ are independently selected from

• • hydrogen, halogen, —NO₂, —OR¹¹, —NR¹¹R¹², —SR¹¹, —S(O)₂R, —OS(O)₂ R¹¹, CH₂OC(O)R¹¹, —OC(O)R¹¹, —OC₁-C₆-alkyl-C(O)OR¹¹, —OC₁-C₆-alkyl-OR¹¹, —SC₁-C₆-alkyl-C(O)OR¹¹, —C(O)OR¹¹, or —C₂-C₆-alkenyl-C(═O)R¹¹,
  • C₁-C₆-alkyl or C₁-C₆-alkenyl which may each optionally be substituted with one or more substituents independently selected from R¹³
  • aryl, aryloxy, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, heteroaryl,
  • of which each of the cyclic moieties optionally may be substituted with one or more substituents independently selected from R¹⁴

In another embodiment R⁷, R⁸, R⁹ and R¹⁰ are independently selected from

• • hydrogen, halogen, —NO₂, —OR¹¹, —NR¹¹R¹², —SR¹¹, —S(O)₂R¹¹, —OS(O)₂ R¹¹, CH₂OC(O)R¹¹, —OC(O)R¹¹, —OC₁-C₆-alkyl-C(O)OR¹¹, —OC₁-C₆-alkyl-OR¹¹, —SC₁-C₆-alkyl-C(O)OR¹¹, —C(O)OR¹¹, or —C₂-C₆-alkenyl-C(═O)R¹¹,
  • C₁-C₆-alkyl or C₁-C₆— which may each optionally be substituted with one or more substituents independently selected from R¹³
  • aryl, aryloxy, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, heteroaryl,
  • of which each of the cyclic moieties optionally may be substituted with one or more substituents independently selected from R¹⁴.

In another embodiment R⁷, R⁸, R⁹ and R¹⁰ are independently selected from

• • hydrogen, halogen, —OR¹¹, —OC₁-C₆-alkyl-C(O)OR¹¹, or —C(O)OR¹¹,
  • C₁-C₆-alkyl which may each optionally be substituted with one or more substituents independently selected from R¹³
  • aryl, aryloxy, aryl-C₁-C₆-alkoxy,
  • of which each of the cyclic moieties optionally may be substituted with one or more substituents independently selected from R¹⁴.

In another embodiment R⁷, R⁸, R⁹ and R¹⁰ are independently selected from

• • hydrogen, halogen, —OR¹¹, —OC₁-C₆-alkyl-C(O)OR¹¹, or —C(O)OR¹¹,
  • C₁-C₆-alkyl which may optionally be substituted with one or more substituents independently selected from R¹³
  • phenyl, phenyloxy, phenyl-C₁-C₆-alkoxy, wherein each of the cyclic moieties optionally may be substituted with one or more substituents independently selected from R¹⁴.

In another embodiment R¹¹ and R¹² are independently selected from hydrogen, C₁-C₂₀-alkyl, aryl or aryl-C₁-C₆-alkyl, wherein the alkyl groups may optionally be substituted with one or more substituents independently selected from R¹⁵, and the aryl groups may optionally be substituted one or more substituents independently selected from R¹⁶; R¹¹ and R¹² when attached to the same nitrogen atom may form a 3 to 8 membered heterocyclic ring with the said nitrogen atom, the heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulphur, and optionally containing one or two double bonds.

In another embodiment R¹¹ and R¹² are independently selected from hydrogen, C₁-C₂₀-alkyl, aryl or aryl-C₁-C₆-alkyl, wherein the alkyl groups may optionally be substituted with one or more substituents independently selected from R¹⁵, and the aryl groups may optionally be substituted one or more substituents independently selected from R¹⁶.

In another embodiment R¹¹ and R¹² are independently selected from phenyl or phenyl-C₁-C₆-alkyl.

In another embodiment R¹¹ and R¹² are methyl.

In another embodiment R¹³ is independently selected from halogen, CF₃, OR¹¹ or NR¹¹R¹².

In another embodiment R¹³ is independently selected from halogen or OR¹¹.

In another embodiment R¹³ is OR¹¹.

In another embodiment R¹⁴ is independently selected from halogen, —C(O)OR¹¹, —CN, —CF₃, —OR¹¹, S(O)₂R¹¹, and C₁-C₆-alkyl.

In another embodiment R¹⁴ is independently selected from halogen, —C(O)OR¹¹, or —OR¹¹.

In another embodiment R¹⁵ is independently selected from halogen, —CN, —CF₃, —C(O)OC₁-C₆-alkyl, and —COOH.

In another embodiment R¹⁵ is independently selected from halogen or —C(O)OC₁-C₆-alkyl.

In another embodiment R¹⁶ is independently selected from halogen, —C(O)OC₁-C₆-alkyl, —COOH, —NO₂, —OC₁-C₆-alkyl, —NH₂, C(═O) or C₁-C₆-alkyl.

In another embodiment R¹⁶ is independently selected from halogen, —C(O)OC₁-C₆-alkyl, —COOH, —NO₂, or C₁-C₆-alkyl. In another embodiment CGr is wherein

• R¹⁹ is hydrogen or C₁-C₆-alkyl,
• R²⁰ is hydrogen or C₁-C₆-alkyl,
• D and F are a valence bond or C₁-C₆-alkylene optionally substituted with one or more substituents independently selected from R⁷²,
• R⁷² is independently selected from hydroxy, C₁-C₆-alkyl, or aryl,
• E is C₁-C₆-alkylene, arylene or heteroarylene, wherein the arylene or heteroarylene is optionally substituted with up to three substituents R²′, R²² and R²³,
• G is C₁-C₆-alkylene, arylene or heteroarylene, wherein the arylene or heteroarylene is optionally substituted with up to three substituents R²⁴, R²⁵ and R²⁶,
• R¹⁷ R¹⁸, R²¹, R²², R²³, R²⁴, R²⁵ and R²⁶ are independently selected from
  • hydrogen, halogen, —CN, —CH₂CN, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —S(O)₂CF₃, —SCF₃, —NO₂, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷S(O)₂R²⁸, S(O)NR²⁷R²⁸, —S(O)NR²⁷R²⁸—S(O)R²⁷, —S(O)₂R²⁷, —C(O)NR²⁷R, —OC(O)NR¹¹R¹², —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —CH₂C(O)NR²⁷R²⁸, —OCH₂C(O)NR²⁷R², —CH₂OR²⁷, —CH₂NR²⁷R²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, -C₂-C₆-alkenyl-C(═O—O)O R²⁷—NR²⁷-C(═O)-C₁-C₆-alkyl-C(═O)OR²⁷, —NR²⁷—C(═O)-C₁-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, which may optionally be substituted with one or more substituents independently selected from R²⁹,
  • aryl, aryloxy, aryloxycarbonyl, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl or heteroaryl-C₂-C₆-alkynyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰,
• R²⁷ and R²⁸ are independently selected from hydrogen, C₁-C₆-alkyl, aryl-C₁-C₆-alkyl or aryl, or R²⁷ and R²⁸ when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulphur, and optionally containing one or two double bonds,
• R²⁹ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OR²⁷, and —NR²⁷R²⁸,
• R³⁰ is independently selected from halogen, —C(O)OR²⁷, —CN, —CF₃, —OCF₃, —NO₂, —OR²⁷, —NR²⁷R²⁸ and C₁-C₆-alkyl, or any enantiomer, diastereomer, including a racemic mixture, tautomer as well as a salt thereof with a pharmaceutically acceptable acid or base.

In another embodiment D is a valence bond.

In another embodiment D is C₁-C₆-alkylene optionally substituted with one or more hydroxy, C₁-C₆-alkyl, or aryl.

In another embodiment E is arylene or heteroarylene, wherein the arylene or heteroarylene is optionally substituted with up to three substituents independently selected from R²¹, R²² and R²³.

In another embodiment E is arylene optionally substituted with up to three substituents independently selected from R²¹, R²² and R²³.

In another embodiment E is selected from ArG1 and optionally substituted with up to three substituents independently selected from R²¹, R²² and R²³.

In another embodiment E is phenylene optionally substituted with up to three substituents independently selected from R²¹, R²² and R²³. In another embodiment CGr is

In another embodiment R²¹, R²² and R²³ are independently selected from

• • hydrogen, halogen, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —SCF₃, —NO₂, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —C(O)NR²⁷R²⁸, —OC(O)NR²⁷R²⁸, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —CH₂C(O)NR²⁷R²⁸, —OCH₂C(O)NR²⁷R²⁸, —CH₂OR²⁷, —CH₂NR²⁷R²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —NR²⁷—C(═O)-C₁-C₆-alkyl-C(═O)OR²⁷, —NR²⁷—C(═O)C₁-C₆-alkenyl-C(═O)OR²⁷—, —C(═O)NR²⁷—C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl,
  • which may optionally be substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aryloxycarbonyl, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl or heteroaryl-C₂-C₆-alkynyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

In another embodiment R²¹, R²² and R²³ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • C₁-C₆-alkyl optionally substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, heteroaryl, heteroaryl-C₁-C₆-alkyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

In another embodiment R²¹, R²² and R²³ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷—C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • methyl, ethyl propyl optionally substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, heteroaryl, heteroaryl-C₁-C₆-alkyl
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

In another embodiment R²¹, R²² and R²³ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • methyl, ethyl propyl optionally substituted with one or more substituents independently selected from R²⁹
  • ArG1, ArG1-O—, ArG1-C(O)—, ArG1-C₁-C₆-alkoxy, ArG1-C₁-C₆-alkyl, Het3, Het3-C₁-C₆-alkyl
• of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

In another embodiment R²¹, R²² and R²³ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)R²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • C₁-C₆-alkyl optionally substituted with one or more substituents independently selected from R²⁹
  • phenyl, phenyloxy, phenyl-C₁-C₆-alkoxy, phenyl-C₁-C₆-alkyl,
• of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

In another embodiment R¹⁹ is hydrogen or methyl.

In another embodiment R¹⁹ is hydrogen.

In another embodiment R²⁷ is Hydrogen, C₁-C₆-alkyl or aryl.

In another embodiment R²⁷ is hydrogen or C₁-C₆-alkyl.

In another embodiment R²⁸ is hydrogen or C₁-C₆-alkyl.

In another embodiment F is a valence bond.

In another embodiment F is C₁-C₆-alkylene optionally substituted with one or more hydroxy, C₁-C₆-alkyl, or aryl.

In another embodiment G is C₁-C₆-alkylene or arylene, wherein the arylene is optionally substituted with up to three substituents R²⁴, R²⁵ and R²⁶.

In another embodiment G is C₁-C₆-alkylene or ArG1, wherein the arylene is optionally substituted with up to three substituents R²⁴, R²⁵ and R²⁶.

In another embodiment G is C₁-C₆-alkylene.

In another embodiment G is phenylene optionally substituted with up to three substituents R²⁴, R²⁵ and R²⁶.

In another embodiment R²⁴, R²⁵ and R²⁶ are independently selected from

• • hydrogen, halogen, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —SCF₃, —NO₂, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —C(O)NR²⁷R²⁸, —OC(O)NR²⁷R²⁸, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —CH₂C(O)NR²⁷R²⁸, —OCH₂C(O)NR²⁷R²⁸, —CH₂OR²⁷, —CH₂NR²⁷R²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)O R²⁷, —C₂-C₆-alkenyl-C(═O)OR¹²⁷-NR²⁷—C(═O)-C₁-C₆-alkyl-C(═O)OR²⁷, —NR²⁷—C(═O)-C₁-C₆-alkenyl-C(═O)OR²⁷—, —C(═O)NR²⁷—C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl,
  • which may optionally be substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aryloxycarbonyl, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl or heteroaryl-C₂-C₆-alkynyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

In another embodiment R²⁴, R²⁵ and R²⁶ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)O R²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl,
  • which may optionally be substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aryloxycarbonyl, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl or heteroaryl-C₂-C₆-alkynyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

In another embodiment R²⁴, R²⁵ and R²⁶ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)R²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • C₁-C₆-alkyl optionally substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, heteroaryl, heteroaryl-C₁-C₆-alkyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

In another embodiment R²⁴, R²⁵ and R²⁶ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • methyl, ethyl propyl optionally substituted with one or more substituents independently selected from R²⁹
  • ArG1, ArG1-O—, ArG1-C(O)—, ArG1-C₁-C₆-alkoxy, ArG1-C₁-C₆-alkyl, Het3, Het3-C₁-C₆-alkyl
• of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

In another embodiment R²⁴, R²⁵ and R²⁶ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • methyl, ethyl propyl optionally substituted with one or more substituents independently selected from R²⁹
  • ArG1, ArG1-O—, ArG1-C(O)—, ArG1-C₁-C₆-alkoxy, ArG1-C₁-C₆-alkyl, Het3, Het3-C₁-C₆-alkyl
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

In another embodiment R²⁴, R²⁵ and R²⁶ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • methyl, ethyl propyl optionally substituted with one or more substituents independently selected from R²⁹
  • ArG1, ArG1-O—, ArG1-C₁-C₆-alkoxy, ArG1-C₁-C₆-alkyl,
• of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

In another embodiment R²⁰ is hydrogen or methyl.

In another embodiment R²⁰ is hydrogen.

In another embodiment R²⁷ is hydrogen, C₁-C₆-alkyl or aryl.

In another embodiment R²⁷ is hydrogen or C₁-C₆-alkyl or ArG1.

In another embodiment R²⁷ is hydrogen or C₁-C₆-alkyl.

In another embodiment R²⁸ is hydrogen or C₁-C₆-alkyl.

In another embodiment R¹⁷ and R¹³ are independently selected from

• • hydrogen, halogen, —CN, —CF₃, —OCF₃, —NO₂, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —S(O)R²⁷, —S(O)₂R²⁷—C(O)NR²⁷R²⁸, —CH₂OR²⁷, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR, —SC₁-C₆-alkyl-C(O)OR, or —C(O)OR²⁷,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, optionally substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, heteroaryl, heteroaryl-C₁-C₆-alkyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

In another embodiment R¹⁷ and R¹⁸ are independently selected from

• • hydrogen, halogen, —CN, —CF₃, —NO₂, —OR²⁷, —NR²⁷R²⁸, or —C(O)OR²⁷,
  • C₁-C₆-alkyl optionally substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, heteroaryl, heteroaryl-C₁-C₆-alkyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

In another embodiment R¹⁷ and R¹⁸ are independently selected from

• • hydrogen, halogen, —CN, —CF₃, —NO₂, —OR²⁷, —NR²⁷R²⁸, or —C(O)OR²⁷
  • methyl, ethyl propyl optionally substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, heteroaryl, heteroaryl-C₁-C₆-alkyl
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

In another embodiment R¹⁷ and R¹⁸ are independently selected from

• • hydrogen, halogen, —CN, —CF₃, —NO₂, —OR²⁷, —NR²⁷R²⁸, or —C(O)OR²⁷
  • methyl, ethyl propyl optionally substituted with one or more substituents independently selected from R²⁹
  • ArG1, ArG1-O—, ArG1-C(O)—, ArG1-C₁-C₆-alkoxy, ArG1-C₁-C₆-alkyl, Het3, Het3-C₁-C₆-alkyl
• of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

In another embodiment R¹⁷ and R¹⁸ are independently selected from

• • hydrogen, halogen, —CN, —CF₃, —NO₂, —OR²⁷, —NR²⁷R²⁸, or —C(O)OR²⁷
  • C₁-C₆-alkyl optionally substituted with one or more substituents independently selected from R²⁹
  • phenyl, phenyloxy, phenyl-C₁-C₆-alkoxy, phenyl-C₁-C₆-alkyl,
• of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

In another embodiment R²⁷ is hydrogen or C₁-C₆-alkyl.

In another embodiment R²⁷ is hydrogen, methyl or ethyl.

In another embodiment R²⁸ is hydrogen or C₁-C₆-alkyl.

In another embodiment R²⁸ is hydrogen, methyl or ethyl.

In another embodiment R⁷² is —OH or phenyl.

In another embodiment CGr is

In another embodiment CGr is of the form H-1-Jwherein H is wherein the phenyl, naphthalene or benzocarbazole rings are optionally substituted with one or more substituents independently selected from R³¹

• I is selected from
  • a valence bond,
  • —CH₂N(R³²)— or —SO₂N(R³³)—, wherein Z¹ is S(O)₂ or CH₂, Z² is —NH—, —O— or —S—, and n is 1 or 2,
• J is
  • C₁-C₆-alkylene, C₂-C₆-alkenylene or C₂-C₆-alkynylene, which may each optionally be substituted with one or more substituents selected from R³⁴,
  • Arylene, -aryloxy-, arylene-oxycarbonyl-, -aroyl, arylene-C₁-C₆-alkoxy-, arylene-C₁-C₆-alkylene, arylene-C₂-C₆-alkenylene, arylene-C₂-C₆-alkynylene, heteroarylene, heteroarylene-C₁-C₆-alkylene-, heteroarylene-C₂-C₆-alkenylene or heteroarylene-C₂-C₆-alkynylene, wherein the cyclic moieties are optionally substituted with one or more substituents selected from R³⁷,
• R³¹ is independently selected from hydrogen, halogen, —CN, —CH₂CN, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —S(O)₂CF₃, —SCF₃, —NO₂, —OR³⁵, —C(O)R³⁵, —NR³⁵R³⁶, —SR³⁵, —NR³⁵S(O)₂R³⁶, —S(O)₂NR³⁵R³⁶, —S(O)NR³⁵R³⁶, —S(O)R³⁵, —S(O)₂R³⁵, —C(O)NR³⁵ R³⁶, —OC(O)NR³⁵R³⁶, —NR³⁵C(O)R³⁶, —CH₂C(O)NR³⁵R³⁶, —OCH₂C(O)NR³⁵R³⁶, —CH₂OR³⁵, —CH₂NR³⁵R³⁶, —OC(O)R³⁵, —OC₁-C₆-alkyl-C(O)OR³⁵, —SC, —C₆-alkyl-C(O)OR³⁵—C₂-C₆-alkenyl-C(═O)OR³⁵, —NR³⁵—C(═O)-C₁-C₆-alkyl-C(═O)OR³⁵, —NR³⁵—C(═O)-C₁-C₆-alkenyl-C(═O)OR³⁵—, C₁-C₆-alkyl, C₁-C₆-alkanoyl or —C(O)OR³⁵,
• R³² and R³³ are independently selected from hydrogen, C₁-C₆-alkyl or C₁-C₆-alkanoyl,
• R³⁴ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OR³⁵, and —NR³⁵R³⁶,
• R³⁵ and R³⁶ are independently selected from hydrogen, C₁-C₆-alkyl, aryl-C₁-C₆-alkyl or aryl, or R³⁵ and R³⁶ when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulphur, and optionally containing one or two double bonds,
• R³⁷ is independently selected from halogen, —C(O)OR³⁵, —C(O)H, —CN, —CF₃, —OCF₃, —NO₂, —OR³⁵, —NR³⁵R³⁶, C₁-C₆-alkyl or C₁-C₆-alkanoyl,
• or any enantiomer, diastereomer, including a racemic mixture, tautomer as well as a salt thereof with a pharmaceutically acceptable acid or base.

In another embodiment H is

In another embodiment H is

In another embodiment H is

In another embodiment I is a valence bond, —CH₂N(R³²)—, or —SO₂N(R³³)—.

In another embodiment I is a valence bond.

In another embodiment J is

• • C₁-C₆-alkylene, C₂-C₆-alkenylene or C₂-C₆-alkynylene,
  • which may optionally be substituted with one or more substituents selected from halogen, —CN, —CF₃, —OCF₃, —OR³⁵, and —NR³⁵R³⁶,
  • arylene, or heteroarylene, wherein the cyclic moieties are optionally substituted with one or more substituents independently selected from R³⁷.

In another embodiment J is

• • arylene or heteroarylene, wherein the cyclic moieties are optionally substituted with one or more substituents independently selected from R³⁷. In another embodiment J is
  • ArG1 or Het3, wherein the cyclic moieties are optionally substituted with one or more substituents independently selected from R³⁷.

In another embodiment J is

• • phenylene or naphthylene optionally substituted with one or more substituents independently selected from R³⁷.

In another embodiment R³² and R³³ are independently selected from hydrogen or C₁-C₆-alkyl.

In another embodiment R³⁴ is hydrogen, halogen, —CN, —CF₃, —OCF₃, —SCF₃, —NO₂, —OR³⁵, —C(O)R³⁵, —NR³⁵R³⁶, —SR³⁵, —C(O)NR³⁵R³⁶, —OC(O)NR³⁵R³⁶, —NR³⁵C(O)R³⁶, —OC(O)R³⁵, —OC₁-C₆-alkyl-C(O)OR³⁵, —SC, —C₆-alkyl-C(O)OR³⁵ or —C(O)OR³⁵.

In another embodiment R³⁴ is hydrogen, halogen, —CF₃, —NO₂, —OR³⁵, —NR³⁵R³, —SR³⁵, —NR³⁵C(O)R³⁶, or —C(O)OR³⁵.

In another embodiment R³⁴ is hydrogen, halogen, —CF₃, —NO₂, —OR³⁵, —NR³⁵R³⁶, or —NR³⁵C(O)R³⁶.

In another embodiment R³⁴ is hydrogen, halogen, or —OR³⁵.

In another embodiment R³⁵ and R³⁶ are independently selected from hydrogen, C₁-C₆-alkyl, or aryl.

In another embodiment R³⁵ and R³⁶ are independently selected from hydrogen or C₁-C₆-alkyl.

In another embodiment R³⁷ is halogen, —C(O)OR³⁵, —CN, —CF₃, —OR³⁵, —NR³⁵R³⁶, C₁-C₆-alkyl or C₁-C₆-alkanoyl.

In another embodiment R³⁷ is halogen, —C(O)OR³⁵, —OR³⁵, —NR³⁵R³⁶, C₁-C₆-alkyl or C₁-C₆-alkanoyl.

In another embodiment R³⁷ is halogen, —C(O)OR³⁵ or —OR³⁵. In another embodiment CGr is wherein K is a valence bond, C₁-C₆-alkylene, —NH—C(═O)—U—, -C₁-C₆-alkyl-S—, -C₁-C₆-alkyl-O—, —C(═O)—, or —C(═O)—NH—, wherein any C₁-C₆-alkyl moiety is optionally substituted with R³⁸,

• U is a valence bond, C₁-C₆-alkenylene, -C₁-C₆-alkyl-O— or C₁-C₆-alkylene wherein any C₁-C₆-alkyl moiety is optionally substituted with C₁-C₆-alkyl,
• R³⁸ is C₁-C₆-alkyl, aryl, wherein the alkyl or aryl moieties are optionally substituted with one or more substituents independently selected from R³⁹,
• R³⁹ is independently selected from halogen, cyano, nitro, amino,
• M is a valence bond, arylene or heteroarylene, wherein the aryl or heteroaryl moieties are optionally substituted with one or more substituents independently selected from R⁴⁰,
• R⁴⁰ is selected from
  • hydrogen, halogen, —CN, —CH₂CN, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —S(O)₂CF₃, —OS(O)₂CF₃, —SCF₃, —NO₂, —OR⁴, —NR⁴¹R⁴², —SR⁴¹, —NR⁴¹S(O)₂R⁴², —S(O)₂NR⁴¹R⁴², —S(O)NR⁴¹R⁴², —S(O)R⁴, —S(O)₂R⁴, —OS(O)₂ R⁴′-C(O)NR⁴²—OC(O)NR⁴¹R⁴²—NR⁴¹C(O)R⁴², —CH₂C(O)NR⁴¹R⁴², —OC₁-C₆ alkyl-C(O)NR⁴¹R⁴², —CH₂OR⁴¹, —CH₂OC(O)R⁴, —CH₂NR⁴¹R⁴², —OC(O)R⁴¹, —OC₁-C₆-alkyl-C(O)OR⁴′, —OC₁-C₆-alkyl-OR⁴¹, —S-C₁-C₆-alkyl-C(O)O R⁴¹, —C₂-C₆-alkenyl-C(═O)OR⁴¹, —NR⁴—C(═O)-C₁-C₆-alkyl-C(═O)OR⁴¹, —NR⁴¹—C(═O)-C₁-C₆-alkenyl-C(═O)OR⁴, —C(O)OR⁴, —C₂-C₆-alkenyl-C(═O)R⁴¹, ═O, —NH—C(═O)—O-C₁-C₆-alkyl, or —NH—C(═O)—C(═O)—O-C₁-C₆-alkyl,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, which may each optionally be substituted with one or more substituents selected from R⁴³,
  • aryl, aryloxy, aryloxycarbonyl, aroyl, arylsulfanyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aroyl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl or heteroaryl-C₂-C₆-alkynyl, wherein the cyclic moieties optionally may be substituted with one or more substituents selected from R⁴⁴,
• R⁴¹ and R⁴² are independently selected from hydrogen, —OH, C₁-C₆-alkyl, C₁-C₆-alkenyl, aryl-C₁-C₆-alkyl or aryl, wherein the alkyl moieties may optionally be substituted with one or more substituents independently selected from R⁴⁵, and the aryl moieties may optionally be substituted with one or more substituents independently selected from R⁴⁶; R⁴¹ and R⁴² when attached to the same nitrogen atom may form a 3 to 8 membered heterocyclic ring with the said nitrogen atom, the heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulphur, and optionally containing one or two double bonds,
• R⁴³ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OR⁴¹, and —NR⁴¹R⁴²
• R⁴⁴ is independently selected from halogen, —C(O)OR⁴, —CH₂C(O)OR⁴, —CH₂OR⁴¹, —CN, —CF₃, —OCF₃, —NO₂, —OR⁴¹, —NR⁴¹R⁴² and C₁-C₆-alkyl,
• R⁴⁵ is independently selected from halogen, —CN, —CF₃, —OCF₃, —O-C₁-C₆-alkyl, —C(O)—O-C₁-C₆-alkyl, —COOH and —NH₂,
• R⁴⁶ is independently selected from halogen, —C(O)OC₁-C₆-alkyl, —COOH, —CN, —CF₃, —OCF₃, —NO₂, —OH, —OC₁-C₆-alkyl, —NH₂, C(═O) or C₁-C₆-alkyl,
• Q is a valence bond, C₁-C₆-alkylene, -C₁-C₆-alkyl-O—, -C₁-C₆-alkyl-NH—, —NH-C₁-C₆-alkyl, —NH—C(═O)—, —C(═O)—NH—, —O-C₁-C₆-alkyl, —C(═O)—, or -C₁-C₆-alkyl-C(═O)—N(R⁴⁷)— wherein the alkyl moieties are optionally substituted with one or more substituents independently selected from R⁴⁸,
• R⁴⁷ and R⁴⁸ are independently selected from hydrogen, C₁-C₆-alkyl, aryl optionally substituted with one or more R⁴⁹,
• R⁴⁹ is independently selected from halogen and —COOH,
• T is
  • C₁-C₆-alkylene, C₂-C₆-alkenylene, C₂-C₆-alkynylene, -C₁-C₆-alkyloxy-carbonyl, wherein the alkylene, alkenylene and alkynylene moieties are optionally substituted with one or more substituents independently selected from R⁵⁰,
  • arylene, -aryloxy-, -aryloxy-carbonyl-, arylene-C₁-C₆-alkylene, -aroyl-, arylene-C₁-C₆-alkoxy-, arylene-C₂-C₆-alkenylene, arylene-C₂-C₆-alkynylene, heteroarylene, heteroarylene-C₁-C₆-alkylene, heteroarylene-C₂-C₆-alkenylene, heteroarylene-C₂-C₆-alkynylene,
  • wherein any alkylene, alkenylene, alkynylene, arylene and heteroarylene moiety is optionally substituted with one or more substituents independently selected from R⁵⁰,
• R⁵⁰ is C₁-C₆-alkyl, C₁-C₆-alkoxy, aryl, aryloxy, aryl-C₁-C₆-alkoxy, —C(═O)—NH-C₁-C₆-alkyl-aryl, heteroaryl, heteroaryl-C₁-C₆-alkoxy, -C₁-C₆-alkyl-COOH, —O-C₁-C₆-alkyl-COOH, —S(O)₂R⁵¹, —C₂-C₆-alkenyl-COOH, —OR⁵¹, —NO₂, halogen, —COOH, —CF₃, —CN, ═O, —N(R⁵¹R⁵²), wherein the aryl or heteroaryl moieties are optionally substituted with one or more R⁵³,
• R⁵¹ and R⁵² are independently selected from hydrogen and C₁-C₆-alkyl,
• R⁵³ is independently selected from C₁-C₆-alkyl, C₁-C₆-alkoxy, -C₁-C₆-alkyl-COOH, —C₂-C₆-alkenyl-COOH, —OR⁵′, —NO₂, halogen, —COOH, —CF₃, —CN, or —N(R⁵¹R⁵²),
• or any enantiomer, diastereomer, including a racemic mixture, tautomer as well as a salt thereof with a pharmaceutically acceptable acid or base.

In another embodiment K is a valence bond, C₁-C₆-alkylene, —NH—C(═O)—U—, -C₁-C₆-alkyl-S—, -C₁-C₆-alkyl-O—, or —C(═O)—, wherein any C₁-C₆-alkyl moiety is optionally substituted with R³⁸.

In another embodiment K is a valence bond, C₁-C₆-alkylene, —NH—C(═O)—U—, -C₁-C₆-alkyl-S—, or -C₁-C₆-alkyl-O, wherein any C₁-C₆-alkyl moiety is optionally substituted with R³⁸.

In another embodiment K is a valence bond, C₁-C₆-alkylene, or —NH—C(═O)—U, wherein any C₁-C₆-alkyl moiety is optionally substituted with R³⁸.

In another embodiment K is a valence bond or C₁-C₆-alkylene, wherein any C₁-C₆-alkyl moiety is optionally substituted with R³⁸.

In another embodiment K is a valence bond or —NH—C(═O)—U.

In another embodiment K is a valence bond.

In another embodiment U is a valence bond or -C₁-C₆-alkyl-O—.

In another embodiment U is a valence bond

In another embodiment M is arylene or heteroarylene, wherein the arylene or heteroarylene moieties are optionally substituted with one or more substituents independently selected from R⁴⁰.

In another embodiment M is ArG1 or Het1, wherein the arylene or heteroarylene moieties are optionally substituted with one or more substituents independently selected from R⁴⁰.

In another embodiment M is ArG1 or Het2, wherein the arylene or heteroarylene moieties are optionally substituted with one or more substituents independently selected from R⁴⁰.

In another embodiment M is ArG1 or Het3, wherein the arylene or heteroarylene moieties are optionally substituted with one or more substituents independently selected from R⁴⁰.

In another embodiment M is phenylene optionally substituted with one or more substituents independently selected from R⁴⁰.

In another embodiment M is indolylene optionally substituted with one or more substituents independently selected from R⁴⁰.

In another embodiment M is

In another embodiment M is carbazolylene optionally substituted with one or more substituents independently selected from R⁴⁰.

In another embodiment M is

In another embodiment R⁴⁰ is selected from

• • hydrogen, halogen, —CN, —CF₃, —OCF₃, —NO₂, —OR⁴¹, —NR⁴, R⁴², —SR⁴, —S(O)₂R⁴¹, —NR⁴¹C(O)R⁴², —OC₁-C₆-alkyl-C(O)NR⁴, R⁴², —C₂-C₆-alkenyl-C(═O)OR⁴, —C(O)OR⁴¹, ═O, —NH—C(═O)—O-C₁-C₆-alkyl, or —NH—C(═OC(═O)—O-C₁-C₆-alkyl,
  • C₁-C₆-alkyl or C₂-C₆— alkenyl which may each optionally be substituted with one or more substituents independently selected from R⁴³,
  • aryl, aryloxy, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, or heteroaryl-C₂-C₆-alkenyl, wherein the cyclic moieties optionally may be substituted with one or more substituents selected from R⁴⁴.

In another embodiment R⁴⁰ is selected from

• • hydrogen, halogen, —CN, —CF₃, —OCF₃, —NO₂, —OR⁴¹, —NR⁴¹R⁴², —SR⁴′, —S(O)₂R⁴¹, —NR⁴¹C(O)R⁴², —OC, —C₆-alkyl-C(O)NR⁴¹R⁴², —C₂-C₆-alkenyl-C(═O)OR⁴¹, —C(O)OR⁴¹, ═O, —NH—C(═O)—O-C₁-C₆-alkyl, or —NH—C(═O)—C(═O)—O-C₁-C₆-alkyl,
  • C₁-C₆-alkyl or C₂-C₆- alkenyl which may each optionally be substituted with one or more substituents independently selected from R⁴³,
  • ArG1, ArG1-O—, ArG1-C₁-C₆-alkoxy, ArG1-C₁-C₆-alkyl, ArG1-C₂-C₆-alkenyl, Het3, Het3-C₁-C₆-alkyl, or Het3-C₂-C₆-alkenyl, wherein the cyclic moieties optionally may be substituted with one or more substituents selected from R⁴⁴.

In another embodiment R⁴⁰ is selected from

• • hydrogen, halogen, —CF₃, —NO₂, —OR⁴, —NR⁴¹R⁴², —C(O)OR⁴¹, ═O, or —NR⁴¹C(O)R⁴²,
  • C₁-C₆-alkyl,
  • ArG1.

In another embodiment R⁴⁰ is selected from

• • Halogen, —NO₂, —OR⁴¹, —NR⁴¹R⁴², —C(O)OR⁴¹, or —NR⁴¹C(O)R⁴²,
  • Methyl,
  • Phenyl.

In another embodiment R⁴¹ and R⁴² are independently selected from hydrogen, C₁-C₆-alkyl, or aryl, wherein the aryl moieties may optionally be substituted with halogen or —COOH. In another embodiment R⁴¹ and R⁴² are independently selected from hydrogen, methyl, ethyl, or phenyl, wherein the phenyl moieties may optionally be substituted with halogen or —COOH.

In another embodiment Q is a valence bond, C₁-C₆-alkylene, -C₁-C₆-alkyl-O—, -C₁-C₆-alkyl-NH—, —NH-C₁-C₆-alkyl, —NH—C(═O)—, —C(═O)—NH—, —O-C₁-C₆-alkyl, —C(═O)—, or -C₁-C₆-alkyl-C(═O)—N(R⁴⁷)— wherein the alkyl moieties are optionally substituted with one or more substituents independently selected from R⁴⁸.

In another embodiment Q is a valence bond, —CH₂—, —CH₂—CH₂—, —CH₂—O—, —CH₂—CH₂-O—, —CH₂—NH—, —CH₂—CH₂-NH—, —NH—CH₂—, —NH—CH₂—CH₂—, —NH—C(═O)—, —C(═O)—NH—, —O—CH₂—, —O—CH₂—CH₂—, or —C(═O)—.

In another embodiment R⁴⁷ and R⁴⁸ are independently selected from hydrogen, methyl and phenyl.

In another embodiment T is

• • C₁-C₆-alkylene optionally substituted with one or more substituents independently selected from R⁵⁰,
  • arylene, arylene-C₁-C₆-alkylene, heteroarylene, wherein the alkylene, arylene and heteroarylene moieties are optionally substituted with one or more substituents independently selected from R⁵⁰.

In another embodiment T is

• • C₁-C₆-alkylene optionally substituted with one or more substituents independently selected from R⁵⁰,
  • ArG1, ArG1-C₁-C₆-alkylene, Het3, wherein the alkyl, aryl and heteroaryl moieties are optionally substituted with one or more substituents independently selected from R⁵⁰.

In another embodiment T is

• • C₁-C₆-alkylene, optionally substituted with one or more substituents independently selected from R⁵⁰,
  • phenylene, phenylene-C₁-C₆-alkylene, wherein the alkylene and phenylene moieties are optionally substituted with one or more substituents independently selected from R⁵⁰.

In another embodiment R⁵⁰ is C₁-C₆-alkyl, C₁-C₆-alkoxy, aryl, aryloxy, aryl-C₁-C₆-alkoxy, —C(═O)—NH-C₁-C₆-alkyl-aryl, heteroaryl, -C₁-C₆-alkyl-COOH, —O-C₁-C₆-alkyl-COOH, —S(O)₂R⁵¹, —C₂-C₆-alkenyl-COOH, —OR⁵¹, —NO₂, halogen, —COOH, —CF₃, —CN, ═O, —N(R⁵¹R⁵²), wherein the aryl or heteroaryl moieties are optionally substituted with one or more R⁵³.

In another embodiment R⁵⁰ is C₁-C₆-alkyl, C₁-C₆-alkoxy, aryl, aryloxy, aryl-C₁-C₆-alkoxy —OR⁵¹, —NO₂, halogen, —COOH, —CF₃, wherein any aryl moiety is optionally substituted with one or more R⁵³.

In another embodiment R⁵⁰ is C₁-C₆-alkyl, aryloxy, aryl-C₁-C₆-alkoxy, —OR⁵¹, halogen, —COOH, —CF₃, wherein any aryl moiety is optionally substituted with one or more R⁵³.

In another embodiment R⁵⁰ is C₁-C₆-alkyl, ArG1-O—, ArG1-C₁-C₆-alkoxy, —OR⁵¹, halogen, —COOH, —CF₃, wherein any aryl moiety is optionally substituted with one or more R⁵³.

In another embodiment R⁵⁰ is phenyl, methyl or ethyl.

In another embodiment R⁵⁰ is methyl or ethyl.

In another embodiment R⁵¹ is methyl.

In another embodiment R⁵³ is C₁-C₆-alkyl, C₁-C₆-alkoxy, —OR⁵′, halogen, or —CF₃. In another embodiment CGr is wherein V is C₁-C₆-alkylene, arylene, heteroarylene, arylene-C_1-6-alkylene or arylene-C_2-6-alkenylene, wherein the alkylene or alkenylene is optionally substituted with one or more substituents independently selected from R⁵⁴, and the arylene or heteroarylene is optionally substituted with one or more substituents independently selected from R⁵⁵,

• R⁵⁴ is independently selected from halogen, —CN, —CF₃, —OCF₃, aryl, —COOH and —NH₂,
• R⁵⁵ is independently selected from
  • hydrogen, halogen, —CN, —CH₂CN, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —S(O)₂CF₃, —OS(O)₂CF₃, —SCF₃, —NO₂, —OR⁵⁶, —NR⁵⁶R⁵⁷, —SR⁵⁶, —NR⁵⁶S(O)₂R⁵⁷, —S(O)₂NR⁵⁶R⁵⁷, —S(O)NR⁵⁶R⁵⁷, —S(O)R⁵⁶, —S(O)₂R⁵⁶, —OS(O)₂ R⁵⁶, —C(O)NR⁵⁶R⁵⁷, —OC(O)NR⁵⁶R⁵⁷, —NR⁵⁶C(O)R⁵⁷, —CH₂C(O)NR⁵⁶R⁵⁷, —OC₁-C₆-alkyl-C(O)NR⁵⁶R⁵⁷, —CH₂OR⁵⁶, —CH₂OC(O)R⁵⁶, —CH₂NR⁵⁶R⁵⁷, —OC(O)R⁵⁶, —OC₁-C₈-alkyl-C(O)O R⁵⁶, —OC₁-C₆-alkyl-OR⁵⁶, —SC₁-C₆-alkyl-C(O)OR⁵⁶, —C₂-C₆-alkenyl-C(═O)OR⁵⁶, —NR⁵⁶—C(═O)-C₁-C₆-alkyl-C(═O)OR⁵⁶, —NR⁵⁶—C(═O)-C₁-C₆-alkenyl-C(═O)OR⁵⁶, —C(O)OR⁵⁶, or —C₂-C₆-alkenyl-C(═O)R⁵⁶,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl,
  • which may optionally be substituted with one or more substituents selected from R⁵⁸,
  • aryl, aryloxy, aryloxycarbonyl, aroyl, arylsulfanyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aroyl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl or heteroaryl-C₂-C₆-alkynyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R⁵⁹,
• R⁵⁶ and R⁵⁷ are independently selected from hydrogen, OH, CF₃, C₁-C₁₂-alkyl, aryl-C₁-C₆-alkyl, —C(═O)-C₁-C₆-alkyl or aryl, wherein the alkyl groups may optionally be substituted with one or more substituents independently selected from R⁶⁰, and the aryl groups may optionally be substituted with one or more substituents independently selected from R⁶¹; R⁵⁶ and
• R⁵⁷ when attached to the same nitrogen atom may form a 3 to 8 membered heterocyclic ring with the said nitrogen atom, the heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulphur, and optionally containing one or two double bonds,
• R⁵⁸ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OR⁵⁶, and —NR⁵⁶R⁵⁷,
• R⁵⁹ is independently selected from halogen, —C(O)OR⁵⁶, —CH₂C(O)OR⁵⁶, —CH₂OR⁵⁶, —CN, —CF₃, —OCF₃, —NO₂, —OR⁵⁶, —NR⁵⁶R⁵⁷ and C₁-C₆-alkyl,
• R⁶⁰ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OC₁-C₆-alkyl, —C(O)OC₁-C₆-alkyl, —C(═O)—R⁶², —COOH and —NH₂,
• R⁶¹ is independently selected from halogen, —C(O)OC₁-C₆-alkyl, —COOH, —CN, —CF₃, —OCF₃, —NO₂, —OH, —OC₁-C₆-alkyl, —NH₂, C(═O) or C₁-C₆-alkyl,
• R⁶² is C₁-C₆-alkyl, aryl optionally substituted with one or more substituents independently selected from halogen, or heteroaryl optionally substituted with one or more C₁-C₆-alkyl independently, or any enantiomer, diastereomer, including a racemic mixture, tautomer as well as a salt thereof with a pharmaceutically acceptable acid or base.

In another embodiment V is arylene, heteroarylene, or arylene-C₁-C₆-alkylene, wherein the alkylene is optionally substituted with one or more substituents independently selected R⁵⁴, and the arylene or heteroarylene is optionally substituted with one or more substituents independently selected from R⁵⁵.

In another embodiment V is arylene, Het1, or arylene-C₁-C₆-alkylene, wherein the alkylene is optionally substituted with one or more substituents independently selected from R⁵⁴, and the arylene or heteroarylene moiety is optionally substituted with one or more substituents independently selected from R⁵⁵.

In another embodiment V is arylene, Het2, or arylene-C₁-C₆-alkylene, wherein the alkylene is optionally substituted with one or more substituents independently selected from R⁵⁴, and the arylene or heteroarylene moiety is optionally substituted with one or more substituents independently selected from R⁵⁵.

In another embodiment V is arylene, Het3, or arylene-C₁-C₆-alkylene, wherein the alkylene is optionally substituted with one or more substituents independently selected from R⁵⁴, and the arylene or heteroarylene moiety is optionally substituted with one or more substituents independently selected from R⁵⁵.

In another embodiment V is arylene optionally substituted with one or more substituents independently selected from R⁵⁵.

In another embodiment V is ArG1 optionally substituted with one or more substituents independently selected from R⁵⁵.

In another embodiment V is phenylene, naphthylene or anthranylene optionally substituted with one or more substituents independently selected from R⁵⁵.

In another embodiment V is phenylene optionally substituted with one or more substituents independently selected from R⁵⁵.

In another embodiment R⁵⁵ is independently selected from

• • halogen, C₁-C₆-alkyl, —CN, —OCF₃, —CF₃, —NO₂, —OR⁵⁶, —NR⁵⁶R⁵⁷, —NR⁵⁶C(O)R⁵⁷—SR⁵⁶, —OC₁-C₈-alkyl-C(O)OR⁵⁶, or —C(O)OR⁵⁶,
  • C₁-C₆-alkyl optionally substituted with one or more substituents independently selected from R⁵⁶,
  • aryl, aryl-C₁-C₆-alkyl, heteroaryl, or heteroaryl-C₁-C₆-alkyl of which the cyclic moieties optionally may be substituted with one or more substituents independently selected from R⁵⁹.

In another embodiment R⁵⁵ is independently selected from

• • halogen, C₁-C₆-alkyl, —CN, —OCF₃, —CF₃, —NO₂, —OR⁵⁶, —NR⁵⁶R⁵⁷, —NR⁵⁶C(O)R⁵⁷—SR⁵⁵, —OC₁-C₈-alkyl-C(O)OR⁵⁶, or —C(O)OR⁵⁶
  • C₁-C₆-alkyl optionally substituted with one or more substituents independently selected from R⁵⁸
  • ArG1, ArG₁-C₁-C₆-alkyl, Het3, or Het3-C₁-C₆-alkyl
  • of which the cyclic moieties optionally may be substituted with one or more substituents independently selected from R⁵⁹.

In another embodiment R⁵⁵ is independently selected from halogen, —OR⁵⁶, —NR⁵⁶R⁵⁷, —C(O)OR⁵⁶, —OC₁-C₈-alkyl-C(O)OR⁵⁶, —NR⁵⁶C(O)R⁵⁷ or C₁-C₆-alkyl.

In another embodiment R⁵⁵ is independently selected from halogen, —OR⁵⁶, —NR⁵⁶R⁵⁷, —C(O)OR⁵⁶, —OC₁-C₈-alkyl-C(O)OR⁵⁶, —NR⁵⁶C(O)R⁵⁷, methyl or ethyl.

In another embodiment R⁵⁶ and R⁵⁷ are independently selected from hydrogen, CF₃, C₁-C₁₂-alkyl, or —C(═O)-C₁-C₆-alkyl; R⁵⁶ and R⁵⁷ when attached to the same nitrogen atom may form a 3 to 8 membered heterocyclic ring with the said nitrogen atom.

In another embodiment R⁵⁶ and R⁵⁷ are independently selected from hydrogen or C₁-C₁₂-alkyl, R⁵⁶ and R⁵⁷ when attached to the same nitrogen atom may form a 3 to 8 membered heterocyclic ring with the said nitrogen atom.

In another embodiment R⁵⁶ and R⁵⁷ are independently selected from hydrogen or methyl, ethyl, propyl butyl, R⁵⁶ and R⁵⁷ when attached to the same nitrogen atom may form a 3 to 8 membered heterocyclic ring with the said nitrogen atom.

In another embodiment CGr is wherein AA is C₁-C₆-alkylene, arylene, heteroarylene, arylene-C₁-C₆-alkylene or arylene-C₂-C₆-alkenylene, wherein the alkylene or alkenylene is optionally substituted with one or more substituents independently selected from R⁶³, and the arylene or heteroarylene is optionally substituted with one or more substituents independently selected from R⁶⁴,

• R⁶³ is independently selected from halogen, —CN, —CF₃, —OCF₃, aryl, —COOH and —NH₂,
• R⁶⁴ is independently selected from
  • hydrogen, halogen, —CN, —CH₂CN, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —S(O)₂CF₃, —OS(O)₂CF₃, —SCF₃, —NO₂, —OR⁶⁵, —NR⁶⁵R⁶⁶, —SR⁶⁵, —NR⁶⁵S(O)₂R⁶⁶, —S(O)₂NR⁶⁵R⁶⁶, —S(O)NR⁶⁵R⁶⁶, —S(O)R⁶⁵, —S(O)₂R⁶⁵, —OS(O)₂ R⁶⁵, —C(O)NR⁶⁵R⁶⁶, —OC(O)NR⁶⁵R⁶⁶, —NR⁶⁵C(O)R⁶⁶, —CH₂C(O)NR⁶⁵R⁶⁶, —OC₁-C₆-alkyl-C(O)NR⁶⁵R⁶⁶, —CH₂OR⁶⁵, —CH₂OC(O)R⁶⁵, —CH₂NR⁶⁵R⁶⁶, —OC(O)R⁶⁵, —OC₁-C₆-alkyl-C(O)OR⁶⁵, —OC₁-C₆-alkyl-OR⁶⁵, —SC₁-C₆-alkyl-C(O)OR⁶⁵, —C₂-C₆-alkenyl-C(═O)OR⁶, —NR⁶⁵—C(═O)-C₁-C₆-alkyl-C(═O)OR⁶⁵, —NR⁶⁵—C(═O)-C₁-C₆-alkenyl-C(═O)OR⁶⁵, —C(O)OR⁶⁵ or C₂-C₆-alkenyl-C(═O)R⁶⁵,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, each of which may optionally be substituted with one or more substituents selected from R⁶⁷,
  • aryl, aryloxy, aryloxycarbonyl, aroyl, arylsulfanyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aroyl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl or heteroaryl-C₂-C₆-alkynyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R⁶⁸,
• R⁶⁵ and R⁶⁶ are independently selected from hydrogen, OH, CF₃, C₁-C₁₂-alkyl, aryl-C₁-C₆-alkyl, —C(═O)—R⁶⁹, aryl or heteroaryl, wherein the alkyl groups may optionally be substituted with one or more substituents selected from R⁷⁰, and the aryl and heteroaryl groups may optionally be substituted with one or more substituents independently selected from R⁷¹; R⁶⁵ and R⁶⁶ when attached to the same nitrogen atom may form a 3 to 8 membered heterocyclic ring with the said nitrogen atom, the heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulphur, and optionally containing one or two double bonds,
• R⁶⁷ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OR⁶⁵, and —NR⁶⁵R⁶⁶,
• R⁶⁸ is independently selected from halogen, —C(O)OR⁶⁵, —CH₂C(O)OR⁶⁵, —CH₂OR⁶⁵, —CN, —CF₃, —OCF₃, —NO₂, —OR⁶⁵, —NR⁶⁵R⁶⁶ and C₁-C₆-alkyl,
• R⁶⁹ is independently selected from C₁-C₆-alkyl, aryl optionally substituted with one or more halogen, or heteroaryl optionally substituted with one or more C₁-C₆-alkyl,
• R⁷⁰ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OC₁-C₆-alkyl, —C(O)OC, —C₆-alkyl, —COOH and —NH₂,
• R⁷¹ is independently selected from halogen, —C(O)OC₁-C₆-alkyl, —COOH, —CN, —CF₃, —OCF₃, —NO₂, —OH, —OC₁-C₆-alkyl, —NH₂, C(═O) or C₁-C₆-alkyl,
• or any enantiomer, diastereomer, including a racemic mixture, tautomer as well as a salt thereof with a pharmaceutically acceptable acid or base.

In another embodiment AA is arylene, heteroarylene or arylene-C₁-C₆-alkylene, wherein the alkylene is optionally substituted with one or more R⁶³, and the arylene or heteroarylene is optionally substituted with one or more substituents independently selected from R⁶⁴.

In another embodiment AA is arylene or heteroarylene, wherein the arylene or heteroarylene is optionally substituted with one or more substituents independently selected from R⁶⁴.

In another embodiment AA is ArG1 or Het1 optionally substituted with one or more substituents independently selected from R⁶⁴.

In another embodiment AA is ArG1 or Het2 optionally substituted with one or more substituents independently selected from R⁶⁴.

In another embodiment AA is ArG1 or Het3 optionally substituted with one or more substituents independently selected from R⁶⁴.

In another embodiment AA is phenylene, naphtylene, anthrylene, carbazolylene, thienylene, pyridylene, or benzodioxylene optionally substituted with one or more substituents independently selected from R⁶⁴.

In another embodiment AA is phenylene or naphtylene optionally substituted with one or more substituents independently selected from R⁶⁴.

In another embodiment R⁶⁴ is independently selected from hydrogen, halogen, —CF₃, —OCF₃, —OR⁶⁵, —NR⁶⁵R⁶⁶, C₁-C₆-alkyl, —OC(O)R⁶⁵, —OC₁-C₆-alkyl-C(O)OR⁶⁵, aryl-C₂-C₆-alkenyl, aryloxy or aryl, wherein C₁-C₆-alkyl is optionally substituted with one or more substituents independently selected from R⁶⁷, and the cyclic moieties optionally are substituted with one or more substituents independently selected from R⁶³.

In another embodiment R⁶⁴ is independently selected from halogen, —CF₃, —OCF₃, —OR⁶⁵, —NR⁶⁵R⁶⁶, methyl, ethyl, propyl, —OC(O)R⁶⁵, —OCH₂—C(O)OR⁶⁵, —OCH₂—CH₂-C(O)OR⁶⁵ phenoxy optionally substituted with one or more substituents independently selected from R⁶⁸.

In another embodiment R⁶⁵ and R⁶⁶ are independently selected from hydrogen, CF₃, C₁-C₁₂-alkyl, aryl, or heteroaryl optionally substituted with one or more substituents independently selected from R⁷¹.

In another embodiment R⁶⁵ and R⁶⁶ are independently hydrogen, C₁-C₁₂-alkyl, aryl, or heteroaryl optionally substituted with one or more substituents independently selected from R⁷¹.

In another embodiment R⁶⁵ and R⁶⁶ are independently hydrogen, methyl, ethyl, propyl, butyl, 2,2-dimethyl-propyl, ArG1 or Het1 optionally substituted with one or more substituents independently selected from R⁷¹.

In another embodiment R⁶⁵ and R⁶⁶ are independently hydrogen, methyl, ethyl, propyl, butyl, 2,2-dimethyl-propyl, ArG1 or Het2 optionally substituted with one or more substituents independently selected from R⁷′.

In another embodiment R⁶⁵ and R⁶⁶ are independently hydrogen, methyl, ethyl, propyl, butyl, 2,2-dimethyl-propyl, ArG1 or Het3 optionally substituted with one or more substituents independently selected from R⁷′.

In another embodiment R⁶⁵ and R⁶⁶ are independently hydrogen, methyl, ethyl, propyl, butyl, 2,2-dimethyl-propyl, phenyl, naphtyl, thiadiazolyl optionally substituted with one or more R⁷¹ independently; or isoxazolyl optionally substituted with one or more substituents independently selected from R⁷¹.

In another embodiment R⁷¹ is halogen or C₁-C₆-alkyl.

In another embodiment R⁷¹ is halogen or methyl.

In another embodiment Frg1 consists of 0 to 5 neutral amino acids independently selected from the group consisting of Gly, Ala, Thr, and Ser.

In another embodiment Frg1 consists of 0 to 5 Gly.

In another embodiment Frg1 consists of 0 Gly.

In another embodiment Frg1 consists of 1 Gly.

In another embodiment Frg1 consists of 2 Gly.

In another embodiment Frg1 consists of 3 Gly.

In another embodiment Frg1 consists of 4 Gly.

In another embodiment Frg1 consists of 5 Gly.

In another embodiment G^B is of the formula B¹—B²—C(O)—, B¹—B²—SO₂— or B¹—B²—CH₂—, wherein B¹ and B² are as defined in claim 1.

In another embodiment G^B is of the formula B¹—B²—C(O)—, B¹—B²—SO₂— or B¹—B²—NH—, wherein B¹ and B² are as defined in claim 1.

In another embodiment G^B is of the formula B¹—B²—C(O)—, B¹—B²—CH₂— or B¹—B²—NH—, wherein B¹ and B² are as defined in claim 1.

In another embodiment G^B is of the formula B¹—B²—CH₂—, B¹—B²—SO₂— or B¹—B²—NH—, wherein B¹ and B² are as defined in claim 1.

In another embodiment G^B is of the formula B¹—B²—C(O)— or B¹—B²—SO₂—, wherein B¹ and B² are as defined in claim 1.

In another embodiment G^B is of the formula B¹—B²—C(O) or B¹—B²—CH₂—, wherein B¹ and B² are as defined in claim 1.

In another embodiment G^B is of the formula B¹—B²—C(O)— or B¹—B²—NH—, wherein B¹ and B² are as defined in claim 1.

In another embodiment G^B is of the formula B¹—B²—CH₂— or B¹—B²—SO₂—, wherein B¹ and B² are as defined in claim 1.

In another embodiment G^B is of the formula B¹—B²—NH— or B¹—B²—SO₂—, wherein B¹ and B² are as defined in claim 1.

In another embodiment G^B is of the formula B¹—B²—CH₂— or B¹—B²—NH—, wherein B¹ and B² are as defined in claim 1.

In another embodiment G^B is of the formula B¹—B²—C(O)—.

In another embodiment G^B is of the formula B¹—B²—CH₂—.

In another embodiment G^B is of the formula B¹—B²—SO₂—.

In another embodiment G^B is of the formula B¹—B²—NH—.

In another embodiment B¹ is a valence bond, —O—, or —S—.

In another embodiment B¹ is a valence bond, —O—, or —N(R⁶)—.

In another embodiment B¹ is a valence bond, —S—, or —N(R⁶)—.

In another embodiment B¹ is —O—, —S— or —N(R⁶)—.

In another embodiment B¹ is a valence bond or —O—.

In another embodiment B¹ is a valence bond or —S—.

In another embodiment B¹ is a valence bond or —N(R⁶)—.

In another embodiment B¹ is —O— or —S—.

In another embodiment B¹ is —O— or —N(R⁶)—.

In another embodiment B¹ is —S— or —N(R⁶)—.

In another embodiment B¹ is a valence bond.

In another embodiment B¹ is —O—.

In another embodiment B¹ is —S—.

In another embodiment B¹ is —N(R⁶)—.

In another embodiment B² is a valence bond, C₁-C₁₈-alkylene, C₂-C₁₈-alkenylene, C₂-C₁₈-alkynylene, arylene, heteroarylene, -C₁-C₁₈-alkyl-aryl-, —C(═O)-C₁-C₁₈-alkyl-C(═O)—, —C(═O)C₁-C₁₈-alkyl-O-C₁-C₁₈-alkyl-C(═O)—, —C(═O)-C₁-C₁₈-alkyl-S-C₁-C₁₈-alkyl-C(═O)—, —C(═O)-C₁-C₁₈-alkyl-NR⁶-C₁-C₁₈-alkyl-C(═O)—; and the alkylene and arylene moieties are optionally substituted as defined in claim 1.

In another embodiment B² is a valence bond, C₁-C₁₈-alkylene, C₂-C₁₈-alkenylene, C₂-C₁₈-alkynylene, arylene, heteroarylene, -C₁-C₁₈-alkyl-aryl-, —C(═O)-C₁-C₁₈-alkyl-C(═O)—, —C(═O)—C₁-C₁₈-alkyl-O-C₁-C₁₈-alkyl-C(═O)—, and the alkylene and arylene moieties are optionally substituted as defined in claim 1.

In another embodiment B² is a valence bond, C₁-C₁₈-alkylene, C₂-C₁₈-alkenylene, C₂-C₁₈-alkynylene, arylene, heteroarylene, —C₀-C₁₈-alkyl-aryl-, —C(═O)-C₁-C₁₈-alkyl-C(═O)—, and the alkylene and arylene moieties are optionally substituted as defined in claim 1.

In another embodiment B² is a valence bond, C₁-C₁₈-alkylene, arylene, heteroarylene, -C₁-C₁₈-alkyl-aryl-, —C(═O)-C₁-C₁₈-alkyl-C(═O)—, and the alkylene and arylene moieties are optionally substituted as defined in claim 1.

In another embodiment B² is a valence bond, C₁-C₁₈-alkylene, arylene, heteroarylene, -C₁-C₁₈-alkyl-aryl-, and the alkylene and arylene moieties are optionally substituted as defined in claim 1.

In another embodiment B² is a valence bond, C₁-C₁₈-alkylene, arylene, -C₁-C₁₈-alkyl-aryl-, and the alkylene and arylene moieties are optionally substituted as defined in claim 1.

In another embodiment B² is a valence bond or -C₁-C₁₈-alkylene, and the alkylene moieties are optionally substituted as defined in claim 1.

In another embodiment Frg2 comprises 1 to 16 positively charged groups.

In another embodiment Frg2 comprises 1 to 12 positively charged groups.

In another embodiment Frg2 comprises 1 to 10 positively charged groups.

In another embodiment Frg2 is a fragment containing basic amino acids independently selected from the group consisting of Lys and Arg and D-isomers of these.

In another embodiment the basic amino acid is Arg.

In another embodiment X is —OH or —NH₂.

In another embodiment X is —NH₂.

In another embodiment the pharmaceutical preparation further comprises at least 3 phenolic molecules.

In another embodiment the acid-stabilised insulin is selected from the group consisting of

• A21G
• A21G, B28K, B29P
• A21G, B28D
• A21G, B28E
• A21G, B3K, B29E
• A21G, desB27
• A21G, B9E
• A21G, B9D
• A21G, B10E

In another embodiment zinc ions are present in an amount corresponding to 10 to 40 μg Zn/100 U insulin

In another embodiment zinc ions are present in an amount corresponding to 10 to 26 μg Zn/100 U insulin.

In another embodiment the ratio between insulin and the zinc-binding ligand of the invention is in the range from 99:1 to 1:99.

In another embodiment the ratio between insulin and the zinc-binding ligand of the invention is in the range from 95:5 to 5:95.

In another embodiment the ratio between between insulin and the zinc-binding ligand of the invention is in the range from 80:20 to 20:80 In another embodiment the ratio between between insulin and the zinc-binding ligand of the invention is in the range from 70:30 to 30:70

In another aspect the invention relates to a method of preparing a zinc-binding ligand of the invention comprising the steps of

• • Identifying starter compounds that binds to the R-state His^B10-Zn²⁺ site
  • optionally attaching a fragment consisting of 0 to 5 neutral α- or β-amino acids
  • attaching a fragment comprising 1 to 20 positively charged groups independently selected from amino or guanidino groups

In another aspect the invention relates to a method of prolonging the action of an acid-stabilised insulin preparation which comprises adding a zinc-binding ligand of the invention to the acid-stabilised insulin preparation.

In another aspect the invention relates to a method of treating type 1 or type 2 diabetes comprising administering to a patient in need thereof a theraputically effective amount of a pharmaceutical preparation comprising

• • 1. Acid-stabilised insulin
  • 2. Zinc ions
  • 3. A zinc-binding ligand that binds to the R-state His^B10-Zn²⁺ site, where said ligand may be as described in the embodiments above.

In another aspect the invention provides an embodiment 1, which is a pharmaceutical preparation comprising

• • 1. Acid-stabilised insulin
  • 2. Zinc ions
  • 3. A zinc-binding ligand of the following general formula (I) CGr-Lnk-Frg1-Frg2-X  (I) wherein:
• CGr is a chemical group which reversibly binds to a His^B10 Zn²⁺ site of an insulin hexamer;
• Lnk is a linker selected from
  • a valence bond
  • a chemical group GB of the formula —B¹—B²—C(O)—, —B¹—B²—SO₂—, —B¹—B²—CH₂—, or —B¹—B²—NH—; wherein B¹ is a valence bond, —O—, —S—, or —NR^{6B—, B2} is a valence bond, C₁-C₁₈-alkylene, C₂-C₁₈-alkenylene, C₂-C₁₈-alkynylene, arylene, heteroarylene, -C₁-C₁₈-alkyl-aryl-, —C₂-C₁₈-alkenyl-aryl-, —C₂-C₁₈-alkynyl-aryl-, —C(═O)—C₁-C₁₈-alkyl-C(═O)—, —C(═O)-C₁-C₁₈-alkenyl-C(═O)—, —C(═O)-C₁-C₁₈-alkyl-O-C₁-C₁₈-alkyl-C(═O)—, —C(═O)-C₁-C₁₈-alkyl-S-C₁-C₁₈-alkyl-C(═O)—, —C(═O)-C₁-C₁₈-alkyl-NR⁶-C₁-C₁₈-alkyl-C(═O)—, —C(═O)-aryl-C(═O)—, —C(═O)-heteroaryl-C(═O)—;
  • wherein the alkylene, alkenylene, and alkynylene moieties are optionally substituted by —CN, —CF₃, —OCF₃, OR^6B, or —NR^6BR^7B and the arylene and heteroarylene moieties are optionally substituted by halogen, —C(O)OR⁶, —C(O)H, OCOR^6B, —SO₂, —CN, —CF₃, —OCF₃, —NO₂, —OR^6B, —NR^6BR^7B, C₁-C₁₈-alkyl, or C₁-C₁₈-alkanoyl;
  • R^6B and R^7B are independently H, C₁-C₄-alkyl;
• Frg1 is a fragment consisting of 0 to 5 neutral α- or β-amino acids
• Frg2 is a fragment comprising 1 to 20 positively charged groups independently selected from amino or guanidino groups; and
• X is —OH, —NH₂ or a diamino group,
• or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.

Embodiment 2

A pharmaceutical preparation according to embodiment 1 wherein CGr is a chemical structure selected from the group consisting of carboxylates, dithiocarboxylates, phenolates, thiophenolates, alkylthiolates, sulfonamides, imidazoles, triazoles, 4-cyano-1,2,3-triazoles, benzimidazoles, benzotriazoles, purines, thiazolidinediones, tetrazoles, 5-mercaptotetrazoles, rhodanines, N-hydroxyazoles, hydantoines, thiohydantoines, barbiturates, naphthoic acids and salicylic acids.

Embodiment 3

A pharmaceutical preparation according to embodiment 2 wherein CGr is a chemical structure selected from the group consisting of benzotriazoles, 3-hydroxy 2-napthoic acids, salicylic acids, tetrazoles, thiazolidinediones, 5-mercaptotetrazoles, or 4-cyano-1,2,3-triazoles.

Embodiment 4

A pharmaceutical composition according to any one of the embodiments 1 to 3 wherein CGr is wherein

• X is ═O, ═S or ═NH
• Y is —S—, —O— or —NH—
• R¹, R^1A and R⁴ are independently selected from hydrogen or C₁-C₆-alkyl, R² and R^2A are hydrogen or C₁-C₆-alkyl or aryl, R¹ and R² may optionally be combined to form a double bond, R^1A and R^2A may optionally be combined to form a double bond, R³, R^3A and R⁵ are independently selected from hydrogen, halogen, aryl optionally substituted with one or more substituents independently selected from R¹⁶, C₁-C₆-alkyl, or —C(O)NR¹¹R¹²,
• A, A¹ and B are independently selected from C₁-C₆-alkyl, aryl, aryl-C₁-C₆-alkyl, —NR¹¹-aryl, aryl-C₂-C₆-alkenyl or heteroaryl, wherein the alkyl or alkenyl is optionally substituted with one or more substituents independently selected from R⁶ and the aryl or heteroaryl is optionally substituted with up to four substituents R⁷, R⁸, R⁹, and R¹⁰,
• A and R³ may be connected through one or two valence bonds, B and R⁵ may be connected through one or two valence bonds, R⁶ is independently selected from halogen, —CN, —CF₃, —OCF₃, aryl, —COOH and —NH₂,
• R⁷, R⁸, R⁹ and R¹⁰ are independently selected from
  • hydrogen, halogen, —CN, —CH₂CN, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —S(O)₂CF₃, —OS(O)₂CF₃, —SCF₃, —NO₂, —OR¹¹, —NR¹¹R¹², —SR¹¹, —NR¹¹S(O)₂R¹², —S(O)₂NR¹¹R¹², —S(O)NR¹¹R¹², —S(O)R¹¹, —S(O)₂R¹¹, —OS(O)₂ R¹¹, —C(O)NR¹¹R¹², —OC(O)NR¹¹R¹², —NR¹¹C(O)R¹², —CH₂C(O)NR¹¹R¹², —OC₁-C₆-alkyl-C(O)NR¹¹R¹², —CH₂OR¹¹, —CH₂OC(O)R¹¹, —CH₂NR¹¹R¹², —OC(O)R¹¹, —OC₁-C₁₅-alkyl-C(O)OR¹¹, —OC₁-C₆-alkyl-O R¹¹, —SC₁-C₆-alkyl-C(O)OR¹¹-C₂-C₆-alkenyl-C(═O)OR¹¹, —NR¹¹—C(═O)-C₁-C₆-alkyl-C(═O)OR¹¹, —NR¹¹—C(═O)-C₁-C₆-alkenyl-C(═O)OR¹¹, —C(O)OR¹¹, C(O)R¹¹, or —C₂-C₆-alkenyl-C(═O)R¹¹, ═O, or —C₂-C₆-alkenyl-C(═O)—NR¹¹R¹²,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, each of which may optionally be substituted with one or more substituents independently selected from R¹³,
  • aryl, aryloxy, aryloxycarbonyl, aroyl, arylsulfanyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aroyl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl, heteroaryl-C₂-C₆-alkynyl, or C₃-C₆ cycloalkyl,
  • of which each cyclic moiety may optionally be substituted with one or more substituents independently selected from R¹⁴,
• R¹¹ and R¹² are independently selected from hydrogen, OH, C₁-C₂₀-alkyl, aryl-C₁-C₆-alkyl or aryl, wherein the alkyl groups may optionally be substituted with one or more substituents independently selected from R¹⁵, and the aryl groups may optionally be substituted one or more substituents independently selected from R¹⁶; R¹¹ and R¹² when attached to the same nitrogen atom may form a 3 to 8 membered heterocyclic ring with the said nitrogen atom, the heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulphur, and optionally containing one or two double bonds,
• R¹³ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OR¹¹, —C(O)OR¹¹, —NR¹¹R¹², and —C(O)NR¹¹R¹²,
• R¹⁴ is independently selected from halogen, —C(O)OR¹¹, —CH₂C(O)OR¹¹, —CH₂OR¹¹, —CN, —CF₃, —OCF₃, —NO₂, —OR¹¹, —NR¹¹R¹², —NR¹¹C(O)R¹¹, —S(O)₂R¹¹, aryl and C₁-C₆-alkyl,
• R¹⁵ is independently selected from halogen, —CN, —CF₃, ═O, —OCF₃, —OC₁-C₆-alkyl, —C(O)OC, —C₆-alkyl, —COOH and —NH₂,
• R¹⁶ is independently selected from halogen, —C(O)OC₁-C₆-alkyl, —COOH, —CN, —CF₃, —OCF₃, —NO₂, —OH, —OC₁-C₆-alkyl, —NH₂, C(═O) or C₁-C₆-alkyl, or any enantiomer, diastereomer, including a racemic mixture, tautomer as well as a salt thereof with a pharmaceutically acceptable acid or base.

Embodiment 5

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein X is ═O or ═S.

Embodiment 6

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein X is ═O.

Embodiment 7

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein X is ═S.

Embodiment 8

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein Y is —O— or —S—.

Embodiment 9

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein Y is —O—.

Embodiment 10

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein Y is —NH—.

Embodiment 11

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein Y is —S—.

Embodiment 12

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein A is aryl optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

Embodiment 13

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein A is selected from ArG1 optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

Embodiment 14

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein A is phenyl or naphtyl optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

Embodiment 15

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein A is 16. A pharmaceutical composition according to embodiment Error! Reference source not found. wherein A is phenyl.

Embodiment 17

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein A is heteroaryl optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

Embodiment 18

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein A is selected from Het1 optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

Embodiment 19

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein A is selected from Het2 optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

Embodiment 20

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein A is selected from Het3 optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

Embodiment 21

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein A is selected from the group consisting of indolyl, benzofuranyl, quinolyl, furyl, thienyl, or pyrrolyl, wherein each heteroaryl may optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

Embodiment 22

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein A is benzofuranyl optionally substituted with up to four substituents R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

Embodiment 23

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein A is 24. A pharmaceutical composition according to embodiment Error! Reference source not found. wherein A is carbazolyl optionally substituted with up to four substituents R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

Embodiment 25

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein A is

Embodiment 26

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein A is quinolyl optionally substituted with up to four substituents R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

Embodiment 27

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein A is

Embodiment 28

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein A is indolyl optionally substituted with up to four substituents R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

Embodiment 29

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein A is

Embodiment 30

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R¹ is hydrogen.

Embodiment 31

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R² is hydrogen.

Embodiment 32

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R¹ and R² are combined to form a double bond.

Embodiment 33

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R³ is C₁-C₆-alkyl, halogen, or C(O)NR⁶R¹⁷.

Embodiment 34

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R³ is C₁-C₆-alkyl or C(O)NR¹⁶R⁷.

Embodiment 35

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R³ is methyl.

Embodiment 36

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein B is phenyl optionally substituted with up to four substituents, R⁷, R⁸, R⁹, and R¹⁰ which may be the same or different.

Embodiment 37

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. or Error! Reference source not found. wherein R⁴ is hydrogen.

Embodiment 38

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. or Error! Reference source not found. to Error! Reference source not found. wherein R⁵ is hydrogen.

Embodiment 39

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R⁶ is aryl.

Embodiment 40

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁶ is phenyl.

Embodiment 41

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R⁷, R⁸, R⁹ and R¹⁰ are independently selected from

• • hydrogen, halogen, —NO₂, —OR¹¹, —NR¹¹R¹², —SR¹¹, —NR¹¹S(O)₂R¹², —S(O)₂NR¹¹R¹², —S(O)NR¹¹R¹², —S(O)R¹¹, —S(O)₂R¹¹, —OS(O)₂ R¹¹, —NR¹¹C(O)R¹², —CH₂OR¹¹, —CH₂OC(O)R¹¹, —CH₂NR¹¹ R¹², —OC(O)R¹¹, —OC₁-C₆-alkyl-C(O)OR¹¹, —OC₁-C₆-alkyl-C(O)NR¹¹R¹², —OC₁-C₆-alkyl-OR¹¹, —SC₁-C₆-alkyl-C(O)OR¹¹, —C₂-C₆-alkenyl-C(═O)OR¹¹, —C(O)OR¹¹, or —C₂-C₆-alkenyl-C(═O)R¹¹,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, which may each optionally be substituted with one or more substituents independently selected from R¹³
  • aryl, aryloxy, aroyl, arylsulfanyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aroyl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, wherein each of the cyclic moieties optionally may be substituted with one or more substituents independently selected from R¹⁴.

Embodiment 42

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁷, R⁸, R⁹ and R¹⁰ are independently selected from

• • hydrogen, halogen, —NO₂, —OR¹¹, —NR¹¹R¹², —SR′R″, —S(O)₂R, —OS(O)₂ R¹¹, CH₂OC(O)R¹¹, —OC(O)R¹¹, —OC₁-C₆-alkyl-C(O)OR¹¹, —OC₁-C₆-alkyl-OR¹¹, —SC₁-C₆-alkyl-C(O)OR¹¹, —C(O)OR¹¹, or —C₂-C₆-alkenyl-C(═O)R¹,
  • C₁-C₆-alkyl or C₁-C₆-alkenyl which may each optionally be substituted with one or more substituents independently selected from R¹³
  • aryl, aryloxy, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, heteroaryl,
  • of which each of the cyclic moieties optionally may be substituted with one or more substituents independently selected from R¹⁴.

Embodiment 43

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁷, R⁸, R⁹ and R¹⁰ are independently selected from

• • hydrogen, halogen, —NO₂, —OR¹¹, —NR¹¹R¹², —SR¹¹, —S(O)₂R¹¹, —OS(O)₂ R¹¹, CH₂OC(O)R¹¹, —OC(O)R¹¹, —OC₁-C₆-alkyl-C(O)OR¹¹, —OC₁-C₆-alkyl-OR¹¹, —SC₁-C₆-alkyl-C(O)OR¹¹, —C(O)OR¹¹, or —C₂-C₆-alkenyl-C(═O)R¹¹,
  • C₁-C₆-alkyl or C₁-C₆— which may each optionally be substituted with one or more substituents independently selected from R¹³
  • aryl, aryloxy, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, heteroaryl,
  • of which each of the cyclic moieties optionally may be substituted with one or more substituents independently selected from R¹⁴.

Embodiment 44

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁷, R⁸, R⁹ and R¹⁰ are independently selected from

• • hydrogen, halogen, —OR¹¹, —OC₁-C₆-alkyl-C(O)OR¹¹, or —C(O)OR¹¹,
  • C₁-C₆-alkyl which may each optionally be substituted with one or more substituents independently selected from R¹³
  • aryl, aryloxy, aryl-C₁-C₆-alkoxy,
  • of which each of the cyclic moieties optionally may be substituted with one or more substituents independently selected from R¹⁴.

Embodiment 45

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁷, R⁸, R⁹ and R¹⁰ are independently selected from

• • hydrogen, halogen, —OR¹¹, —OC₁-C₆-alkyl-C(O)OR¹¹, or —C(O)OR¹¹,
  • C₁-C₆-alkyl which may each optionally be substituted with one or more substituents independently selected from R¹³
  • ArG1, ArG1oxy, ArG1-C₁-C₆-alkoxy, of which each of the cyclic moieties optionally may be substituted with one or more substituents independently selected from R¹⁴.

Embodiment 46

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁷, R⁸, R⁹ and R¹⁰ are independently selected from

• • hydrogen, halogen, —OR¹¹, —OC₁-C₆-alkyl-C(O)OR¹¹, or —C(O)OR¹¹,
  • C₁-C₆-alkyl which may optionally be substituted with one or more substituents independently selected from R¹³
  • phenyl, phenyloxy, phenyl-C₁-C₆-alkoxy, wherein each of the cyclic moieties optionally may be substituted with one or more substituents independently selected from R¹⁴.

Embodiment 47

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R¹¹ and R¹² are independently selected from hydrogen, C₁-C₂₀-alkyl, aryl or aryl-C₁-C₆-alkyl, wherein the alkyl groups may optionally be substituted with one or more substituents independently selected from R¹⁵, and the aryl groups may optionally be substituted one or more substituents independently selected from R¹⁶; R¹¹ and R¹² when attached to the same nitrogen atom may form a 3 to 8 membered heterocyclic ring with the said nitrogen atom, the heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulphur, and optionally containing one or two double bonds.

Embodiment 48

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R¹¹ and R¹² are independently selected from hydrogen, C₁-C₂₀-alkyl, aryl or aryl-C₁-C₆-alkyl, wherein the alkyl groups may optionally be substituted with one or more substituents independently selected from R¹⁵, and the aryl groups may optionally be substituted one or more substituents independently selected from R¹⁶.

Embodiment 49

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R¹¹ and R¹² are independently selected from phenyl or phenyl-C₁-C₆-alkyl.

Embodiment 50

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein one or both of R¹¹ and R¹² are methyl.

Embodiment 51

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R¹³ is independently selected from halogen, CF₃, OR¹¹ or NR¹¹R¹².

Embodiment 52

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R¹³ is independently selected from halogen or OR¹¹.

Embodiment 53

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R¹³ is OR¹¹.

Embodiment 54

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R¹⁴ is independently selected from halogen, —C(O)OR¹¹, —CN, —CF₃, —OR¹¹, S(O)₂R¹¹, and C₁-C₆-alkyl.

Embodiment 55

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R¹⁴ is independently selected from halogen, —C(O)OR¹¹, or —OR¹¹.

Embodiment 56

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R¹⁵ is independently selected from halogen, —CN, —CF₃, —C(O)OC₁-C₆-alkyl, and —COOH.

Embodiment 57

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R¹⁵ is independently selected from halogen or —C(O)OC₁-C₆-alkyl.

Embodiment 58

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R¹⁶ is independently selected from halogen, —C(O)OC₁-C₆-alkyl, —COOH, —NO₂, —OC₁-C₆-alkyl, —NH₂, C(═O) or C₁-C₆-alkyl.

Embodiment 59

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R¹⁶ is independently selected from halogen, —C(O)OC₁-C₆-alkyl, —COOH, —NO₂, or C₁-C₆-alkyl.

Embodiment 60

A pharmaceutical composition according to any one of the embodiment s 1 to 3 wherein CGr is wherein

• R¹⁹ is hydrogen or C₁-C₆-alkyl,
• R²⁰ is hydrogen or C₁-C₆-alkyl,
• D, D¹ and F are a valence bond, C₁-C₆-alkylene or C₁-C₆-alkenylene optionally substituted with one or more substituents independently selected from R⁷²,
• R⁷² is independently selected from hydroxy, C₁-C₆-alkyl, or aryl,
• E is C₁-C₆-alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with up to three substituents R², R²² and R²³,
• G and G¹ are C₁-C₆-alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with up to three substituents R²⁴, R²⁵ and R²⁶,
• R¹⁷ R¹⁸, R²¹, R²², R²³, R²⁴, R²⁵ and R²⁶ are independently selected from
  • hydrogen, halogen, —CN, —CH₂CN, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —S(O)₂CF₃, —SCF₃, —NO₂, ═O, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷S(O)₂R²⁸, —S(O)₂NR²⁷R²⁸, —S(O)NR²⁷R²⁸, —S(O)R²⁷, —S(O)₂R²⁷, —C(O)NR²⁷R²⁸, —OC(O)NR²⁷R²⁸, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —CH₂C(O)NR²⁷R²⁸, —OCH₂C(O)NR²⁷R², —CH₂OR²⁷, —CH₂NR²⁷R²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, -C₂-C₆-alkenyl-C(═O)OR²⁷, —NR²⁷—C(═O)-C₁-C₆-alkyl-C(═O)OR²⁷, —NR²⁷—C(═O)-C₁-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl,
  • which may optionally be substituted with one or more substituents independently selected from R²⁹,
  • aryl, aryloxy, aryloxycarbonyl, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl or heteroaryl-C₂-C₆-alkynyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰,
• R²⁷ and R²⁸ are independently selected from hydrogen, C₁-C₆-alkyl, aryl-C₁-C₆-alkyl or aryl, or R²⁷ and R²⁸ when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulphur, and optionally containing one or two double bonds,
• R²⁹ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OR²⁷, and —NR²⁷R²⁸,
• R³⁰ is independently selected from halogen, —C(O)OR²⁷, —CN, —CF₃, —OCF₃, —NO₂, —OR²⁷, —NR²⁷R²⁸ and C₁-C₆-alkyl, or any enantiomer, diastereomer, including a racemic mixture, tautomer as well as a salt thereof with a pharmaceutically acceptable acid or base.

Embodiment 61

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein D is a valence bond.

Embodiment 62

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein D is C₁-C₆-alkylene optionally substituted with one or more hydroxy, C₁-C₆-alkyl, or aryl.

Embodiment 63

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein E is aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with up to three substituents independently selected from R², R²² and R²³.

Embodiment 64

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein E is aryl optionally substituted with up to three substituents independently selected from R², R²² and R²³.

Embodiment 65

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein E is selected from ArG1 and optionally substituted with up to three substituents independently selected from R², R²² and R²³.

Embodiment 66

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein E is phenyl optionally substituted with up to three substituents independently selected from R², R²² and R²³.

Embodiment 67

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein CGr is

Embodiment 68

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R²¹, R²² and R²³ are independently selected from

• • hydrogen, halogen, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —SCF₃, —NO₂, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —C(O)NR²⁷R²⁸, —OC(O)NR²⁷R²⁸, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —CH₂C(O)NR²⁷R²⁸, —OCH₂C(O)NR²⁷R²⁸, —CH₂OR²⁷, —CH₂NR²⁷R²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —NR²⁷—C(═O)-C₁-C₆-alkyl-C(═O)OR²⁷, —NR²⁷—C(═O)-C₁-C₆-alkenyl-C(═O)OR²⁷—, —C(═O)NR²⁷—C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl,
  • which may optionally be substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aryloxycarbonyl, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl or heteroaryl-C₂-C₆-alkynyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

Embodiment 69

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R²¹, R²² and R²³ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • C₁-C₆-alkyl optionally substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, heteroaryl, heteroaryl-C₁-C₆-alkyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

Embodiment 70

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R²¹, R²² and R²³ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • methyl, ethyl propyl optionally substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, heteroaryl, heteroaryl-C₁-C₆-alkyl
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

Embodiment 71

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R²¹, R²² and R²³ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)R²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)O R²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • methyl, ethyl propyl optionally substituted with one or more substituents independently selected from R²⁹
  • ArG1, ArG1-O—, ArG1-C(O)—, ArG1-C₁-C₆-alkoxy, ArG1-C₁-C₆-alkyl, Het3, Het3-C₁-C₆-alkyl
• of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

Embodiment 72

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R²¹, R²² and R²³ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl -C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • C₁-C₆-alkyl optionally substituted with one or more substituents independently selected from R²⁹
  • phenyl, phenyloxy, phenyl-C₁-C₆-alkoxy, phenyl-C₁-C₆-alkyl,
• of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

Embodiment 73

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R¹⁹ is hydrogen or methyl.

Embodiment 74

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R¹⁹ is hydrogen.

Embodiment 75

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R²⁷ is Hydrogen, C₁-C₆-alkyl or aryl.

Embodiment 76

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R²⁷ is hydrogen or C₁-C₆-alkyl.

Embodiment 77

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R²³ is hydrogen or C₁-C₆-alkyl.

Embodiment 78

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein F is a valence bond.

Embodiment 79

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein F is C₁-C₆-alkylene optionally substituted with one or more hydroxy, C₁-C₆-alkyl, or aryl.

Embodiment 80

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. to Error! Reference source not found. wherein G is C₁-C₆-alkyl or aryl, wherein the aryl is optionally substituted with up to three substituents R²⁴, R²⁵ and R²⁶.

Embodiment 81

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. to Error! Reference source not found. wherein G is C₁-C₆-alkyl or ArG1, wherein the aryl is optionally substituted with up to three substituents R²⁴, R²⁵ and R²⁶.

Embodiment 82

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein G is C₁-C₆-alkyl.

Embodiment 83

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein G is phenyl optionally substituted with up to three substituents R²⁴, R²⁵ and R²⁶.

Embodiment 84

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R²⁴, R²⁵ and R²⁶ are independently selected from

• • hydrogen, halogen, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —SCF₃, —NO₂, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —C(O)NR²⁷R²⁸, —OC(O)NR²⁷R²⁸, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —CH₂C(O)NR²⁷R²⁸, —OCH₂C(O)NR²⁷R²⁸, —CH₂OR²⁷, —CH₂NR²⁷R²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —NR²⁷—C(═O)-C₁-C₆-alkyl-C(═O)OR²⁷, —NR²⁷—C(═O)-C₁-C₆-alkenyl-C(═O)OR²⁷—, —C(═O)NR²⁷—C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl,
  • which may optionally be substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aryloxycarbonyl, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl or heteroaryl-C₂-C₆-alkynyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

Embodiment 85

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R²⁴, R²⁵ and R²⁶ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)O²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl,
  • which may optionally be substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aryloxycarbonyl, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl or heteroaryl-C₂-C₆-alkynyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

Embodiment 86

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R²⁴, R²⁵ and R²⁶ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC, —C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • C₁-C₆-alkyl optionally substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, heteroaryl, heteroaryl-C₁-C₆-alkyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

Embodiment 87

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R²¹, R²² and R²³ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC, —C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • methyl, ethyl propyl optionally substituted with one or more substituents independently selected from R²⁹
  • ArG1, ArG1-O—, ArG1-C(O)—, ArG1-C₁-C₆-alkoxy, ArG1-C₁-C₆-alkyl, Het3, Het3-C₁-C₆-alkyl
• of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

Embodiment 88

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R²¹, R²² and R²³ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)O²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • methyl, ethyl propyl optionally substituted with one or more substituents independently selected from R²⁹
  • ArG1, ArG1-O—, ArG1-C(O)—, ArG1-C₁-C₆-alkoxy, ArG1-C₁-C₆-alkyl, Het3, Het3-C₁-C₆-alkyl
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

Embodiment 89

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R²¹, R²² and R²³ are independently selected from

• • hydrogen, halogen, —OCF₃, —OR²⁷, —NR²⁷R²⁸, —SR²⁷, —NR²⁷C(O)R²⁸, —NR²⁷C(O)OR²⁸, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR²⁷, —SC₁-C₆-alkyl-C(O)OR²⁷, —C₂-C₆-alkenyl-C(═O)OR²⁷, —C(═O)NR²⁷-C₁-C₆-alkyl-C(═O)OR²⁷, -C₁-C₆-alkyl-C(═O)OR²⁷, or —C(O)OR²⁷,
  • methyl, ethyl propyl optionally substituted with one or more substituents independently selected from R²⁹
  • ArG1, ArG1-O—, ArG1-C₁-C₆-alkoxy, ArG1-C₁-C₆-alkyl,
• of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

Embodiment 90

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. to Error! Reference source not found. wherein R²⁰ is hydrogen or methyl.

Embodiment 91

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R²⁰ is hydrogen.

Embodiment 92

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. to Error! Reference source not found. wherein R²⁷ is hydrogen, C₁-C₆-alkyl or aryl.

Embodiment 93

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R²⁷ is hydrogen or C₁-C₆-alkyl or ArG1.

Embodiment 94

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R²⁷ is hydrogen or C₁-C₆-alkyl.

Embodiment 95

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. to Error! Reference source not found. wherein R²⁸ is hydrogen or C₁-C₆-alkyl.

Embodiment 96

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R¹⁷ and R¹⁸ are independently selected from

• • hydrogen, halogen, —CN, —CF₃, —OCF₃, —NO₂, —OR²⁷, —NR²⁷R², —SR²⁷, —S(O)R²⁷, —S(O)₂R²⁷—C(O)NR²⁷R²⁸, —CH₂OR²⁷, —OC(O)R²⁷, —OC₁-C₆-alkyl-C(O)OR, —SC₁-C₆-alkyl-C(O)OR²⁷, or —C(O)OR²⁷,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, optionally substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, heteroaryl, heteroaryl-C₁-C₆-alkyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

Embodiment 97

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R¹⁷ and R¹⁸ are independently selected from

• • hydrogen, halogen, —CN, —CF₃, —NO₂, —OR²⁷, —NR²⁷R²⁸, or —C(O)OR²⁷,
  • C₁-C₆-alkyl optionally substituted with one or more substituents independently selected from R²⁹ aryl, aryloxy, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, heteroaryl, heteroaryl-C₁-C₆-alkyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

Embodiment 98

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R¹⁷ and R¹⁸ are independently selected from

• • hydrogen, halogen, —CN, —CF₃, —NO₂, —OR²⁷, —NR²⁷R²⁸, or —C(O)OR²⁷
  • methyl, ethyl propyl optionally substituted with one or more substituents independently selected from R²⁹
  • aryl, aryloxy, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, heteroaryl, heteroaryl-C₁-C₆-alkyl
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

Embodiment 99

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R¹⁷ and R¹⁸ are independently selected from

• • hydrogen, halogen, —CN, —CF₃, —NO₂, —OR²⁷, —NR²⁷R²⁸, or —C(O)OR²⁷
  • methyl, ethyl propyl optionally substituted with one or more substituents independently selected from R²⁹
  • ArG1, ArG1-O—, ArG1-C(O)—, ArG1-C₁-C₆-alkoxy, ArG1-C₁-C₆-alkyl, Het3, Het3-C₁-C₆-alkyl
• of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

Embodiment 100

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R¹⁷ and R¹⁸ are independently selected from

• • hydrogen, halogen, —CN, —CF₃, —NO₂, —OR²⁷, —NR², R²⁸, or —C(O)OR²⁷
  • C₁-C₆-alkyl optionally substituted with one or more substituents independently selected from R²⁹
  • phenyl, phenyloxy, phenyl-C₁-C₆-alkoxy, phenyl-C₁-C₆-alkyl,
• of which the cyclic moieties optionally may be substituted with one or more substituents selected from R³⁰.

Embodiment 101

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R²⁷ is hydrogen or C₁-C₆-alkyl.

Embodiment 102

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R²⁷ is hydrogen, methyl or ethyl.

Embodiment 103

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R²⁸ is hydrogen or C₁-C₆-alkyl.

Embodiment 104

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R²⁸ is hydrogen, methyl or ethyl.

Embodiment 105

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R⁷² is —OH or phenyl.

Embodiment 106

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein CGr is

Embodiment 107

A pharmaceutical composition according to any one of the embodiment s 1 to 3 wherein CGr is of the form H-I-J wherein H is wherein the phenyl, naphthalene or benzocarbazole rings are optionally substituted with one or more substituents independently selected from R³¹

• I is selected from
  • a valence bond,
  • —CH₂N(R³²)— or —SO₂N(R³³)—, wherein Z¹ is S(O)₂ or CH₂, Z² is —NH—, —O— or —S—, and n is 1 or 2,
• J is
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, which may each optionally be substituted with one or more substituents selected from R³⁴,
  • Aryl, aryloxy, aryl-oxycarbonyl-, aroyl, aryl-C₁-C₆-alkoxy-, aryl-C₁-C₆-alkyl-, aryl-C₂-C₆-alkenyl-, aryl-C₂-C₆-alkynyl-, heteroaryl, heteroaryl-C₁-C₆-alkyl-, heteroaryl-C₂-C₆-alkenyl- or heteroaryl-C₂-C₆-alkynyl-, wherein the cyclic moieties are optionally substituted with one or more substituents selected from R³⁷,
  • hydrogen,
  • R³¹ is independently selected from hydrogen, halogen, —CN, —CH₂CN, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —S(O)₂CF₃, —SCF₃, —NO₂, —OR³⁵, —C(O)R³⁵, —NR³⁵R³⁶, —SR³⁵, —NR³⁵S(O)₂R³⁶, —S(O)₂NR³⁵R³⁶, —S(O)NR³⁵R³⁶, —S(O)R³⁵, —S(O)₂R³⁵, —C(O)NR³⁵R³⁶, —OC(O)NR³⁵R³⁶, —NR³⁵C(O)R³⁶, —CH₂C(O)NR³⁵R³⁶, —OCH₂C(O)NR³⁵R³⁶, —CH₂OR³⁵, —CH₂NR³⁵R³⁶, —OC(O)R³⁵, —OC₁-C₆-alkyl-C(O)OR³⁵, —SC₁-C₆-alkyl-C(O)OR³⁵—C₂-C₆-alkenyl-C(═O)OR³⁵, —NR³⁵—C(═O)—C₁-C₆-alkyl-C(═O)OR³⁵, —NR³⁵—C(=)—C—C₆-alkenyl-C(═O)OR³⁵—, C₁-C₆-alkyl, C₁-C₆-alkanoyl or —C(O)OR³⁵,
• R³² and R³³ are independently selected from hydrogen, C₁-C₆-alkyl or C₁-C₆-alkanoyl,
• R³⁴ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OR³⁵, and —NR³⁵R³⁶,
• R³⁵ and R³⁶ are independently selected from hydrogen, C₁-C₆-alkyl, aryl-C₁-C₆-alkyl or aryl, or R³⁵ and R³⁶ when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulphur, and optionally containing one or two double bonds,
• R³⁷ is independently selected from halogen, —C(O)OR³⁵, —C(O)H, —CN, —CF₃, —OCF₃, —NO₂, —OR³⁵—NR³⁵R³⁶, C₁-C₆-alkyl or C₁-C₆-alkanoyl,
• or any enantiomer, diastereomer, including a racemic mixture, tautomer as well as a salt thereof with a pharmaceutically acceptable acid or base.

Embodiment 108

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein CGr is of the form H-I-J, wherein H is wherein the phenyl, naphthalene or benzocarbazole rings are optionally substituted with one or more substituents independently selected from R³¹,

• I is selected from
  • a valence bond,
  • —CH₂N(R³²)— or —SO₂N(R³³)—, wherein Z¹ is S(O)₂ or CH₂, Z² is N, —O— or —S—, and n is 1 or 2,
• J is
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, which may each optionally be substituted with one or more substituents selected from R³⁴,
  • Aryl, aryloxy, aryl-oxycarbonyl-, aroyl, aryl-C₁-C₆-alkoxy-, aryl-C₁-C₆-alkyl-, aryl-C₂-C₆-alkenyl-, aryl-C₂-C₆-alkynyl-, heteroaryl, heteroaryl-C₁-C₆-alkyl-, heteroaryl-C₂-C₆-alkenyl- or heteroaryl-C₂-C₆-alkynyl-, wherein the cyclic moieties are optionally substituted with one or more substituents selected from R³⁷,
  • hydrogen,
• R³¹ is independently selected from hydrogen, halogen, —CN, —CH₂CN, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —S(O)₂CF₃, —SCF₃, —NO₂, —OR³⁵, —C(O)R³⁵, —NR³⁵R³⁶, —SR³⁵, —NR³⁵S(O)₂R³⁶, —S(O)₂NR³⁵R³⁶, —S(O)NR³⁵R³⁶, —S(O)R³⁵, —S(O)₂R³⁵, —C(O)NR³⁵R³⁶, —OC(O)NR³⁵R³⁶, —NR³⁵C(O)R³⁶, —CH₂C(O)NR³⁵R³⁶, —OCH₂C(O)NR³⁵R³⁶, —CH₂OR³⁵, —CH₂NR³⁵R³⁶, —OC(O)R³⁵, —OC₁-C₆-alkyl-C(O)OR³⁵, —SC₁-C₆-alkyl-C(O)OR³⁵—C₂-C₆-alkenyl-C(═O)OR³⁵, —NR³⁵—C(═O)-C₁-C₆-alkyl-C(═O)OR³⁵, —NR³⁵—C(═O)—C₁-C₆-alkenyl-C(═O)OR³⁵—, C₁-C₆-alkyl, C₁-C₆-alkanoyl or —C(O)OR³⁵,
• R³² and R³³ are independently selected from hydrogen, C₁-C₆-alkyl or C₁-C₆-alkanoyl,
• R³⁴ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OR³⁵, and —NR³⁵R³⁶,
• R³⁵ and R³⁶ are independently selected from hydrogen, C₁-C₆-alkyl, aryl-C₁-C₆-alkyl or aryl, or R³⁵ and R³⁶ when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulphur, and optionally containing one or two double bonds,
• R³⁷ is independently selected from halogen, —C(O)OR³⁵, —C(O)H, —CN, —CF₃, —OCF₃, —NO₂, —OR³⁵, —NR³⁵R³⁶, C₁-C₆-alkyl or C₁-C₆-alkanoyl,
• or any enantiomer, diastereomer, including a racemic mixture, tautomer as well as a salt thereof with a pharmaceutically acceptable acid or base,
• With the proviso that R³¹ and J cannot both be hydrogen.

Embodiment 109

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. wherein H is

Embodiment 110

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein H is

Embodiment 111

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein H is

Embodiment 112

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found.wherein I is a valence bond, —CH₂N(R³²)—, or —SO₂N(R³³)—.

Embodiment 113

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein I is a valence bond.

Embodiment 114

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein J is

• • hydrogen,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, which may optionally be substituted with one or more substituents selected from halogen, —CN, —CF₃, —OCF₃, —OR³⁵, and —NR³⁵R³⁶,
  • aryl, or heteroaryl, wherein the cyclic moieties are optionally substituted with one or more substituents independently selected from R³⁷.

Embodiment 115

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein J is

• • hydrogen,
  • aryl or heteroaryl, wherein the cyclic moieties are optionally substituted with one or more substituents independently selected from R³⁷.

Embodiment 116

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein J is

• • hydrogen,
  • ArG1 or Het3, wherein the cyclic moieties are optionally substituted with one or more substituents independently selected from R³⁷.

Embodiment 117

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein J is

• • hydrogen,
  • phenyl or naphthyl optionally substituted with one or more substituents independently selected from R³⁷.

Embodiment 118

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein J is hydrogen.

Embodiment 119

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R³² and R³³ are independently selected from hydrogen or C₁-C₆-alkyl.

Embodiment 120

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R³⁴ is hydrogen, halogen, —CN, —CF₃, —OCF₃, —SCF₃, —NO₂, —OR³⁵, —C(O)R³⁵, —NR³⁵R³⁶, —SR³⁵, —C(O)NR³⁵R³⁶, —OC(O)NR³⁵R³⁶, —NR³⁵C(O)R³⁶, —OC(O)R³⁵, —OC₁-C₆-alkyl-C(O)OR³⁵, —SC₁-C₆-alkyl-C(O)OR³⁵ or —C(O)OR³⁵.

Embodiment 121

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R³⁴ is hydrogen, halogen, —CF₃, —NO₂, —OR³⁵, —NR³⁵R³⁶, —SR³⁵, —NR³⁵C(O)R³⁶, or —C(O)OR³⁵.

Embodiment 122

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R³⁴ is hydrogen, halogen, —CF₃, —NO₂, —OR³⁵, —NR³⁵R³⁵, or —NR³⁵C(O)R³⁶.

Embodiment 123

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R³⁴ is hydrogen, halogen, or —OR³⁵.

Embodiment 124

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R³⁵ and R³⁶ are independently selected from hydrogen, C₁-C₆-alkyl, or aryl.

Embodiment 125

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R³⁵ and R³⁶ are independently selected from hydrogen or C₁-C₆-alkyl.

Embodiment 126

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R³⁷ is halogen, —C(O)OR³⁵, —CN, —CF₃, —OR³⁵, —NR³⁵R³⁶, C₁-C₆-alkyl or C₁-C₆-alkanoyl.

Embodiment 127

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R³⁷ is halogen, —C(O)OR³⁵, —OR³⁵, —NR³⁵R³⁶, C₁-C₆-alkyl or C₁-C₆-alkanoyl.

Embodiment 128

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R³⁷ is halogen, —C(O)OR³⁵ or —OR³⁵.

Embodiment 129

A pharmaceutical composition according to any one of the embodiment s 1 to 3 wherein CGr is wherein K is a valence bond, C₁-C₆-alkylene, —NH—C(═O)—U—, -C₁-C₆-alkyl-S—, -C₁-C₆-alkyl-O—, —C(═O)—, or —C(═O)—NH—, wherein any C₁-C₆-alkyl moiety is optionally substituted with R³⁸,

• U is a valence bond, C₁-C₆-alkenylene, -C₁-C₆-alkyl-O— or C₁-C₆-alkylene wherein any C₁-C₆-alkyl moiety is optionally substituted with C₁-C₆-alkyl,
• R³⁸ is C₁-C₆-alkyl, aryl, wherein the alkyl or aryl moieties are optionally substituted with one or more substituents independently selected from R³⁹,
• R³⁹ is independently selected from halogen, cyano, nitro, amino,
• M is a valence bond, arylene or heteroarylene, wherein the aryl or heteroaryl moieties are optionally substituted with one or more substituents independently selected from R⁴⁰,
• R⁴⁰ is selected from
  • hydrogen, halogen, —CN, —CH₂CN, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —S(O)₂CF₃, —OS(O)₂CF₃, —SCF₃, —NO₂, —OR⁴′, —NR⁴′ R⁴², —SR⁴¹, —NR⁴¹S(O)₂R⁴², —S(O)₂NR⁴¹R⁴², —S(O)NR⁴¹R⁴², —S(O)R⁴¹, —S(O)₂R⁴, —OS(O)₂ R⁴¹, —C(O)NR⁴¹R⁴², —OC(O)NR⁴¹R⁴², —NR⁴¹C(O)R⁴², —CH₂C(O)NR⁴¹R⁴², -C₁-C₆-alkyl-C(O)NR⁴¹R⁴², —CH₂OR⁴¹, —CH₂OC(O)R⁴, —CH₂NR⁴¹ R⁴², —OC(O)R⁴¹, —OC₁-C₆-alkyl-C(O)OR⁴¹, —OC₁-C₆-alkyl-OR⁴¹, —S-C₁-C₆-alkyl-C(O)OR⁴¹, —C₂-C₆-alkenyl-C(═O)OR⁴¹, —NR⁴—C(═O)-C₁-C₆-alkyl-C(═O)OR⁴¹, —NR⁴¹—C(═O)-C₁-C₆-alkenyl-C(═O)OR⁴¹, —C(O)OR⁴, —C₂-C₆-alkenyl-C(═O)R⁴¹, ═O, —NH—C(═O)—O-C₁-C₆-alkyl, or —NH—C(═O)—C(═O)—O-C₁-C₆-alkyl,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, which may each optionally be substituted with one or more substituents selected from R⁴³,
  • aryl, aryloxy, aryloxycarbonyl, aroyl, arylsulfanyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aroyl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl or heteroaryl-C₂-C₆-alkynyl, wherein the cyclic moieties optionally may be substituted with one or more substituents selected from R⁴⁴,
• R⁴¹ and R⁴² are independently selected from hydrogen, —OH, C₁-C₆-alkyl, C₁-C₆-alkenyl, aryl-C₁-C₆-alkyl or aryl, wherein the alkyl moieties may optionally be substituted with one or more substituents independently selected from R⁴⁵, and the aryl moieties may optionally be substituted with one or more substituents independently selected from R⁴⁶; R⁴¹ and R⁴² when attached to the same nitrogen atom may form a 3 to 8 membered heterocyclic ring with the said nitrogen atom, the heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulphur, and optionally containing one or two double bonds,
• R⁴³ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OR⁴¹, and —NR⁴¹R⁴²
• R⁴⁴ is independently selected from halogen, —C(O)OR⁴¹, —CH₂C(O)OR⁴¹, —CH₂OR⁴¹, —CN, —CF₃, —OCF₃, —NO₂, —OR⁴¹, —NR⁴¹R⁴² and C₁-C₆-alkyl,
• R⁴⁵ is independently selected from halogen, —CN, —CF₃, —OCF₃, —O-C₁-C₆-alkyl, —C(O)—O-C₁-C₆-alkyl, —COOH and —NH₂,
• R⁴⁶ is independently selected from halogen, —C(O)OC₁-C₆-alkyl, —COOH, —CN, —CF₃, —OCF₃, —NO₂, —OH, —OC₁-C₆-alkyl, —NH₂, C(═O) or C₁-C₆-alkyl,
• Q is a valence bond, C₁-C₆-alkylene, -C₁-C₆-alkyl-O—, -C₁-C₆-alkyl-NH—, —NH-C₁-C₆-alkyl, —NH—C(═O)—, —C(═O)—NH—, —O-C₁-C₆-alkyl, —C(═O)—, or -C₁-C₆-alkyl-C(═O)—N(R⁴⁷)— wherein the alkyl moieties are optionally substituted with one or more substituents independently selected from R⁴⁸,
• R⁴⁷ and R⁴⁸ are independently selected from hydrogen, C₁-C₆-alkyl, aryl optionally substituted with one or more R⁴⁹,
• R⁴⁹ is independently selected from halogen and —COOH,
• T is
  • hydrogen,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl , C₂-C₆-alkynyl, C₁-C₆-alkyloxy-carbonyl, wherein the alkyl, alkenyl and alkynyl moieties are optionally substituted with one or more substituents independently selected from R⁵⁰,
  • aryl, aryloxy, aryloxy-carbonyl, aryl-C₁-C₆-alkyl, aroyl, aryl-C₁-C₆-alkoxy, aryl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkyny-, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl, heteroaryl-C₂-C₆-alkynyl,
  • wherein any alkyl, alkenyl , alkynyl, aryl and heteroaryl moiety is optionally substituted with one or more substituents independently selected from R⁵⁰,
• R⁵⁰ is C₁-C₆-alkyl, C₁-C₆-alkoxy, aryl, aryloxy, aryl-C₁-C₆-alkoxy, —C(═O)—NH-C₁-C₆-alkyl-aryl, —C(═O)—NR^50A-C₁-C₆-alkyl, —C(═O)—NH—(CH₂CH₂O)_mC₁-C₆-alkyl-COOH, heteroaryl, heteroaryl-C₁-C₆-alkoxy, -C₁-C₆-alkyl-COOH, —O-C₁-C₆-alkyl-COOH, —S(O)₂R⁵¹, —C₂-C₆-alkenyl-COOH, —OR⁵¹, —NO₂, halogen, —COOH, —CF₃, —CN, ═O, —N(R⁵¹R⁵²), wherein m is 1, 2, 3 or 4, and wherein the aryl or heteroaryl moieties are optionally substituted with one or more R⁵³, and the alkyl moieties are optionally substituted with one or more R^50B.

Embodiment R^50A and R^50B are independently selected from —C(O)OC₁-C₆-alkyl, —COOH, -C₁-C₆-alkyl-C(O)OC, —C₆-alkyl, -C₁-C₆-alkyl-COOH, or C₁-C₆-alkyl,

• R⁵¹ and R⁵² are independently selected from hydrogen and C₁-C₆-alkyl,
• R⁵³ is independently selected from C₁-C₆-alkyl, C₁-C₆-alkoxy, -C₁-C₆-alkyl-COOH, —C₂-C₆-alkenyl-COOH, —OR⁵′, —NO₂, halogen, —COOH, —CF₃, —CN, or —N(R⁵¹R⁵²),
• or any enantiomer, diastereomer, including a racemic mixture, tautomer as well as a salt thereof with a pharmaceutically acceptable acid or base.

Embodiment 130

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein K is a valence bond, C₁-C₆-alkylene, —NH—C(═O)—U—, -C₁-C₆-alkyl-S—, -C₁-C₆-alkyl-O—, or —C(═O)—, wherein any C₁-C₆-alkyl moiety is optionally substituted with R³⁸.

Embodiment 131

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein K is a valence bond, C₁-C₆-alkylene, —NH—C(═O)—U—, -C₁-C₆-alkyl-S—, or -C₁-C₆-alkyl-0, wherein any C₁-C₆-alkyl moiety is optionally substituted with R³⁸.

Embodiment 132

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein K is a valence bond, C₁-C₆-alkylene, or —NH—C(═O)—U, wherein any C₁-C₆-alkyl moiety is optionally substituted with R³⁸.

Embodiment 133

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein K is a valence bond or C₁-C₆-alkylene, wherein any C₁-C₆-alkyl moiety is optionally substituted with R³⁸.

Embodiment 134

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein K is a valence bond or —NH—C(═O)—U.

Embodiment 135

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein K is a valence bond.

Embodiment 136

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein U is a valence bond or -C₁-C₆-alkyl-O—.

Embodiment 137

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein U is a valence bond.

Embodiment 138

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein M is arylene or heteroarylene, wherein the arylene or heteroarylene moieties are optionally substituted with one or more substituents independently selected from R⁴⁰.

Embodiment 139

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein M is ArG1 or Het1, wherein the arylene or heteroarylene moieties are optionally substituted with one or more substituents independently selected from R⁴⁰.

Embodiment 140

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein M is ArG1 or Het2, wherein the arylene or heteroarylene moieties are optionally substituted with one or more substituents independently selected from R⁴⁰.

Embodiment 141

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein M is ArG1 or Het3, wherein the arylene or heteroarylene moieties are optionally substituted with one or more substituents independently selected from R⁴⁰.

Embodiment 142

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein M is phenylene optionally substituted with one or more substituents independently selected from R⁴⁰.

Embodiment 143

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein M is indolylene optionally substituted with one or more substituents independently selected from R⁴⁰.

Embodiment 144

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein M is 145. A pharmaceutical composition according to embodiment Error! Reference source not found. wherein M is carbazolylene optionally substituted with one or more substituents independently selected from R⁴⁰.

Embodiment 146

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein M is

Embodiment 147

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R⁴⁰ is selected from

• • hydrogen, halogen, —CN, —CF₃, —OCF₃, —NO₂, —OR⁴¹, —NR⁴¹R⁴², —SR⁴¹, —S(O)₂R⁴¹, —NR⁴¹C(O)R⁴², —OC₁-C₆-alkyl-C(O)NR⁴, R⁴², —C₂-C₆-alkenyl-C(═O)OR⁴¹, —C(O)OR⁴¹, ═O, —NH—C(═O)—O-C₁-C₆-alkyl, or —NH—C(═O)—C(═O)—O-C₁-C₆-alkyl,
  • C₁-C₆-alkyl or C₂-C₆— alkenyl which may each optionally be substituted with one or more substituents independently selected from R⁴³,
  • aryl, aryloxy, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, or heteroaryl-C₂-C₆-alkenyl, wherein the cyclic moieties optionally may be substituted with one or more substituents selected from R⁴⁴.

Embodiment 148

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁴⁰ is selected from

• • hydrogen, halogen, —CN, —CF₃, —OCF₃, —NO₂, —OR⁴′, —NR⁴′ R⁴², —SR⁴′, —S(O)₂R⁴¹, —NR⁴¹C(O)R⁴², —OC₁-C₆-alkyl-C(O)NR⁴¹R⁴², —C₂-C₆-alkenyl-C(═O)OR⁴¹, —C(O)OR⁴¹, ═O, —NH—C(═O)—O-C₁-C₆-alkyl, or —NH—C(═O)—C(═O)—O-C₁-C₆-alkyl,
  • C₁-C₆-alkyl or C₂-C₆— alkenyl which may each optionally be substituted with one or more substituents independently selected from R⁴³,
  • ArG1, ArG1-O—, ArG1-C₁-C₆-alkoxy, ArG1-C₁-C₆-alkyl, ArG1-C₂-C₆-alkenyl, Het3, Het3-C₁-C₆-alkyl, or Het3-C₂-C₆-alkenyl, wherein the cyclic moieties optionally may be substituted with one or more substituents selected from R⁴⁴.

Embodiment 149

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁴⁰ is selected from

• • hydrogen, halogen, —CF₃, —NO₂, —OR⁴, —NR⁴¹R⁴², —C(O)OR⁴¹, ═O, or —NR⁴¹C(O)R⁴²,
  • C₁-C₆-alkyl,
  • ArG1.

Embodiment 150

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁴⁰ is hydrogen.

Embodiment 151

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁴⁰ is selected from

• • halogen, —NO₂, —OR⁴¹, —NR⁴¹R⁴², —C(O)OR⁴¹, or —NR⁴¹C(O)R⁴²,
  • methyl,
  • phenyl.

Embodiment 152

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R⁴¹ and R⁴² are independently selected from hydrogen, C₁-C₆-alkyl, or aryl, wherein the aryl moieties may optionally be substituted with halogen or —COOH.

Embodiment 153

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁴¹ and R⁴² are independently selected from hydrogen, methyl, ethyl, or phenyl, wherein the phenyl moieties may optionally be substituted with halogen or —COOH.

Embodiment 154

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein Q is a valence bond, C₁-C₆-alkylene, -C₁-C₆-alkyl-O—, -C₁-C₆-alkyl-NH—, —NH-C₁-C₆-alkyl, —NH—C(═O)—, —C(═O)—NH—, —O-C₁-C₆-alkyl, —C(═O)—, or -C₁-C₆-alkyl-C(═O)—N(R⁴⁷)— wherein the alkyl moieties are optionally substituted with one or more substituents independently selected from R⁴⁸.

Embodiment 155

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein Q is a valence bond, —CH₂—, —CH₂—CH₂—, —CH₂—O—, —CH₂—CH₂—O—, —CH₂—NH—, —CH₂—CH₂-NH—, —NH—CH₂—, —NH—CH₂—CH₂—, —NH—C(═O)—, —C(═O)—NH—, —O—CH₂—, —O—CH₂—CH₂-, or —C(═O)—.

Embodiment 156

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R⁴⁷ and R⁴⁸ are independently selected from hydrogen, methyl and phenyl.

Embodiment 157

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein T is

• • hydrogen,
  • C₁-C₆-alkyl optionally substituted with one or more substituents independently selected from R⁵⁰,
  • aryl, aryl-C₁-C₆-alkyl, heteroaryl, wherein the alkyl, aryl and heteroaryl moieties are optionally substituted with one or more substituents independently selected from R⁵⁰.

Embodiment 158

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein T is

• • hydrogen,
  • C₁-C₆-alkyl optionally substituted with one or more substituents independently selected from R⁵⁰,
  • ArG1, ArG1-C₁-C₆-alkyl, Het3, wherein the alkyl, aryl and heteroaryl moieties are optionally substituted with one or more substituents independently selected from R⁵⁰.

Embodiment 159

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein T is

• • hydrogen,
  • C₁-C₆-alkyl, optionally substituted with one or more substituents independently selected from R⁵⁰,
  • phenyl, phenyl-C₁-C₆-alkyl, wherein the alkyl and phenyl moieties are optionally substituted with one or more substituents independently selected from R⁵⁰.

Embodiment 160

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein T is phenyl substituted with R⁵⁰.

Embodiment 161

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R⁵⁰ is C₁-C₆-alkyl, C₁-C₆-alkoxy, aryl, aryloxy, aryl-C₁-C₆-alkoxy, —C(═O)—NH-C₁-C₆-alkyl-aryl, —C(═O)—NR^50A-C₁-C₆-alkyl, —C(═O)—NH—(CH₂CH₂O)_mC₁-C₆-alkyl-COOH, heteroaryl, -C₁-C₆-alkyl-COOH, —O-C₁-C₆-alkyl-COOH, —S(O)₂R⁵¹, —C₂-C₆-alkenyl-COOH, —OR⁵¹, —NO₂, halogen, —COOH, —CF₃, —CN, ═O, —N(R⁵¹R⁵²), wherein the aryl or heteroaryl moieties are optionally substituted with one or more R⁵³.

Embodiment 162

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁵⁰ is C₁-C₆-alkyl, C₁-C₆-alkoxy, aryl, aryloxy, —C(═O)—NR^50A-C₁-C₆-alkyl, —C(═O)—NH—(CH₂-CH₂O)_mC₁-C₆-alkyl-COOH, aryl-C₁-C₆-alkoxy , —OR⁵′, —NO₂, halogen, —COOH, —CF₃, wherein any aryl moiety is optionally substituted with one or more R⁵³.

Embodiment 163

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁵⁰ is C₁-C₆-alkyl, aryloxy, —C(═O)—NR^50A-C₁-C₆-alkyl, —C(═O)—NH—(CH₂CH₂O)_mC₁-C₆-alkyl-COOH, aryl-C₁-C₆-alkoxy, —OR⁵¹, halogen, —COOH, —CF₃, wherein any aryl moiety is optionally substituted with one or more R⁵³.

Embodiment 164

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁵⁰ is C₁-C₆-alkyl, ArG1-O—, —C(═O)—NR^50A-C₁-C₆-alkyl, —C(═O)—NH—(CH₂CH₂O)_mC₁-C₆-alkyl-COOH, ArG1-C₁-C₆-alkoxy , —OR⁵′, halogen, —COOH, —CF₃, wherein any aryl moiety is optionally substituted with one or more R⁵³.

Embodiment 165

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁵⁰ is —C(═O)—NR^50ACH₂, —C(═O)—NH—(CH₂CH₂O)₂CH₂₁—COOH, or —C(═O)—NR^50ACH₂CH₂.

Embodiment 166

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁵⁰ is phenyl, methyl or ethyl.

Embodiment 167

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁵⁰ is methyl or ethyl.

Embodiment 168

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein m is 1 or 2.

Embodiment 169

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R⁵¹ is methyl.

Embodiment 170

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R⁵³ is C₁-C₆-alkyl, C₁-C₆-alkoxy, —OR⁵′, halogen, or —CF₃.

Embodiment 171

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R^50A is —C(O)OCH₃, —C(O)OCH₂CH₃—COOH, —CH₂C(O)OCH₃, —CH₂C(O)OCH₂CH₃, —CH₂CH₂C(O)OCH₃, —CH₂CH₂C(O)OCH₂CH₃, —CH₂COOH, methyl, or ethyl.

Embodiment 172

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R^50B is —C(O)OCH₃, —C(O)OCH₂CH₃—COOH, —CH₂C(O)OCH₃, —CH₂C(O)OCH₂CH₃, —CH₂CH₂C(O)OCH₃, —CH₂CH₂C(O)OCH₂CH₃, —CH₂COOH, methyl, or ethyl.

Embodiment 173

A pharmaceutical composition according to any one of the embodiment s 1 to 3 wherein CGr is wherein V is C₁-C₆-alkyl, aryl, heteroaryl, aryl-C_1-6-alkyl- or aryl-C_2-6-alkenyl-, wherein the alkyl or alkenyl is optionally substituted with one or more substituents independently selected from R⁵⁴, and the aryl or heteroaryl is optionally substituted with one or more substituents independently selected from R⁵⁵,

• R⁵⁴ is independently selected from halogen, —CN, —CF₃, —OCF₃, aryl, —COOH and —NH₂,
• R⁵⁵ is independently selected from
  • hydrogen, halogen, —CN, —CH₂CN, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —S(O)₂CF₃, —OS(O)₂CF₃, —SCF₃, —NO₂, —OR⁵⁶, —NR⁵⁶R⁵⁷, —SR⁵⁶, —NR⁵⁶S(O)₂R⁵⁷, —S(O)₂NR⁵⁶R⁵⁷, —S(O)NR⁵⁶R⁵⁷, —S(O)R⁵⁶, —S(O)₂R⁵⁶, —OS(O)₂ R⁵⁶, —C(O)NR⁵⁶R⁵⁷, —OC(O)NR⁵⁶R⁵⁷, —NR⁵⁶C(O)R⁵⁷, —CH₂C(O)NR⁵⁶R⁵⁷, —OC₁-C₆-alkyl-C(O)NR⁵⁶R⁵⁷, —CH₂OR⁵, —CH₂OC(O)R⁵⁶—CH₂NR⁵⁶R⁵⁷, —OC(O)R⁵⁶, —OC₁-C₈-alkyl-C(O)OR⁵⁶, —OC₁-C₆-alkyl-OR⁵⁶, —SC₁-C₆-alkyl-C(O)OR⁵⁶, -C₂—C₆-alkenyl-C(═O)OR⁵⁶, —NR⁵⁶—C(═O)-C₁-C₆-alkyl-C(═O)OR⁵⁶, —NR⁵⁶—C(═O)-C₁-C₆-alkenyl-C(═O)OR⁵⁶, —C(O)OR⁵⁶, or —C₂-C₆-alkenyl-C(═O)R⁵⁶,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl,
  • which may optionally be substituted with one or more substituents selected from R⁵⁸,
  • aryl, aryloxy, aryloxycarbonyl, aroyl, arylsulfanyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aroyl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl or heteroaryl-C₂-C₆-alkynyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R⁵⁹,
• R⁵⁶ and R⁵⁷ are independently selected from hydrogen, OH, CF₃, C₁-C₁₂-alkyl, aryl-C₁-C₆-alkyl, —C(═O)-C₁-C₆-alkyl or aryl, wherein the alkyl groups may optionally be substituted with one or more substituents independently selected from R⁶⁰, and the aryl groups may optionally be substituted with one or more substituents independently selected from R⁶¹; R⁵⁶ and R⁵⁷ when attached to the same nitrogen atom may form a 3 to 8 membered heterocyclic ring with the said nitrogen atom, the heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulphur, and optionally containing one or two double bonds,
• R⁵⁸ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OR⁵⁶, and —NR⁵⁶R⁵⁷,
• R⁵⁹ is independently selected from halogen, —C(O)OR⁵⁶, —CH₂C(O)OR⁵⁶, —CH₂OR⁵⁶, —CN, —CF₃, —OCF₃, —NO₂, —OR⁵⁶, —NR⁵⁶R⁵⁷ and C₁-C₆-alkyl,
• R⁶⁰ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OC₁-C₆-alkyl, —C(O)OC₁-C₆-alkyl, —C(═O)—R⁶², —COOH and —NH₂,
• R⁶¹ is independently selected from halogen, —C(O)OC₁-C₆-alkyl, —COOH, —CN, —CF₃, —OCF₃, —NO₂, —OH, —OC₁-C₆-alkyl, —NH₂, C(═O) or C₁-C₆-alkyl,
• R⁶² is C₁-C₆-alkyl, aryl optionally substituted with one or more substituents independently selected from halogen, or heteroaryl optionally substituted with one or more C₁-C₆-alkyl independently,
• or any enantiomer, diastereomer, including a racemic mixture, tautomer as well as a salt thereof with a pharmaceutically acceptable acid or base.

Embodiment 174

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein V is aryl, heteroaryl, or aryl-C_1-6-alkyl-, wherein the alkyl is optionally substituted with one or more substituents independently selected R⁵⁴, and the aryl or heteroaryl is optionally substituted with one or more substituents independently selected from R⁵⁵.

Embodiment 175

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein V is aryl, Het1, or aryl-C_1-6-alkyl-, wherein the alkyl is optionally substituted with one or more substituents independently selected from R⁵⁴, and the aryl or heteroaryl moiety is optionally substituted with one or more substituents independently selected from R⁵⁵.

Embodiment 176

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein V is aryl, Het2, or aryl-C_1-6-alkyl-, wherein the alkyl is optionally substituted with one or more substituents independently selected from R⁵⁴, and the aryl or heteroaryl moiety is optionally substituted with one or more substituents independently selected from R⁵⁵.

Embodiment 177

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein V is aryl, Het3, or aryl-C_1-6alkyl-, wherein the alkyl is optionally substituted with one or more substituents independently selected from R⁵⁴, and the aryl or heteroaryl moiety is optionally substituted with one or more substituents independently selected from R⁵⁵.

Embodiment 178

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein V is aryl optionally substituted with one or more substituents independently selected from R⁵⁵.

Embodiment 179

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein V is ArG1 optionally substituted with one or more substituents independently selected from R⁵⁵.

Embodiment 180

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein V is phenyl, naphthyl or anthranyl optionally substituted with one or more substituents independently selected from R⁵⁵.

Embodiment 181

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein V is phenyl optionally substituted with one or more substituents independently selected from R⁵⁵.

Embodiment 182

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R⁵⁵ is independently selected from

• • halogen, C₁-C₆-alkyl, —CN, —OCF₃, —CF₃, —NO₂, —OR⁵⁶, —NR⁵⁶R⁵⁷, —NR⁵⁶C(O)R⁵⁷—SR⁵⁶, —OC₁-C₈-alkyl-C(O)OR⁵⁶, or —C(O)OR⁵⁶,
  • C₁-C₆-alkyl optionally substituted with one or more substituents independently selected from R⁵⁸
  • aryl, aryl-C₁-C₆-alkyl, heteroaryl, or heteroaryl-C₁-C₆-alkyl of which the cyclic moieties optionally may be substituted with one or more substituents independently selected from R⁵⁹.

Embodiment 183

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁵⁵ is independently selected from

• • halogen, C₁-C₆-alkyl, —CN, —OCF₃, —CF₃, —NO₂, —OR⁵⁶, —NR⁵⁶R⁵⁷, —NR⁵⁶C(O)R⁵⁷-SR⁵⁵, —OC₁-C₈-alkyl-C(O)OR⁵⁶, or —C(O)OR⁵⁶
  • C₁-C₆-alkyl optionally substituted with one or more substituents independently selected from R⁵⁸
  • ArG1, ArG1-C₁-C₆-alkyl, Het3, or Het3-C₁-C₆-alkyl
  • of which the cyclic moieties optionally may be substituted with one or more substituents independently selected from R⁵⁹.

Embodiment 184

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁵⁵ is independently selected from halogen, —OR⁵⁶, —NR⁵⁶R⁵⁷, —C(O)OR⁵⁶, —OC, —C₈-alkyl-C(O)OR⁵⁶, —NR⁵⁶C(O)R⁵⁷ or C₁-C₆-alkyl.

Embodiment 185

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁵⁵ is independently selected from halogen, —OR⁵⁶, —NR⁵⁶R⁵⁷, —C(O)OR⁵⁶, —OC₁-C₈-alkyl-C(O)OR⁵⁶, —NR⁵⁶C(O)R⁵⁷, methyl or ethyl.

Embodiment 186

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R⁵⁶ and R⁵⁷ are independently selected from hydrogen, CF₃, C₁-C₁₂-alkyl, or —C(═O)-C₁-C₆-alkyl; R⁵⁶ and R⁵⁷ when attached to the same nitrogen atom may form a 3 to 8 membered heterocyclic ring with the said nitrogen atom.

Embodiment 187

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁵⁶ and R⁵⁷ are independently selected from hydrogen or C₁-C₁₂-alkyl, R⁵⁶ and R⁵⁷ when attached to the same nitrogen atom may form a 3 to 8 membered heterocyclic ring with the said nitrogen atom.

Embodiment 188

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁵⁶ and R⁵⁷ are independently selected from hydrogen or methyl, ethyl, propyl butyl, R⁵⁶ and R⁵⁷ when attached to the same nitrogen atom may form a 3 to 8 membered heterocyclic ring with the said nitrogen atom.

Embodiment 189

A pharmaceutical composition according to any one of the embodiment s 1 to 3 wherein CGr is wherein AA is C₁-C₆-alkyl, aryl, heteroaryl, aryl-C_1-6alkyl- or aryl-C_2-6-alkenyl-, wherein the alkyl or alkenyl is optionally substituted with one or more substituents independently selected from R⁶³, and the aryl or heteroaryl is optionally substituted with one or more substituents independently selected from R⁶⁴,

• R⁶³ is independently selected from halogen, —CN, —CF₃, —OCF₃, aryl, —COOH and —NH₂,
• R⁶⁴ is independently selected from
  • hydrogen, halogen, —CN, —CH₂CN, —CHF₂, —CF₃, —OCF₃, —OCHF₂, —OCH₂CF₃, —OCF₂CHF₂, —S(O)₂CF₃, —OS(O)₂CF₃, —SCF₃, —NO₂, —OR⁶⁵, —NR⁶⁵R⁶⁶, —SR⁶⁵, —NR⁶⁵S(O)₂R⁶⁶, —S(O)₂NR⁶⁵R⁶⁶, —S(O)NR⁶⁵R⁶⁶, —S(O)R⁶⁵, —S(O)₂R⁶⁵, —OS(O)₂ R⁶⁵, —C(O)NR⁶⁵R⁶⁶, —OC(O)NR⁶⁵R⁶⁶, —NR⁶⁵C(O)R⁶⁶, —CH₂C(O)NR⁶⁵R⁶⁶, —OC₁-C₆ alkyl-C(O)NR⁶⁵R⁶⁶, —CH₂OR⁶⁵, —CH₂OC(O)R⁶⁵, —CH₂NR⁶⁵R⁶⁶, —OC(O)R⁶⁵, —OC₁-C₆-alkyl-C(O)OR⁶⁵, —OC₁-C₆-alkyl-OR⁶⁵, —SC₁-C₆-alkyl-C(O)OR⁶⁵, —C₂-C₆-alkenyl-C(═O)OR⁶⁵, —NR⁶⁵—C(═O)-C₁-C₆-alkyl-C(═O)OR⁶⁵, —NR⁶⁵—C(═O)-C₁-C₆-alkenyl-C(═O)OR⁶⁵, —C(O)OR⁶⁵, or —C₂-C₆-alkenyl-C(═O)R⁶⁵,
  • C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl, each of which may optionally be substituted with one or more substituents selected from R⁶′,
  • aryl, aryloxy, aryloxycarbonyl, aroyl, arylsulfanyl, aryl-C₁-C₆-alkoxy, aryl-C₁-C₆-alkyl, aryl-C₂-C₆-alkenyl, aroyl-C₂-C₆-alkenyl, aryl-C₂-C₆-alkynyl, heteroaryl, heteroaryl-C₁-C₆-alkyl, heteroaryl-C₂-C₆-alkenyl or heteroaryl-C₂-C₆-alkynyl,
  • of which the cyclic moieties optionally may be substituted with one or more substituents selected from R⁶⁸,
• R⁶⁵ and R⁶⁶ are independently selected from hydrogen, OH, CF₃, C₁-C₁₂-alkyl, aryl-C₁-C₆-alkyl, —C(═O)—R⁶⁹, aryl or heteroaryl, wherein the alkyl groups may optionally be substituted with one or more substituents selected from R⁷⁰, and the aryl and heteroaryl groups may optionally be substituted with one or more substituents independently selected from R⁷¹; R⁶⁵ and R⁶⁶ when attached to the same nitrogen atom may form a 3 to 8 membered heterocyclic ring with the said nitrogen atom, the heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulphur, and optionally containing one or two double bonds,
• R⁶⁷ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OR⁶⁵, and —NR⁶⁵R⁶⁶,
• R⁶⁸ is independently selected from halogen, —C(O)OR⁶⁵, —CH₂C(O)OR⁶⁵, —CH₂OR⁶⁵, —CN, —CF₃, —OCF₃, —NO₂, —OR⁶⁵, —NR⁶⁵R⁶⁶ and C₁-C₆-alkyl,
• R⁶⁹ is independently selected from C₁-C₆-alkyl, aryl optionally substituted with one or more halogen, or heteroaryl optionally substituted with one or more C₁-C₆-alkyl,
• R⁷⁰ is independently selected from halogen, —CN, —CF₃, —OCF₃, —OC₁-C₆-alkyl, —C(O)OC₁-C₆-alkyl, —COOH and —NH₂, R⁷¹ is independently selected from halogen, —C(O)OC₁-C₆-alkyl, —COOH, —CN, —CF₃, —OCF₃, —NO₂, —OH, —OC₁-C₆-alkyl, —NH₂, C(═O) or C₁-C₆-alkyl,
• or any enantiomer, diastereomer, including a racemic mixture, tautomer as well as a salt thereof with a pharmaceutically acceptable acid or base.

Embodiment 190

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein AA is aryl, heteroaryl or aryl-C_1-6-alkyl-, wherein the alkyl is optionally substituted with one or more R⁶³, and the aryl or heteroaryl is optionally substituted with one or more substituents independently selected from R⁶⁴.

Embodiment 191

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein AA is aryl or heteroaryl optionally substituted with one or more substituents independently selected from R⁶⁴.

Embodiment 192

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein AA is ArG1 or Het1 optionally substituted with one or more substituents independently selected from R⁶⁴.

Embodiment 193

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein AA is ArG1 or Het2 optionally substituted with one or more substituents independently selected from R⁶⁴.

Embodiment 194

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein M is ArG1 or Het3 optionally substituted with one or more substituents independently selected from R⁶⁴.

Embodiment 195

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein AA is phenyl, naphtyl, anthryl, carbazolyl, thienyl, pyridyl, or benzodioxyl optionally substituted with one or more substituents independently selected from R⁶⁴.

Embodiment 196

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein M is phenyl or naphtyl optionally substituted with one or more substituents independently selected from R⁶⁴.

Embodiment 197

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R⁶⁴ is independently selected from hydrogen, halogen, —CF₃, —OCF₃, —OR⁶⁵, —NR⁶⁵R⁶⁶, C₁-C₆-alkyl —OC(O)R⁶⁵, —OC₁-C₆-alkyl-C(O)OR⁶⁵, aryl-C₂-C₆-alkenyl, aryloxy or aryl, wherein C₁-C₆-alkyl is optionally substituted with one or more substituents independently selected from R⁶⁷, and the cyclic moieties optionally are substituted with one or more substituents independently selected from R⁶⁸.

Embodiment 198

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁶⁴ is independently selected from halogen, —CF₃, —OCF₃, —OR⁶⁵, —NR⁶⁵R⁶⁶, methyl, ethyl, propyl, —OC(O)R⁶⁵, —OCH₂—C(O)OR⁶⁵, —OCH₂—CH₂-C(O)OR⁶⁵ phenoxy optionally substituted with one or more substituents independently selected from R⁶⁸.

Embodiment 199

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R⁶⁵ and R⁶⁶ are independently selected from hydrogen, CF₃, C₁-C₁₂-alkyl, aryl, or heteroaryl optionally substituted with one or more substituents independently selected from R⁷¹.

Embodiment 200

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁶⁵ and R⁶⁶ are independently hydrogen, C₁-C₁₂-alkyl, aryl, or heteroaryl optionally substituted with one or more substituents independently selected from R⁷¹.

Embodiment 201

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁶⁵ and R⁶⁶ are independently hydrogen, methyl, ethyl, propyl, butyl, 2,2-dimethyl-propyl, ArG1 or Het1 optionally substituted with one or more substituents independently selected from R⁷¹.

Embodiment 202

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁶⁵ and R⁶⁶ are independently hydrogen, methyl, ethyl, propyl, butyl, 2,2-dimethyl-propyl, ArG1 or Het2 optionally substituted with one or more substituents independently selected from R⁷¹.

Embodiment 203

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁶⁵ and R⁶⁶ are independently hydrogen, methyl, ethyl, propyl, butyl, 2,2-dimethyl-propyl, ArG1 or Het3 optionally substituted with one or more substituents independently selected from R⁷¹.

Embodiment 204

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁶⁵ and R⁶⁶ are independently hydrogen, methyl, ethyl, propyl, butyl, 2,2-dimethyl-propyl, phenyl, naphtyl, thiadiazolyl optionally substituted with one or more R⁷¹ independently; or isoxazolyl optionally substituted with one or more substituents independently selected from R⁷¹.

Embodiment 205

A pharmaceutical composition according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein R⁷¹ is halogen or C₁-C₆-alkyl.

Embodiment 206

A pharmaceutical composition according to embodiment Error! Reference source not found. wherein R⁷¹ is halogen or methyl.

Embodiment 207

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. wherein Frg1 consists of 0 to 5 neutral amino acids independently selected from the group consisting of Gly, Ala, Thr, and Ser.

Embodiment 208

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein Frg1 consists of 0 to 5 Gly.

Embodiment 209

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein Frg1 consists of 0 Gly.

Embodiment 210

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein Frg1 consists of 1 Gly.

Embodiment 211

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein Frg1 consists of 2 Gly.

Embodiment 212

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein Frg1 consists of 3 Gly.

Embodiment 213

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein Frg1 consists of 4 Gly.

Embodiment 214

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein Frg1 consists of 5 Gly.

Embodiment 215

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. wherein G^B is of the formula B¹—B²—C(O)—, B¹—B²-SO₂— or B¹—B²—CH₂—, wherein B¹ and B² are as defined in embodiment 1.

Embodiment 216

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. wherein G^B is of the formula B¹—B²—C(O)—, B¹—B²-SO₂— or B¹—B²—NH—, wherein B¹ and B² are as defined in embodiment 1.

Embodiment 217

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. wherein G^B is of the formula B¹—B²—C(O)—, B¹—B²-CH₂— or B¹—B²—NH—, wherein B¹ and B² are as defined in embodiment 1.

Embodiment 218

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. wherein G^B is of the formula B¹—B²—CH₂—, B¹—B²—SO₂— or B¹—B²—NH—, wherein B¹ and B² are as defined in embodiment 1.

Embodiment 219

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. wherein G^B is of the formula B¹—B²—C(O)— or B¹—B²—SO₂—, wherein B¹ and B² are as defined in embodiment 1.

Embodiment 220

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. wherein G^B is of the formula B¹—B²—C(O)— or B¹—B²—CH₂—, wherein B¹ and B² are as defined in embodiment 1.

Embodiment 221

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. wherein G^B is of the formula B¹—B²—C(O)— or B¹—B²—NH—, wherein B¹ and B² are as defined in embodiment 1.

Embodiment 222

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. wherein G^B is of the formula B¹—B²—CH₂— or B¹—B²—SO₂—, wherein B¹ and B² are as defined in embodiment 1.

Embodiment 223

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. wherein G^B is of the formula B¹—B²—NH— or B¹—B²—SO₂—, wherein B¹ and B² are as defined in embodiment 1.

Embodiment 224

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. wherein G^B is of the formula B¹—B²—CH₂— or B¹—B²—NH—, wherein B¹ and B² are as defined in embodiment 1.

Embodiment 225

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found., Error! Reference source not found., or Error! Reference source not found. wherein G^B is of the formula B¹—B²—C(O)—.

Embodiment 226

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found., Error! Reference source not found. or Error! Reference source not found. wherein G^B is of the formula B¹—B²—CH₂—.

Embodiment 227

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found., Error! Reference source not found. or Error! Reference source not found. wherein G^B is of the formula B¹—B²—SO₂—.

Embodiment 228

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found., Error! Reference source not found. or Error! Reference source not found. wherein G^B is of the formula B¹—B²—NH—.

Embodiment 229

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. wherein B¹ is a valence bond, —O—, or —S—.

Embodiment 230

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. wherein B¹ is a valence bond, —O—, or —N(R^6B)—.

Embodiment 231

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. wherein B¹ is a valence bond, —S—, or —N(R^6B)—.

Embodiment 232

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. wherein B¹ is —O—, —S— or —N(R^6B)—.

Embodiment 233

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. wherein B¹ is a valence bond or —O—.

Embodiment 234

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. wherein B¹ is a valence bond or —S—.

Embodiment 235

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. wherein B¹ is a valence bond or —N(R^6B)—.

Embodiment 236

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. wherein B¹ is —O— or —S—.

Embodiment 237

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. wherein B¹ is —O— or —N(R^6B)—.

Embodiment 238

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found. or Error! Reference source not found. wherein B¹ is —S— or —N(R^6B)—.

Embodiment 239

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found., Error! Reference source not found. or Error! Reference source not found. wherein B¹ is a valence bond.

Embodiment 240

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found., Error! Reference source not found. or Error! Reference source not found. wherein B¹ is —O—.

Embodiment 241

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found., Error! Reference source not found. or Error! Reference source not found. wherein B¹ is —S—.

Embodiment 242

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found., Error! Reference source not found. or Error! Reference source not found. wherein B¹ is —N(R^6B)—.

Embodiment 243

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. wherein B² is a valence bond, C₁-C₁₈-alkylene, C₂-C₁₈-alkenylene, C₂-C₁₈-alkynylene, arylene, heteroarylene, -C₁-C₁₈-alkyl-aryl-, —C(═O)-C₁-C₁₈-alkyl-C(═O)—, —C(═O)-C₁-C₁₈-alkyl-O-C₁-C₁₈-alkyl-C(═O)—, —C(═O)-C₁-C₁₈-alkyl-S-C₁-C₁₈-alkyl-C(═O)—, —C(═O)-C₁-C₁₈-alkyl-NR⁶-C₁-C₁₈-alkyl-C(═O)—; and the alkylene and arylene moieties are optionally substituted as defined in embodiment 1.

Embodiment 244

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein B² is a valence bond, C₁-C₁₈-alkylene, C₂-C₁₈-alkenylene, C₂-C₁₈-alkynylene, arylene, heteroarylene, -C₁-C₁₈-alkyl-aryl-, —C(═O)-C₁-C₁₈-alkyl-C(═O)—, —C(═O)—C₁-C₁₈-alkyl-O-C₁-C₁₈-alkyl-C(═O)—, and the alkylene and arylene moieties are optionally substituted as defined in embodiment 1.

Embodiment 245

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein B² is a valence bond, C₁-C₁₈-alkylene, C₂-C₁₈-alkenylene, C₂-C₁₈-alkynylene, arylene, heteroarylene, -C₁-C₁₈-alkyl-aryl-, —C(═O)-C₁-C₁₈-alkyl-C(═O)—, and the alkylene and arylene moieties are optionally substituted as defined in embodiment 1.

Embodiment 246

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein B² is a valence bond, C₁-C₁₈-alkylene, arylene, heteroarylene, -C₁-C₁₈-alkyl-aryl-, —C(═O)-C₁-C₁₈-alkyl-C(═O)—, and the alkylene and arylene moieties are optionally substituted as defined in embodiment 1.

Embodiment 247

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein B² is a valence bond, C₁-C₁₈-alkylene, arylene, heteroarylene, -C₁-C₁₈-alkyl-aryl-, and the alkylene and arylene moieties are optionally substituted as defined in embodiment 1.

Embodiment 248

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein B² is a valence bond, C₁-C₁₈-alkylene, arylene, -C₁-C₁₈-alkyl-aryl- and the alkylene and arylene moieties are optionally substituted as defined in embodiment 1.

Embodiment 249

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein B² is a valence bond or -C₁-C₁₈-alkylene, and the alkylene moieties are optionally substituted as defined in embodiment 1.

Embodiment 250

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. whereiin Frg2 comprises 1 to 16 positively charged groups.

Embodiment 251

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein Frg2 comprises 1 to 12 positively charged groups.

Embodiment 252

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein Frg2 comprises 1 to 10 positively charged groups.

Embodiment 253

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. wherein Frg2 comprises 10 to 20 positively charged groups.

Embodiment 254

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein Frg2 comprises 12 to 20 positively charged groups.

Embodiment 255

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein Frg2 comprises 16 to 20 positively charged groups.

Embodiment 256

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein the positively charged groups of Frg2 are basic amino acids independently selected from the group consisting of Lys and Arg and D-isomers of these.

Embodiment 257

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein the basic amino acids are all Arg.

Embodiment 258

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found., wherein Frg2 comprises one or more neutral amino acids independently selected from the group consisting of Gly, Ala, Thr, and Ser.

Embodiment 259

A pharmaceutical preparation according to embodiment Error! Reference source not found., wherein Frg2 comprises one or more Gly.

Embodiment 260

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. wherein X is —OH or —NH₂.

Embodiment 261

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein X is —NH₂.

Embodiment 262

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. which further comprises at least 3 phenolic molecules per putative insulin hexamer.

Embodiment 263

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. wherein the acid-stabilised insulin is an analogue of human insulin wherein A21 is Ala, Gln, Glu, Gly, His, Ile, Leu, Met, Phe, Ser, Thr, Trp, Tyr, Val, and hSer.

Embodiment 264

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein the acid-stabilised insulin is an analogue of human insulin wherein A21 is Ala, Gly, Ile, Leu, Phe, Ser, Thr, Val, and hSer.

Embodiment 265

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein the acid-stabilised insulin is an analogue of human insulin wherein A21 is Ala or Gly.

Embodiment 266

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein the acid-stabilised insulin is an analogue of human insulin wherein A21 is Gly.

Embodiment 267

A pharmaceutical preparation according to any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein the acid-stabilised insulin is an analogue of human insulin further modified by exchange or deletion of one or more amino acid residues according to the following:

• B3 is selected from Thr, Ser, Lys or Ala
• A18 is Gln
• B28 is Lys, Asp or Glu
• B29 is Pro or Glu
• B9 is Glu or Asp
• B10 is Glu
• B25 is deleted
• B30 is deleted.

Embodiment 268

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein the acid-stabilised insulin is an analogue of human insulin further modified by exchange of B28 to Lys or Asp.

Embodiment 269

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein the acid-stabilised insulin is an analogue of human insulin further modified by exchange of B28 to Asp.

Embodiment 270

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein the acid-stabilised insulin is an analogue of human insulin further modified by exchange of B28 to Lys.

Embodiment 271

A pharmaceutical preparation according any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein the acid-stabilised insulin is an analogue of human insulin further modified by exchange of B29 to Pro.

Embodiment 272

A pharmaceutical preparation according any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein the acid-stabilised insulin is an analogue of human insulin further modified by exchange of B3 to Lys or Ala.

Embodiment 273

A pharmaceutical preparation according any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein the acid-stabilised insulin is an analogue of human insulin further modified by exchange of A18 to Gln.

Embodiment 274

A pharmaceutical preparation according any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein the acid-stabilised insulin is an analogue of human insulin further modified by deletion of B25.

Embodiment 275

A pharmaceutical preparation according any one of the embodiment s Error! Reference source not found. to Error! Reference source not found. wherein the acid-stabilised insulin is an analogue of human insulin further modified by deletion of B30.

Embodiment 276

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein the acid-stabilised insulin is selected from the group

• A21G
• A21G, B28K, B29P
• A21G, B28D
• A21G, B28E
• A21G, B3K, B29E
• A21G, desB27
• A21G, B9E
• A21G, B9D
• A21G, B10E
• A21G, desB25
• A21G, desB30
• A21G, B28K, B29P, desB30
• A21G, B28D, desB30
• A21G, B28E, desB30
• A21G, B3K, B29E, desB30
• A21G, desB27, desB30
• A21G, B9E, desB30
• A21G, B9D, desB30
• A21 G, B10E, desB30
• A21G, desB25, desB30.

Embodiment 277

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. wherein zinc ions are present in an amount corresponding to 10 to 40 μg Zn/100 U insulin.

Embodiment 278

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein zinc ions are present in an amount corresponding to 10 to 26 μg Zn/100 U insulin.

Embodiment 279

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. wherein the ratio between insulin and the zinc-binding ligand according to any one of the embodiment s 1 to Error! Reference source not found. is in the range from 99:1 to 1:99.

Embodiment 280

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein the ratio between insulin and the zinc-binding ligand according to any one of the embodiment s 1 to Error! Reference source not found. is in the range from 95:5 to 5:95.

Embodiment 281

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein the ratio between between insulin and the zinc-binding ligand according to any one of the embodiment s 1 to Error! Reference source not found. is in the range from 80:20 to 20:80.

Embodiment 282

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein the ratio between between insulin and the zinc-binding ligand according to any one of the embodiment s 1 to Error! Reference source not found. is in the range from 70:30 to 30:70.

Embodiment 283

A pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found. wherein the concentration of insulin is 60 to 3000 nmol/ml.

Embodiment 284

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein the concentration of insulin is 240 to 1200 nmol/ml.

Embodiment 285

A pharmaceutical preparation according to embodiment Error! Reference source not found. wherein the concentration of insulin is about 600 nmol/ml.

Embodiment 286

A method of preparing a zinc-binding ligand according to embodiment 1 comprising the steps of

• • Identifying starter compounds that binds to the R-state His^B10—Zn²⁺ site
  • optionally attaching a fragment consisting of 0 to 5 neutral α- or β-amino acids
  • attaching a fragment comprising 1 to 20 positively charged groups independently selected from amino or guanidino groups.

Embodiment 287

Method of prolonging the action of an acid-stabilised insulin preparation which comprises adding a zinc-binding ligand according to any of embodiment s 1 to Error! Reference source not found. to the acid-stabilised insulin preparation.

Embodiment 288

A method of treating type 1 or type 2 diabetes comprising administering to a patient in need thereof a theraputically effective amount of a pharmaceutical preparation according to any one of the embodiment s 1 to Error! Reference source not found.

Embodiment 289

Use of a preparation according to any one of the embodiment s 1 to Error! Reference source not found. for the preparation of a medicament for treatment of type 1 or type 2 diabetes.

Pharmaceutical Preparations

The present invention also relates to a pharmaceutical preparation for the treatment of diabetes in a patient in need of such a treatment comprising an R-state hexamer of insulin according to the invention together with a pharmaceutically acceptable carrier.

In one embodiment of the invention the insulin preparation comprises 60 to 3000 nmol/ml of insulin.

In another embodiment of the invention the insulin preparation comprises 240 to 1200 nmol/ml of insulin.

In another embodiment of the invention the insulin preparation comprises about 600 nmol/ml of insulin.

Zinc ions may be present in an amount corresponding to 10 to 40 μg Zn/100 U insulin, more preferably 10 to 26 μg Zn/100 U insulin.

Insulin formulations of the invention are usually administered from multi-dose containers where a preservative effect is desired. Since phenolic preservatives also stabilize the R-state hexamer the formulations may contain up to 50 mM of phenolic molecules. The phenolic molecules in the insulin formulation may be selected from the group consisting of phenol, m-cresol, chloro-cresol, thymol, 7-hydroxyindole or any mixture thereof.

In one embodiment of the invention 0.5 to 4.0 mg/ml of phenolic compound may be employed.

In another embodiment of the invention 0.6 to 4.0 mg/ml of m-cresol may be employed.

In another embodiment of the invention 0.5 to 4.0 mg/ml of phenol may be employed.

In another embodiment of the invention 1.4 to 4.0 mg/ml of phenol may be employed.

In another embodiment of the invention 0.5 to 4.0 mg/ml of a mixture of m-cresol or phenol may be employed.

In another embodiment of the invention 1.4 to 4.0 mg/ml of a mixture of m-cresol or phenol may be employed.

The pharmaceutical preparation may further comprises a buffer substance, such as a TRIS, phosphate, glycine or glycylglycine (or another zwitterionic substance) buffer, an isotonicity agent, such as NaCl, glycerol, mannitol and/or lactose. Chloride would be used at moderate concentrations (e.g. up to 50 mM) to avoid competition with the zinc-site ligands of the present invention.

The action of insulin may further be slowed down in vivo by the addition of physiologically acceptable agents that increase the viscosity of the pharmaceutical preparation. Thus, the pharmaceutical preparation according to the invention may furthermore comprise an agent which increases the viscosity, such as polyethylene glycol, polypropylene glycol, copolymers thereof, dextrans and/or polylactides.

In a particular embodiment the insulin preparation of the invention comprises between 0.001% by weight and 1% by weight of a non-ionic surfactant, for example tween 20 or Polox 188.

A nonionic detergent can be added to stabilise insulin against fibrillation during storage and handling.

The insulin preparation of the present invention may have a pH value in the range of 2.5 to 4.5, more preferably pH 3 to 4.

In one embodiment the preparations of the invention are used in connection with insulin pumps. The insulin pumps may be prefilled and disposable, or the insulin preparations may be supplied from a reservoir which is removable. Insulin pumps may be skin-mounted or carried, and the path of the insulin preparation from the storage compartment of the pump to the patient may be more or less tortuous. Non-limiting examples of insulin pumps are disclosed in U.S. Pat. No. 5,957,895, U.S. Pat. No. 5,858,001, U.S. Pat. No. 4,468,221, U.S. Pat. No. 4,468,221, U.S. Pat. No. 5,957,895, U.S. Pat. No. 5,858,001, U.S. Pat. No. 6,074,369, U.S. Pat. No. 5,858,001, U.S. Pat. No. 5,527,288, and U.S. Pat. No. 6,074,369.

In another embodiment the preparations of the invention are used in connection with pen-like injection devices, which may be prefilled and disposable, or the insulin preparations may be supplied from a reservoir which is removable. Non-limiting examples of pen-like injection devices are FlexPen®, InnoLet®, InDuo™, Innovo®.

In a further embodiment preparations of the invention are used in connection with devices for pulmonary administration of aqueous insulin preparations, a non-limiting example of which is the AerX® device.

Combination Treatment

The invention furthermore relates to treatment of a patient in which the pharmaceutical preparation of the invention, i.e. comprising zinc ions, acid-stabilised insulin analogue and a ligand for the R-state His^B10 Zn²⁺ site, is combined with another form of treatment.

In one aspect of the invention, treatment of a patient with the pharmaceutical preparation of the invention is combined with diet and/or exercise.

In another aspect of the invention the pharmaceutical preparation of the invention is administered in combination with one or more further active substances in any suitable ratios.

Such further active substances may e.g. be selected from antiobesity agents, antidiabetics, antihypertensive agents, agents for the treatment of complications resulting from or associated with diabetes and agents for the treatment of complications and disorders resulting from or associated with obesity.

Thus, in a further aspect of the invention the pharmaceutical preparation of the invention may be administered in combination with one or more antiobesity agents or appetite regulating agents.

Such agents may be selected from the group consisting of CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) agonists, MC3 (melanocortin 3) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, β3 adrenergic agonists such as CL-316243, AJ-9677, GW-0604, LY362884, LY377267 or AZ-40140, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin re-uptake inhibitors such as fluoxetine, seroxat or citalopram, serotonin and noradrenaline re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone, growth factors such as prolactin or placental lactogen, growth hormone releasing compounds, TRH (thyreotropin releasing hormone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, PPAR (peroxisome proliferator-activated receptor) modulators, RXR (retinoid X receptor) modulators, TR βagonists, AGRP (Agouti related protein) inhibitors, H3 histamine antagonists, opioid antagonists (such as naltrexone), exendin-4, GLP-1 and ciliary neurotrophic factor.

In one embodiment of the invention the antiobesity agent is leptin.

In another embodiment the antiobesity agent is dexamphetamine or amphetamine.

In another embodiment the antiobesity agent is fenfluramine or dexfenfluramine.

In still another embodiment the antiobesity agent is sibutramine.

In a further embodiment the antiobesity agent is orlistat.

In another embodiment the antiobesity agent is mazindol or phentermine.

In still another embodiment the antiobesity agent is phendimetrazine, diethylpropion, fluoxetine, bupropion, topiramate or ecopipam.

The orally active hypoglycemic agents comprise imidazolines, sulphonylureas, biguanides, meglitinides, oxadiazolidinediones, thiazolidinediones, insulin sensitizers, insulin secretagogues such as glimepride, α-glucosidase inhibitors, agents acting on the ATP-dependent potassium channel of the β-cells eg potassium channel openers such as those disclosed in WO 97/26265, WO 99/03861 and WO 00/37474 (Novo Nordisk A/S) which are incorporated herein by reference, or mitiglinide, or a potassium channel blocker, such as BTS-67582, nateglinide, glucagon antagonists such as those disclosed in WO 99/01423 and WO 00/39088 (Novo Nordisk A/S and Agouron Pharmaceuticals, Inc.), which are incorporated herein by reference, GLP-1 agonists such as those disclosed in WO 00/42026 (Novo Nordisk A/S and Agouron Pharmaceuticals, Inc.), which are incorporated herein by reference, DPP-IV (dipeptidyl peptidase-IV) inhibitors, PTPase (protein tyrosine phosphatase) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenolysis, glucose uptake modulators, GSK-3 (glycogen synthase kinase-3) inhibitors, compounds modifying the lipid metabolism such as antilipidemic agents, compounds lowering food intake, PPAR (peroxisome proliferator-activated receptor) and RXR (retinoid X receptor) agonists, such as ALRT-268, LG-1268 or LG-1069.

In a further embodiment of the invention the pharmaceutical preparation of the invention is administered in combination with a sulphonylurea e.g. tolbutamide, chlorpropamide, tolazamide, glibenclamide, glipizide, glimepiride, glicazide or glyburide.

In another embodiment of the invention the pharmaceutical preparation of the invention is administered in combination with a biguanide, e.g. metformin.

In yet another embodiment of the invention the pharmaceutical preparation of the invention is administered in combination with a meglitinide eg repaglinide or nateglinide.

In still another embodiment of the invention the pharmaceutical preparation of the invention is administered in combination with a thiazolidinedione insulin sensitizer, e.g. troglitazone, ciglitazone, pioglitazone, rosiglitazone, isaglitazone, darglitazone, englitazone, CS-011/CI-1037 or T 174 or the compounds disclosed in WO 97/41097, WO 97/41119, WO 97/41120, WO 00/41121 and WO 98/45292 (Dr. Reddy's Research Foundation), which are incorporated herein by reference.

In still another embodiment of the invention the pharmaceutical preparation of the invention may be administered in combination with an insulin sensitizer, e.g. such as GI 262570, YM-440, MCC-555, JTT-501, AR-H039242, KRP-297, GW-409544, CRE-16336, AR-H049020, LY510929, MBX-102, CLX-0940, GW-501516 or the compounds disclosed in WO 99/19313, WO 00/50414, WO 00/63191, WO 00/63192, WO 00/63193 (Dr. Reddy's Research Foundation) and WO 00/23425, WO 00/23415, WO 00/23451, WO 00/23445, WO 00/23417, WO 00/23416, WO 00/63153, WO 00/63196, WO 00/63209, WO 00/63190 and WO 00/63189 (Novo Nordisk A/S), which are incorporated herein by reference.

In a further embodiment of the invention the pharmaceutical preparation of the invention is administered in combination with an α-glucosidase inhibitor, e.g. voglibose, emiglitate, miglitol or acarbose.

In another embodiment of the invention the pharmaceutical preparation of the invention is administered in combination with an agent acting on the ATP-dependent potassium channel of the β-cells, e.g. tolbutamide, glibenclamide, glipizide, glicazide, BTS-67582 or repaglinide.

In yet another embodiment of the invention the pharmaceutical preparation of the invention may be administered in combination with nateglinide.

In still another embodiment of the invention the pharmaceutical preparation of the invention is administered in combination with an antilipidemic agent, e.g. cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.

In another aspect of the invention, the pharmaceutical preparation of the invention is administered in combination with more than one of the above-mentioned compounds, e.g. in combination with metformin and a sulphonylurea such as glyburide; a sulphonylurea and acarbose; nateglinide and metformin; acarbose and metformin; a sulphonylurea, metformin and troglitazone; metformin and a sulphonylurea; etc.

Furthermore, the pharmaceutical preparation of the invention may be administered in combination with one or more antihypertensive agents. Examples of antihypertensive agents are β-blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and α-blockers such as doxazosin, urapidil, prazosin and terazosin. The pharmaceutical preparation of the invention may also be combined with NEP inhibitors such as candoxatril.

Further reference can be made to Remington: The Science and Practice of Pharmacy, 19^th Edition, Gennaro, Ed., Mack Publishing Co., Easton, Pa., 1995.

It should be understood that any suitable combination of the compounds according to the invention with diet and/or exercise, one or more of the above-mentioned compounds and optionally one or more other active substances are considered to be within the scope of the present invention.

EXAMPLES

The following examples and general procedures refer to intermediate compounds and final products identified in the specification and in the synthesis schemes. The preparation of the compounds of the present invention is described in detail using the following examples, but the chemical reactions described are disclosed in terms of their general applicability to the preparation of compounds of the invention. Occasionally, the reaction may not be applicable as described to each compound included within the disclosed scope of the invention. The compounds for which this occurs will be readily recognised by those skilled in the art. In these cases the reactions can be successfully performed by conventional modifications known to those skilled in the art, that is, by appropriate protection of interfering groups, by changing to other conventional reagents, or by routine modification of reaction conditions. Alternatively, other reactions disclosed herein or otherwise conventional will be applicable to the preparation of the corresponding compounds of the invention. In all preparative methods, all starting materials are known or may easily be prepared from known starting materials. All temperatures are set forth in degrees Celsius and unless otherwise indicated, all parts and percentages are by weight when referring to yields and all parts are by volume when referring to solvents and eluents.

HPLC-MS (Method A)

The following instrumentation was used:

• • Hewlett Packard series 1100 G1312A Bin Pump
  • Hewlett Packard series 1100 Column compartment
  • Hewlett Packard series 1100 G13 15A DAD diode array detector
  • Hewlett Packard series 1100 MSD

The instrument was controlled by HP Chemstation software.

The HPLC pump was connected to two eluent reservoirs containing:

A: 0.01% TFA in water
B: 0.01% TFA in acetonitrile

The analysis was performed at 40° C. by injecting an appropriate volume of the sample (preferably 1 μL) onto the column, which was eluted with a gradient of acetonitrile. The HPLC conditions, detector settings and mass spectrometer settings used are given in the following table.

Column    Waters Xterra MS C-18 × 3 mm id
Gradient  10%-100% acetonitrile lineary during 7.5 min at 1.0 mL/min
Detection UV: 210 nm (analog output from DAD)
MS        lonisation mode: API-ES
          Scan 100-1000 amu step 0.1 amu

HPLC-MS (Method B)

The following instrumentation was used:

• Sciex API 100 Single quadropole mass spectrometer
• Perkin Elmer Series 200 Quard pump
• Perkin Elmer Series 200 autosampler
• Applied Biosystems 785A UV detector
• Sedex 55 evaporative light scattering detector A Valco column switch with a Valco actuator controlled by timed events from the pump.

The Sciex Sample control software running on a Macintosh PowerPC 7200 computer was used for the instrument control and data acquisition.

The HPLC pump was connected to four eluent reservoirs containing:

A: Acetonitrile
B: Water
C: 0.5% TFA in water
D: 0.02 M ammonium acetate

The requirements for samples are that they contain approximately 500 μg/mL of the compound to be analysed in an acceptable solvent such as methanol, ethanol, acetonitrile, THF, water and mixtures thereof. (High concentrations of strongly eluting solvents will interfere with the chromatography at low acetonitrile concentrations.) The analysis was performed at room temperature by injecting 20 μL of the sample solution on the column, which was eluted with a gradient of acetonitrile in either 0.05% TFA or 0.002 M ammonium acetate. Depending on the analysis method varying elution conditions were used.

The eluate from the column was passed through a flow splitting T-connector, which passed approximately 20 μL/min through approx. 1 m. 75μ fused silica capillary to the API interface of API 100 spectrometer.

The remaining 1.48 mL/min was passed through the UV detector and to the ELS detector.

During the LC-analysis the detection data were acquired concurrently from the mass spectrometer, the UV detector and the ELS detector.

The LC conditions, detector settings and mass spectrometer settings used for the different methods are given in the following table.

Column	YMC ODS-A 120 Ås − 5μ 3 mm × 50 mm id
Gradient	5%-90% acetonitrile in 0.05% TFA linearly during 7.5 min
	at 1.5 mL/min
Detection	UV: 214 nm	ELS: 40° C.
MS	Experiment:  Start: 100 amu  Stop: 800 amu  Step:
	0.2 amu
	Dwell: 0.571 msec
	Method: Scan 284 times = 9.5 min

HPLC-MS (Method C) The following instrumentation is used:

• • Hewlett Packard series 1100 G1312A Bin Pump
  • Hewlett Packard series 1100 Column compartment
  • Hewlett Packard series 1100 G1315A DAD diode array detector
  • Hewlett Packard series 1100 MSD
  • Sedere 75 Evaporative Light Scattering detector

The instrument is controlled by HP Chemstation software.

The HPLC pump is connected to two eluent reservoirs containing:

A 0.01% TFA in water
B 0.01% TFA in acetonitrile

The analysis is performed at 40° C. by injecting an appropriate volume of the sample (preferably 1 μl) onto the column which is eluted with a gradient of acetonitrile.

The HPLC conditions, detector settings and mass spectrometer settings used are given in the following table.

Column    Waters Xterra MS C-18 × 3 mm id 5 μm
Gradient  5%-100% acetonitrile linear during 7.5 min at 1.5 ml/min
Detection 210 nm (analogue output from DAD)
          ELS (analogue output from ELS)
MS        ionisation mode API-ES
          Scan 100-1000 amu step 0.1 amu

After the DAD the flow is divided yielding approximately 1 ml/min to the ELS and 0.5 ml/min to the MS.

HPLC-MS (Method D)

The following instrumentation was used:

• Sciex API 150 Single Quadropole mass spectrometer
• Hewlett Packard Series 1100 G1312A Bin pump
• Gilson 215 micro injector
• Hewlett Packard Series 1100 G1315A DAD diode array detector
• Sedex 55 evaporative light scattering detector

A Valco column switch with a Valco actuator controlled by timed events from the pump.

The Sciex Sample control software running on a Macintosh Power G3 computer was used for the instrument control and data acquisition.

The HPLC pump was connected to two eluent reservoirs containing:

A: Acetonitrile containing 0.05% TFA
B: Water containing 0.05% TFA

The requirements for the samples are that they contain approximately 500 μg/ml of the compound to be analysed in an acceptable solvent such as methanol, ethanol, acetonitrile, THF, water and mixtures thereof. (High concentrations of strongly eluting solvents will interfere with the chromatography at low acetonitrile concentrations.)

The analysis was performed at room temperature by injecting 20 μl of the sample solution on the column, which was eluted with a gradient of acetonitrile in 0.05% TFA

The eluate from the column was passed through a flow splitting T-connector, which passed approximately 20 μl/min through approx. 1 m 75μ fused silica capillary to the API interface of API 150 spectrometer.

The remaining 1.48 ml/min was passed through the UV detector and to the ELS detector.

During the LC-analysis the detection data were acquired concurrently from the mass spectrometer, the UV detector and the ELS detector.

The LC conditions, detector settings and mass spectrometer settings used for the different methods are given in the following table.

Column	Waters X-terra C18 5μ 3 mm × 50 mm id
Gradient	5%-90% acetonitrile in 0.05% TFA linearly during 7.5 min at
	1.5 ml/min
Detection	UV: 214 nm	ELS: 40° C.
MS	Experiment:  Start: 100 amu  Stop: 800 amu  Step:
	0.2 amu
	Dwell: 0.571 msec
	Method: Scan 284 times = 9.5 min

Examples

0102-0000-0273Example 1 HBOL

1H-Benzotriazole

0102-0000-0274Example 2 HBOL

5,6-Dimethyl-1H-benzotriazole

0102-0000-0275Example 3 HBOL

1H-Benzotriazole-5-carboxylic acid

0102-0000-0280Example 4 HBOL

4-Nitro-1H-benzotriazole

0102-0000-0284Example 5 HBOL

5-Amino-1H-benzotriazole

0102-0000-0287Example 6 HBOL

5-Chloro-1H-benzotriazole

0102-0000-0286Example 7 HBOL

5-Nitro-1H-benzotriazole

0102-0000-3015Example 8 PEM

4-[(1H-Benzotriazole-5-carbonyl)amino]benzoic acid

4-[(1H-Benzotriazole-5-carbonyl)amino]benzoic acid methyl ester (5.2 g, 17.6 mmol) was dissolved in THF (60 mL) and methanol (10 mL) was added followed by 1N sodium hydroxide (35 mL). The mixture was stirred at room temperature for 16 hours and then 1N hydrochloric acid (45 mL) was added. The mixture was added water (200 mL) and extracted with ethyl acetate (2×500 mL). The combined organic phases were evaporated in vacuo to afford 0.44 g of 4-[(1H-benzotriazole-5-carbonyl)amino]benzoic acid. By filtration of the aqueous phase a further crop of 4-[(1H-benzotriazole-5-carbonyl)amino]benzoic acid was isolated (0.52 g).

¹H-NMR (DMSO-d₆): δ 7.97 (4H, s), 8.03 (2H, m), 8.66 (1H, bs), 10.7 (1H, s), 12.6 (1H, bs); HPLC-MS (Method A): m/z: 283 (M+1); Rt=1.85 min.

General procedure (A) for preparation of compounds of general formula I₁: wherein D, E and R¹⁹ are as defined above, and E is optionally substituted with up to three substituents R²¹, R²² and R²³ independently as defined above.

The carboxylic acid of 1H-benzotriazole-5-carboxylic acid is activated, ie the OH functionality is converted into a leaving group L (selected from eg fluorine, chlorine, bromine, iodine, 1-imidazolyl, 1,2,4-triazolyl, 1-benzotriazolyloxy, 1-(4-aza benzotriazolyl)oxy, pentafluorophenoxy, N-succinyloxy 3,4-dihydro-4-oxo-3-(1,2,3-benzotriazinyl)oxy, benzotriazole 5-COO, or any other leaving group known to act as a leaving group in acylation reactions. The activated benzotriazole-5-carboxylic acid is then reacted with R²—(CH₂)_n-B′ in the presence of a base. The base can be either absent (i.e. R²—(CH₂)_n-B′ acts as a base) or triethylamine, N-ethyl-N,N.-diisopropylamine, N-methylmorpholine, 2,6-lutidine, 2,2,6,6-tetramethylpiperidine, potassium carbonate, sodium carbonate, caesium carbonate or any other base known to be useful in acylation reactions. The reaction is performed in a solvent solvent such as THF, dioxane, toluene, dichloromethane, DMF, NMP or a mixture of two or more of these. The reaction is performed between 0° C. and 80° C., preferably between 20° C. and 40° C. When the acylation is complete, the product is isolated by extraction, filtration, chromatography or other methods known to those skilled in the art.

The general procedure (A) is further illustrated in the following example:

0102-0000-1020Example 9 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid phenylamide

Benzotriazole-5-carboxylic acid (856 mg), HOAt (715 mg) and EDAC (1.00 g) were dissolved in DMF (17.5 mL) and the mixture was stirred at room temperature 1 hour. A 0.5 mL aliqot of this mixture was added to aniline (13.7 μL, 0.15 mmol) and the resulting mixture was vigorously shaken at room temperature for 16 hours. 1N hydrochloric acid (2 mL) and ethyl acetate (1 mL) were added and the mixture was vigorously shaken at room temperature for 2 hours. The organic phase was isolated and concentrated in vacuo to afford the title compound.

HPLC-MS (Method B): m/z: 239 (M+1); Rt=3.93 min.

The compounds in the following examples were similarly made. Optionally, the compounds may be isolated by filtration or by chromatography.

0102-0000-1019Example 10 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid (4-methoxyphenyl)amide

HPLC-MS (Method A): m/z: 269 (M+1) & 291 (M+23); Rt=2.41 min

HPLC-MS (Method B): m/z: 239 (M+1); Rt=3.93 min.

0102-0000-1021 Example 11 (General Procedure (A))PEM

{4-[(1H-Benzotriazole-5-carbonyl)amino]phenyl}carbamic acid tert-butyl ester

HPLC-MS (Method B): m/z: 354 (M+1); Rt=4.58 min.

0102-0000-1022Example 12 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid (4-acetylaminophenyl)amide

HPLC-MS (Method B): m/z: 296 (M+1); Rt=3.32 min.

0102-0000-1023Example 13 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid (3-fluorophenyl)amide

HPLC-MS (Method B): m/z: 257 (M+1); Rt=4.33 min.

0102-0000-1024Example 14 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid (2-chlorophenyl)amide

HPLC-MS (Method B): m/z: 273 (M+1); Rt=4.18 min.

0102-0000-1025Example 15 (General Procedure (A))PEM

4-[(1H-Benzotriazole-5-carbonyl)amino]benzoic acid methyl ester

HPLC-MS (Method A):m/z: 297 (M+1); Rt: 2,60 min. HPLC-MS (Method B): m/z: 297 (M+1);

Rt=4.30 min.

0102-0000-1026Example 16 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid (4-butylphenyl)amide

HPLC-MS (Method B): m/z: 295 (M+1); Rt=5.80 min.

0102-0000-1027Example 17 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid (1-phenylethyl)amide

HPLC-MS (Method B): m/z: 267 (M+1); Rt=4.08 min.

0102-0000-1028Example 18 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid benzylamide

HPLC-MS (Method B): m/z: 253 (M+1); Rt=3.88 min.

0102-0000-1029Example 19 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid 4-chlorobenzylamide

HPLC-MS (Method B): m/z: 287 (M+1); Rt=4.40 min.

0102-0000-1030Example 20 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid 2-chlorobenzylamide

HPLC-MS (Method B): m/z: 287 (M+1); Rt=4.25 min.

0102-0000-1031 Example 21 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid 4-methoxybenzylamide

HPLC-MS (Method B): m/z: 283 (M+1); Rt=3.93 min.

0102-0000-1032Example 22 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid 3-methoxybenzylamide

HPLC-MS (Method B): m/z: 283 (M+1); Rt=3.97 min.

0102-0000-1033Example 23 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid (1,2-diphenylethyl)amide

HPLC-MS (Method B): m/z: 343 (M+1); Rt=5.05 min.

0102-0000-1034Example 24 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid 3-bromobenzylamide

HPLC-MS (Method B): m/z: 331 (M+1); Rt=4.45 min.

0102-0000-1035Example 25 (General Procedure (A))PEM

4-{[(1H-Benzotriazole-5-carbonyl)amino]methyl}benzoic acid

HPLC-MS (Method B): m/z: 297 (M+1); Rt=3.35 min.

0102-0000-1036Example 26 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid phenethylamide

HPLC-MS (Method B): m/z: 267 (M+1); Rt=4.08 min.

0102-0000-1037Example 27 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid [2-(4-chlorophenyl)ethyl]amide

HPLC-MS (Method B): m/z: 301 (M+1); Rt=4.50 min.

0102-0000-1038Example 28 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid [2-(4-methoxyphenyl)ethyl]amide

HPLC-MS (Method B): m/z: 297 (M+1); Rt=4.15 min.

0102-0000-1039Example 29 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid [2-(3-methoxyphenyl)ethyl]amide

HPLC-MS (Method B): m/z: 297 (M+1); Rt=4.13 min.

0102-0000-1040Example 30 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid [2-(3-chlorophenyl)ethyl]amide

HPLC-MS (Method B): m/z: 301 (M+1); Rt=4.55 min.

0102-0000-1041 Example 31 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid (2,2-diphenylethyl)amide

HPLC-MS (Method B): m/z: 343 (M+1); Rt=5.00 min.

0102-0000-1042Example 32 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid (3,4-dichlorophenyl)methylamide

HPLC-MS (Method B): m/z: 321 (M+1); Rt=4.67 min.

0102-0000-1043Example 33 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid methylphenylamide

HPLC-MS (Method B): m/z: 253 (M+1); Rt=3.82 min.

0102-0000-1044Example 34 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid benzylmethylamide

HPLC-MS (Method B): m/z: 267 (M+1); Rt=4.05 min.

0102-0000-1045Example 35 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid [2-(3-chloro-4-methoxyphenyl)ethyl]methyl-amide

HPLC-MS (Method B): m/z: 345 (M+1); Rt=4.37 min.

0102-0000-1046Example 36 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid methylphenethylamide

HPLC-MS (Method B): m/z: 281 (M+1); Rt=4.15 min.

0102-0000-1047Example 37 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid [2-(3,4-dimethoxyphenyl)ethyl]methyla mide

HPLC-MS (Method B): m/z: 341 (M+1); Rt=3.78 min;

0102-0000-1048Example 38 (General Procedure (A))PEM

1H-Benzotriazole-5-carboxylic acid (2-hydroxy-2-phenylethyl)methylamide

HPLC-MS (Method B): m/z: 297 (M+1); Rt=3.48 min.

Example 39 (General Procedure (A))

1H-Benzotriazole-5-carboxylic acid (3-bromophenyl)amide

HPLC-MS (Method A): m/z: 317 (M+1); Rt=3.19 min.

Example 40 (General Procedure (A))

1H-Benzotriazole-5-carboxylic acid (4-bromophenyl)amide

HPLC-MS (Method A): m/z: 317 (M+1); Rt=3.18 min.

Example 41 (General Procedure (A))

{4-[(1H-Benzotriazole-5-carbonyl)amino]benzoylamino}acetic acid

HPLC-MS (Method A): m/z: 340 (M+1); Rt=1.71 min.

Example 42 (General Procedure (A))

{4-[(1H-Benzotriazole-5-carbonyl)amino]phenyl}acetic acid

HPLC-MS (Method A): m/z: 297 (M+1); Rt=2.02 min.

Example 43 (General Procedure (A))

3-{4-[(1H-Benzotriazole-5-carbonyl)amino]phenyl}acrylic acid

HPLC-MS (Method A): m/z: 309 (M+1); Rt=3.19 min.

Example 44 (General Procedure (A))

{3-[(1H-Benzotriazole-5-carbonyl)amino]phenyl}acetic acid

HPLC-MS (Method A): m/z: 297 (M+1); Rt=2.10 min.

Example 45 (General Procedure (A))

2-{4-[(1H-Benzotriazole-5-carbonyl)amino]phenoxy}-2-methylpropionic acid

HPLC-MS (Method A): m/z: 341 (M+1); Rt=2.42 min.

Example 46 (General Procedure (A))

3-{4-[(1H-Benzotriazole-5-carbonyl)amino]benzoylamino}propionic acid

HPLC-MS (Method A): m/z: 354 (M+1); Rt=1.78 min.

Example 47 (General Procedure (A))

3-{4-[(1H-Benzotriazole-5-carbonyl)amino]phenyl}propionic acid

HPLC-MS (Method A): m/z: 311 (M+1); Rt=2.20 min.

Example 48 (General Procedure (A))

1H-Benzotriazole-5-carboxylic acid (4-benzyloxyphenyl)amide

HPLC-MS (Method A): m/z: 345 (M+1); Rt=3.60 min.

Example 49 (General Procedure (A))

1H-Benzotriazole-5-carboxylic acid (3-chloro-4-methoxyphenyl)amide

HPLC-MS (Method A): m/z: 303 (M+1); Rt=2.88 min.

Example 50 (General Procedure (A))

1H-Benzotriazole-5-carboxylic acid (4-phenoxyphenyl)amide

HPLC-MS (Method A): m/z: 331 (M+1); Rt=3.62 min.

Example 51 (General Procedure (A))

1H-Benzotriazole-5-carboxylic acid (4-butoxyphenyl)amide

HPLC-MS (Method A): m/z: 311 (M+1); Rt=3.59 min.

Example 52 (General Procedure (A))

1H-Benzotriazole-5-carboxylic acid (3-bromo-4-trifluoromethoxyphenyl)amide

HPLC-MS (Method A): m/z: 402 (M+1); Rt=3.93 min.

Example 53 (General Procedure (A))

1H-Benzotriazole-5-carboxylic acid (3,5-dichloro-4-hydroxyphenyl)amide

HPLC-MS (Method A): m/z: 323 (M+1); Rt=2.57 min.

Example 54 (General Procedure (A))

4-{[(1H-Benzotriazole-5-carbonyl)amino]methyl}benzoic acid

HPLC-MS (Method A): m/z: 297 (M+1); Rt=1.86 min.

Example 55 (General Procedure (A))

{4-[(1H-Benzotriazole-5-carbonyl)amino]phenylsulfanyl}acetic acid

HPLC-MS (Method A): m/z: 329 (M+1); Rt=2.34 min.

Example 56

N-(1H-Benzotriazol-5-yl)acetamide

HPLC-MS (Method A): m/z: 177 (M+1); Rt=0.84 min.

Example 57 (General Procedure (A))

1H-Benzotriazole-5-carboxylic acid 4-nitrobenzylamide

The following compound is prepared according to general procedure (N) as described below:

Example 58 (General Procedure (N))

1H-Benzotriazole-5-carboxylic acid 4-chlorobenzylamide

HPLC-MS (Method B): m/z: 287 (M+1); Rt=4.40 min.

Example 59

2-[(1H-Benzotriazol-5-ylimino)methyl]-4,6-dichlorophenol

Example 60

Diethyl 2-[(1H-benzotriazol-6-ylamino)methylidene]malonate

Example 61

N1-(1H-Benzotriazol-5-yl)-3-chlorobenzamide

Example 62

N1-(1H-Benzotriazol-5-yl)-3,4,5-trimethoxybenzamide

Example 63

N2-(1H-Benzotriazol-5-yl)-3-chlorobenzo[b]thiophene-2-carboxamide

Example 64

6-Bromo-1H-benzotriazole

Example 65

2-[(1H-Benzotriazol-5-ylimino)methyl]-4-bromophenol

General procedure (B) for preparation of compounds of general formula I₂: wherein X, Y, A and R³ are as defined above and A is optionally substituted with up to four substituents R⁷, R⁸, R⁹, and R¹⁰ as defined above.

The chemistry is well known (eg Lohray et al., J. Med. Chem., 1999, 42, 2569-81) and is generally performed by reacting a carbonyl compound (aldehyde or ketone) with the heterocyclic ring (eg thiazolidine-2,4-dione (X=O; Y=S), rhodanine (X═Y═S) and hydantoin (X=O; Y=NH) in the presence of a base, such as sodium acetate, potassium acetate, ammonium acetate, piperidinium benzoate or an amine (eg piperidine, triethylamine and the like) in a solvent (eg acetic acid, ethanol, methanol, DMSO, DMF, NMP, toluene, benzene) or in a mixture of two or more of these solvents. The reaction is performed at room temperature or at elevated temperature, most often at or near the boiling point of the mixture. Optionally, azeotropic removal of the formed water can be done.

This general procedure (B) is further illustrated in the following example:

Example 66 (General Procedure (B))

5-(3-Phenoxybenzylidene)thiazolidine-2,4-dione

A solution of thiazolidine-2,4-dione (90%, 78 mg, 0.6 mmol) and ammonium acetate (92 mg, 1.2 mmol) in acetic acid (1 mL) was added to 3-phenoxybenzaldehyde (52 μL, 0.6 mmol) and the resulting mixture was shaken at 115° C. for 16 hours. After cooling, the mixture was concentrated in vacuo to afford the title compound.

HPLC-MS (Method A): m/z: 298 (M+1); Rt=4.54 min.

The compounds in the following examples were similarly prepared. Optionally, the compounds can be further purified by filtration and washing with water, ethanol and/or heptane instead of concentration in vacuo. Also optionally the compounds can be purified by washing with ethanol, water and/or heptane, or by chromatography, such as preparative HPLC.

Example 67 (General Procedure (B))

5-(4-Dimethylaminobenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 249 (M+1); Rt=4.90 min

Example 68 (General Procedure (B))

5-Naphthalen-1-ylmethylenethiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 256 (M+1); Rt=4,16 min.

Example 69 (General Procedure (B))

5-Benzylidene-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 206 (M+1); Rt=4,87 min.

Example 70 (General Procedure (B))

5-(4-Diethylaminobenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 277 (M+1); Rt=4.73 min.

Example 71 (General Procedure (B))

5-(4-Methoxy-benzylidene)-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 263 (M+1); Rt=4,90 min.

Example 72 (General Procedure (B))

5-(4-Chloro-benzylidene)-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 240 (M+1); Rt=5,53 min.

Example 73 (General Procedure (B))

5-(4-Nitro-benzylidene)-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 251 (M+1); Rt=4,87 min.

Example 74 (General Procedure (B))

5-(4-Hydroxy-3-methoxy-benzylidene)-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 252 (M+1); Rt=4,07 min.

Example 75 (General Procedure (B))

5-(4-Methylsulfanylbenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 252 (M+1); Rt=5,43 min.

Example 76 (General Procedure (B))

5-(2-Pentyloxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 292 (M+1); Rt=4.75 min.

¹H NMR (DMSO-d₆): δ=0.90 (3H, t), 1.39 (4H, m), 1.77 (2H, p), 4.08 (2H, t), 7.08 (1H, t), 7.14 (1H, d), 7.43 (2H, m), 8.03 (1H, s), 12.6 (1H, bs).

Example 77 (General Procedure (B))

5-(3-Fluoro-4-methoxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 354 (M+1); Rt=4,97 min.

Example 78 (General Procedure (B))

5-(4-tert-Butylbenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 262 (M+1); Rt=6,70 min.

Example 79 (General Procedure (B))

N-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenyl]acetamide

HPLC-MS (Method A): m/z: 263 (M+1); Rt=3,90 min.

Example 80 (General Procedure (B))

5-Biphenyl-4-ylmethylene-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 282 (M+1); Rt=4,52 min.

Example 81 (General Procedure (B))

5-(4-Phenoxy-benzylidene)-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 298 (M+1); Rt=6,50 min.

Example 82 (General Procedure (B))

5-(3-Benzyloxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 312 (M+1); Rt=6,37 min.

Example 83 (General Procedure (B))

5-(3-p-Tolyloxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 312 (M+1); Rt=6,87 min.

Example 84 (General Procedure (B))

5-Naphthalen-2-ylmethylene-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 256 (M+1); Rt=4.15 min.

Example 85 (General Procedure (B))

5-Benzo[1,3]dioxol-5-ylmethylenethiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 250 (M+1), Rt=3.18 min.

Example 86 (General Procedure (B))

5-(4-Chlorobenzylidene)-2-thioxothiazolidin-4-one

HPLC-MS (Method A): m/z: 256 (M+1); Rt=4,51 min.

Example 87 (General Procedure (B))

5-(4-Dimethylaminobenzylidene)-2-thioxothiazolidin-4-one

HPLC-MS (Method A): m/z: 265 (M+1); Rt=5,66 min.

Example 88 (General Procedure (B))

5-(4-Nitrobenzylidene)-2-thioxothiazolidin-4-one

HPLC-MS (Method A): m/z: 267 (M+1); Rt=3,94 min.

Example 89 (General Procedure (B))

5-(4-Methylsulfanylbenzylidene)-2-thioxothiazolidin-4-one

HPLC-MS (Method A): m/z: 268 (M+1); Rt=6,39 min.

Example 90 (General Procedure (B))

5-(3-Fluoro-4-methoxybenzylidene)-2-thioxothiazolidin-4-one

HPLC-MS (Method A): m/z: 270 (M+1); Rt=5,52 min.

Example 91 (General Procedure (B))

5-Naphthalen-2-ylmethylene-2-thioxothiazolidin-4-one

HPLC-MS (Method A): m/z: 272 (M+1); Rt=6,75 min.

Example 92 (General Procedure (B))

5-(4-Diethylaminobenzylidene)-2-thioxothiazolidin-4-one

HPLC-MS (Method A): m/z: 293 (M+1); Rt=5,99 min.

Example 93 (General Procedure (B))

5-Biphenyl-4-ylmethylene-2-thioxothiazolidin-4-one

HPLC-MS (Method A): m/z: 298 (M+1); Rt=7,03 min.

Example 94 (General Procedure (B))

5-(3-Phenoxybenzylidene)-2-thioxothiazolidin-4-one

HPLC-MS (Method A): m/z: 314 (M+1); Rt=6,89 min.

Example 95 (General Procedure (B))

5-(3-Benzyloxybenzylidene)-2-thioxothiazolidin-4-one

HPLC-MS (Method A): m/z: 328 (M+1); Rt=6,95 min.

Example 96 (General Procedure (B))

5-(4-Benzyloxybenzylidene)-2-thioxothiazolidin-4-one

HPLC-MS (Method A): m/z: 328 (M+1); RT=6,89 min.

Example 97 (General Procedure (B))

5-Naphthalen-1-ylmethylene-2-thioxothiazolidin-4-one

HPLC-MS (Method A): m/z: 272 (M+1); Rt=6,43 min.

Example 98 (General Procedure (B))

5-(3-Methoxybenzyl)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 236 (M+1); Rt=3,05 min.

Example 99 (General Procedure (D))

4-[2-Chloro-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]butyric acid ethyl ester

HPLC-MS (Method A): m/z: 392 (M+23), Rt=4.32 min.

Example 100 (General Procedure (D))

4-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)-phenoxy]-butyric acid

HPLC-MS (Method A): m/z: 410 (M+23); Rt=3,35 min.

Example 101 (General Procedure (B))

5-(3-Bromobenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 285 (M+1); Rt=4.01 min.

Example 102 (General Procedure (B))

5-(4-Bromobenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 285 (M+1); Rt=4.05 min.

Example 103 (General Procedure (B))

5-(3-Chlorobenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 240 (M+1); Rt=3.91 min.

Example 104 (General Procedure (B))

5-Thiophen-2-ylmethylenethiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 212 (M+1); Rt=3.09 min.

Example 105 (General Procedure (B))

5-(4-Bromothiophen-2-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 291 (M+1); Rt=3.85 min.

Example 106 (General Procedure (B))

5-(3,5-Dichlorobenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 274 (M+1); Rt=4.52 min.

Example 107 (General Procedure (B))

5-(1-Methyl-1H-indol-3-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 259 (M+1); Rt=3.55 min.

Example 108 (General Procedure (B))

5-(1H-Indol-3-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 245 (M+1); Rt=2.73 min.

Example 109 (General Procedure (B))

5-Fluoren-9-ylidenethiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 280 (M+1); Rt=4.34 min.

Example 110 (General Procedure (B))

5-(1-Phenylethylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 220 (M+1); Rt=3,38 min.

Example 111 (General Procedure (B))

5-[1-(4-Methoxyphenyl)-ethylidene]-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 250 (M+1); Rt=3.55 min.

Example 112 (General Procedure (B))

5-(1-Naphthalen-2-yl-ethylidene)-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 270 (M+1); Rt=4,30 min.

Example 113 (General Procedure (B))

5-[1-(4-Bromophenyl)-ethylidene]-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 300 (M+1); Rt=4,18 min.

Example 114 (General Procedure (B))

5-(2,2-Diphenylethylidene)-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 296 (M+1); Rt=4,49 min.

Example 115 (General Procedure (B))

5-[1-(3-Methoxyphenyl)-ethylidene]-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 250 (M+1); Rt=3,60 min.

Example 116 (General Procedure (B))

5-[1-(6-Methoxynaphthalen-2-yl)-ethylidene]-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 300 (M+1); Rt=4,26 min.

Example 117 (General Procedure (B))

5-[1-(4-Phenoxyphenyl)-ethylidene]-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 312 (M+1); Rt=4,68 min.

Example 118 (General Procedure (B))

5-[1-(3-Fluoro-4-methoxyphenyl)ethylidene]thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 268 (M+1); Rt=3,58 min.

Example 119 (General Procedure (B))

5-[1-(3-Bromophenyl)-ethylidene]-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 300 (M+1); Rt=4,13 min.

Example 120 (General Procedure (B))

5-Anthracen-9-ylmethylenethiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 306 (M+1); Rt=4,64 min.

Example 121 (General Procedure (B))

5-(2-Methoxynaphthalen-1-ylmethylene)-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 286 (M+1); Rt=4,02 min.

Example 122 (General Procedure (B))

5-(4-Methoxynaphthalen-1-ylmethylene)-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 286 (M+1); Rt=4,31 min.

Example 123 (General Procedure (B))

5-(4-Dimethylaminonaphthalen-1-ylmethylene)-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 299 (M+1); Rt=4,22 min.

Example 124 (General Procedure (B))

5-(4-Methylnaphthalen-1-ylmethylene)-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 270 (M+1); Rt=4,47 min.

Example 125 (General Procedure (B))

5-Pyridin-2-ylmethylene-thiazolidine-2,4-dione

Example 126

5-Pyridin-2-ylmethyl-thiazolidine-2,4-dione

5-Pyridin-2-ylmethylene-thiazolidine-2,4-dione (5 g) in tetrahydrofuran (300 ml) was added 10% Pd/C (1 g) and the mixture was hydrogenated at ambient pressure for 16 hours. More 10% Pd/C (5 g) was added and the mixture was hydrogenated at 50 psi for 16 hours. After filtration and evaporation in vacuo, the residue was purified by column chromatography eluting with a mixture of ethyl acetate and heptane (1:1). This afforded the title compound (0.8 g, 16%) as a solid.

TLC: R_f=0.30 (SiO₂; EtOAc: heptane 1:1)

Example 127 (General Procedure (B))

5-(1H-Imidazol-4-ylmethylene)-thiazolidine-2,4-dione

Example 128 (General Procedure (B))

5-(4-Benzyloxy-benzylidene)-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 6,43 min; 99% (2A)

Example 129 (General Procedure (B))

5-[4-(4-Fluorobenzyloxy)benzylidenel-2-thioxothiazolidin-4-one

Example 130 (General Procedure (B))

5-(4-Butoxybenzylidene)-2-thioxothiazolidin-4-one

Example 131 (General Procedure (B))

5-(3-Methoxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 236 (M+1); Rt=4,97 min

Example 132 (General Procedure (B))

5-(3-Methoxybenzylidene)imidazolidine-2,4-dione

HPLC-MS (Method A): m/z: 219 (M+1); Rt=2.43 min.

Example 133 (General Procedure (B))

5-(4-Methoxybenzylidene)imidazolidine-2,4-dione

HPLC-MS (Method A): m/z: 219 (M+1); Rt=2.38 min.

Example 134 (General Procedure (B))

5-(2,3-Dichlorobenzylidene)thiazolidine-2,4-dione

Example 135 (General Procedure (B))

5-Benzofuran-7-ylmethylenethiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 247 (M+1); Rt=4,57 min.

Example 136 (General Procedure (B))

5-Benzo[1,3]dioxol-4-ylmethylenethiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 250 (M+1); Rt=4,00 min.

Example 137 (General Procedure (B))

5-(4-Methoxy-2,3-dimethylbenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 264 (M+1); Rt=5,05 min.

Example 138 (General Procedure (B))

5-(2-Benzyloxy-3-methoxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 342 (M+1); Rt=5,14 min.

Example 139 (General Procedure (B))

5-(2-Hydroxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 222 (M+1); Rt=3,67 min.

Example 140 (General Procedure (B))

5-(2,4-Dichlorobenzylidene)thiazolidine-2,4-dione

¹H-NMR (DMSO-d₆): 7.60 (2H, “s”), 7.78 (1H, s), 7.82 (1H, s).

Example 141 (General Procedure (B))

5-(2-Chlorobenzylidene)thiazolidine-2,4-dione

¹H-NMR (DMSO-d₆): 7.40 (1H, t), 7.46 (1H, t), 7.57 (1H, d), 7.62 (1H, d), 7.74 (1H, s).

Example 142 (General Procedure (B))

5-(2-Bromobenzylidene)thiazolidine-2,4-dione

¹H-NMR (DMSO-d₆): 7.33 (1H, t), 7.52 (1H, t), 7.60 (1H, d), 7.71 (1H, s), 7.77 (1H, d).

Example 143 (General Procedure (B))

5-(2,4-Dimethoxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 266 (M+1) Rt=4,40 min.

Example 144 (General Procedure (B))

5-(2-Methoxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 236 (M+1); Rt=4,17 min.

Example 145 (General Procedure (B))

5-(2,6-Difluorobenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 242 (M+1); Rt=4,30 min.

Example 146 (General Procedure (B))

5-(2,4-Dimethylbenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 234 (M+1); Rt=5,00 min.

Example 147 (General Procedure (B))

5-(2,4,6-Trimethoxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 296 (M+1); Rt=4,27 min.

Example 148 (General Procedure (B))

5-(4-Hydroxy-2-methoxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 252 (M+1); Rt=3,64 min.

Example 149 (General Procedure (B))

5-(4-Hydroxynaphthalen-1-ylmethylene)thiazolidine-2,4-dione

¹H-NMR (DMSO-d₆): δ=7.04 (1H, d), 7.57 (2H, m), 7.67 (1H, t), 8.11 (1H, d), 8.25 (1H, d), 8.39 (1H, s) 11.1 (1H, s), 12.5 (1H, bs). HPLC-MS (Method C): m/z: 272 (M+1); Rt=3.44 min.

Example 150 (General Procedure (B))

5-(2-Trifluoromethoxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 290 (M+1); Rt=4,94 min.

Example 151 (General Procedure (B))

5-Biphenyl-2-ylmethylenethiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 282 (M+1); Rt=5,17 min.

Example 152 (General Procedure (B))

5-(2-Benzyloxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 312 (M+1); Rt=5,40 min.

Example 153 (General Procedure (B))

5-Adamantan-2-ylidenethiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 250 (M+1); Rt=4,30 min.

Example 154 (General Procedure (B))

5-[3-(4-Nitrophenyl)allylidene]thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 277 (M+1); Rt=3.63 min.

Example 155 (General Procedure (B))

5-[3-(2-Methoxyphenyl)allylidene]thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 262 (M+1); Rt=3.81 min.

Example 156 (General Procedure (B))

5-[3-(4-Methoxyphenyl)allylidene]thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 262 (M+1); Rt=3.67 min.

Example 157 (General Procedure (B))

5-(4-Hydroxybenzylidene)thiazolidine-2,4-dione

Example 158 (General Procedure (B))

5-(4-Dimethylaminobenzylidene)pyrimidine-2,4,6-trione

HPLC-MS (Method C): m/z=260 (M+1) Rt=2,16 min.

Example 159 (General Procedure (B))

5-(9-Ethyl-9H-carbazol-2-ylmethylene)-pyrimidine-2,4,6-trione

HPLC-MS (Method C): m/z=334 (M+1); Rt=3,55 min.

Example 160 (General Procedure (B))

5-(4-Hexyloxynaphthalen-1-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=356 (M+1); Rt=5.75 min.

Example 161 (General Procedure (B))

5-(4-Decyloxynaphthalen-1-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=412 (M+1); Rt=6.44 min.

Example 162 (General Procedure (B))

5-[4-(2-Aminoethoxy)-naphthalen-1-ylmethylene]-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=315 (M+1); Rt=3,24 min.

Example 163 (General Procedure (B))

5-(2,4-Dimethyl-9H-carbazol-3-ylmethylene)-pyrimidine-2,4,6-trione

HPLC-MS (Method C): m/z=334 (M+1); Rt=3,14 min.

Example 164 (General Procedure (B))

4-(4-Hydroxy-3-methoxybenzylidine)hydantoin

Example 165 (General Procedure (B))

5-Benzylidenehydantoin

General procedure (C) for preparation of compounds of general formula I₂: wherein X, Y, A, and R³ are as defined above and A is optionally substituted with up to four substituents R⁷, R⁸, R⁹, and R¹⁰ as defined above.

This general procedure (C) is quite similar to general procedure (B) and is further illustrated in the following example:

Example 166 (General Procedure (C))

5-(3,4-Dibromobenzylidene)thiazolidine-2,4-dione

A mixture of thiazolidine-2,4-dione (90%, 65 mg, 0.5 mmol), 3,4-dibromobenzaldehyde (132 mg, 0.5 mmol), and piperidine (247 μL, 2.5 mmol) was shaken in acetic acid (2 mL) at 110° C. for 16 hours. After cooling, the mixture was concentrated to dryness in vacuo.

The resulting crude product was shaken with water, centrifuged, and the supernatant was discarded. Subsequently the residue was shaken with ethanol, centrifuged, the supernatant was discarded and the residue was further evaporated to dryness to afford the title compound.

¹H NMR (Acetone-d₆): δ_H 7.99 (d, 1H), 7.90 (d, 1H), 7.70 (s, 1H), 7.54 (d, 1H); HPLC-MS (Method A): m/z: 364 (M+1); Rt=4.31 min.

The compounds in the following examples were similarly prepared. Optionally, the compounds can be further purified by filtration and washing with water instead of concentration in vacuo. Also optionally the compounds can be purified by washing with ethanol, water and/or heptane, or by preparative HPLC.

Example 167 (General Procedure (C))

5-(4-Hydroxy-3-iodo-5-methoxybenzylidene)thiazolidine-2,4-dione

Mp=256° C.; ¹H NMR (DMSO-d₆) δ=12.5 (s,broad, 1H), 10.5 (s,broad, 1H), 7.69 (s, 1H), 7.51 (d, 1H), 7.19 (d, 1H)3.88 (s, 3H), ¹³C NMR (DMSO-d₆) δ_C=168.0, 167.7, 149.0, 147.4, 133.0, 131.2, 126.7, 121.2, 113.5, 85.5, 56.5; HPLC-MS (Method A): m/z: 378 (M+1); Rt=3.21 min.

Example 168 (General Procedure (C))

5-(4-Hydroxy-2,6-dimethylbenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 250 (M+1); Rt.=2.45 min.

Example 169 (General Procedure (C))

4-[5-Bromo-6-(2,4-dioxothiazolidin-5-ylidenemethyl)-naphthalen-2-yloxymethyl]-benzoic acid

HPLC-MS (Method C): m/z: 506 (M+23); Rt.=4.27 min.

Example 170 (General Procedure (C))

5-(4-Bromo-2,6-dichlorobenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 354 (M+1); Rt.=4.36 min.

Example 171 (General Procedure (C))

5-(6-Hydroxy-2-naphthylmethylene) thiazolidine-2,4-dione

Mp 310-314° C., ¹H NMR (DMSO-d₆): δ_H=12.5 (s,broad, 1H), 8.06(d, 1H), 7.90-7.78(m,2H), 7.86 (s, 1H), 7.58 (dd, 1H), 7.20 7.12 (m,2H). ¹³C NMR (DMSO-d₆): δ_C=166.2, 165.8, 155.4, 133.3, 130.1, 129.1, 128.6, 125.4, 125.3, 125.1, 124.3, 120.0, 117.8, 106.8; HPLC-MS (Method A): m/z: 272 (M+1); Rt=3.12 min.

Preparation of the starting material, 6-hydroxy-2-naphtalenecarbaldehyde:

6-Cyano-2-naphthalenecarbaldehyde (1.0 g, 5.9 mmol) was dissolved in dry hexane (15 mL) under nitrogen. The solution was cooled to −60° C. and a solution of diisobutyl aluminium hydride (DIBAH) (15 mL, 1M in hexane) was added dropwise. After the addition, the solution was left at room temperature overnight. Saturated ammonium chloride solution (20 mL) was added and the mixture was stirred at room temperature for 20 min, subsequently aqueous H₂SO₄ (10% solution, 15 mL) was added followed by water until all salt was dissolved. The resulting solution was extracted with ethyl acetate (3×), the combined organic phases were dried with MgSO₄, evaporated to dryness to afford 0.89 g of 6-hydroxy-2-naphtalenecarbaldehyde.

Mp.: 153.5-156.5° C.; HPLC-MS (Method A): m/z: 173 (M+1); Rt=2.67 min; ¹H NMR (DMSO-d₆): δ_H=10.32(s, 1H), 8.95 (d, 1H), 10.02 (s, 1H), 8.42 (s,broad, 1H), 8.01 (d, 1H), 7.82-7.78 (m,2H), 7.23-7.18 (m,2H).

Alternative preparation of 6-hydroxy-2-naphtalenecarbaldehyde:

To a stirred cooled mixture of 6-bromo-2-hydroxynaphthalene (25.3 g, 0.113 mol) in THF (600 mL) at −78° C. was added n-BuLi (2.5 M, 100 mL, 0.250 mol) dropwise. The mixture turned yellow and the temperature rose to −64° C. After ca 5 min a suspension appeared.

After addition, the mixture was maintained at −78° C. After 20 minutes, a solution of DMF (28.9 mL, 0.373 mol) in THF (100 mL) was added over 20 minutes. After addition, the mixture was allowed to warm slowly to room temperature. After 1 hour, the mixture was poured in ice/water (200 mL). To the mixture citric acid was added to a pH of 5. The mixture was stirred for 0.5 hour. Ethyl acetate (200 mL) was added and the organic layer was separated and washed with brine (100 mL), dried over Na₂SO₄ and concentrated. To the residue was added heptane with 20% ethyl acetate (ca 50 mL) and the mixture was stirred for 1 hour. The mixture was filtered and the solid was washed with ethyl acetate and dried in vacuo to afford 16 g of the title compound.

Example 172 (General Procedure (C))

5-(3-Iodo-4-methoxybenzylidene)thiazolidiene-2,4-dione

¹H NMR (DMSO-d₆): δ_H 12.55 (s,broad,1H), 8.02 (d, 1H), 7.72 (s, 1H), 7.61 (d, 1H)7.18(d, 1H), 3.88 (s, 3H); ¹³C NMR (DMSO-d₆): δC 168.1, 167.7, 159.8, 141.5, 132.0, 130.8, 128.0, 122.1, 112.5, 87.5, 57.3. HPLC-MS (Method A): m/z: 362 (M+1); Rt=4.08 min.

Preparation of the Starting Material, 3-iodo-4-methoxybenzaldehyde:

4-Methoxybenzaldehyde (0.5 g, 3.67 mmol) and silver trifluoroacetate (0.92 g, 4.19 mmol) were mixed in dichloromethane (25 mL). Iodine (1.19 g, 4.7 mmol) was added in small portions and the mixture was stirred overnight at room temperature under nitrogen. The mixture was subsequently filtered and the residue washed with DCM. The combined filtrates were treated with an acqueous sodium thiosulfate solution (1M) until the colour disappeared.

Subsequent extraction with dichloromethane (3×20 mL) followed by drying with MgSO₄ and evaporation in vacuo afforded 0.94 g of 3-iodo-4-methoxybenzaldehyde.

Mp 104-107° C.; HPLC-MS (Method A): m/z:263 (M+1); Rt=3.56 min.; ¹H NMR (CDCl₃): δ_H=8.80 (s, 1H), 8.31 (d, 1H), 7.85 (dd, 1H) 6.92 (d, 1H), 3.99 (s, 3H).

Example 173 (General Procedure (C))

5-(1-Bromonaphthalen-2-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: =336 (M+1); Rt=4.46 min.

Example 174 (General Procedure (C))

1-[5-(2,4-Dioxothiazolidin-5-ylidenemethyl)thiazol-2-yl]piperidine-4-carboxylic acid ethyl ester

¹H NMR (DMSO-d₆): δ_H=7.88 (s, 1H), 7.78 (s, 1H), 4.10 (q,2H), 4.0-3.8 (m,2H), 3.40-3.18 (m,2H), 2.75-2.60 (m, 1H), 2.04-1.88 (m,2H), 1.73-1.49 (m,2H), 1.08 (t,3H); HPLC-MS (Method A): m/z: 368 (M+1); Rt=3.41 min.

Example 175 (General Procedure (C))

5-(2-Phenyl-[1,2,3]triazol-4-ylmethylene) thiazolidine-2,4-dione

¹H NMR (DMSO-d₆): δ_H=12.6 (s,broad,1H), 8.46 (s, 1H), 8.08 (dd,2H), 7.82 (s, 1H), 7.70-7.45 (m, 3H). HPLC-MS (Method A): m/z: 273 (M+1); Rt=3.76 min.

Example 176 (General Procedure (C))

5-(Quinolin-4-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 257 (M+1); Rt=2.40 min.

Example 177 (General Procedure (C))

5-(6-Methylpyridin-2-ylmethylene)thiazolidine-2,4-dione

¹H NMR (DMSO-d₆): δ_H=12.35 (s,broad,1H), 7.82 (t, 1H), 7.78 (s, 1H), 7.65 (d, 1H), 7.18 (d, 1H), 2.52 (s, 3H); HPLC-MS (Method A): m/z: 221 (M+1); Rt=3.03 min.

Example 178 (General Procedure (C))

5-(2,4-dioxothiazolidin-5-ylidenemethyl)-furan-2-ylmethylacetate

¹H NMR (DMSO-d₆): δ_H=12.46 (s,broad, 1H), 7.58 (s, 1H), 7.05 (d, 1H), 6.74 (s, 1H), 5.13 (s, 2H), 2.10 (s, 3H). HPLC-MS (Method A): m/z: 208 (M-CH₃COO); Rt=2.67 min.

Example 179 (General Procedure (C))

5-(2,4-Dioxothiazolidin-5-ylidenemethyl)furan-2-sulfonic acid

HPLC-MS (Method A): m/z:276 (M+1); Rt=0.98 min.

Example 180 (General Procedure (C))

5-(5-Benzyloxy-1H-pyrrolo[2,3-c]pyridin-3-ylmethylene)-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 352 (M+1); Rt=3.01 min.

Example 181 (General Procedure (C))

5-(Quinolin-2-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 257 (M+1); Rt=3.40 min.

Example 182 (General Procedure (C))

5-(2,4-Dioxothiazolidin-5-ylidenemethyl)thiophene-2-carboxylic acid

HPLC-MS (Method A): m/z: 256 (M+1); Rt=1.96 min.

Example 183 (General Procedure (C))

5-(2-Phenyl-1H-imidazol-4-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 272 (M+1); Rt=2.89 min.

Example 184 (General Procedure (C))

5-(4-Imidazol-1-yl-benzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 272 (M+1); Rt=1.38 min.

Example 185 (General Procedure (C))

5-(9-Ethyl-9H-carbazol-3-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 323 (M+1); Rt=4.52 min.

Example 186 (General Procedure (C))

5-(1,4-Dimethyl-9H-carbazol-3-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 323 (M+1); Rt=4.35 min.

Example 187 (General Procedure (C))

5-(2-Methyl-1H-indol-3-yl methylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 259 (M+1); Rt=3.24 min.

Example 188 (General Procedure (C))

5-(2-Ethylindol-3-ylmethylene)thiazolidine-2,4-dione

2-Methylindole (1.0 g, 7.6 mmol) dissolved in diethyl ether (100 mL) under nitrogen was treated with n-Butyl lithium (2 M in pentane, 22.8 mmol) and potassium tert-butoxide (15.2 mmol) with stirring at RT for 30 min. The temperature was lowered to −70 C and methyl Iodide (15.2 mmol) was added and the resulting mixture was stirred at −70 for 2 h. Then 5 drops of water was added and the mixture allowed to warm up to RT. Subsequently, the mixture was poured into water (300 mL), pH was adjusted to 6 by means of 1N hydrochloric acid and the mixture was extracted with diethyl ether. The organic phase was dried with Na₂SO₄ and evaporated to dryness. The residue was purified by column chromatography on silica gel using heptane/ether(4/1) as eluent. This afforded 720 mg (69%) of 2-ethylindole.

¹H NMR (DMSO-d₆): δ=10.85 (1H,s); 7.39 (1H,d); 7.25 (1H,d); 6.98(1H,t); 6.90(1H,t); 6.10 (1H,s); 2.71 (2H,q); 1.28 (3H,t).

2-Ethylindole (0.5 g, 3.4 mmol) dissolved in DMF (2 mL) was added to a cold (0° C.) premixed (30 minutes) mixture of DMF (1.15 mL) and phosphorous oxychloride(0.64 g, 4.16 mmol). After addition of 2-ethylindole, the mixture was heated to 40° C. for 1 h, water (5 mL) was added and the pH adjusted to 5 by means of 1N sodium hydroxide. The mixture was subsequently extracted with diethyl ether, the organic phase isolated, dried with MgSO₄ and evaporated to dryness affording 2-ethylindole-3-carbaldehyde (300 mg).

HPLC-MS (Method C): m/z:174 (M+1); Rt.=2.47 min.

2-Ethylindole-3-carbaldehyde (170 mg) was treated with thiazolidine-2,4-dione using the general procedure (C) to afford the title compound (50 mg).

HPLC-MS (Method C):m/z: 273 (M+1); Rt.=3.26 min.

Example 189 (General Procedure (C))

5-[2-(4-Bromophenylsulfanyl)-1-methyl-1H-indol-3-ylmethylene]thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 447 (M+1); Rt=5.25 min.

Example 190 (General Procedure (C))

5-[2-(2,4-Dichlorobenzyloxy)-naphthalen-1-ylmethylene]thiazolidine-2,4-dione

HPLC-MS (Method A): (anyone 1) m/z: 430 (M+1); Rt=5.47 min.

Example 191 (General Procedure (C))

5-{4-[3-(4-Bromophenyl)-3-oxopropenyl]-benzylidene}thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 416 (M+1); Rt=5.02 min.

Example 192 (General Procedure (C))

5-(4-Pyridin-2-ylbenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 283 (M+1), Rt=2.97 min.

Example 193 (General Procedure (C))

5-(3,4-Bisbenzyloxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 418 (M+1); Rt=5.13 min.

Example 194 (General Procedure (C))

5-[4-(4-Nitrobenzyloxy)-benzylidene]thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 357 (M+1); Rt=4.45 min.

Example 195 (General Procedure (C))

5-(2-Phenyl-1H-indol-3-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 321 (M+1); Rt=3.93 min.

Example 196 (General Procedure (C))

5-(5-Benzyloxy-1H-indol-3-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 351 (M+1); Rt=4.18 min.

Example 197 (General Procedure (C))

5-(4-Hydroxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 222 (M+1); Rt=2.42 min.

Example 198 (General Procedure (C))

5-(1-Methyl-1H-indol-2-ylmethylene)thiazolidine-2,4-dione

¹H NMR (DMSO-d₆): δ_H=12.60 (s,broad, 1H), 7.85 (s, 1H), 7.68 (dd, 1H), 7.55 (dd, 1H), 7.38 (dt, 1H), 7.11 (dt, 1H) 6.84 (s, 1H), 3.88 (s, 3H); HPLC-MS (Method A): m/z: 259 (M+1); Rt=4.00 min.

Example 199 (General Procedure (C))

5-(5-Nitro-1H-indol-3-ylmethylene)thiazolidine-2,4-dione

.Mp 330-333° C., ¹H NMR (DMSO-d₆): δ_H=12.62 (s,broad,1H), 8.95 (d, 1H), 8.20 (s, 1H), 8.12 (dd, 1H), 7.98 (s,broad, 1H), 7.68 (d, 1H); HPLC-MS (Method A): m/z: 290 (M+1); Rt=3.18 min.

Example 200 (General Procedure (C))

5-(6-Methoxynaphthalen-2-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 286 (M+1); Rt=4.27 min.

Example 201 (General Procedure (C))

5-(3-Bromo-4-methoxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 314 (M+1), Rt=3.96 min.

Example 202 (General Procedure (C))

3-{(2-Cyanoethyl)-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenyl]amino}propionitrile

HPLC-MS (Method A): m/z: 327 (M+1); Rt=2.90 min.

Example 203 (General Procedure (C))

3-(2,4-Dioxothiazolidin-5-ylidenemethyl)indole-6-carboxylic acid methyl ester

HPLC-MS (Method A): m/z: 303 (M+1); Rt=3.22-3-90 min.

Example 204

3-(2,4-Dioxothiazolidin-5-ylidenemethyl)indole-6-carboxylic acid pentyl ester

3-(2,4-Dioxothiazolidin-5-ylidenemethyl)indole-6-carboxylic acid methyl ester (example 203, 59 mg; 0.195 mmol) was stirred in pentanol (20 mL) at 145° C. for 16 hours. The mixture was evaporated to dryness affording the title compound (69 mg).

HPLC-MS (Method C): m/z: 359 (M+1); Rt.=4.25 min.

Example 205 (General Procedure (C))

3-(2,4-Dioxothiazolidin-5-ylidenemethyl)indole-7-carboxylic acid

HPLC-MS (Method A): m/z: 289 (M+1); Rt=2.67 min.

Example 206 (General Procedure (C))

5-(1-Benzylindol-3-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 335 (M+1); Rt=4.55 min.

Example 207 (General Procedure (C))

5-(1-Benzenesulfonylindol-3-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: =385 (M+1); Rt=4.59 min.

Example 208 (General Procedure (C))

5-(4-[1,2,3]Thiadiazol-4-ylbenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 290 (M+1); Rt=3.45 min.

Example 209 (General Procedure (C))

5-[4-(4-Nitrobenzyloxy)-benzylidene]thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 357 (M+1); Rt=4.42 min.

Example 210 (General Procedure (C))

3-(2,4-Dioxothiazolidin-5-ylidenemethyl)indole-1-carboxylic acid ethyl ester

HPLC-MS (Method A): m/z: 317 (M+1); Rt=4.35 min.

Example 211 (General Procedure (C))

5-[2-(4-Pentylbenzoyl)-benzofura n-5-ylmethylene]thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 420 (M+1); Rt=5.92 min.

Example 212 (General Procedure (C))

5-[1-(2-Fluorobenzyl)-4-nitroindol-3-ylmethylene]thiazolidine-2,4-dione

HPLC-MS (Method A): (Anyone 1) m/z: 398 (M+1); Rt=4.42 min.

Example 213 (General Procedure (C))

5-(4-Benzyloxyindol-3-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 351 (M+1); Rt=3.95 min.

Example 214 (General Procedure (C))

5-(4-Isobutylbenzylidene)-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 262 (M+1); Rt=4.97 min.

Example 215 (General Procedure (C))

Trifluoromethanesulfonic acid 4-(2,4-dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yl Ester

HPLC-MS (Method A): m/z: 404 (M+1); Rt=4.96 min.

Preparation of Starting Material:

4-Hydroxy-1-naphthaldehyde (10 g, 58 mmol) was dissolved in pyridin (50 ml) and the mixture was cooled to 0-5° C. With stirring, trifluoromethanesulfonic acid anhydride (11.7 ml, 70 mmol) was added drop-wise. After addition was complete, the mixture was allowed to warm up to room temperature, and diethyl ether (200 ml) was added. The mixture was washed with water (2×250 ml), hydrochloric acid (3N, 200 ml), and saturated aqueous sodium chloride (100 ml). After drying (MgSO4), filtration and concentration in vacuo, the residue was purified by column chromatography on silica gel eluting with a mixture of ethyl acetate and heptane (1:4). This afforded 8.35 g (47%) trifluoromethanesulfonic acid 4-formylnaphthalen-1-yl ester, mp 44-46.6° C.

Example 216 (General Procedure (C))

5-(4-Nitroindol-3-ylmethylene)-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 290 (M+1); Rt=3.14 min.

Example 217 (General Procedure (C))

5-(3,5-Dibromo-4-hydroxy-benzylidene)thiazolidine-2,4-dione

¹H NMR (DMSO-d₆): δ_H=12.65 (broad, 1H), 10.85 (broad, 1H), 7.78 (s, 2H), 7.70 (s, 1H); HPLC-MS (Method A): m/z: 380 (M+1); Rt=3.56 min.

Example 218 (General Procedure (C))

HPLC-MS (Method A): m/z: 385 (M+1); Rt=5.08 min.

General procedure for preparation of starting materials for examples 218-221: Indole-3-carbaldehyde (3.8 g, 26 mmol) was stirred with potassium hydroxide (1.7 g) in acetone (200 mL) at RT until a solution was obtained indicating full conversion to the indole potassium salt. Subsequently the solution was evaporated to dryness in vacuo. The residue was dissolved in acetone to give a solution containing 2.6 mmol/20 mL.

20 mL portions of this solution were mixed with equimolar amounts of arylmethylbromides in acetone (10 mL). The mixtures were stirred at RT for 4 days and subsequently evaporated to dryness and checked by HPLC-MS. The crude products, 1-benzylated indole-3-carbaldehydes, were used for the reaction with thiazolidine-2,4-dione using the general procedure C.

Example 219 (General Procedure (C))

4-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)indol-1-ylmethyl]benzoic acid methyl ester

HPLC-MS (Method A): m/z: 393 (M+1); Rt=4.60 min.

Example 220 (General Procedure (C))

5-[1-(9,10-Dioxo-9,10-dihydroanthracen-2-ylmethyl)-1H-indol-3-ylmethylene]thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 465 (M+1); Rt=5.02 min.

Example 221 (General Procedure (C))

4′-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)indol-1-ylmethyl]biphenyl-2-carbonitrile

HPLC-MS (Method A): m/z: 458 (M+23); Rt=4.81 min.

Example 222 (General Procedure (C))

3-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)-2-methylindol-1-ylmethyl]benzonitrile

2-Methylindole-3-carbaldehyde (200 mg, 1.26 mmol) was added to a slurry of 3-bromomethylbenzenecarbonitrile (1.26 mmol) followed by sodium hydride, 60%, (1.26 mmol) in DMF (2 mL). The mixture was shaken for 16 hours, evaporated to dryness and washed with water and ethanol. The residue was treated with thiazolidine-2,4-dione following the general procedure C to afford the title compound (100 mg).

HPLC-MS (Method C): m/z: 374 (M+1); Rt.=3.95 min.

Example 223 (General Procedure (C))

5-(1-Benzyl-2-methylindol-3-ylmethylene)thiazolidine-2,4-dione

This compound was prepared in analogy with the compound described in example 222 from benzyl bromide and 2-methylindole-3-carbaldehyde, followed by reaction with thiazolidine-2,4-dione resulting in 50 mg of the title compound.

HPLC-MS (Method C): m/z: 349 (M+1); Rt.=4.19 min.

Example 224

4-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)-2-methylindol-1-ylmethyl]benzoic acid methyl ester

This compound was prepared in analogy with the compound described in example 222 from 4-(bromomethyl)benzoic acid methyl ester and 2-methylindole-3-carbaldehyde, followed by reaction with thiazolidine-2,4-dione.

HPLC-MS (Method C): m/z: 407 (M+1); Rt.=4.19 min.

Example 225 (General Procedure (C))

5-(2-Chloro-1-methyl-1H-indol-3-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 293 (M+1); Rt=4.10 min.

Example 226 (General Procedure (C))

5-(4-Hydroxy-3,5-diiodo-benzylidene)-thiazolidine-2,4-dione

HPLC-MS (Method A): m/z: 474 (M+1); Rt=6.61 min.

Example 227 (General Procedure (C))

5-(4-Hydroxy-3-iodobenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 348 (M+1); Rt.=3.13 min

¹H-NMR: (DMSO-d₆): 11.5 (1H,broad); 7.95(1H,d); 7.65(1H,s); 7.45 (1H,dd); 7.01(1H,dd); 3.4 (1H,broad).

Example 228 (General Procedure (C))

5-(2,3,6-Trichlorobenzylidene)thiazolidine-2,4-dione

H PLC-MS (Method C): m/z: 309 (M+1); Rt.=4.07 min

Example 229 (General Procedure (C))

5-(2,6-Dichlorobenzylidene)thiazolidine-2,4-dione

Mp. 152-154° C.

HPLC-MS (Method C): m/z: 274 (M+1), Rt.=3.70 min

¹H-NMR: (DMSO-d₆): 12.8 (1H, broad); 7.72 (1H,s); 7.60 (2H,d); 7.50 (1H,t).

Example 230 (General Procedure (C))

5-[1-(2,6-Dichloro-4-trifluoromethylphenyl)-2,5-dimethyl-1H-pyrrol-3-ylmethylene]thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 436 (M+1); Rt. 4.81 min

Example 231 (General Procedure (C))

5-[1-(3,5-Dichlorophenyl)-5-(4-methanesulfonylphenyl)-2-methyl-1H-pyrrol-3-ylmethylene]-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 508 (M+1); Rt. =4.31 min

Example 232 (General Procedure (C))

5-[1-(2,5-Dimethoxyphenyl)-5-(4-methanesulfonylphenyl)-2-methyl-1H-pyrrol-3-ylmethylene]-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 499 (M+1); Rt. =3.70 min

Example 233 (General Procedure (C))

4-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)-2,5-dimethylpyrrol-1-yl]benzoic acid

HPLC-MS (Method C): m/z:342 (M+1); Rt.=3.19 min

Example 234 (General Procedure (C))

5-(4-Hydroxy-2,6-dimethoxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z:282(M+1); Rt.=2.56, mp=331-333° C.

Example 235 (General Procedure (C))

5-(2,6-Dimethylbenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 234 (M+1); Rt.=3.58 min,

Example 236 (General Procedure (C))

5-(2,6-Dimethoxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 266 (M+1); Rt.=3.25 min;

Example 237 (General Procedure (C))

5-[4-(2-Fluoro-6-nitrobenzyloxy)-2,6-dimethoxybenzylidene]thiazolidine-2,4-dione

Mp: 255-256° C.

HPLC-MS (Method C): m/z: 435 (M+1), Rt=4.13 min,

Example 238 (General Procedure (C))

5-Benzofuran-2-ylmethylenethiazolidine-2,4-dione

HPLC-MS (Method C): m/z:246 (M+1); Rt.=3.65 min, mp=265-266° C.

Example 239 (General Procedure (C))

5-[3-(4-Dimethylaminophenyl)allylidene]thiazolidine-2,4-dione

HPLC-MS (Method C): m/z:276(M+1); Rt.=3.63, mp=259-263° C.

¹H-NMR: (DMSO-d₆) δ=12.3 (1H,broad); 7.46 (2H,d); 7.39 (1H,d); 7.11 (1H,d); 6.69 (2H,d); 6.59 (1H, dd); 2.98 (3H,s).

Example 240 (General Procedure (C))

5-(2-Methyl-3-phenylallylidene)thiazolidine-2,4-dione

Mp: 203-210° C.

HPLC-MS (Method C): m/z: 246 (M+1); Rt=3.79 min.

Example 241 (General Procedure (C))

5-(2-Chloro-3-phenylallylidene)thiazolidine-2,4-dione

Mp: 251-254° C.

HPLC-MS (Method C): m/z: 266 (M+1; Rt=3.90 min

Example 242 (General Procedure (C))

5-(2-Oxo-1,2-dihydroquinolin-3-ylmethylene)thiazolidine-2,4-dione

Mp: 338-347° C.

HPLC-MS (Method C): m/z: 273 (M+1); Rt. =2.59 min.

Example 243 (General Procedure (C))

5-(2,4,6-Tribromo-3-hydroxybenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 459 (M+1);Rt.=3.65 min.

Example 244 (General Procedure (C))

5-(5-Bromo-2-methylindol-3-ylmethylene)thiazolidi ne-2,4-dione

HPLC-MS (Method C): m/z: 339 (M+1); Rt=3.37 min.

Example 245 (General Procedure (C))

5-(7-Bromo-2-methylindol-3-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 319 (M+1); Rt=3.48 min.

Example 246 (General Procedure (C))

5-(6-Bromoindol-3-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 325 (M+1); Rt=3.54 min.

Example 247 (General Procedure (C))

5-(8-Methyl-2-oxo-1,2-dihydroquinolin-3-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 287 (M+1); Rt=2.86 min.

Example 248 (General Procedure (C))

5-(6-Methoxy-2-oxo-1,2-dihydroquinolin-3-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 303 (M+1); Rt=2.65 min.

Example 249 (General Procedure (C))

5-Quinolin-3-ylmethylenethiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 257 (M+1); Rt=2.77 min.

Example 250 (General Procedure (C))

5-(8-Hydroxyquinolin-2-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 273 (M+1); Rt=3.44 min.

Example 251 (General Procedure (C))

5-Quinolin-8-ylmethylenethiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 257 (M+1); Rt=3.15 min.

Example 252 (General Procedure (C))

5-(1-Bromo-6-methoxynaphthalen-2-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 366 (M+1); Rt=4.44 min.

Example 253 (General Procedure (C))

5-(6-Methyl-2-oxo-1,2-dihydroquinolin-3-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 287 (M+1); Rt. =2.89 min.

Example 254 (General Procedure (D))

5-(2,6-Dichloro-4-dibenzylaminobenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 469 (M+1); Rt=5.35 min.

Example 255 (General Procedure (C))

7-(2,4-Dioxothiazolidin-5-ylidenemethyl)-4-methoxybenzofuran-2-carboxylic acid

HPLC-MS (Method C): m/z: 320 (M+1); Rt=2.71 mln.

Preparation of the intermediate, 7-formyl-4-methoxybenzofuran-2-carboxylic acid:

A mixture of 2-hydroxy-6-methoxybenzaldehyde (6.4 g, 42 mmol), ethyl bromoacetate (14.2 mL, 128 mmol) and potassium carbonate (26 g, 185 mmol) was heated to 130° C. After 3 h the mixture was cooled to room temperature and acetone (100 mL) was added, the mixture was subsequently filtered and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with a mixture of ethyl acetate and heptane (1:4). This afforded 7.5 g (55%) of ethyl 4-methoxybenzofuran-2-carboxylate.

A solution of ethyl 4-methoxybenzofuran-2-carboxylate (6.9 g, 31.3 mmol) in dichloromethane (70 ml) was cooled to 0° C. and a solution of titanium tetrachloride (13.08 g, 69 mmol) was added drop wise. After 10 minutes dichloromethoxymethane (3.958 g, 34 mmol) was added over 10 minutes. After addition, the mixture was warmed to room temperature for 18 hours and the mixture poured into hydrochloric acid (2N, 100 mL). The mixture was stirred for 0.5 hour and then extracted with a mixture of ethyl acetate and toluene (1:1). The organic phase was dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with a mixture of ethyl acetate and heptane (1:4).

This afforded 5.8 g (80%) of ethyl 7-formyl-4-methoxybenzofuran-2-carboxylate. 7-formyl-4-methoxybenzofuran-2-carboxylate (5.0 g, 21.5 mmol) and sodium carbonate (43 mmol) in water (100 mL) was refluxed until a clear solution appeared (about 0.5 hour). The solution was filtered and acidified to pH=1 with hydrochloric acid (2 N), the resulting product was filtered off and washed with ethyl acetate and ethanol and dried to afford 3.5 g (74%) of 7-formyl-4-methoxybenzofuran-2-carboxylic acid as a solid.

¹H NMR (DMSO-d₆): δ=10.20 (s, 1H); 8.07 (d, 1H); 7.70 (s, 1H); 7.17 (d, 1H); 4.08 (s, 3H).

Example 256 (General Procedure (C))

5-(4-Methoxybenzofuran-7-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 267 (M+1); Rt=3.30 min.

Preparation of the intermediate, 4-methoxybenzofuran-7-carbaldehyde:

A mixture of 7-formyl-4-methoxybenzofuran-2-carboxylic acid (3.0 g, 13.6 mmol) and Cu (0.6 g, 9.44 mmol) in quinoline (6 mL) was refluxed. After 0.5 h the mixture was cooled to room temperature and water (100 mL) and hydrochloric acid (10 N, 20 mL) were added. The mixture was extracted with a mixture of ethyl acetate and toluene (1:1), filtered through celite and the organic layer separated and washed with a sodium carbonate solution, dried over Na₂SO₄ and concentrated in vacuo to afford 1.5 g crude product. Column chromatography SiO₂, EtOAc/heptanes=1/4 gave 1.1 g (46%) of 4-methoxybenzofuran-7-carbaldehyde as a solid.

¹H NMR (CDCl₃): δ: 10.30 (s, 1H); 7.85 (d, 1H); 7.75 (d, 1H); 6.98 (d, 1H); 6.87 (d, 1H); 4.10 (s, 3H). HPLC-MS (Method C):m/z: 177 (M+1); Rt. =7.65 min.

Example 257 (General Procedure (C))

5-(4-Hydroxybenzofuran-7-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: =262 (M+1); Rt=2.45 min.

Preparation of the intermediate, 4-hydroxybenzofuran-7-carbaldehyde

A mixture of 4-methoxybenzofuran-7-carbaldehyde (1.6 g, 9.1 mmol) and pyridine hydrochloride (4.8 g, 41.7 mmol) in quinoline (8 mL) was refluxed. After 8 h the mixture was cooled to room temperature and poured into water (100 mL) and hydrochloric acid (2 N) was added to pH=2. The mixture was extracted with a mixture of ethyl acetate and toluene (1:1), washed with a sodium carbonate solution, dried with Na₂SO₄ and concentrated in vacuo to afford 0.8 g crude product. This was purified by column chromatography on silica gel, eluting with a mixture of ethyl acetate and heptane (1:3). This afforded 250 mg of 4-hydroxybenzofuran-7-carbaldehyde as a solid.

¹H NMR (DMSO-d₆): δ=11.35 (s, broad,1H); 10.15 (s, 1H); 8.05 (d, 1H); 7.75 (d, 1H); 7.10 (d, 1H); 6.83 (d, 1H). HPLC-MS (Method C): m/z: 163 (M+1); Rt. =6.36 min.

Example 258 (General Procedure (C))

5-(5-Bromo-2,3-dihydrobenzofuran-7-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 328 (M+1); Rt=3.66 min.

Preparation of the Intermediate, 5-bromo-2,3-dihydrobenzofuran-7-carbaldehyde:

To a cooled (15° C.) stirred mixture dihydrobenzofuran (50.9 g, 0.424 mol) in acetic acid (500 mL), a solution of bromine (65.5 mL, 1.27 mol) in acetic acid (200 mL) was added drop wise over 1 hour. After stirring for 18 hours, a mixture of Na₂S₂O₅ (150 g) in water (250 mL) was added carefully, and the mixture was concentrated in vacuo. Water (200 mL) was added and the mixture was extracted with ethyl acetate containing 10% heptane, dried over Na₂SO₄ and concentrated in vacuo to give crude 5,7-dibromo-2,3-dihydrobenzofuran which was used as such for the following reaction steps. To a cooled solution (−78° C.) of crude 5,7-dibromo-2,3-dihydrobenzofuran (50.7 g, 0.182 mol) in THF (375 mL) a solution of n-BuLi (2.5 M, 80 mL, 0.200 mol) in hexane was added. After addition, the mixture was stirred for 20 min. DMF (16 mL) was then added drop wise at −78° C. After addition, the mixture was stirred at room temperature for 3 h and then the mixture was poured into a mixture of ice water, (500 mL) and hydrochloric acid (10 N, 40 mL) and extracted with toluene, dried over Na₂SO₄ and concentrated in vacuo. Column chromatography on silica gel eluting with a mixture of ethyl acetate and heptane (1:4) afforede 23 g of 5-bromo-2,3-dihydrobenzofuran-7-carbaldehyde as a solid.

¹H NMR (CDCl₃): δ: 10.18 (s, 1H); 7.75 (d, 1H); 7.55 (d, 1H); 4.80 (t,2H); 3.28 (t,2H).

Example 259 (General Procedure (C))

5-(4-Cyclohexylbenzylidene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z: 288 (M+1); Rt=5.03 min.

Preparation of the intermediate, 4-cyclohexylbenzaldehyde:

This compound was synthesized according to a modified literature procedure (J. Org. Chem., 37, No.24, (1972), 3972-3973).

Cyclohexylbenzene (112.5 g, 0.702 mol) and hexamethylenetetramine (99.3 g, 0.708 mol) were mixed in TFA (375 mL). The mixture was stirred under nitrogen at 90° C. for 3 days. After cooling to room temperature the red-brown mixture was poured into ice-water (3600 ml) and stirred for 1 hour. The solution was neutralized with Na₂CO₃ (2 M solution in water) and extracted with dichloromethane (2.5 L). The organic phase was dried (Na₂SO₄) and the solvent was removed in vacuo. The remaining red-brown oil was purified by fractional distillation to afford the title compound (51 g, 39%).

¹H NMR (CDCl₃): δ 9.96 (s, 1H), 7.80 (d, 2H), 7.35 (d, 2H), 2.58 (m, 1H), 1.94-1.70 (m, 5H), 1.51-1.17 (m, 5H)

Other ligands of the invention include

3′,5′-Dichloro-4′-(2,4-dioxothiazolidin-5-ylidenemethyl)biphenyl-4-carboxylic acid

Example 260 (General Procedure (C))

5-(1-Bromo-6-hydroxynaphthalen-2-ylmethylene)-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=350 (M+1); Rt. =3.45 min.

Example 261 (General Procedure (C))

5-[4-(2-Bromoethoxy)-naphthalen-1-ylmethylene]-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=380 (M+1); Rt=3.52 min.

Example 262 (General Procedure (C))

5-(2-Methyl-5-nitro-1H-indol-3-ylmethylene)-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=304 (M+1); Rt=2.95 min.

Example 263 (General Procedure (C))

5-(4-Naphthalen-2-yl-thiazol-2-ylmethylene)-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=339 (M+1); Rt.=4.498 min.

Example 264 (General Procedure (C))

5-[4-(4-Methoxy-naphthalen-1-yl)-thiazol-2-ylmethylene]-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=369 (M+1); Rt.=4.456 min.

Example 265 (General Procedure (C))

5-(2-Pyridin-4-yl-1H-indol-3-ylmethylene)-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=322 (M+1); Rt. =2.307 min.

Example 266 (General Procedure (C))

5-[5-(4-Chlorophenyl)-1H-pyrazol-4-ylmethylene]-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=306 (M+1); Rt.=3.60 min.

Example 267 (General Procedure (C))

5-[5-(2,5-Dimethylphenyl)-1H-pyrazol-4-ylmethylene]-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=300 (M+1); Rt. =3.063 min.

Example 268 (General Procedure (C))

5-(2-Phenyl-benzo[d]imidazo[2,1-b]thiazol-3-ylmethylene)-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=378 (M+1); Rt=3.90 min.

Example 269 (General Procedure (C))

N-{4-[2-(2,4-Dioxothiazolidin-5-ylidenemethyl)-phenoxy]-phenyl}-acetamide

HPLC-MS (Method C): m/z=355 (M+1); Rt=3.33 min.

Example 270 (General Procedure (C))

5-(2-Phenyl-imidazo[1,2-a]pyridin-3-ylmethylene)-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=322 (M+1); Rt. =2.78 min.

Example 271 (General Procedure (C))

5-(2-Naphtha len-2-yl-imidazo[1,2-a]pyridin-3-ylmethylene)-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=372 (M+1); Rt. =2.78 min.

Example 272 (General Procedure (C))

5-[6-B romo-2-(3-methoxyphenyl)-imidazo[1,2-a]pyridin-3-ylmethylene]-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=431 (M+1); Rt.=3.30 min.

Example 273 (General Procedure (C))

5-(1,2,3,4-Tetrahydrophenanthren-9-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=310 (M+1); Rt.=4.97 min.

Example 274 (General Procedure (C))

5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethylene)thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=330 (M+1); Rt.=5.33 min.

Example 275 (General Procedure (C))

5-[6-(2,4-Dichloro-phenyl)-imidazo[2,1-b]thiazol-5-ylmethylene]-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=396 (M+1); Rt. =3.82 min.

Example 276 (General Procedure (C))

5-(5-Bromobenzofuran-7-ylmethylene)-thiazolidine-2,4-dione

HPLC-MS (Method C): m/z=324 (M+1); Rt. =3.82 min.

Example 277 (General Procedure (C))

4-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)-1,4-dimethylcarbazol-9-ylmethyl]-benzoic acid

HPLC-MS (Method C): m/z=457 (M+1); Rt=4,23 min.

Preparation of Intermediary Aldehyde:

1,4 Dimethylcarbazol-3-carbaldehyde (0.68 g, 3.08 mmol) was dissolved in dry DMF (15 mL), NaH (diethyl ether washed) (0.162 g, 6.7 mol) was slowly added under nitrogen and the mixture was stirred for 1 hour at room temperature. 4-Bromomethylbenzoic acid (0.73 g, 3.4 mmol) was slowly added and the resulting slurry was heated to 40° C. for 16 hours. Water (5 mL) and hydrochloric acid (6N, 3 mL) were added. After stirring for 20 min at room temperature, the precipitate was filtered off and washed twice with acetone to afford after drying 0.38 g (34%) of 4-(3-formyl-1,4-dimethylcarbazol-9-ylmethyl)benzoic acid.

HPLC-MS (Method C): m/z=358 (M+1), RT. =4.15 min.

Example 278 (General Procedure (C))

Starting aldehyde commercially available (Syncom BV, NL)

HPLC-MS (Method C): m/z=366 (M+1); Rt. =3.37 min.

Example 279 (General Procedure (C))

4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)-2-nitrophenoxy]-benzoic acid methyl ester

HPLC-MS (Method C): m/z=401 (M+1); Rt. =4.08 min.

Example 280 (General Procedure (C))

3′,5′-Dichloro-4′-(2,4-dioxothiazolidin-5-ylidenemethyl)-biphenyl-4-carboxylic acid

Starting aldehyde commercially available (Syncom BV, NL)

HPLC-MS (Method C): m/z=394 (M+1); Rt. =3.71 min.

Example 281 (General Procedure (C))

HPLC-MS (Method C): m/z=232(M+1); Rt.=3.6 min.

Example 282

5-(2-Methyl-1H-indol-3-ylmethyl)-thiazolidine-2,4-dione

5-(2-Methyl-1H-indol-3-ylmethylene)thiazolidine-2,4-dione (prepared as described in example 187, 1.5 g, 5.8 mmol) was dissolved in pyridine (20 mL) and THF (50 mL), LiBH₄ (2 M in THF, 23.2 mmol) was slowly added with a syringe under cooling on ice. The mixture was heated to 85° C. for 2 days. After cooling, the mixture was acidified with concentrated hydrochloric acid to pH 1. The aquous layer was extracted 3 times with ethyl acetate, dried with MgSO₄ treated with activated carbon, filtered and the resulting filtrate was evaporated in vacuo to give 1.3 g (88%) of the title compound.

HPLC-MS (Method C): m/z=261 (M+1); Rt. =3.00 min.

Example 283

4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyric acid

4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyric acid (4.98 g, 13.9 mmol, prepared as described in example 469) was dissolved in dry THF (50 mL) and added dry pyridine (50 mL) and, in portions, lithium borohydride (2.0 M, in THF, 14 mL). The resulting slurry was refluxed under nitrogen for 16 hours, added (after cooling) more lithium borohydride (2.0 M, in THF, 7 mL). The resulting mixture was refluxed under nitrogen for 16 hours. The mixture was cooled and added more lithium borohydride (2.0 M, in THF, 5 mL). The resulting mixture was refluxed under nitrogen for 16 hours. After cooling to 5° C., the mixture was added water (300 mL) and hydrochloric acid (150 mL). The solid was isolated by filtration, washed with water (3×500 mL) and dried. Recrystallization from acetonitrile (500 mL) afforded 2.5 g of the title compound.

¹H-NMR (DMSO-d₆, selected peaks): δ=3.42 (1H, dd), 3.90 (1H, dd), 4.16 (2H, “t”), 4.95 (1H, dd), 6.92 (1H, d), 7.31 (1H, d), 7.54 (1H, t), 7.62 (1H, t), 8.02 (1H, d), 8.23 (1H, d), 12.1 (1H, bs), 12.2 (1H, bs).

HPLC-MS (Method C): m/z=382 (M+23); Rt=3,23 min.

Example 284

5-Naphthalen-1-ylmethylthiazolidine-2,4-dione

5-Naphthalen-1-ylmethylenethiazolidine-2,4-dione (1.08 g, 4.2 mmol, prepared as described in example 68) was dissolved in dry THF (15 mL) and added dry pyridine (15 mL) and, in portions, lithium borohydride (2.0 M, in THF, 4.6 mL). The resulting mixture was refluxed under nitrogen for 16 hours. After cooling to 5° C., the mixture was added water (100 mL), and, in portions, concentrated hydrochloric acid (40 mL). More water (100 mL) was added, and the mixture was extracted with ethyl acetate (200 mL). The organic phase was washed with water (3×100 mL), dried and concentrated in vacuo. The residue was dissolved in ethyl acetate (50 mL) added activated carbon, filtered and concentrated in vacuo and dried to afford 0.82 g (75%) of the title compound.

¹H-NMR (DMSO-d₆): δ=3.54 (1H, dd), 3.98 (1H, dd), 5.00 (1H, dd), 7.4-7.6 (4H, m), 7.87 (1H, d), 7.96 (1H, d), 8.11 (1H, d), 12.2 (1H, bs).

HPLC-MS (Method C): m/z=258 (M+1); Rt=3,638 min.

The following preferred compounds of the invention may be prepared according to procedures similar to those described in the three examples above:

Example 285
Example 286
Example 287
Example 288
Example 289
Example 290
Example 291
Example 292
Example 293
Example 294
Example 295
Example 296
Example 297
Example 298
Example 299
Example 300
Example 301
Example 302
Example 303
Example 304
Example 305
Example 306
Example 307
Example 308
Example 309
Example 310
Example 311
Example 312
Example 313
Example 314
Example 315
Example 316
Example 317
Example 318
Example 319
Example 323
Example 321
Example 322
Example 323
Example 324
Example 325
Example 326
Example 327
Example 328
Example 329
Example 330
Example 331
Example 332
Example 333
Example 334
Example 335
Example 336
Example 337
Example 338
Example 339
Example 340
Example 341
Example 342
Example 343
Example 344
Example 345
Example 346
Example 347
Example 348
Example 349
Example 350
Example 351
Example 352
Example 353
Example 354
Example 355
Example 356
Example 357
Example 358
Example 359
Example 360
Example 361
Example 362
Example 363
Example 364
Example 365
Example 366
Example 367
Example 368
Example 369
Example 370
Example 371
Example 372
Example 373
Example 374
Example 375
Example 376
Example 377
Example 378
Example 379

The following compounds are commercially available and may be prepared using general procedures (B) and/or (C).

Example 380

5-(5-Bromo-1H-indol-3-ylmethylene)thiazolidine-2,4-dione

Example 381

5-Pyridin-4-ylmethylenethiazolidine-2,4-dione

Example 382

5-(3-Bromo-4-methoxybenzylidene)thiazolidine-2,4-dione

Example 383

5-(3-Nitrobenzylidene)thiazolidine-2,4-dione

Example 384

5-Cyclohexylidene-1,3-thiazolidine-2,4-dione

Example 385

5-(3,4-Dihydroxybenzylidene)thiazolidine-2,4-dione

Example 386

5-(3-Ethoxy-4-hydroxybenzylidene)thiazolidine-2,4-dione

Example 387

5-(4-Hydroxy-3-methoxy-5-nitrobenzylidene)thiazolidine-2,4-dione

Example 388

5-(3-Ethoxy-4-hydroxybenzylidene)thiazolidine-2,4-dione

Example 389

5-(4-Hydroxy-3,5-dimethoxybenzylidene)thiazolidine-2,4-dione

Example 390

5-(3-Bromo-5-ethoxy-4-hydroxybenzylidene)thiazolidine-2,4-dione

Example 391

5-(3-Ethoxy-4-hydroxy-5-nitrobenzylidene)thiazolidine-2,4-dione

Example 392

Example 393

Example 394

Example 395

Example 396

Example 397

Example 398

Example 399

Example 400

Example 401

Example 402

Example 403

Example 404

Example 405

5-(3-Hydroxy-5-methyl-phenylamino)-thiazolidine-2,4-dione

Example 406

Example 407

Example 408

Example 409

Example 410

Example 411

Example 412

Example 413

Example 414

Example 415

Example 416

Example 417

Example 418

Example 419

Example 420

Example 421

Example 422

Example 423

Example 424

Example 425

Example 426

Example 427

Example 428

Example 429

Example 430

Example 431

5-(4-Diethylamino-2-methoxy-benzylidene)-imidazolidine-2,4-dione

Example 432

Example 433

Example 434

Example 435

Example 436

Example 437

Example 438

Example 439

Example 440

Example 441

Example 442

Example 443

Example 444

Example 445

Example 446

Example 447

Example 448

Example 449

Example 450

Example 451

Example 452

Example 453

Example 454

5-(4-Diethylamino-benzylidene)-2-imino-thiazolidin-4-one

Example 455

Example 456

Example 457

Example 458

Example 459

General Procedure (D) for Preparation of Compounds of General Formula wherein X, Y, and R³ are as defined above,

• n is 1 or 3-20,
• E is arylene or heterarylene (including up to four optional substituents, R¹³, R¹⁴, R¹⁵, and R¹⁵A as defined above),
• R′ is a standard carboxylic acid protecting group, such as C₁-C₆-alkyl or benzyl and Lea is a leaving group, such as chloro, bromo, iodo, methanesulfonyloxy, toluenesulfonyloxy or the like.

Step 1 is an alkylation of a phenol moiety. The reaction is preformed by reacting R¹⁰—C(═O)E-OH with an ω-bromo-alkane-carboxylic acid ester (or a synthetic equivalent) in the presence of a base such as sodium or potassium carbonate, sodium or potassium hydroxide, sodium hydride, sodium or potassium alkoxide in a solvent, such as DMF, NMP, DMSO, acetone, acetonitrile, ethyl acetate or isopropyl acetate. The reaction is performed at 20-160° C., usually at room temperature, but when the phenol moiety has one or more substituents heating to 50° C. or more can be beneficial, especially when the substituents are in the ortho position relatively to the phenol. This will readily be recognised by those skilled in the art.

Step 2 is a hydrolysis of the product from step 1.

Step 3 is similar to general procedure (B) and (C).

This general procedure (D) is further illustrated in the following examples:

Example 460 (General Procedure (D))

4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]butyric acid

Step 1:

A mixture of 4-hydroxybenzaldehyde (9.21 g, 75 mmol), potassium carbonate (56 g, 410 mmol) and 4-bromobutyric acid ethyl ester (12.9 mL, 90 mmol) in N,N-dimethylformamide (250 mL) was stirred vigorously for 16 hours at room temperature. The mixture was filtered and concentrated in vacuo to afford 19.6 g (100%) of 4-(4-formylphenoxy)butyric acid ethyl ester as an oil. ¹H-NMR (DMSO-d₆): δ 1.21 (3H, t), 2.05 (2H, p), 2.49 (2H, t), 4.12 (4H, m), 7.13 (2H, d), 7.87 (2H, d), 9.90 (1H, s). HPLC-MS (Method A): m/z=237 (M+1); Rt=3.46 min.

Step 2:

4-(4-Formylphenoxy)butyric acid ethyl ester (19.6 g, 75 mmol) was dissolved in methanol (250 mL) and 1N sodium hydroxide (100 mL) was added and the resulting mixture was stirred at room temperature for 16 hours. The organic solvent was evaporated in vacuo (40° C., 120 mBar) and the residue was acidified with 1N hydrochloric acid (110 mL). The mixture was filtered and washed with water and dried in vacuo to afford 14.3 g (91%) 4-(4-formylphenoxy)butyric acid as a solid. ¹H-NMR (DMSO-d₆): δ 1.99 (2H, p), 2.42 (2H, t), 4.13 (2H, t), 7.14 (2H, d), 7.88 (2H, d), 9.90 (1H, s), 12.2 (1H, bs). HPLC-MS (Method A): m/z=209 (M+1); Rt=2.19 min.

Step 3:

Thiazolidine-2,4-dione (3.55 g, 27.6 mmol), 4-(4-formylphenoxy)butyric acid (5.74 g, 27.6 mmol), anhydrous sodium acetate (11.3 g, 138 mmol) and acetic acid (100 mL) was refluxed for 16 h. After cooling, the mixture was filtered and washed with acetic acid and water. Drying in vacuo afforded 2.74 g (32%) of 4-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]butyric acid as a solid.

¹H-NMR (DMSO-d₆): δ 1.97 (2H, p), 2.40 (2H, t), 4.07 (2H, t), 7.08 (2H, d), 7.56 (2H, d), 7.77 (1H, s), 12.2 (1H, bs), 12.5 (1H, bs); HPLC-MS (Method A): m/z: 308 (M+1); Rt=2.89 min.

Example 461 (General Procedure (D))

[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]acetic acid

Step 3:

Thiazolidine-2,4-dione (3.9 g, 33 mmol), 3-formylphenoxyacetic acid (6.0 g, 33 mmol), anhydrous sodium acetate (13.6 g, 165 mmol) and acetic acid (100 mL) was refluxed for 16 h. After cooling, the mixture was filtered and washed with acetic acid and water. Drying in vacuo afforded 5.13 g (56%) of [3-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]acetic acid as a solid.

¹H-NMR (DMSO-d₆): δ 4.69 (2H, s), 6.95 (1H, dd), 7.09 (1H, t), 7.15 (1H, d), 7.39 (1H, t),7.53 (1H, s); HPLC-MS (Method A): m/z=280 (M+1) (poor ionisation); R_t=2.49 min.

The compounds in the following examples were similarly prepared.

Example 462 (General Procedure (D))

3-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenyl]acrylic acid

¹H-NMR (DMSO-d₆): δ6.63 (1H, d), 7.59-7.64 (3H, m), 7.77 (1H, s), 7.83 (2H, m).

Example 463 (General Procedure (D))

[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]acetic acid

Triethylamine salt: ¹H-NMR (DMSO-d₆): δ 4.27 (2H, s), 6.90 (2H, d), 7.26 (1H, s), 7.40 (2H, d).

Example 464 (General Procedure (D))

4-(2,4-Dioxothiazolidin-5-ylidenemethyl)benzoic acid

Example 465 (General Procedure (D))

3-(2,4-Dioxothiazolidin-5-ylidenemethyl)benzoic acid

¹H-NMR (DMSO-d₆): δ 7.57 (1H, s), 7.60 (1H, t), 7.79 (1H, dt), 7.92 (1H, dt), 8.14 (1H, t).

Example 466 (General Procedure (D))

4-[2-Chloro-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]butyric acid

¹H-NMR (DMSO-d₆): δ 2.00 (2H, p), 2.45 (2H, t), 4.17 (2H, t), 7.31 (1H, d), 7.54 (1H, dd), 7.69 (1H, d), 7.74 (1H, s), 12.2 (1H, bs), 12.6 (1H, bs). HPLC-MS (Method A): m/z: 364 (M+23); Rt=3.19 min.

Example 467 (General Procedure (D))

4-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]butyric acid

¹H-NMR (DMSO-d₆): δ 1.99 (2H, p), 2.46 (2H, t), 4.17 (2H, t), 7.28 (1H, d), 7.57 (1H, dd), 7.25 (1H, s), 7.85 (1H, d), 12.2 (1H, bs), 12.6 (1H, bs). HPLC-MS (Method A): m/z: 410 (M+23); Rt=3.35 min.

Example 468 (General Procedure (D))

4-[2-Bromo-4-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)phenoxy]butyric acid

¹H-NMR (DMSO-d₆): δ 1.99 (2H, p), 2.45 (2H, t), 4.18 (2H, t), 7.28 (1H, d), 7.55 (1H, dd), 7.60 (1H, s), 7.86 (1H, d), 12.2 (1H, bs), 13.8 (1H, bs). HPLC-MS (Method A): m/z: 424 (M+23); Rt=3.84 min.

HPLC-MS (Method A): m/z: 424 (M+23); Rt=3,84 min

Example 469 (General Procedure (D))

4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyric acid

¹H-NMR (DMSO-d₆): δ 2.12 (2H, p), 2.5 (below DMSO), 4.28 (2H, t), 7.12 (1H, d), 7.6-7.7 (3H, m), 8.12 (1H, d), 8.31 (1H, d), 8.39 (1H, s), 12.2 (1H, bs), 12.6 (1H, bs). HPLC-MS (Method A): m/z: 380 (M+23); Rt=3.76 min.

Example 470 (General Procedure (D))

5-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]pentanoic acid

HPLC-MS (Method A): m/z: 394 (M+23); Rt=3.62 min.

¹H-NMR (DMSO-d₆): δ 1.78 (2H, m), 1.90 (2H, m), 2.38 (2H, t), 4.27 (2H, t), 7.16 (1H, d), 7.6-7.75 (3H, m), 8.13 (1H, d), 8.28 (1H, d), 8.39 (1H, s), 12.1 (1H, bs), 12.6 (1H, bs).

Example 471

5-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]pentanoic acid

5-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)-naphthalen-1-yloxy]pentanoic acid (example 470, 185 mg, 0.5 mmol) was treated with an equimolar amount of bromine in acetic acid (10 mL). Stirring at RT for 14 days followed by evaporation to dryness afforded a mixture of the brominated compound and unchanged starting material. Purification by preparative HPLC on a C18 column using acetonitrile and water as eluent afforded 8 mg of the title compound.

HPLC-MS (Method C): m/z: 473 (M+23), Rt.=3.77 min

Example 472

4-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyric acid

Starting with 4-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)-naphthalen-1-yloxy]-butyric acid (example 469, 0.5 mmol) using the same method as in example 471 afforded 66 mg of the title compound.

HPLC-MS (Method C): m/z: 459 (M+23); Rt.=3.59 min.

Example 473 (General Procedure (D))

[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]acetic acid

¹H-NMR (DMSO-d₆): δ 4.90 (2H, s), 7.12 (1H, d), 7.52 (1H, dd), 7.65 (1H, s) 7.84 (1H, d).HPLC-MS (Method A): m/z: not observed; Rt=2.89 min.

Example 474 (General Procedure (D))

4-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]butyric acid

¹H-NMR (DMSO-d₆): δ 1.98 (2H, p), 2.42 (2H, t), 4.04 (2H, t), 7.05 (1H, dd), 7.15 (2H, m), 7.45 (1H, t), 7.77 (1H, s), 12.1 (1H, bs), 12.6 (1H, bs). HPLC-MS (Method A): m/z: 330 (M+23); Rt=3.05 min.

Example 475 (General Procedure (D))

[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)-3-methoxyphenoxy]acetic acid

HPLC-MS (Method B): m/z: 310 (M+1); Rt=3,43 min.

Example 476 (General Procedure (D))

[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]acetic acid

HPLC-MS (Method A): m/z: 330 (M+1); Rt=3.25 min.

Example 477 (General Procedure (D))

8-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalene-1-carboxylic acid

HPLC-MS (Method A): m/z: 299 (M+1); Rt=2,49 min.

Example 478 (General Procedure (D))

[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)indol-1-yl]acetic acid

HPLC-MS (Method A): m/z: 303 (M+1); Rt=2.90 min.

Preparation of Starting Material:

3-Formylindol (10 g, 69 mmol) was dissolved in N,N-dimethylformamide (100 mL) and under an atmosphere of nitrogenand with external cooling, keeping the temperature below 15° C., sodium hydride (60% in mineral oil, 3.0 g, 76 mmol) was added in portions. Then a solution of ethyl bromoacetate (8.4 mL, 76 mmol) in N,N-dimethylformamide (15 mL) was added dropwise over 30 minutes and the resulting mixture was stirred at room temperature for 16 hours. The mixture was concentrated in vacuo and the residue was partitioned between water (300 mL) and ethyl acetate (2×150 mL). The combined organic extracts were washed with a saturated aqueous solution of ammonium chloride (100 mL), dried (MgSO₄) and concentrated in vacuo to afford 15.9 g (quant.) of (3-formylindol-1-yl)acetic acid ethyl ester as an oil.

¹H-NMR (CDCl₃): δ_H=1.30 (3H, t), 4.23 (2H, q), 4.90 (2H, s), 7.3 (3H, m), 7.77 (1H, s), 8.32 (1H, d), 10.0 (1H, s).

(3-Formylindol-1-yl)acetic acid ethyl ester (15.9 g 69 mmol) was dissolved in 1,4-dioxane (100 mL) and 1N sodium hydroxide (10 mL) was added and the resulting mixture was stirred at room temperature for 4 days. Water (500 mL) was added and the mixture was washed with diethyl ether (150 mL). The aqueous phase was acidified with 5N hydrochloric acid and extracted with ethyl acetate (250+150 mL). The combined organic extracts were dried (MgSO₄) and concentrated in vacuo to afford 10.3 g (73%) of (3-formylindol-1-yl)acetic acid as a solid.

¹H-NMR (DMSO-d₆): δ_H=5.20 (2H, s), 7.3 (2H, m), 7.55 (1H, d), 8.12 (1H, d), 8.30 (1H, s), 9.95 (1H, s), 13.3 (1H, bs).

Example 479 (General Procedure (D))

3-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)indol-1-yl]propionic acid

HPLC-MS (Method A): m/z: 317 (M+1); Rt=3.08 min.

Preparation of Starting Material:

A mixture of 3-formylindol (10 g, 69 mmol), ethyl 3-bromopropionate (10.5 mL, 83 mmol) and potassium carbonate (28.5 g, 207 mmol) and acetonitrile (100 mL) was stirred vigorously at refux temperature for 2 days. After cooling, the mixture was filtered and the filtrate was concentrated in vacuo to afford 17.5 g (quant.) of 3-(3-formylindol-1-yl)propionic acid ethyl ester as a solid.

¹H-NMR (DMSO-d₆): δ_H=1.10 (3H, t), 2.94 (2H, t), 4.02 (2H, q), 4.55 (2H, t), 7.3 (2H, m), 7.67 (1H, d), 8.12 (1H, d), 8.30 (1H, s), 9.90 (1H, s).

3-(3-Formylindol-1-yl)propionic acid ethyl ester (17.5 g 69 mmol) was hydrolysed as described above to afford 12.5 g (83%) of 3-(3-formylindol-1-yl)propionic acid as a solid.

¹H-NMR (DMSO-d₆): δ_H=2.87 (2H, t), 4.50 (2H, t), 7.3 (2H, m), 7.68 (1H, d), 8.12 (1H, d), 8.31 (1H, s), 9.95 (1H, s), 12.5 (1H, bs).

Example 480 (General Procedure (D))

{5-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)benzylidene]-4-oxo-2-thioxothiazolidin-3-yl}acetic acid

HPLC-MS (Method A): m/z: 429 (M+23); Rt=3.89 min.

Example 481 (General Procedure (D))

6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxyoctanoic acid

HPLC-MS (Method C): m/z: 436 (M+23); Rt.=4.36 min

The intermediate aldehyde for this compound was prepared by a slightly modified procedure: 6-Hydroxynaphthalene-2-carbaldehyde (1.0 g, 5.8 mmol) was dissolved in DMF (10 mL) and sodium hydride 60% (278 mg) was added and the mixture stirred at RT for 15 min. 8-Bromooctanoic acid (0.37 g, 1.7 mmol) was converted to the sodium salt by addition of sodium hydride 60% and added to an aliquot (2.5 mL) of the above naphtholate solution and the resulting mixture was stirred at RT for 16 hours. Aqueous acetic acid (10%) was added and the mixture was extracted 3 times with diethyl ether. The combined organic phases were dried with MgSO₄ and evaporated to dryness affording 300 mg of 8-(6-formylnaphthalen-2-yloxy)octanoic acid.

HPLC-MS (Method C): m/z 315 (M+1); Rt. =4.24 min.

Example 482 (General Procedure (D))

12-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]dodecanoic acid

HPLC-MS (Method C): m/z: 492 (M+23); Rt.=5.3 min.

The intermediate aldehyde was prepared similarly as described in example 481.

Example 483 (General Procedure (D))

11-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]undecanoic acid

HPLC-MS (Method C): m/z:478 (M+23); Rt.=5.17 min.

The intermediate aldehyde was prepared similarly as described in example 481.

Example 484 (General Procedure (D))

15-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]pentadecanoic acid

HPLC-MS (Method C): m/z: 534 (M+23); Rt.=6.07 min.

The intermediate aldehyde was prepared similarly as described in example 481.

Example 485 (General Procedure (D))

6-[6-(2,4-Dioxothiazolidin-5-yl idenemethyl)naphthalen-2-yloxy]hexanoic acid

HPLC-MS (Method C): m/z: 408 (M+23); Rt.=3.71 min.

Example 486 (General Procedure (D))

4-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]butyric acid

HPLC-MS (Method C): m/z: 380 (M+23); Rt.=3.23 min.

Example 487 (General Procedure (D))

6-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]hexanoic acid ethyl ester

HPLC-MS (Method C): m/z: 436 (M+23); Rt.=4.64 min.

Example 488 (General Procedure (D))

4-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]butyric acid ethyl ester

HPLC-MS (Method C): m/z: 408 (M+23); Rt.=4.28 min.

Example 489 (General Procedure (D))

2-{5-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]pentyl}malonic acid

HPLC-MS (Method C): m/z=444 (M+1); Rt=3,84 min.

Example 490 (General Procedure (D) 2-{5-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]pentyl}malonic acid diethyl ester

HPLC-MS (Method C): m/z=500 (M+1); Rt=5.18 min.

Example 491 (General Procedure (D))

4-[4-(2,4,6-Trioxotetrahydropyrimidin-5-ylidenemethyl)naphthalen-1-yloxy]butyric acid

HPLC-MS (Method C): m/z=369 (M+1); Rt=2,68 min.

Example 492

N-(3-Aminopropyl)-4-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)-naphthalen-1-yloxy]-butyramide

To a mixture of 4-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyric acid (example 469, 5.9 g, 16.5 mmol) and 1-hydroxybenzotriazole (3.35 g, 24.8 mmol) in DMF (60 mL) was added 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide hydrochloride (4.75 g, 24.8 mmol) and the resulting mixture was stirred at room temperature for 2 hours. N-(3-aminopropylcarbamic acid tert-butyl ester (3.45 g, 19.8 mmol) was added and the resulting mixture was stirred at room temperature for 16 hours. The mixture was concentrated in vacuo and ethyl acetate and dichloromethane were added to the residue. The mixture was filtered, washed with water and dried in vacuo to afford 4.98 g (59%) of (3-{4-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyrylamino}propyl)carbamic acid tert-butyl ester.

HPLC-MS (Method C): m/z: 515 (M+1); Rt=3.79 min.

(3-{4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy] butyrylamino}-propyl)carbamic acid tert-butyl ester (4.9 g, 9.5 mmol) was added dichloromethane (50 mL) and trifluoroacetic acid (50 mL) and the resulting mixture was stirred at room temperature for 45 minutes. The mixture was concentrated in vacuo and co-evaporated with toluene. To the residue was added ethyl acetate (100 mL) and the mixture was filtered and dried in vacuo to afford the title compound as the trifluoroacetic acid salt.

HPLC-MS (Method C): m/z: 414 (M+1); Rt=2,27 min.

Compounds of the invention includes:

Example 493
Example 494
Example 495
Example 496
Example 497
Example 498
Example 499
Example 500
Example 501
Example 502
Example 503

Example 504 (Prepared analogously to General Procedure (D))

2-{5-[4-(2,4-Thiazolidindion-5-ylidenemethyl)naphthalen-1-yloxy]pentyl}malonic acid

A solution of 4-hydroxy-1-naphtaldehyde (1.0 g, 5.81 mmol), 2-(5-bromopentyl)malonic acid diethyl ester (2.07 g, 6.68 mmol) and potassium carbonate (4.01 g, 29 mmol) in DMF (50 mL) was stirred at 100° C. for 3 hours. The mixture was cooled and the salt was filtered off. The solvent was then removed under reduced pressure to afford 2.9 g of crude 2-[5-(4-formylnaphtalen-1-yloxy)pentyl]malonic acid diethyl ester which was used for the next reaction without further purification.

HPLC-MS (Method C): m/z: 401 (M+1); Rt=5.16 min. ¹H-NMR (DMSO-d₆): δ=1.18 (t, 6H), 1,39 (m, 2H), 1.55 (m, 2H), 1.87 (m, 4H), 3.48 (t, 1H), 4.13 (m, 4H), 4.27 (t, 2H), 7.17 (d, 1H), 7.64(t, 1H), 7.75 (t, 1H), 8.13 (d, 1H), 8.29 (d, 1H), 9.24 (d, 1H), 10.19 (s, 1H). 1.4 g (3.5 mmol) of crude 2-[5-(4-formylnaphtalen-1-yloxy)pentyl]malonic acid diethyl ester was treated with aqueous sodium hydroxide (1N, 8.75 mL, 8.75 mmol) and methanol (50 mL). The solution was stirred at 70° C. for 5 hours and the mixture was concentrated under reduced pressure. Hydrochloric acid (6 N) was added until pH<2. The resulting slurry was stirred untill it solidified. The crystals were filtered off, washed with water and then dried in vacuo to afford 1.1 g (92%) of 2-[5-(4-formylnaphtalen-1-yloxy)pentyl]malonic acid. The product was used in the next step without further purification.

HPLC-MS (Method C): m/z: 345 (M+1); Rt=3.52 min. ¹H-NMR(DMSO-d₆): δ=1,40 (m, 2H), 1.55 (m, 2H), 1.80 (m, 2H), 1.90 (m, 2H), 3.24 (t, 1H), 4.29 (t, 2H), 7.19 (d, 1H), 7.64(t, 1H), 7.75 (t, 1H), 8.14 (d, 1H), 8.30 (d, 1H), 9.23 (d, 1H), 10.18 (s, 1H), 12.69 (s, 2H).

To a solution of 2-[5-(4-formylnaphtalen-1-yloxy) pentyl]malonic acid (0.36 g, 1.05 mmol) in acetic acid (10 mL) was added 2,4-thiazolidindione (0.16 g, 1.36 mmol) and piperidine (0.52 mL, 5.25 mmol). The solution was heated to 105° C. for 24 hours. After cooling to room temperature, the solvents were removed in vacuo. Water was added to the residue. The precipitate was filtered off and washed with water. Recrystalisation from acetonitrile afforded 200 mg (43%) of the title compound as a solid.

HPLC-MS (Method C): m/z: 422 (M-CO₂+Na); Rt=4.08 min. ¹H-NMR(DMSO-d₆): δ=1,41 (m, 2H), 1.55 (m, 4H), 1.88 (m, 2H), 2.23 (t, 1H), 4.24 (t, 2H), 7.61-7.74 (m, 3H), 8.12 (d, 1H), 8.28 (d, 1H), 8.38 (s, 1H), 12.00 (s, 1H), 12.59 (s, 2H).

The following compounds are commercially available and may be prepared according to general procedure (D):

Example 505

Example 506

Example 507

Example 508

Example 509

Example 510

Example 511

The following salicylic acid derivatives do all bind to the His B10 Zn²⁺ site of the insulin hexamer:

Example 512

Salicylic Acid

Example 513

Thiosalicylic acid (or: 2-Mercaptobenzoic acid)

Example 514

2-Hydroxy-5-nitrobenzoic acid

Example 515

3-Nitrosalicyclic acid

Example 516

5,5′-Methylenedisalicylic acid

Example 517

2-Amino-5-trifluoromethylbenzoesyre

Example 518

2-Amino-4-chlorobenzoic acid

Example 519

2-Amino-5-methoxybenzoesyre

Example 520

Example 521

Example 522

Example 523

Example 524

Example 525

Example 526

5-Iodosalicylic acid

Example 527

5-Chlorosalicylic acid

Example 528

1-Hydroxy-2-naphthoic acid

Example 529

3,5-Dihydroxy-2-naphthoic acid

Example 530

3-Hydroxy-2-naphthoic acid

Example 531

3,7-Dihydroxy-2-naphthoic acid

Example 532

2-Hydroxybenzo[a]carbazole-3-carboxylic acid

Example 533

7-Bromo-3-hydroxy-2-naphthoic acid

This compound was prepared according to Murphy et al., J. Med. Chem. 1990, 33, 171-8.

HPLC-MS (Method A): m/z: 267 (M+1); Rt: =3.78 min.

Example 534

1,6-Dibromo-2-hydroxynaphthalene-3-carboxylic acid

This compound was prepared according to Murphy et al., J. Med. Chem. 1990, 33,171-8.

HPLC-MS (Method A): m/z: 346 (M+1); Rt: =4,19 min.

Example 535

7-Formyl-3-hydroxynaphthalene-2-carboxylic acid

A solution of 7-bromo-3-hydroxynaphthalene-2-carboxylic acid (15.0 g, 56.2 mmol) (example 533) in tetrahydrofuran (100 mL) was added to a solution of lithium hydride (893 mg, 112 mmol) in tetrahydrofuran (350 mL). After 30 minutes stirring at room temperature, the resulting solution was heated to 50° C. for 2 minutes and then allowed to cool to ambient temperature over a period of 30 minutes. The mixture was cooled to −78° C., and butyllithium (1.6 M in hexanes, 53 mL, 85 mmol) was added over a period of 15 minutes. N,N-Dimethylformamide (8.7 mL, 8.2 g, 112 mmol) was added after 90 minutes additional stirring. The cooling was discontinued, and the reaction mixture was stirred at room temperature for 17 hours before it was poured into 1N hydrochloric acid (aq.) (750 mL). The organic solvents were evaporated in vacuo, and the resulting precipitate was filtered off and rinsed with water (3×100 mL) to yield the crude product (16.2 g). Purification on silica gel (dichloromethane/methanol/acetic acid =90:9:1) furnished the title compound as a solid.

¹H-NMR (DMSO-d₆): δ 11.95 (1H, bs), 10.02 (1H, s), 8.61 (1H, s), 8.54 (1H, s), 7.80 (2H, bs), 7.24 (1H, s); HPLC-MS (Method (A)): m/z: 217 (M+1); Rt=2.49 min.

Example 536

3-Hydroxy-7-methoxy-2-naphthoic acid

Example 537

4-Amino-2-hydroxybenzoic acid

Example 538

5-Acetylamino-2-hydroxybenzoic acid

Example 539

2-Hydroxy-5-methoxybenzoic acid

The following compounds were prepared as described below:

Example 540

4-Bromo-3-hydroxynaphthalene-2-carboxylic acid

3-Hydroxynaphthalene-2-carboxylic acid (3.0 g, 15.9 mmol) was suspended in acetic acid (40 mL) and with vigorous stirring a solution of bromine (817 μL, 15.9 mmol) in acetic acid (10 mL) was added drop wise during 30 minutes. The suspension was stirred at room temperature for 1 hour, filtered and washed with water. Drying in vacuo afforded 3.74 g (88%) of 4-bromo-3-hydroxynaphthalene-2-carboxylic acid as a solid.

¹H-NMR (DMSO-d₆): δ 7.49 (1H, t), 7.75 (1H, t), 8.07 (2H, “t”), 8.64 (1H, s). The substitution pattern was confirmed by a COSY experiment, showing connectivities between the 3 (4 hydrogen) “triplets”. HPLC-MS (Method A): m/z: 267 (M+1); Rt=3.73 min.

Example 541

3-Hydroxy-4-iodonaphthalene-2-carboxylic acid

3-Hydroxynaphthalene-2-carboxylic acid (0.5 g, 2.7 mmol) was suspended in acetic acid (5 mL) and with stirring iodine monochloride (135 μL, 2.7 mml) was added. The suspension was stirred at room temperature for 1 hour, filtered and washed with water. Drying afforded 0.72 g (85%) of 4-iodo-3-hydroxynaphthalene-2-carboxylic acid as a solid.

¹H-NMR (DMSO-d₆): δ 7.47 (1H, t), 7.73 (1H, t), 7.98 (1H, d), 8.05 (1H, d), 8.66 (1H, s).

HPLC-MS (Method A): m/z: 315 (M+1); Rt=3.94 min.

Example 542

2-Hydroxy-5-[(4-methoxyphenylamino)methyl]benzoic acid

p-Anisidine (1.3 g, 10.6 mmol) was dissolved in methanol (20 mL) and 5-formylsalicylic acid (1.75 g, 10.6 mmol)was added and the resulting mixture was stirred at room temperature for 16 hours. The solid formed was isolated by filtration, re-dissolved in N-methylpyrrolidone (20 mL) and methanol (2 mL). To the mixture was added sodium cyanoborohydride (1.2 g) and the mixture was heated to 70° C. for 3 hours. To the cooled mixture was added ethyl acetate (100 mL) and the mixture was extracted with water (100 mL) and saturated aqueous ammonium chloride (100 mL). The combined aqueous phases were concentrated in vacuo and a 2 g aliquot was purified by SepPac chromatography eluting with mixtures of aetonitrile and water containing 0.1% trifluoroacetic acid to afford the title compound.

HPLC-MS (Method A): m/z: 274 (M+1); Rt=1.77 min.

¹H-NMR (methanol-d₄): δ 3.82 (3H, s), 4.45 (2H, s), 6.96 (1H, d), 7.03 (2H, d), 7.23 (2H, d), 7.45 (1H, dd), 7.92 (1H, d).

Example 543

2-Hydroxy-5-(4-methoxyphenylsulfamoyl)benzoic acid

A solution of 5-chlrosulfonylsalicylic acid (0.96 g, 4.1 mmol) in dichloromethane (20 mL) and triethylamine (1.69 mL, 12.2 mmol) was added p-anisidine (0.49 g, 4.1 mmol) and the resulting mixture was stirred at room temperature for 16 hours. The mixture was added dichloromethane (50 mL) and was washed with water (2×100 mL). Drying (MgSO₄) of the organic phase and concentration in vacuo afforded 0.57 g crude product. Purification by column chromatography on silica gel eluting first with ethyl acetate:heptane (1:1) then with methanol afforded 0.1 g of the title compound.

HPLC-MS (Method A): m/z: 346 (M+23); Rt=2.89 min.

¹H-NMR (DMSO-d₆): δ 3.67 (3H, s), 6.62 (1H, d), 6.77 (2H, d), 6.96 (2H, d), 7.40 (1H, dd), 8.05 (1H, d), 9.6 (1H, bs). General Procedure (E) for Preparation of Compounds of General Formula I₄: wherein Lea is a leaving group such as Cl, Br, I or OSO₂CF₃, R is hydrogen or C₁-C₆-alkyl, optionally the two R-groups may together form a 5-8 membered ring, a cyclic boronic acid ester, and J is as defined above.

An analogous chemical transformation has previously been described in the literature (Bumagin et al., Tetrahedron, 1997, 53, 14437-14450). The reaction is generally known as the Suzuki coupling reaction and is generally performed by reacting an aryl halide or triflate with an arylboronic acid or a heteroarylboronic acid in the presence of a palladium catalyst and a base such as sodium acetate, sodium carbonate or sodium hydroxide. The solvent can be water, acetone, DMF, NMP, HMPA, methanol, ethanol toluene or a mixture of two or more of these solvents. The reaction is performed at room temperature or at elevated temperature.

The general procedure (E) is further illustrated in the following example:

Example 544 (General Procedure (E))

7-(4-Acetylphenyl)-3-hydroxynaphthalene-2-carboxylic acid

To 7-bromo-3-hydroxynaphthalene-2-carboxylic acid (100 mg, 0.37 mmol) (example 533) was added a solution of 4-acetylphenylboronic acid (92 mg, 0.56 mmol) in acetone (2.2 mL) followed by a solution of sodium carbonate (198 mg, 1.87 mmol) in water (3.3 mL). A suspension of palladium(II) acetate (4 mg, 0.02 mmol) in acetone (0.5 mL) was filtered and added to the above solution. The mixture was purged with N₂ and stirred vigorously for 24 hours at room temperature. The reaction mixture was poured into 1N hydrochloric acid (aq.) (60 mL) and the precipitate was filtered off and rinsed with water (3×40 mL). The crude product was dissolved in acetone (25 mL) and dried with magnesium sulfate (1 h). Filtration followed by concentration furnished the title compound as a solid (92 mg).

¹H-NMR (DMSO-d₆): δ 12.60 (1H, bs), 8.64 (1H, s), 8.42 (1H, s), 8.08 (2H, d), 7.97 (2H, d), 7.92 (2H, m), 7.33 (1H, s), 2.63 (3H, s); HPLC-MS (Method (A): m/z: 307 (M+1); Rt=3.84 min.

The compounds in the following examples were prepared in a similar fashion. Optionally, the compounds can be further purified by recrystallization from e.g. ethanol or by chromatography.

Example 545 (General Procedure (E))

3-Hydroxy-7-(3-methoxyphenyl)naphthalene-2-carboxylic acid

HPLC-MS (Method (A)): m/z: 295 (M+1); Rt=4.60 min.

Example 546 (General Procedure (E))

3-Hydroxy-7-phenylnaphthalene-2-carboxylic acid

HPLC-MS (Method (A)): m/z: 265 (M+1); Rt=4.6 min.

Example 547 (General Procedure (E))

3-Hydroxy-7-p-tolyinaphthalene-2-carboxylic acid

HPLC-MS (Method (A)): m/z: 279 (M+1); Rt=4.95 min.

Example 548 (General Procedure (E))

7-(4-Formylphenyl)-3-hydroxynaphthalene-2-carboxylic acid

HPLC-MS (Method (A)): m/z: 293 (M+1); Rt=4.4 min.

Example 549 (General Procedure (E))

6-Hydroxy-[1,2]binaphthalenyl-7-carboxylic acid

HPLC-MS (Method (A)): m/z: 315 (M+1); Rt=5.17 min.

Example 550 (General Procedure (E))

7-(4-Carboxy-phenyl)-3-hydroxynaphthalene-2-carboxylic acid

HPLC-MS (Method (A)): m/z: 309 (M+1); Rt=3.60 min.

Example 551 (General Procedure (E))

7-Benzofuran-2-yl-3-hydroxynaphthalene-2-carboxylic acid

HPLC-MS (Method (A)): m/z: 305 (M+1); Rt=4.97 min.

Example 552 (General Procedure (E))

3-Hyd roxy-7-(4-methoxyphenyl)-naphthalene-2-carboxylic acid

HPLC-MS (Method (A)): m/z: 295 (M+1); Rt=4.68 min.

Example 553 (General Procedure (E))

7-(3-Ethoxyphenyl)-3-hydroxynaphthalene-2-carboxylic acid

HPLC-MS (Method (A)): m/z: 309 (M+1); Rt=4.89 min.

Example 554 (General Procedure (E))

7-Benzo[1,3]dioxol-5-yl-3-hydroxynaphthalene-2-carboxylic acid

HPLC-MS (Method (A)): m/z: 309 (M+1); Rt=5.61 min.

Example 555 (General Procedure (E))

7-Biphenyl-3-yl-3-hydroxynaphthalene-2-carboxylic acid

HPLC-MS (Method (A)): m/z: 341 (M+1); Rt=5.45 min. General Procedure (F) for Preparation of Compounds of General Formula I₅: wherein R³⁰ is hydrogen or C₁-C₆-alkyl and T is as defined above This general procedure (F) is further illustrated in the following example:

Example 556 (General Procedure (F))

3-Hydroxy-7-[(4-(2-propyl)phenylamino)methyl]naphthalene-2-carboxylic acid

7-Formyl-3-hydroxynaphthalene-2-carboxylic acid (40 mg, 0.19 mmol) (example 535) was suspended in methanol (300 μL). Acetic acid (16 μL, 17 mg, 0.28 mmol) and 4-(2-propyl)aniline (40 μL, 40 mg, 0.30 mmol) were added consecutively, and the resulting mixture was stirred vigorously at room temperature for 2 hours. Sodium cyanoborohydride (1.0 M in tetrahydrofuran, 300 μL, 0.3 mmol) was added, and the stirring was continued for another 17 hours. The reaction mixture was poured into 6 N hydrochloric acid (aq.) (6 mL), and the precipitate was filtered off and rinsed with water (3×2 mL) to yield the title compound (40 mg) as its hydrochloride salt. No further purification was necessary.

¹H-NMR (DMSO-d₆): δ 10.95 (1H, bs), 8.45 (1H, s), 7.96 (1H, s), 7.78 (1H, d), 7.62 (1H, d), 7.32 (1H, s), 7.13 (2H, bd), 6.98 (2H, bd), 4.48 (2H, s), 2.79 (1H, sept), 1.14 (6H, d); HPLC-MS (Method (A)): m/z: 336 (M+1); Rt=3.92 min.

The compounds in the following examples were made using this general procedure (F).

Example 557 (General Procedure (F))

7-{[(4-Bromophenyl)amino]methyl}-3-hydroxynaphthalene-2-carboxylic acid

HPLC-MS (Method C): m/z: 372 (M+1); Rt=4.31 min.

Example 558 (General Procedure (F))

7-{[(3,5-Dichlorophenyl)amino]methyl}-3-hydroxynaphthalene-2-carboxylic acid

HPLC-MS (Method C): m/z: 362 (M+1); Rt=4.75 min.

Example 559 (General Procedure (F))

7-{[(Benzothiazol-6-yl)amino]methyl}-3-hydroxynaphthalene-2-carboxylic acid

HPLC-MS (Method C): m/z: 351 (M+1); Rt=3.43 min.

Example 560 (General Procedure (F))

3-Hydroxy-7-{[(quinolin-6-yl)amino]methyl}naphthalene-2-carboxylic acid

HPLC-MS (Method C): m/z: 345 (M+1); Rt=2.26 min.

Example 561 (General Procedure (F))

3-Hydroxy-7-{[(4-methoxyphenyl)amino]methyl}naphthalene-2-carboxylic acid

HPLC-MS (Method C): m/z: 324 (M+1); Rt=2.57 min.

Example 562 (General Procedure (F))

7-{[(2,3-Dihydrobenzofuran-5-ylmethyl)amino]methyl}-3-hydroxynaphthalene-2-carboxylic acid

HPLC-MS (Method C): m/z: 350 (M+1); Rt=2.22 min.

Example 563 (General Procedure (F))

7-{[(4-Chlorobenzyl)amino]methyl}-3-hydroxynaphthalene-2-carboxylic acid

HPLC-MS (Method C): m/z: 342 (M+1); Rt=2.45 min.

Example 564 (General Procedure (F))

3-Hydroxy-7-{[(naphthalen-1-ylmethyl)amino]methyl}naphthalene-2-carboxylic acid

HPLC-MS (Method C): m/z: 357 (M+1); Rt=2.63 min.

Example 565 (General Procedure (F))

7-{[(Biphenyl-2-ylmethyl)amino]methyl}-3-hydroxynaphthalene-2-carboxylic acid

HPLC-MS (Method C): m/z: 384 (M+1); Rt=2.90 min.

Example 566 (General Procedure (F))

3-Hydroxy-7-{[(4-phenoxybenzyl)amino]methyl}naphthalene-2-carboxylic acid

HPLC-MS (Method C): m/z: 400 (M+1); Rt=3.15 min.

Example 567 (General Procedure (F))

3-Hydroxy-7-{[(4-methoxybenzyl)amino]methyl}naphthalene-2-carboxylic acid

HPLC-MS (Method C): m/z: 338 (M+1); Rt=2.32 min. General Procedure (G) for Preparation of Compounds of General Formula I₆: wherein J is as defined above and the moiety (C₁-C₆-alkanoyl)₂O is an anhydride.

The general procedure (G) is illustrated by the following example:

Example 568 (General Procedure (G))

N-Acetyl-3-hydroxy-7-[(4-(2-propyl)phenylamino)methyl]naphthalene-2-carboxylic acid

3-Hydroxy-7-[(4-(2-propyl)phenylamino)methyl]naphthalene-2-carboxylic acid (25 mg, 0.07 mmol) (example 556) was suspended in tetrahydrofuran (200 μL). A solution of sodium hydrogencarbonate (23 mg, 0.27 mmol) in water (200 μL) was added followed by acetic anhydride (14 μL, 15 mg, 0.15 mmol). The reaction mixture was stirred vigorously for 65 hours at room temperature before 6 N hydrochloric acid (4 mL) was added. The precipitate was filtered off and rinsed with water (3×1 mL) to yield the title compound (21 mg). No further purification was necessary.

¹H-NMR (DMSO-d₆): δ 10.96 (1H, bs), 8.48 (1H, s), 7.73 (1H, s), 7.72 (1H, d), 7.41 (1H, dd), 7.28 (1H, s), 7.23 (2H, d), 7.18 (2H, d), 4.96 (2H, s), 2.85 (1H, sept), 1.86 (3H, s), 1.15 (6H, d); HPLC-MS (Method (A)): m/z: 378 (M+1); Rt=3.90 min.

The compounds in the following examples were prepared in a similar fashion.

Example 569 (General Procedure (G))

N-Acetyl-7-{[(4-bromophenyl)amino]methyl}-3-hydroxynaphthalene-2-carboxylic acid

HPLC-MS (Method C): m/z: 414 (M+1); Rt=3.76 min.

Example 570 (General Procedure (G))

N-Acetyl-7-{[(2,3-dihydrobenzofuran-5-ylmethyl)amino]methyl}-3-hydroxynaphthalene-2-carboxylic acid

HPLC-MS (Method C): m/z: 392 (M+1); Rt=3.26 min.

Example 571 (General Procedure (G))

N-Acetyl-7-{[(4-chlorobenzyl)amino]methyl}-3-hydroxynaphthalene-2-carboxylic acid

HPLC-MS (Method C): m/z: 384 (M+1); Rt=3.67 min.

Compounds of the invention may also include tetrazoles:

Example 572

5-(3-(Naphthalen-2-yloxymethyl)-phenyl)-1H-tetrazole

To a mixture of 2-naphthol (10 g, 0.07 mol) and potassium carbonate (10 g, 0.073 mol) in acetone (150 mL), alpha-bromo-m-tolunitril (13.6 g, 0.07 mol) was added in portions. The reaction mixture was stirred at reflux temperature for 2.5 hours. The cooled reaction mixture was filtered and evaporated in vacuo affording an oily residue (19 g) which was dissolved in diethyl ether (150 mL) and stirred with a mixture of active carbon and MgSO₄ for 16 hours. The mixture was filtered and evaporated in vacuo affording crude 18.0 g (100%) of 3-(naphthalen-2-yloxymethyl)-benzonitrile as a solid.

12 g of the above benzonitrile was recrystallised from ethanol (150 mL) affording 8.3 g (69%) of 3-(naphthalen-2-yloxymethyl)-benzonitrile as a solid.

M.p. 60-61° C.

Calculated for C₁₈H₁₃NO: C, 83.37%; H, 5.05%; N, 5.40%; Found C, 83.51%; H, 5.03%; N, 5.38%.

To a mixture of sodium azide (1.46 g, 22.5 mmol) and ammonium chloride (1.28 g, 24.0 mmol) in dry dimethylformamide (20 mL) under an atmosphere of nitrogen, 3-(naphthalen-2-yloxymethyl)-benzonitrile (3.9 g, 15 mmol) was added and the reaction mixture was stirred at 125° C. for 4 hours. The cooled reaction mixture was poured on to ice water (300 mL) and acidified to pH=1 with 1N hydrochloric acid. The precipitate was filtered off and washed with water, dried at 100° C. for 4 hours affording 4.2 g (93%) of the title compound.

M.p. 200-202° C.

Calculated for C₁₈H₁₄N₄O: C, 71.51%; H, 4.67%; N, 18.54%; Found C, 72.11%; H, 4.65%; N, 17.43%.

¹H NMR (400 MHz, DMSO-d₆) δ_H 5.36 (s, 2H), 7.29 (dd, 1H), 7.36 (dt, 1H), 7.47 (m, 2H), 7.66 (t, 1H), 7.74 (d, 1H), 7.84 (m, 3H), 8.02 (d, 1H), 8.22 (s, 1H).

Example 573

N-(3-(Tetrazol-5-yl)phenyl)-2-naphtoic acid amide

2-Naphtoic acid (10 g, 58 mmol) was dissolved in dichloromethane (100 mL) and N,N-dimethylformamide (0.2 mL) was added followed by thionyl chloride (5.1 ml, 70 mmol). The mixture was heated at reflux temperature for 2 hours. After cooling to room temperature, the mixture was added dropwise to a mixture of 3-aminobenzonitril (6.90 g, 58 mmol) and triethyl amine (10 mL) in dichloromethane (75 mL). The resulting mixture was stirred at room temperature for 30 minutes. Water (50 mL) was added and the volatiles was exaporated in vacuo. The resulting mixture was filtered and the filter cake was washed with water followed by heptane (2×25 mL). Drying in vacuo at 50° C. for 16 hours afforded 15.0 g (95%) of N-(3-cyanophenyl)-2-naphtoic acid amide.

M.p. 138-140° C.

The above naphthoic acid amide (10 g, 37 mmol) was dissolved in N,N-dimethylformamide (200 mL) and sodium azide (2.63 g, 40 mmol) and ammonium chloride (2.16 g, 40 mmol) were added and the mixture heated at 125° C. for 6 hours. Sodium azide (1.2 g) and ammonium chloride (0.98 g) were added and the mixture heated at 125° C. for 16 hours. After cooling, the mixture was poured into water (1.5 I) and stirred at room temperature for 30 minutes. The solid formed was filtered off, washed with water and dried in vacuo at 50° C. for 3 days affording 9.69 g (84%) of the title compound as a solid which could be further purified by treatment with ethanol at reflux temperature.

¹H NMR (200 MHz, DMSO-d₆): δ_H 7.58-7.70 (m, 3H), 7.77 (d, 1H), 8.04-8.13 (m, 5H), 8.65 (d, 1H), 10.7 (s, 1H).

Calculated for C₁₈H₁₃N₅O, 0.75H₂O: C, 65.74%; H, 4.44%; N, 21.30%. Found: C, 65.58%; H, 4.50%; N, 21.05%.

Example 574

5-[3-(Biphenyl-4-yloxymethyl)phenyl]-1H-tetrazole

To a solution of 4-phenylphenol (10.0 g, 59 mmol) in dry N,N-dimethyl-formamide (45 mL) kept under an atmosphere of nitrogen, sodium hydride (2.82 g, 71 mmol, 60% dispersion in oil) was added in portions and the reaction mixture was stirred until gas evolution ceased. A solution of m-cyanobenzyl bromide (13 g, 65 mmol) in dry N,N-dimethylformamide (45 mL) was added dropwise and the reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was poured on to ice water (150 mL). The precipitate was filtered of and washed with 50% ethanol (3×50 mL), ethanol (2×50 mL), diethyl ether (80 mL), and dried in vacuo at 50° C. for 18 hours affording crude 17.39 g of 3-(biphenyl-4-yloxymethyl)-benzonitrile as a solid.

¹H NMR (200 MHz, CDCl₃) δ_H 5.14 (s, 2H), 7.05 (m, 2H), 7.30-7.78 (m, 11H).

To a mixture of sodium azide (2.96 g, 45.6 mmol) and ammonium chloride (2.44 g, 45.6 mmol) in dry N,N-dimethylformamide (100 mL) under an atmosphere of nitrogen, 3-(biphenyl-4-yloxymethyl)-benzonitrile (10.0 g, 35.0 mmol) was added and the reaction mixture was stirred at 125° C. for 18 hours. The cooled reaction mixture was poured on to a mixture of 1N hydrochloric acid (60 mL) and ice water (500 mL). The precipitate was filtered off and washed with water (3×100 mL), 50% ethanol (3×100 mL), ethanol (50 mL), diethyl ether (50 mL), ethanol (80 mL), and dried in vacuo at 50° C. for 18 hours affording 8.02 g (70%) of the title compound.

¹H NMR (200 MHz, DMSO-d₆) δ_H 5.31 (s, 2H), 7.19 (m, 2H), 7.34 (m, 1H), 7.47 (m, 2H), 7.69 (m, 6H), 8.05 (dt, 1H), 8.24 (s, 1H).

Example 575

5-(3-Phenoxymethyl)-phenyl)-tetrazole

3-Bromomethylbenzonitrile (5.00 g, 25.5 mmol) was dissolved in N,N-dimethylformamide (50 mL), phenol (2.40 g, 25.5 mmol) and potassium carbonate (10.6 g, 77 mmol) were added.

The mixture was stirred at room temperature for 16 hours. The mixture was poured into water (400 mL) and extracted with ethyl acetate (2×200 mL). The combined organic extracts were washed with water (2×100 mL), dried (MgSO₄) and evaporated in vacuo to afford 5.19 g (97%) 3-(phenoxymethyl)benzonitrile as an oil.

TLC: R_f=0.38 (Ethyl acetate/heptane =1:4)

The above benzonitrile (5.19 g, 24.8 mmol) was dissolved in N,N-dimethylformamide (100 mL) and sodium azide (1.93 g, 30 mmol) and ammonium chloride (1.59 g, 30 mmol) were added and the mixture was heated at 140° C. for 16 hours. After cooling, the mixture was poured into water (800 mL). The aqeous mixture was washed with ethyl acetate (200 mL). The pH of the aqueous phase was adjusted to 1 with 5 N hydrochloric acid and stirred at room temperature for 30 minutes. Filtration, washing with water and drying in vacuo at 50° C. afforded 2.06 g (33%) of the title compound as a solid.

¹H NMR (200 MHz, CDCl₃+DMSO-d₆) δ_H 5.05 (s, 2H), 6.88 (m, 3H), 7.21 (m, 2H), 7.51 (m, 2H), 7.96 (dt, 1H), 8.14 (s, 1H).

Example 576

5-[3-(Biphenyl-4-ylmethoxy)phenyl]-1H-tetrazole

To a solution of 3-cyanophenol (5.0 g, 40.72 mmol) in dry N,N-dimethylformamide (100 mL) kept under an atmosphere of nitrogen, sodium hydride (2 g, 48.86 mmol, 60% dispersion in oil) was added in portions and the reaction mixture was stirred until gas evolution ceased. p-Phenylbenzyl chloride (9.26 g, 44.79 mmol) and potassium iodide (0.2 g, 1.21 mmol) were added and the reaction mixture was stirred at room temperature for 60 hours. The reaction mixture was poured on to a mixture of saturated sodium carbonate (100 mL) and ice water (300 mL). The precipitate was filtered of and washed with water (3×100 mL), n-hexane (2×80 mL) and dried in vacuo at 50° C. for 18 hours affording 11.34 g (98%) of 3-(biphenyl-4-ylmethoxy)-benzonitrile as a solid.

To a mixture of sodium azide (2.37 g, 36.45 mmol) and ammonium chloride (1.95 g, 36.45 mmol) in dry N,N-dimethylformamide (100 mL) under an atmosphere of nitrogen, 3-(biphenyl-4-ylmethoxy)-benzonitrile (8.0 g, 28.04 mmol) was added and the reaction mixture was stirred at 125° C. for 18 hours. To the cooled reaction mixture water (100 mL) was added and the reaction mixture stirred for 0.75 hour. The precipitate was filtered off and washed with water, 96% ethanol (2×50 mL), and dried in vacuo at 50° C. for 18 hours affording 5.13 g (56%) of the title compound.

¹H NMR (200 MHz, DMSO-d₆) δ_H 5.29 (s, 2H), 7.31 (dd, 1H), 7.37-7.77 (m, 12H).

Example 577

5-[4-(Biphenyl-4-ylmethoxy)-3-methoxyphenyl]-1H-tetrazol

This compound was made similarly as described in example 576.

Example 578

Example 579

5-(2-Naphtylmethyl)-1H-tetrazole

This compound was prepared similarly as described in example 572, step 2.

Example 580

5-(1-Naphtylmethyl)-1H-tetrazole

This compound was prepared similarly as described in example 572, step 2.

Example 581

5-[4-(Biphenyl-4-yloxymethyl)phenyl]-1H-tetrazole

A solution of alpha-bromo-p-tolunitrile (5.00 g, 25.5 mmol), 4-phenylphenol (4.56 g, 26.8 mmol), and potassium carbonate (10.6 g, 76.5 mmol) in N,N-dimethylformamide (75 mL) was stirred vigorously for 16 hours at room temperature. Water (75 mL) was added and the mixture was stirred at room temperature for 1 hour. The precipitate was filtered off and washed with thoroughly with water. Drying in vacuo over night at 50° C. afforded 7.09 g (97%) of 4-(biphenyl-4-yloxymethyl)benzonitrile as a solid.

The above benzonitrile (3.00 g, 10.5 mmol) was dissolved in N,N-dimethylformamide (50 mL), and sodium azide (1.03 g, 15.8 mmol) and ammonium chloride (0.84 g, 15.8 mmol) were added and the mixture was stirred 16 hours at 125° C. The mixture was cooled to room temperature and water (50 mL) was added. The suspension was stirred overnight, filtered, washed with water and dried in vacuo at 50° C. for 3 days to give crude 3.07 g (89%) of the title compound. From the mother liquor crystals were colected and washed with water, dried by suction to give 0.18 g (5%) of the title compound as a solid.

¹H NMR (200 MHz, DMSO-d₆): δ_H 5.21 (s, 2H), 7.12 (d, 2H), 7.30 (t, 1H), 7.42 (t, 2H), 7.56-7.63 (m, 6H), 8.03 (d, 2H).

Calculated for C₂₀H₁₆N₄O, 2H₂O: C, 65.92%; H, 5.53%; N, 15.37%. Found: C, 65.65%; H, 5.01%; N, 14.92%

Example 582

This compound was prepared similarly as described in example 576.

Example 583

Example 584

Example 585

Example 586

5-(3-(Biphenyl-4-yloxymethyl)-benzyl)-1H-tetrazole

Example 587

5-(1-Naphthyl)-1H-tetrazole

This compound was prepared similarly as described in example 572, step 2.

Example 588

5-[3-Methoxy-4-(4-methylsulfonylbenzyloxy)phenyl]-1H-tetrazole

This compound was made similarly as described in example 576.

Example 589

5-(2-Naphthyl)-1H-tetrazole

This compound was prepared similarly as described in example 572, step 2.

Example 590

2-Amino-N-(1H-tetrazol-5-yl)-benzamide

Example 591

5-(4-Hydroxy-3-methoxyphenyl)-1H-tetrazole

This compound was prepared similarly as described in example 572, step 2.

Example 592

4-(2H-Tetrazol-5-ylmethoxy)benzoic acid

To a mixture of methyl 4-hydroxybenzoate (30.0 g, 0.20 mol), sodium iodide (30.0 g, 0.20 mol) and potassium carbonate (27.6 g, 0.20 mol) in acetone (2000 mL) was added chloroacetonitrile (14.9 g, 0.20 mol). The mixture was stirred at RT for 3 days. Water was added and the mixture was acidified with 1N hydrochloric acid and the mixture was extracted with diethyl ether. The combined organic layers were dried over Na₂SO₄ and concentrated in vacuo. The residue was dissolved in acetone and chloroacetonitrile (6.04 g, 0.08 mol), sodium iodide (12.0 g, 0.08 mol) and potassium carbonate (11.1 g, 0.08 mol) were added and the mixture was stirred for 16 hours at RT and at 60° C. More chloroacetonitrile was added until the conversion was 97%. Water was added and the mixture was acidified with 1N hydrochloric acid and the mixture was extracted with diethyl ether. The combined organic layers were dried over Na₂SO₄ and concentrated in vacuo to afford methyl 4-cyanomethyloxybenzoate in quantitative yield. This compound was used without further purification in the following step.

A mixture of methyl 4-cyanomethyloxybenzoate (53.5 g, 0.20 mol), sodium azide (16.9 g, 0.26 mol) and ammonium chloride (13.9 g, 0.26 mol) in DMF 1000 (mL) was refluxed overnight under N₂. After cooling, the mixture was concentrated in vacuo. The residue was suspended in cold water and extracted with ethyl acetate. The combined organic phases were washed with brine, dried over Na₂SO₄ and concentrated in vacuo, to afford methyl 4-(2H-tetrazol-5-ylmethoxy)benzoate. This compound was used as such in the following step.

Methyl 4-(2H-Tetrazol-5-ylmethoxy)-benzoate was refluxed in 3N sodium hydroxide. The reaction was followed by TLC (DCM:MeOH =9:1). The reaction mixture was cooled, acidified and the product filtered off. The impure product was washed with DCM, dissolved in MeOH, filtered and purified by column chromatography on silica gel (DCM:MeOH =9:1).The resulting product was recrystallised from DCM:MeOH=95:5. This was repeated until the product was pure. This afforded 13.82 g (30%) of the title compound.

¹H-NMR (DMSO-d₆): 4.70 (2H, s), 7.48 (2H, d), 7.73 (2H, d), 13 (1H, bs).

Example 593

4-(2H-Tetrazol-5-ylmethylsulfanyl)benzoic acid

To a solution of sodium hydroxide (10.4 g, 0.26 mol) in degassed water (600 mL) was added 4-mercaptobenzoic acid (20.0 g, 0.13 mol). This solution was stirred for 30 minutes. To a solution of potassium carbonate (9.0 g, 65 mmol) in degassed water (400 mL) was added chloroacetonitrile (9.8 g, (0.13 mol) portion-wise. These two solutions were mixed and stirred for 48 hours at RT under N₂. The mixture was filtered and washed with heptane. The aqueous phase was acidified with 3N hydrochloric acid and the product was filtered off, washed with water and dried, affording 4-cyanomethylsulfanylbenzoic acid (27.2 g, 88%). This compound was used without further purification in the following step.

A mixture of 4-cyanomethylsulfanylbenzoic acid (27.2 g, 0.14 mol), sodium azide (11.8 g, 0,18 mol) and ammonium chloride (9.7 g, 0.18 mol) in DMF (1000 mL) was refluxed overnight under N₂. The mixture was concentrated in vacuo. The residue was suspended in cold water and extracted with diethyl ether. The combined organic phases were washed with brine, dried over Na₂SO₄ and concentrated in vacuo. Water was added and the precipitate was filtered off. The aqueous layer was concentrated in vacuo, water was added and the precipitate filtered off. The combined impure products were purified by column chromatography using DCM:MeOH =9:1 as eluent, affording the title compound (5.2 g, 16%).

¹H-NMR (DMSO-d₆): 5.58 (2H, s), 7.15 (2H, d), 7.93 (2H, d), 12.7 (1H, bs).

Example 594

3-(2H-Tetrazol-5-yl)-9H-carbazole

3-Bromo-9H-carbazole was prepared as described by Smith et al. in Tetrahedron 1992, 48, 7479-7488.

A solution of 3-bromo-9H-carbazole (23.08 g, 0.094 mol) and cuprous cyanide (9.33 g, 0.103 mol) in N-methyl-pyrrolidone (300 ml) was heated at 200° C. for 5 h. The cooled reaction mixture was poured on to water (600 ml) and the precipitate was filtered off and washed with ethyl acetate (3×50 ml). The filtrate was extracted with ethyl acetate (3×250 ml) and the combined ethyl acetate extracts were washed with water (150 ml), brine (150 ml), dried (MgSO₄) and concentrated in vacuo. The residue was crystallised from heptanes and recrystallised from acetonitrile (70 ml) affording 7.16 g (40%) of 3-cyano-9H-carbazole as a solid.

M.p. 180-181° C.

3-Cyano-9H-carbazole (5.77 g, 30 mmol) was dissolved in N,N-dimethylformamide (150 ml), and sodium azide (9.85 g, 152 mmol), ammonium chloride (8.04 g, 150 mmol) and lithium chloride (1.93 g, 46 mmol) were added and the mixture was stirred for 20 h at 125° C. To the reaction mixture was added an additional portion of sodium azide (9.85 g, 152 mmol) and ammonium chloride (8.04 g, 150 mmol) and the reaction mixture was stirred for an additional 24 h at 125° C. The cooled reaction mixture was poured on to water (500 ml). The suspension was stirred for 0.5 h, and the precipitate was filtered off and washed with water (3×200 ml) and dried in vacuo at 50° C. The dried crude product was suspended in diethyl ether (500 ml) and stirred for 2 h, filtered off and washed with diethyl ether (2×200 ml) and dried in vacuo at 50° C. affording 5.79 g (82%) of the title compound as a solid.

¹H-NMR (DMSO-d₆): δ 11.78 (1H, bs), 8.93 (1H, d), 8.23 (1H, d), 8.14 (1H, dd), 7.72 (1H, d), 7.60 (1H, d), 7.49 (1H, t), 7.28 (1H, t); HPLC-MS (Method C): m/z: 236 (M+1); Rt=2.77 min.

The following commercially available tetrazoles do all bind to the His B10 Zn²⁺ site of the insulin hexamer:

Example 595

5-(3-Tolyl)-1H-tetrazole

Example 596

5-(2-Bromophenyl)tetrazole

Example 597

5-(4-Ethoxalylamino-3-nitrophenyl)tetrazole

Example 598

Example 599

Example 600

Example 601

Example 602

Tetrazole

Example 603

5-Methyltetrazole

Example 604

5-Benzyl-2H-tetrazole

Example 605

4-(2H-Tetrazol-5-yl)benzoic acid

Example 606

5-Phenyl-2H-tetrazole

Example 607

5-(4-Chlorophenylsulfanylmethyl)-2H-tetrazole

Example 608

5-(3-Benzyloxyphenyl)-2H-tetrazole

Example 609

2-Phenyl-6-(1H-tetrazol-5-yl)-chromen-4-one

Example 610

Example 611

Example 612

Example 613

Example 614

Example 615

5-(4-Bromo-phenyl)-1H-tetrazole

Example 616

Example 617

Example 618

Example 619

Example 620

Example 621

Example 622

Example 623

Example 624

Example 625

Example 626

Example 627

Example 628

Example 629

Example 630

Example 631

Example 632

Example 633

Example 634

Example 635

Example 636

Example 637

Example 638

Example 639

Example 640

Example 641

Example 642

Example 643

Example 644

Example 645

Example 646

5-(2,6-Dichlorobenzyl)-2H-tetrazole

General Procedure (H) for Preparation of Compounds of General Formula I₇: wherein K, M, and T are as defined above.

The reaction is generally known as a reductive alkylation reaction and is generally performed by stirring an aldehyde with an amine at low pH (by addition of an acid, such as acetic acid or formic acid) in a solvent such as THF, DMF, NMP, methanol, ethanol, DMSO, dichloromethane, 1,2-dichloroethane, trimethyl orthoformate, triethyl orthoformate, or a mixture of two or more of these. As reducing agent sodium cyano borohydride or sodium triacetoxy borohydride may be used. The reaction is performed between 20° C. and 120° C., preferably at room temperature.

When the reductive alkylation is complete, the product is isolated by extraction, filtration, chromatography or other methods known to those skilled in the art.

The general procedure (H) is further illustrated in the following example 647:

Example 647 (General Procedure (H))

Biphenyl-4-ylmethyl-[3-(2H-tetrazol-5-yl)phenyl]amine

A solution of 5-(3-aminophenyl)-2H-tetrazole (example 874, 48 mg, 0.3 mmol) in DMF (250 μL) was mixed with a solution of 4-biphenylylcarbaldehyde (54 mg, 0.3 mmol) in DMF (250 μL) and acetic acid glacial (250 μL) was added to the mixture followed by a solution of sodium cyano borohydride (15 mg, 0.24 mmol) in methanol (250 μL). The resulting mixture was shaken at room temperature for 2 hours. Water (2 mL) was added to the mixture and the resulting mixture was shaken at room temperature for 16 hours. The mixture was centrifugated (6000 rpm, 10 minutes) and the supernatant was removed by a pipette. The residue was washed with water (3 mL), centrifugated (6000 rpm, 10 minutes) and the supernatant was removed by a pipette. The residue was dried in vacuo at 40° C. for 16 hours to afford the title compound as a solid.

HPLC-MS (Method C): m/z: 328 (M+1), 350 (M+23); Rt=4.09 min.

Example 648 (General Procedure (H))

Benzyl-[3-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 252 (M+1); Rt=3,74 min.

Example 649 (General Procedure (H))

(4-Methoxybenzyl)-[3-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 282,2 (M+1); Rt=3,57 min.

Example 650 (General Procedure (H))

4-{[3-(2H-Tetrazol-5-yl)phenylamino]methyl}phenol

HPLC-MS (Method D): m/z: 268,4 (M+1); Rt=2,64 min.

Example 651 (General Procedure (H))

(4-Nitrobenzyl)-[3-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 297,4 (M+1); Rt=3,94 min.

Example 652 (General Procedure (H))

(4-Chlorobenzyl)-[3-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 287,2 (M+1); Rt=4,30 min.

Example 653 (General Procedure (H))

(2-Chlorobenzyl)-[3-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 286 (M+1); Rt=4,40 min.

Example 654 (General Procedure (H))

(4-Bromobenzyl)-[3-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z:332 (M+1); Rt=4,50 min.

Example 655 (General Procedure (H))

(3-Benzyloxybenzyl)-[3-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 358 (M+1); Rt=4,94 min.

Example 656 (General Procedure (H))

Naphthalen-1-ylmethyl-[3-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 302 (M+1); Rt=4,70 min.

Example 657 (General Procedure (H))

Naphthalen-2-ylmethyl-[3-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 302 (M+1); Rt=4,60 min.

Example 658 (General Procedure (H))

4-{[3-(2H-Tetrazol-5-yl)phenylamino]methyl}benzoic acid

HPLC-MS (Method D): m/z: 296 (M+1); Rt=3,24 min.

Example 659 (General Procedure (H))

[3-(2H-Tetrazol-5-yl)-phenyl]-[3-(3-trifluoromethyl-phenoxy)benzyl]amine

HPLC-MS (Method D): m/z: 412 (M+1); Rt=5,54 min.

Example 660 (General Procedure (H))

(3-Phenoxybenzyl)-[3-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 344 (M+1); Rt=5,04 min.

Example 661 (General Procedure (H))

(4-Phenoxy-benzyl)-[3-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 344 (M+1); Rt=5,00 min.

Example 662 (General Procedure (H))

(4-{[3-(2H-Tetrazol-5-yl)phenylamino]methyl}phenoxy)acetic acid

HPLC-MS (Method D): m/z: 326 (M+1); Rt=3,10 min.

Example 663 (General Procedure (H))

(4-Benzyloxybenzyl)-[3-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 358 (M+1); Rt=4,97 min.

Example 664 (General Procedure (H))

3-(4-{[3-(2H-Tetrazol-5-yl)phenylamino]methyl}phenyl)acrylic acid

HPLC-MS (Method D): m/z: 322 (M+1); Rt=3,60 min.

Example 665 (General Procedure (H))

Dimethyl-(4-{[3-(2H-tetrazol-5-yl)phenylamino]methyl}naphthalen-1-yl)amine

HPLC-MS (Method D): m/z: 345 (M+1); Rt=3,07 min.

Example 666 (General Procedure (H))

(4′-Methoxybiphenyl-4-ylmethyl)-[3-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 358 (M+1); Rt=4,97 min.

Example 667 (General Procedure (H))

(2′-Chlorobiphenyl-4-ylmethyl)-[3-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 362 (M+1); Rt=5,27 min.

Example 668 (General Procedure (H))

Benzyl-[4-(2H-tetrazol-5-yl)phenyl]amine

For preparation of starting material, see example 875.

HPLC-MS (Method D): m/z: 252 (M+1); Rt=3,97 min.

Example 669 (General Procedure (H))

(4-Methoxybenzyl)-[4-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 282 (M+1); Rt=3,94 min.

Example 670 (General Procedure (H))

4-{[4-(2H-Tetrazol-5-yl)phenylamino]methyl}phenol

HPLC-MS (Method D): m/z: 268 (M+1); Rt=3,14 min.

Example 671 (General Procedure (H))

(4-Nitrobenzyl)-[4-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: (M+1); Rt=3,94 min.

Example 672 (General Procedure (H))

(4-Chlorobenzyl)-[4-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: (M+1); Rt=4,47 min.

Example 673 (General Procedure (H))

(2-Chlorobenzyl)-[4-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 286 (M+1); Rt=4,37 min.

Example 674 (General Procedure (H))

(4-Bromobenzyl)-[4-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 331 (M+1); Rt=4,57 min.

Example 675 (General Procedure (H))

(3-Benzyloxybenzyl)-[4-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 358 (M+1); Rt=5,07 min.

Example 676 (General Procedure (H))

Naphthalen-1-ylmethyl-[4-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 302 (M+1); Rt=4,70 min.

Example 677 (General Procedure (H))

Naphthalen-2-ylmethyl-[4-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 302 (M+1); Rt=4,70 min.

Example 678 (General Procedure (H))

Biphenyl-4-ylmethyl-[4-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 328 (M+1); Rt=5,07 min.

Example 679 (General Procedure (H))

4-{[4-(2H-Tetrazol-5-yl)phenylamino]methyl}benzoic acid

HPLC-MS (Method D): m/z: 296 (M+1); Rt=3,34 min.

Example 680 (General Procedure (H))

[4-(2H-Tetrazol-5-yl)phenyl]-[3-(3-trifluoromethylphenoxy)benzyl]amine

HPLC-MS (Method D): m/z: 412 (M+1); Rt=5,54 min.

Example 681 (General Procedure (H))

(3-Phenoxybenzyl)-[4-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 344 (M+1); Rt=5,07 min.

Example 682 (General Procedure (H))

(4-Phenoxybenzyl)-[4-(2H-tetrazol-5-yl)-phenyl]-amine

HPLC-MS (Method D): m/z: 344 (M+1); Rt=5,03 min.

Example 683 (General Procedure (H))

3-{[4-(2H-Tetrazol-5-yl)phenylamino]methyl}benzoic acid

HPLC-MS (Method D): m/z: 286 (M+1); Rt=3,47 min.

Example 684 (General Procedure (H))

(4-{[4-(2H-Tetrazol-5-yl)phenylamino]methyl}phenoxy)acetic acid

HPLC-MS (Method D): m/z: 326 (M+1); Rt=3,40 min.

Example 685 (General Procedure (H))

(4-Benzyloxybenzyl)-[4-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 358 (M+1); Rt=5,14 min.

Example 686 (General Procedure (H))

3-(4-{[4-(2H-Tetrazol-5-yl)phenylamino]methyl}phenyl)acrylic acid

HPLC-MS (Method D): m/z: 322 (M+1); Rt=3,66 min.

Example 687 (General Procedure (H))

Dimethyl-(4-{[4-(2H-tetrazol-5-yl)phenylamino]methyl}naphthalen-1-yl)amine

HPLC-MS (Method D): m/z: 345 (M+1); Rt=3,10 min.

Example 688 (General Procedure (H))

(4′-Methoxybiphenyl-4-ylmethyl)-[4-(2H-tetrazol-5-yl)phenyl]amine

HPLC-MS (Method D): m/z: 358 (M+1); Rt=5,04 min.

Example 689 (General Procedure (H))

(2′-Chlorobiphenyl-4-ylmethyl)-[4-(2H-tetrazol-5-yl)-phenyl]-amine

HPLC-MS (Method D): m/z: 362 (M+1); Rt=5,30 min.

General procedure (I) for preparation of compounds of general formula 18: wherein K, M and T are as defined above.

This procedure is very similar to general procedure (A), the only difference being the carboxylic acid is containing a tetrazole moiety. When the acylation is complete, the product is isolated by extraction, filtration, chromatography or other methods known to those skilled in the art.

The general procedure (I) is further illustrated in the following example 690:

Example 690 (General Procedure (I))

4-[4-(2H-Tetrazol-5-yl)benzoylamino]benzoic acid

To a solution of 4-(2H-tetrazol-5-yl)benzoic acid (example 605, 4 mmol) and HOAt (4.2 mmol) in DMF (6 mL) was added 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide hydrochloride (4.2 mmol) and the resulting mixture was stirred at room temperature for 1 hour. An alquot of this HOAt-ester solution (0.45 mL) was mixed with 0.25 mL of a solution of 4-aminobenzoic acid (1.2 mmol in 1 mL DMF). (Anilines as hydrochlorides can also be utilised, a slight excess of triethylamine was added to the hydrochloride suspension in DMF prior to mixing with the HOAt-ester.) The resulting mixture was shaken for 3 days at room temperature. 1N hydrochloric acid (2 mL) was added and the mixture was shaken for 16 hours at room temperature. The solid was isolated by centrifugation (alternatively by filtration or extraction) and was washed with water (3 mL). Drying in vacuo at 40° C. for 2 days afforded the title compound.

HPLC-MS (Method D): m/z: 310 (M+1); Rt=2.83 min.

Example 691 (General Procedure (I))

3-[4-(2H-Tetrazol-5-yl)benzoylamino]benzoic acid

HPLC-MS (Method D): m/z: 310 (M+1); Rt=2.89 min.

Example 692 (General Procedure (I))

3-{4-[4-(2H-Tetrazol-5-yl)benzoylamino]phenyl}acrylic acid

HPLC-MS (Method D): m/z: 336 (M+1); Rt=3.10 min.

Example 693 (General Procedure (I))

3-{4-[4-(2H-Tetrazol-5-yl)benzoylamino]phenyl}propionic acid

HPLC-MS (Method D): m/z: 338 (M+1); Rt=2.97 min.

Example 694 (General Procedure (I))

3-Methoxy-4-[4-(2H-tetrazol-5-yl)benzoylamino]benzoic acid

HPLC-MS (Method D): m/z: 340 (M+1); Rt=3.03 min.

Example 695 (General Procedure (I))

N-(4-Benzyloxyphenyl)-4-(2H-tetrazol-5-yl)benzamide

HPLC-MS (Method D): m/z: 372 (M+1); Rt=4.47 min.

Example 696 (General Procedure (I))

N-(4-Phenoxyphenyl)-4-(2H-tetrazol-5-yl)benzamide

HPLC-MS (Method D): m/z: 358 (M+1); Rt=4.50 min.

Example 697 (General Procedure (I))

N-(9H-Fluoren-2-yl)-4-(2H-tetrazol-5-yl)benzamide

HPLC-MS (Method D): m/z: 354 (M+1); Rt=4.60 min.

Example 698 (General Procedure (I))

N-(9-Ethyl-9H-carbazol-2-yl)-4-(2H-tetrazol-5-yl)benzamide

HPLC-MS (Method D): m/z: 383 (M+1); Rt=4.60 min.

Example 699 (General Procedure (I))

N-Phenyl-4-(2H-tetrazol-5-yl)benzamide

HPLC-MS (Method D): m/z: 266 (M+1); Rt=3.23 min.

Example 700 (General Procedure (I))

4-[4-(2H-Tetrazol-5-ylmethoxy)benzoylamino]benzoic acid

The starting material was prepared as described in example 592.

HPLC-MS (Method D): m/z: 340 (M+1); Rt=2.83 min.

Example 701 (General Procedure (I))

3-[4-(2H-Tetrazol-5-ylmethoxy)benzoylamino]benzoic acid

HPLC-MS (Method D): m/z: 340 (M+1); Rt=2.90 min.

Example 702 (General Procedure (I))

3-{4-[4-(2H-Tetrazol-5-ylmethoxy)benzoylamino]phenyl}acrylic acid

HPLC-MS (Method D): m/z: 366 (M+1); Rt=3.07 min.

Example 703 (General Procedure (I))

3-{4-[4-(2H-Tetrazol-5-ylmethoxy)benzoylamino]phenyl}propionic acid

HPLC-MS (Method D): m/z: 368 (M+1); Rt=2.97 min.

Example 704 (General Procedure (I))

3-Methoxy-4-[4-(2H-tetrazol-5-ylmethoxy)benzoylamino]benzoic acid

HPLC-MS (Method D): m/z: 370 (M+1); Rt=3.07 min.

Example 705 (General Procedure (I))

N-(4-Benzyloxyphenyl)-4-(2H-tetrazol-5-ylmethoxy)benzamide

HPLC-MS (Method D): m/z: 402 (M+1); Rt=4.43 min.

Example 706 (General Procedure (I))

N-(4-Phenoxyphenyl)-4-(2H-tetrazol-5-ylmethoxy)benzamide

HPLC-MS (Method D): m/z: 388 (M+1); Rt=4.50 min.

Example 707 (General Procedure (I))

N-(9H-Fluoren-2-yl)-4-(2H-tetrazol-5-ylmethoxy)benzamide

HPLC-MS (Method D): m/z: 384 (M+1); Rt=4.57 min.

Example 708 (General Procedure (I))

N-(9-Ethyl-9H-carbazol-2-yl)-4-(2H-tetrazol-5-ylmethoxy)benzamide

HPLC-MS (Method D): m/z: 413 (M+1); Rt=4.57 min.

Example 709 (General Procedure (I))

N-Phenyl-4-(2H-tetrazol-5-ylmethoxy)benzamide

HPLC-MS (Method D): m/z: 296 (M+1); Rt=3.23 min.

Example 710 (General Procedure (I))

4-[4-(2H-Tetrazol-5-ylmethylsulfanyl)benzoylamino]benzoic acid

The starting material was prepared as described in example 593.

HPLC-MS (Method D): m/z: 356 (M+1); Rt=2.93 min.

Example 711 (General Procedure (I))

3-[4-(2H-Tetrazol-5-ylmethylsulfanyl)benzoylamino]benzoic acid

HPLC-MS (Method D): m/z: 356 (M+1); Rt=3.00 min.

Example 712 (General Procedure (I))

3-{4-[4-(2H-Tetrazol-5-ylmethylsulfanyl)benzoylamino]phenyl}acrylic acid

HPLC-MS (Method D): m/z: 382 (M+1); Rt=3.26 min.

Example 713 (General Procedure (I))

3-{4-[4-(2H-Tetrazol-5-ylmethylsulfanyl)benzoylamino]phenyl}propionic acid

HPLC-MS (Method D): m/z: 384 (M+1); Rt=3.10 min.

Example 714 (General Procedure (I)) 3-Methoxy-4-[4-(2H-tetrazol-5-ylmethylsulfanyl)benzoylamino]benzoic acid

HPLC-MS (Method D): m/z: 386 (M+1); Rt=3.20 min.

Example 715 (General Procedure (I))

N-(4-Benzyloxyphenyl)-4-(2H-tetrazol-5-ylmethylsulfanyl)benzamide

HPLC-MS (Method D): m/z: 418 (M+1); Rt=4.57 min.

Example 716 (General Procedure (I))

N-(4-Phenoxyphenyl)-4-(2H-tetrazol-5-ylmethylsulfanyl)benzamide

HPLC-MS (Method D): m/z: 404 (M+1); Rt=4.60 min.

Example 717 (General Procedure (I))

N-(9H-Fluoren-2-yl)-4-(2H-tetrazol-5-ylmethylsulfanyl)benzamide

HPLC-MS (Method D): m/z: 400 (M+1); Rt=4.67 min.

Example 718 (General Procedure (I))

N-(9-Ethyl-9H-carbazol-2-yl)-4-(2H-tetrazol-5-ylmethylsulfanyl)benzamide

HPLC-MS (Method D): m/z: 429 (M+1); Rt=4.67 min.

Example 719 (General Procedure (I))

N-Phenyl-4-(2H-tetrazol-5-ylmethylsulfanyl)benzamide

HPLC-MS (Method D): m/z: 312 (M+1); Rt=3.40 min. General Procedure (J) for Solution Phase Preparation of Amides of General Formula I₉: wherein T is as defined above.

This general procedure (J) is further illustrated in the following example.

Example 720 (General Procedure (J))

9-(3-Chlorobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

3-(2H-Tetrazol-5-yl)-9H-carbazole (example 594,17 g, 72.26 mmol) was dissolved in N,N-dimethylformamide (150 mL). Triphenylmethyl chloride (21.153 g, 75.88 mmol) and triethylamine (20.14 mL, 14.62 g, 144.50 mmol) were added consecutively. The reaction mixture was stirred for 18 hours at room temperature, poured into water (1.5 L) and stirred for an additional 1 hour. The crude product was filtered off and dissolved in dichloromethane (500 mL). The organic phase was washed with water (2×250 mL) and dried with magnesium sulfate (1 h). Filtration followed by concentration yielded a solid which was triturated in heptanes (200 mL). Filtration furnished 3-[2-(triphenylmethyl)-2H-tetrazol-5-yl]-9H-carbazole (31.5 g) which was used without further purification.

¹H-NMR (CDCl₃): δ8.87 (1H, d), 8.28 (1H, bs), 8.22 (1H, dd), 8.13 (1H, d), 7.49 (1H, d), 7.47-7.19 (18H, m); HPLC-MS (Method C): m/z: 243 (triphenylmethyl); Rt=5.72 min.

3-[2-(Triphenylmethyl)-2H-tetrazol-5-yl]-9H-carbazole (200 mg, 0.42 mmol) was dissolved in methyl sulfoxide (1.5 mL). Sodium hydride (34 mg, 60%, 0.85 mmol) was added, and the resulting suspension was stirred for 30 min at room temperature. 3-Chlorobenzyl chloride (85 μL, 108 mg, 0.67 mmol) was added, and the stirring was continued at 40° C. for 18 hours. The reaction mixture was cooled to ambient temperature and poured into 0.1 N hydrochloric acid (aq.) (15 mL). The precipitated solid was filtered off and washed with water (3×10 mL) to furnish 9-(3-chlorobenzyl)-3-[2-(triphenylmethyl)-2H-tetrazol-5-yl]-9H-carbazole, which was dissolved in a mixture of tetrahydrofuran and 6 N hydrochloric acid (aq.) (9:1) (10 mL) and stirred at room temperature for 18 hours. The reaction mixture was poured into water (100 mL). The solid was filtered off and rinsed with water (3×10 mL) and dichloromethane (3×10 mL) to yield the title compound (127 mg). No further purification was necessary.

¹H-NMR (DMSO-d₆): δ 8.89 (1H, d), 8.29 (1H, d), 8.12 (1H, dd), 7.90 (1H, d), 7.72 (1H, d), 7.53 (1H, t), 7.36-7.27 (4H, m), 7.08 (1H, bt), 5.78 (2H, s); HPLC-MS (Method B): m/z: 360 (M+1); Rt=5.07 min.

The compounds in the following examples were prepared in a similar fashion. Optionally, the compounds can be further purified by recrystallization from e.g. aqueous sodium hydroxide (1N) or by chromatography.

Example 721 (General Procedure (J))

9-(4-Chlorobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 360 (M+1); Rt=4.31 min.

Example 722 (General Procedure (J))

9-(4-Methylbenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 340 (M+1); Rt=4.26 min.

Example 723 (General Procedure (J))

3-(2H-Tetrazol-5-yl)-9-(4-trifluoromethylbenzyl)-9H-carbazole

HPLC-MS (Method C): m/z: 394 (M+1); Rt=4.40 min.

Example 724 (General Procedure (J))

9-(4-Benzyloxybenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 432 (M+1); Rt=4.70 min.

Example 725 (General Procedure (J))

9-(3-Methylbenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 340 (M+1); Rt=4.25 min.

Example 726 (General Procedure (J))

9-Benzyl-3-(2H-tetrazol-5-yl)-9H-carbazole

¹H-NMR (DMSO-d₆): 68.91 (1H, dd), 8.30 (1H, d), 8.13 (1H, dd), 7.90 (1H, d), 7.73 (1H, d), 7.53 (1H, t), 7.36-7.20 (6H, m), 5.77 (2H, s).

Example 727 (General Procedure (J))

9-(4-Phenylbenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

¹H-NMR (DMSO-d₆): δ8.94 (1H, s), 8.33 (1H, d), 8.17 (1H, dd), 7.95 (1H, d), 7.77 (1H, d), 7.61-7.27 (11H, m), 5.82 (2H, s).

Example 728 (General Procedure (J))

9-(3-Methoxybenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 356 (M+1); Rt=3.99 min.

Example 729 (General Procedure (J))

9-(Naphtha len-2-ylmethyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 376 (M+1); Rt=4.48 min.

Example 730 (General Procedure (J))

9-(3-Bromobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 404 (M+1); Rt=4.33 min.

Example 731 (General Procedure (J))

9-(Biphenyl-2-ylmethyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 402 (M+1); Rt=4.80 min.

Example 732 (General Procedure (J))

3-(2H-Tetrazol-5-yl)-9-[4-(1,2,3-thiadiazol-4-yl)benzyl]-9H-carbazole

Example 733 (General Procedure (J))

9-(2′-Cyanobiphenyl-4-ylmethyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

¹H-NMR (DMSO-d₆): δ8.91 (1H, d), 8.31 (1H, d), 8.13 (1H, dd), 7.95 (1H, d), 7.92 (1H, d), 7.78 (1H, d), 7.75 (1H, dt), 7.60-7.47 (5H, m), 7.38-7.28 (3H, m), 5.86 (2H, s); HPLC-MS (Method C): m/z: 427 (M+1); Rt=4.38 min.

Example 734 (General Procedure (J))

9-(4-Iodobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 452 (M+1); Rt=4.37 min.

Example 735 (General Procedure (J))

9-(3,5-Bis(trifluoromethyl)benzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 462 (M+1); Rt=4.70 min.

Example 736 (General Procedure (J))

9-(4-Bromobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

¹H-NMR (DMSO-d₆): δ 8.89 (1H, d), 8.29 (1H, d), 8.11 (1H, dd), 7.88 (1H, d), 7.70 (1H, d), 7.52 (1H, t), 7.49 (2H, d), 7.31 (1H, t), 7.14 (2H, d), 5.74 (2H, s); HPLC-MS (Method C): m/z: 404 (M+1); Rt=4.40 min.

Example 737 (General Procedure (J))

9-(Anthracen-9-ylmethyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 426 (M+1); Rt=4.78 min.

Example 738 (General Procedure (J))

9-(4-Carboxybenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

3.6 fold excess sodium hydride was used.

¹H-NMR (DMSO-d₆): δ 12.89 (1H, bs), 8.89 (1H, d), 8.30 (1H, d), 8.10 (1H, dd), 7.87 (1H, d), 7.86 (2H, d), 7.68 (1H, d), 7.51 (1H, t), 7.32 (1H, t), 7.27 (2H, d), 5.84 (2H, s); HPLC-MS (Method C): m/z: 370 (M+1); Rt=3.37 min.

Alternative mode of preparation of 9-(4-Carboxybenzyl)-3-(2H-tetrazol-5-yl)-9Hcarbazole:

Carbazole (52.26 g, 0.30 mol) was dissolved in dichloromethane (3 L) and silicagel (60 mesh, 600 g) was added to the mixture and the mixture was cooled to 10° C. A mixture of N-bromosuccinimide (NBS, 55 g, 0.30 mol) in dichloromethane (400 mL) was added at 10° C. After addition, the mixture was allowed to reach room temperature. After standing for 42 hours, the mixture was filtered, and the solid was washed with dichloromethane (4×200 mL), the combined filtrates were washed with water (300 mL) and dried over Na₂SO₄. Evaporation in vacuo to dryness afforded 77 g of crude product. Recrystallization from 2-propanol (800 mL) afforded 71% 3-bromocarbazole.

To a stirred solution of 3-bromocarbazole (63 g, 0.256 mol) in N-methylpyrrolidone (900 mL) was added cuprous cyanide (CuCN, 25.22 g, 0.28 mol) and the mixture was heated to 190° C. After 9 hours of heating, the mixture was cooled to room temperature. The mixture was concentrated by bulb-to-bulb distillation (100° C., 0.1 mm Hg). The residue was treated with NH₄OH (25%, 300 mL) and subsequently extracted with ethyl acetate (10%) in toluene. The organic layer was dried over Na₂SO₄ and concentrated by bulb-to-bulb distillation (100° C., 0.1 mm Hg) to give 34 g (70%) of 3-cyanocarbazole.

Sodium hydride 55-60% in mineral oil (3.7 g, 0.093 mol) was added in portions to a stirred, cooled (5° C.) mixture of 3-cyanocarbazole (17.5 g, 0.091 mol) in N,N-dimethylformamide (200 mL). After 0.5 hours, a solution of methyl 4-bromomethylbenzoate (22.9 g, 100 mmol) in N,N-dimethylformamide (80 mL) was added dropwise to the cooled mixture. The mixture was subsequently slowly warmed to room temperature and stirred overnight. The mixture was poured into ice water and extracted with dichloromethane (2×200 mL), the organic layer was washed several times with water, dried over Na₂SO₄ and concentrated in vacuo. A mixture of ethyl acetate and heptane (1/1, 50 mL) was added to the concentrate and the solid was product filtered off. Yield 24 g (78%) of 4-(3-cyanocarbazol-9-ylmethyl)benzoic acid methyl ester.

Sodium azide (7.8 g, 0.12 mol) and ammonium chloride (6.42 g, 0.12 mol) were added to a stirred mixture of 4-(3-cyanocarbazol-9-ylmethyl)benzoic acid methyl ester (24.8 g, 0.073 mol) in N,N-dimethylformamide (130 mL) and the mixture was heated to 110° C. After 48 hours, the mixture was cooled to room temperature and poured into water (500 mL) and cooled to 5° C. Hydrochloric acid (10 N) was then added to pH=2. After stirring for 1 hour at 5° C. the precipitate was filtered off and washed with water. The solid obtained was air dried. Yield 27.9 g of 4-[3-(1H-tetrazol-5-yl)carbazol-9-ylmethyl]benzoic acid methyl ester.

31.1 g of 4-[3-(1H-tetrazol-5-yl)carbazol-9-ylmethyl]benzoic acid methyl ester was added to a solution of sodium hydroxide (8.76 g, 0.219 mol) in water (150 mL) and the mixture was heated to 80° C., after 0.5 h activated carbon (0.5 g) was added and the mixture was filtered through celite. The filtrate was treated with hydrochloric acid (10 N) to pH=1 and the formed precipitate was filtered off and air dried. This procedure was repeated as the first treatment did not give complete hydrolysis of the ester. Finally the product was dissolved in 2-propanol, the filtered the mother liquor was concentrated to approximately 100 mL and the product was isolated by filtration to afford 19 g of the title compound. After evaporation of the mother liquor to dryness and re-treatment with 2-propanol further 8 g of product was isolated resulting in a yield of 90%.

Example 739 (General Procedure (J))

9-(2-Chlorobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method B): m/z: 360 (M+1); Rt=5.30 min.

Example 740 (General Procedure (J))

9-(4-Fluorobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

¹H-NMR (DMSO-d₆): δ 8.88 (1H, d), 8.28 (1H, d), 8.10 (1H, dd), 7.89 (1H, d), 7.72 (1H, d), 7.52 (1H, t), 7.31 (1H, t), 7.31-7.08 (4H, m), 5.74 (2H, s); HPLC-MS (Method C): m/z: 344 (M+1); Rt=4.10 min.

Example 741 (General Procedure (J))

9-(3-Fluorobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

¹H-NMR (DMSO-d₆): δ8.89 (1H, d), 8.29 (1H, d), 8.12 (1H, dd), 7.90 (1H, d), 7.72 (1H, d), 7.53 (1H, t), 7.37-7.27 (2H, m), 7.12-7.02 (2H, m), 6.97 (1H, d), 5.78 (2H, s); HPLC-MS (Method C): m/z: 344 (M+1); Rt=4.10 min.

Example 742 (General Procedure (J))

9-(2-Iodobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 452 (M+1); Rt=4.58 min.

Example 743 (General Procedure (J))

9-(3-Carboxybenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

3.6 fold excess sodium hydride was used.

¹H-NMR (DMSO-d₆): δ 12.97 (1H, bs), 8.90 (1H, bs), 8.30 (1H, d), 8.12 (1H, bd), 7.89 (1H, d), δ 7.82 (1H, m), 7.77 (1H, bs), 7.71 (1H, d), 7.53 (1H, t), 7.46-7.41 (2H, m), 7.32 (1H, t), 5.84 (2H, s); HPLC-MS (Method C): m/z: 370 (M+1); Rt=3.35 min.

Example 744 (General Procedure (J))

9-[4-(2-Propyl)benzyl]-3-(2H-tetrazol-5-yl)-9H-carbazole

¹H-NMR (DMSO-d₆): δ 8.87 (1H, d), 8.27 (1H, d), 8.10 (1H, dd), 7.87 (1H, d), 7.71 (1H, d), 7.51 (1H, t), 7.31 (1H, t), 7.15 (2H, d), 7.12 (2H, d), 5.69 (2H, s), 2.80 (1H, sept), 1.12 (6H, d); HPLC-MS (Method C): m/z: 368 (M+1); Rt=4.73 min.

Example 745 (General Procedure (J))

9-(3,5-Dimethoxybenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 386 (M+1); Rt=4.03 min.

Example 746 (General Procedure (J))

3-(2H-Tetrazol-5-yl)-9-(2,4,5-trifluorobenzyl)-9H-carbazole

HPLC-MS (Method B): m/z: 380 (M+1); Rt=5.00 min.

Example 747 (General Procedure (J))

N-Methyl-N-phenyl-2-[3-(2H-tetrazol-5-yl)carbazol-9-yl]acetamide

HPLC-MS (Method B): m/z: 383 (M+1); Rt=4.30 min.

Example 748 (General Procedure (J))

9-(4-Methoxybenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

¹H-NMR (DMSO-d₆): δ8.86 (1H, d), 8.26 (1H, d), 8.10 (1H, dd), 7.90 (1H, d), 7.73 (1H, d), 7.51 (1H, t), 7.30 (1H, t), 7.18 (2H, d), 6.84 (2H, d), 5.66 (2H, s), 3.67 (3H, s); HPLC-MS (Method B): m/z: 356 (M+1); Rt=4.73 min.

Example 749 (General Procedure (J))

9-(2-Methoxybenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

¹H-NMR (DMSO-d₆): δ8.87 (1H, d), 8.27 (1H, d), 8.09 (1H, dd), 7.77 (1H, d), 7.60 (1H, d), 7.49 (1H, t), 7.29 (1H, t), 7.23 (1H, bt), 7.07 (1H, bd), 6.74 (1H, bt), 6.61 (1H, bd), 5.65 (2H, s), 3.88 (3H, s); HPLC-MS (Method B): m/z: 356 (M+1); Rt=4.97 min.

Example 750 (General Procedure (J))

9-(4-Cyanobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 351 (M+1); Rt=3.74 min.

Example 751 (General Procedure (J))

9-(3-Cyanobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 351 (M+1); Rt=3.73 min.

Example 752 (General Procedure (J))

9-(5-Chloro-2-methoxybenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

¹H-NMR (DMSO-d₆): δ8.87 (1H, d), 8.35 (1H, d), 8.10 (1H, dd), 7.73 (1H, d), 7.59 (1H, d), 7.49 (1H, t), 7.29 (1H, t), 7.27 (1H, dd), 7.11 (1H, d), 6.51 (1H, d), 5.63 (2H, s), 3.88 (3H, s); HPLC-MS (Method C): m/z: 390 (M+1); Rt=4.37 min.

Example 753 (General Procedure (J))

N-Phenyl-2-[3-(2H-tetrazol-5-yl)carbazol-9-yl]acetamide

¹H-NMR (DMSO-d₆): δ 10.54 (1H, s), 8.87 (1H, bs), 8.27 (1H, d), 8.12 (1H, bd), 7.83 (1H, d), 7.66 (1H, d), 7.61 (2H, d), 7.53 (1H,t), 7.32 (1H, t), 7.32 (2H, t), 7.07 (1H, t), 5.36 (2H, s); HPLC-MS (Method C): m/z: 369 (M+1); Rt=3.44 min.

Example 754 (General Procedure (J))

N-Butyl-2-[3-(2H-tetrazol-5-yl)carbazol-9-yl]acetamide

¹H-NMR (DMSO-d₆): δ 8.85 (1H, d), 8.31 (1H, t), 8.25 (1H, d), 8.10 (1H, dd), 7.75 (1H, d), 7.58 (1H, d), 7.52 (1H, t), 7.30 (1H, t), 5.09 (2H, s), 3.11 (2H, q), 1.42 (2H, quint), 1.30 (2H, sext), 0.87 (3H, t); HPLC-MS (Method C): m/z: 349 (M+1); Rt=3.20 min.

Example 755 (General Procedure (J))

9-(2,4-Dichlorobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

¹H-NMR (DMSO-d₆): δ8.92 (1H, d), 8.32 (1H, d), 8.09 (1H, dd), 7.76 (1H, d), 7.74 (1H, d), 7.58 (1H, d), 7.51 (1H, t), 7.33 (1H, t), 7.23 (1H, dd), 6.42 (1H, d), 5.80 (2H, s); HPLC-MS (Method B): m/z: 394 (M+1); Rt=5.87 min.

Example 756 (General Procedure (J))

9-(2-Methylbenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

¹H-NMR (DMSO-d₆): δ8.92 (1H, d), 8.32 (1H, d), 8.08 (1H, dd), 7.72 (1H, d), 7.55 (1H, d), 7.48 (1H, t), 7.32 (1H, t), 7.26 (1H, d), 7.12 (1H, t), 6.92 (1H, t), 6.17 (1H, d), 5.73 (2H, s), 2.46 (3H, s); HPLC-MS (Method B): m/z: 340 (M+1); Rt=5.30 min.

Example 757 (General Procedure (J))

9-(3-N itrobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 371 (M+1); Rt=3.78 min.

Example 758 (General Procedure (J))

9-(3,4-Dichlorobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method B): m/z: 394 (M+1); Rt=5.62 min.

Example 759 (General Procedure (J))

9-(2,4-Difluorobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

¹H-NMR (DMSO-d₆): δ 8.89 (1H, d), 8.29 (1H, d), 8.11 (1H, dd), 7.88 (1H, d), 7.69 (1H, d), 7.52 (1H, t), 7.36-7.24 (2H, m), 7.06-6.91 (2H, m), 5.78 (2H, s); HPLC-MS (Method B): m/z: 362 (M+1); Rt=5.17 min.

Example 760 (General Procedure (J))

9-(3,5-Difluorobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

¹H-NMR (DMSO-d₆): δ8.90 (1H, bs), 8.31 (1H, d), 8.13 (1H, bd), 7.90 (1H, d), 7.73 (1H, d), 7.54 (1H, t), 7.34 (1H, t), 7.14 (1H, t), 6.87 (2H, bd), 5.80 (2H, s); HPLC-MS (Method B): m/z: 362 (M+1); Rt=5.17 min.

Example 761 (General Procedure (J))

9-(3,4-Difluorobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

¹H-NMR (DMSO-d₆): δ 8.89 (1H, bs), 8.29 (1H, d), 8.12 (1H, bd), 7.92 (1H, d), 7.74 (1H, d), 7.54 (1H, t), 7.42-7.25 (3H, m), 6.97 (1H, bm), 5.75 (2H, s); HPLC-MS (Method B): m/z: 362 (M+1); Rt=5.17 min.

Example 762 (General Procedure (J))

9-(3-Iodobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method B): m/z: 452 (M+1); Rt=5.50 min.

Example 763 (General Procedure (J))

3-(2H-Tetrazol-5-yl)-9-[3-(trifluoromethyl)benzyl]-9H-carbazole

¹H-NMR (DMSO-d₆): δ 8.89 (1H, d), 8.30 (1H, d), 8.11 (1H, dd), 7.90 (1H, d), 7.72 (1H, d), 7.67 (1H, bs), 7.62 (1H, bd), 7.53 (1H, t), 7.50 (1H, bt), 7.33 (1H, bd), 7.32 (1H, t), 5.87 (2H, s); HPLC-MS (Method B): m/z: 394 (M+1); Rt=5.40 min.

Example 764 (General Procedure (J))

N-(4-Carboxyphenyl)-2-[3-(2H-tetrazol-5-yl)carbazol-9-yl]acetamide

3.6 fold excess sodium hydride was used.

HPLC-MS (Method B): m/z: 413 (M+1); Rt=3.92 min.

Example 765 (General Procedure (J))

N-(2-Propyl)-2-[3-(2H-tetrazol-5-yl)carbazol-9-yl]acetamide

HPLC-MS (Method B): m/z: 335 (M+1); Rt=3.70 min.

Example 766 (General Procedure (J))

N-Benzyl-N-phenyl-2-[3-(2H-tetrazol-5-yl)carbazol-9-yl]acetamide

HPLC-MS (Method B): m/z: 459 (M+1); Rt=5.37 min.

Example 767 (General Procedure (J))

N-[4-(2-Methyl-2-propyl)phenyl]-2-[3-(2H-tetrazol-5-yl)carbazol-9-yl]acetamide

HPLC-MS (Method B): m/z: 425 (M+1); Rt=5.35 min.

Example 768 (General Procedure (J))

N-Phenethyl-2-[3-(2H-tetrazol-5-yl)carbazol-9-yl]acetamide

HPLC-MS (Method C): m/z: 397 (M+1); Rt=3.43 min.

Example 769 (General Procedure (J))

3-(2H-Tetrazol-5-yl)-9-[2-(trifluoromethyl)benzyl]-9H-carbazole

HPLC-MS (Method C): m/z: 394 (M+1); Rt=4.44 min.

Example 770 (General Procedure (J))

9-[2-Fluoro-6-(trifluoromethyl)benzyl]-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 412 (M+1); Rt=4.21 min.

Example 771 (General Procedure (J))

9-[2,4-Bis(trifluoromethyl)benzyl)]-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 462 (M+1); Rt=4.82 min.

Example 772 (General Procedure (J))

3-(2H-Tetrazol-5-yl)-9-(2,4,6-trimethylbenzyl)-9H-carbazole

HPLC-MS (Method C): m/z: 368 (M+1); Rt=4.59 min.

Example 773 (General Procedure (J))

9-(2,3,5,6-Tetramethylbenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 382 (M+1); Rt=4.47 min.

Example 774 (General Procedure (J))

9-[(Naphthalen-1-yl)methyl]-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 376 (M+1); Rt=4.43 min.

Example 775 (General Procedure (J))

9-[Bis(4-fluorophenyl)methyl]-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 438 (M+1); Rt=4.60 min.

Example 776 (General Procedure (J))

9-(2-Bromobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 404 (M+1); Rt=4.50 min.

Example 777 (General Procedure (J))

9-(2-Fluorobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 344 (M+1); Rt=4.09 min.

Example 778 (General Procedure (J))

9-(4-Carboxy-2-methylbenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

In this preparation, a 3.6-fold excess of sodium hydride was used.

HPLC-MS (Method C): m/z: 384 (M+1); Rt=3.56 min.

Example 779 (General Procedure (J))

9-(2-Phenylethyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 340 (M+1); Rt=4.08 min.

Example 780 (General Procedure (J))

9-[2-Fluoro-5-(trifluoromethyl)benzyl]-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z: 412 (M+1); Rt=4.34 min.

Example 781 (General Procedure (J))

9-(4-Carboxy-2-fluorobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

3-Fluoro-4-methylbenzoic acid (3.0 g, 19.5 mmol) and benzoyl peroxide (0.18 g, 0.74 mmol) were suspended in benzene. The mixture was purged with N₂ and heated to reflux. N-Bromosuccinimide (3.47 g, 19.5 mmol) was added portionwise, and reflux was maintained for 18 hours. The reaction mixture was concentrated, and the residue was washed with water (20 mL) at 70° C. for 1 hour. The crude product was isolated by filtration and washed with additional water (2×10 mL). The dry product was recrystallized from heptanes. Filtration furnished 4-bromomethyl-3-fluorobenzoic acid (1.92 g) which was used in the following step according to General Procedure (J).

In this preparation, a 3.6-fold excess of sodium hydride was used.

HPLC-MS (Method C): m/z: 388 (M+1); Rt=3.49 min.

Example 782 (General Procedure (J))

5-{4-[[(3-(2H-Tetrazol-5-yl)carbazol-9-yl)methyl]naphthalen-1-yl]oxy}pentanoic acid

5-[(4-Formylnaphthalen-1-yl)oxy]pentanoic acid intermediate obtained in example 470(3.0 g, 11.0 mmol) was dissolved in a mixture of methanol and tetrahydrofuran (9:1) (100 mL), and sodium borohydride (1.67 g, 44.1 mmol) was added portionwise at ambient temperature. After 30 minutes, the reaction mixture was concentrated to 50 mL and added to hydrochloric acid (0.1N, 500 mL). Additional hydrochloric acid (1N, 40 mL) was added, and 5-[(4-hydroxymethyl-naphthalen-1-yl)oxy]pentanoic acid (2.90 g) was collected by filtration. To the crude product was added concentrated hydrochloric acid (100 mL), and the suspension was stirred vigorously for 48 hours at room temperature. The crude product was filtered off and washed with water, until the pH was essentially neutral. The material was washed with heptanes to furnish 5-[(4-chloromethylnaphthalen-1-yl)oxy]pentanoic acid (3.0 g) which was used in the following step according to General Procedure (J).

In this preparation, a 3.6-fold excess of sodium hydride was used.

HPLC-MS (Method C): m/z: 492 (M+1); Rt=4.27 min.

Example 783 (General Procedure (J))

9-(2,3-Difluorobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z=362 (M+1); Rt=4.13 min.

Example 784 (General Procedure (J))

9-(2,5-Difluorobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z=362 (M+1); Rt=4.08 min.

Example 785 (General Procedure (J))

9-Pentafluorophenylmethyl-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z=416 (M+1); Rt=4.32 min.

Example 786 (General Procedure (J))

9-(2,6-Difluorobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole

HPLC-MS (Method C): m/z=362 (M+1); Rt=3.77 min.

Further compounds of the invention that may be prepared according to general procedure (J), and includes:

Example 787
Example 788
Example 789
Example 790
Example 791
Example 792
Example 793
Example 794
Example 795
Example 796
Example 797
Example 798
Example 799

The following compounds of the invention may be prepared eg. from 9-(4-bromobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole (example 736) or from 9-(3-bromobenzyl)-3-(2H-tetrazol-5-yl)-9H-carbazole (example 730) and aryl boronic acids via the Suzuki coupling reaction eg as described in Littke, Dai & Fu J. Am. Chem. Soc., 2000, 122, 4020-8 (or references cited therein), or using the methodology described in general procedure (E), optionally changing the palladium catalyst to bis(tri-tert-butylphosphine)palladium (0).

Example 800
Example 801
Example 802
Example 803
Example 804
Example 805

General Procedure (K) for Preparation of Compounds of General Formula I₁₀: wherein T is as defined above.

The general procedure (K) is further illustrated by the following example:

Example 806 (General Procedure (K))

1-Benzyl-5-(2H-tetrazol-5-yl)-1H-indole

5-Cyanoindole (1.0 g, 7.0 mmol) was dissolved in N,N-dimethylformamide (14 mL) and cooled in an ice-water bath. Sodium hydride (0.31 g, 60%, 7.8 mmol) was added, and the resulting suspension was stirred for 30 min. Benzyl chloride (0.85 mL, 0.94 g, 7.4 mmol) was added, and the cooling was discontinued. The stirring was continued for 65 hours at room temperature. Water (150 mL) was added, and the mixture was extracted with ethyl acetate (3×25 mL). The combined organic phases were washed with brine (30 mL) and dried with sodium sulfate (1 hour). Filtration and concentration yielded the crude material. Purification by flash chromatography on silica gel eluting with ethyl acetate/heptanes =1:3 afforded 1.60 g 1-benzyl-1H-indole-5-carbonitrile.

HPLC-MS (Method C): m/z: 233 (M+1); Rt=4.17 min.

1-Benzyl-1H-indole-5-carbonitrile was transformed into 1-benzyl-5-(2H-tetrazol-5-yl)-1H-indole by the method described in general procedure (J) and in example 594. Purification was done by flash chromatography on silica gel eluting with dichloromethane/methanol =9:1.

HPLC-MS (Method C): m/z: 276 (M+1); Rt=3.35 min.

The compounds in the following examples were prepared by the same procedure.

Example 807 (General Procedure (K))

1-(4-Bromobenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method C): m/z: 354 (M+1); Rt=3.80 min.

Example 808 (General Procedure (K))

1-(4-Phenylbenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

¹H-NMR (200 MHz, DMSO-d₆): δ=5.52 (2H, s), 6.70 (1H, d), 7.3-7.45 (6H, m), 7.6 (4H, m), 7.7-7.8 (2H, m), 7.85(1H, dd), 8.35 (1H, d).

Calculated for C₂₂H₁₇N₅, H₂O: 73.32% C, 5.03% H, 19.43% N. Found: 73.81% C, 4.90% H, 19.31% N.

Example 809

4′-[5-(2H-Tetrazol-5-yl)indol-1-ylmethyl]biphenyl-4-carboxylic acid

5-(2H-Tetrazol-5-yl)-1H-indole (Syncom BV, Groningen, NL) (1.66 g, 8.9 mmol) was treated with trityl chloride (2.5 g, 8.9 mmol) and triethyl amine (2.5 mL, 17.9 mmol) in DMF(25 mL) by stirring at RT overnight. The resulting mixture was treated with water. The gel was isolated, dissolved in methanol, treated with activated carbon; filtered and evaporated to dryness in vacuo. This afforded 3.6 g (94%) of crude 5-(2-trityl-2H-tetrazol-5-yl)-1H-indole.

HPLC-MS (Method C): m/z=450 (M+23); Rt. =5.32 min. 4-Methylphenylbenzoic acid (5 g, 23.5 mmol) was mixed with CCl₄ (100 mL) and under an atmosphere of nitrogen, the slurry was added N-Bromosuccinimide (4.19 g, 23.55 mmol) and dibenzoyl peroxide (0.228 g, 0.94 mmol). The mixture was subsequently heated to reflux for 0.5 hour. After cooling, DCM and water (each 30 mL) were added. The resulting precipitate was isolated, washed with water and a small amount of methanol. The solid was dried in vacuo to afford 5.27 g (77%) of 4′-bromomethylbiphenyl-4-carboxylic acid.

HPLC-MS (Method C): m/z=291 (M+1); Rt. =3.96 min.

5-(2-Trityl-2H-tetrazol-5-yl)-1H-indole (3.6 g, 8.4 mmol) was dissolved in DMF (100 mL). Under nitrogen, NaH (60% suspension in mineral oil, 34 mmol) was added slowly. 4′-Bromomethylbiphenyl-4-carboxylic acid (2.7 g, 9.2 mmol) was added over 5 minutes and the resulting slurry was heated at 40° C. for 16 hours. The mixture was poured into water (100 mL) and the precipitate was isolated by filtration and treated with THF/6N HCl (9/1) (70 mL) at room temperature for 16 hours. The mixture was subsequently evaporated to dryness in vacuo, the residue was treated with water and the solid was isolated by filtration and washed thoroughly 3 times with DCM. The solid was dissolved in hot THF (400 mL) treated with activated carbon and filtered. The filtrate was evaporated in vacuo to dryness. This afforded 1.6 g (50%) of the title compound.

HPLC-MS (Method C): m/z=396 (M+1); Rt. =3.51 min.

Example 810 (General Procedure (K))

5-(2H-Tetrazol-5-yl)-1H-indole

5-(2H-Tetrazol-5-yl)-1H-indole was prepared from 5-cyanoindole according to the method described in example 594.

HPLC-MS (Method C): m/z: 186 (M+1); Rt=1.68 min.

Example 811 (General Procedure (K))

1-Benzyl-4-(2H-tetrazol-5-yl)-1H-indole

1-Benzyl-1H-indole-4-carbonitrile was prepared from 4-cyanoindole according to the method described in example 806.

HPLC-MS (Method C): m/z: 233 (M+1); Rt=4.24 min.

1-Benzyl-4-(2H-tetrazol-5-yl)-1H-indole was prepared from 1-benzyl-1H-indole-4-carbonitrile according to the method described in example 594.

HPLC-MS (Method C): m/z: 276 (M+1); Rt=3.44 min. General Procedure (L) for Preparation of Compounds of General Formula I₁₁: wherein T is as defined above and

• Pol- is a polystyrene resin loaded with a 2-chlorotrityl linker, graphically shown below:

This general procedure (L) is further illustrated by the following example:

Example 812 (General Procedure (L))

5-(2H-Tetrazol-5-yl)-1-[3-(trifluoromethyl)benzyl]-1H-indole

2-Chlorotritylchloride resin (100 mg, 0.114 mmol active chloride) was swelled in dichloromethane (2 mL) for 30 min. The solvent was drained, and a solution of 5-(2H-tetrazol-5-yl)-1H-indole (example 810) (63 mg, 0.34 mmol) in a mixture of N,N-dimethylformamide, dichloromethane and N,N-di(2-propyl)ethylamine (DIPEA) (5:5:2) (1.1 mL) was added. The reaction mixture was shaken at room temperature for 20 hours. The solvent was removed by filtration, and the resin was washed consecutively with N,N-dimethylformamide (2×4 mL), dichloromethane (6×4 mL) and methyl sulfoxide (2×4 mL). Methyl sulfoxide (1 mL) was added, followed by the addition of a solution of lithium bis(trimethylsilyl)amide in tetrahydrofuran (1.0 M, 0.57 mL, 0.57 mmol). The mixture was shaken for 30 min at room temperature, before 3-(trifluoromethyl)benzyl bromide (273 mg, 1.14 mmol) was added as a solution in methyl sulfoxide (0.2 mL). The reaction mixture was shaken for 20 hours at room temperature. The drained resin was washed consecutively with methyl sulfoxide (2×4 mL), dichloromethane (2×4 mL), methanol (2×4 mL), dichloromethane (2×4 mL) and tetrahydrofuran (4 mL). The resin was treated with a solution of hydrogen chloride in tetrahydrofuran, ethyl ether and ethanol=8:1:1 (0.1M, 3 mL) for 6 hours at room temperature. The resin was drained and the filtrate was concentrated in vacuo. The crude product was re-suspended in dichloromethane (1.5 mL) and concentrated three times to afford the title compound (35 mg). No further purification was necessary.

HPLC-MS (Method B): m/z: 344 (M+1); Rt=4.35 min.

¹H-NMR (DMSO-d₆): δ 8.29 (1H, s), 7.80 (1H, dd), 7.72 (2H, m), 7.64 (2H, bs), 7.56 (1H, t), 7.48 (1H, d), 6.70 (1H, d), 5.62 (2H, s).

The compounds in the following examples were prepared in a similar fashion. Optionally, the compounds can be further purified by recrystallization or by chromatography.

Example 813 (General Procedure (L))

1-(4-Chlorobenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 310 (M+1); Rt=4.11 min.

Example 814 (General Procedure (L))

1-(2-Chlorobenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 310 (M+1); Rt=4.05 min.

Example 815 (General Procedure (L))

1-(4-Methoxybenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 306 (M+1); Rt=3.68 min.

Example 816 (General Procedure (L))

1-(4-Methylbenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 290 (M+1); Rt=3.98 min.

Example 817 (General Procedure (L))

5-(2H-Tetrazol-5-yl)-1-[4-(trifluoromethyl)benzyl]-1H-indole

HPLC-MS (Method B): m/z: 344 (M+1); Rt=4.18 min.

Example 818 (General Procedure (L))

1-(3-Chlorobenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 310 (M+1); Rt=4.01 min.

Example 819 (General Procedure (L))

1-(3-Methylbenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 290 (M+1); Rt=3.98 min.

Example 820 (General Procedure (L))

1-(2,4-Dichlorobenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 344 (M+1); Rt=4.41 min.

Example 821 (General Procedure (L))

1-(3-Methoxybenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 306 (M+1); Rt=3.64 min.

Example 822 (General Procedure (L))

1-(4-Fluorobenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 294 (M+1); Rt=3.71 min.

Example 823 (General Procedure (L))

1-(3-Fluorobenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 294 (M+1); Rt=3.68 min.

Example 824 (General Procedure (L))

1-(2-Iodobenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 402 (M+1); Rt=4.11 min.

Example 825 (General Procedure (L))

1-[(Naphthalen-2-yl)methyl]-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 326 (M+1); Rt=4.18 min.

Example 826 (General Procedure (L))

1-(3-Bromobenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 354 (M+1); Rt=4.08 min.

Example 827 (General Procedure (L))

1-(4-Carboxybenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

In this preparation, a larger excess of lithium bis(trimethylsilyl)amide in tetrahydrofuran (1.0 M, 1.7 mL, 1.7 mmol) was used.

HPLC-MS (Method B): m/z: 320 (M+1); Rt=2.84 min.

Example 828 (General Procedure (L))

1-(3-Carboxybenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

In this preparation, a larger excess of lithium bis(trimethylsilyl)amide in tetrahydrofuran (1.0 M, 1.7 mL, 1.7 mmol) was used.

HPLC-MS (Method B): m/z: 320 (M+1); Rt=2.91 min.

Example 829 (General Procedure (L))

1-(2,4-Difluorobenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 312 (M+1); Rt=3.78 min.

Example 830 (General Procedure (L))

1-(3,5-Difluorobenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 312 (M+1); Rt=3.78 min.

Example 831 (General Procedure (L))

1-(3,4-Difluorobenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 312 (M+1); Rt=3.81 min.

Example 832 (General Procedure (L))

1-[4-(2-Propyl)benzyl]-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 318 (M+1); Rt=4.61 min.

Example 833 (General Procedure (L))

1-(3,5-Dimethoxybenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 336 (M+1); Rt=3.68 min.

Example 834 (General Procedure (L))

1-(2′-Cyanobiphenyl-4-ylmethyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 377 (M+1); Rt=4.11 min.

Example 835 (General Procedure (L))

1-(2-Methylbenzyl)-5-(2H-tetrazol-5-yl)-1H-indole

HPLC-MS (Method B): m/z: 290 (M+1); Rt=3.98 min.

Further compounds of the invention that may be prepared according to general procedure (K) and/or (L) includes:

Example 836
Example 837
Example 838
Example 839
Example 840
Example 841
Example 842
Example 843
Example 844
Example 845
Example 846
Example 847
Example 848
Example 849
Example 850
Example 851
Example 852
Example 853
Example 854
Example 855
Example 856
Example 857
Example 858
Example 859

The following compounds of the invention may be prepared eg. from 1-(4-bromobenzyl)-5-(2H-tetrazol-5-yl)-1H-indole (example 807) or from the analogue 1-(3-bromobenzyl)-5-(2H-tetrazol-5-yl)-1H-indole and aryl boronic acids via the Suzuki coupling reaction eg as described in Littke, Dai & Fu J. Am. Chem. Soc., 2000, 122, 4020-8 (or references cited therein), or using the methodology described in general procedure (E), optionally changing the palladium catalyst to bis(tri-tert-butylphosphine)palladium (0).

Example 860
Example 861
Example 862
Example 863
Example 864

General Procedure (M) for Preparation of Compounds of General Formula I₁₂: wherein T is as defined above.

The general procedure (M) is further illustrated by the following example:

Example 865 (General Procedure (M))

1-Benzoyl-5-(2H-tetrazol-5-yl)-1H-indole

To a solution of 5-cyanoindole (1.0 g, 7.0 mmol) in dichloromethane (8 mL) was added 4-(dimethylamino)pyridine (0.171 g, 1.4 mmol), triethylamine (1.96 mL, 1.42 g, 14 mmol) and benzoyl chloride (0.89 mL, 1.08 g, 7.7 mmol). The resulting mixture was stirred for 18 hours at room temperature. The mixture was diluted with dichloromethane (80 mL) and washed consecutively with a saturated solution of sodium hydrogencarbonate (40 mL) and brine (40 mL). The organic phase was dried with magnesium sulfate (1 hour). Filtration and concentration furnished the crude material which was purified by flash chromatography on silica gel, eluting with ethyl acetate/heptanes =2:3. 1-Benzoyl-1H-indole-5-carbonitrile was obtained as a solid.

HPLC-MS (Method C): m/z: 247 (M+1); Rt=4.07 min.

1-Benzoyl-1H-indole-5-carbonitrile was transformed into 1-benzoyl-5-(2H-tetrazol-5-yl)-1H-indole by the method described in example 594.

HPLC (Method C): Rt=1.68 min.

The compound in the following example was prepared by the same procedure.

Example 866 (General Procedure (M))

1-Benzoyl-4-(2H-tetrazol-5-yl)-1H-indole

1-Benzoyl-1H-indole-4-carbonitrile was prepared from 4-cyanoindole according to the method described in example 865.

HPLC-MS (Method C): m/z: 247 (M+1); Rt=4.24 min.

1-Benzoyl-4-(2H-tetrazol-5-yl)-1H-indole was prepared from 1-benzoyl-1H-indole-4-carbonitrile according to the method described in example 594.

HPLC (Method C): Rt=1.56 min.

Example 867 (General Procedure (M))

(2-Fluoro-3-trifluoromethylphenyl)-[5-(2H-tetrazol-5-yl)-indol-1-yl]-methanone

HPLC-MS (Method B): m/z=376 (M+1); Rt=4.32 min.

Example 868 (General Procedure (M))

(4-Methoxyphenyl)-[5-(2H-tetrazol-5-yl)-indol-1-yl]-methanone

HPLC-MS (Method B): m/z=320 (M+1); Rt=3.70 min.

Example 869 (General Procedure (M))

(3-Nitrophenyl)-[5-(2H-tetrazol-5-yl)-indol-1-yl]-methanone

HPLC-MS (Method B): m/z=335 (M+); Rt=3.72 nm.

Example 870 (General Procedure (M))

(4-Nitrophenyl)-[5-(2H-tetrazol-5-yl)-indol-1-yl]-methanone

HPLC-MS (Method B): m/z=335 (M+1); Rt=3.71 min.

Example 871 (General Procedure (M))

Naphthalen-2-yl-[5-(2H-tetrazol-5-yl)-indol-1-yl]-methanone

HPLC-MS (Method C): m/z=340 (M+1); Rt=4.25 min.

Example 872 (General Procedure (M))

(2,3-Difluorophenyl)-[5-(2H-tetrazol-5-yl)-indol-1-yl]-methanone

HPLC-MS (Method B: m/z=326 (M+1); Rt=3.85 min.

The following known and commercially available compounds do all bind to the His B10 Zn²⁺ site of the insulin hexamer:

Example 873

1-(4-Fluorophenyl)-5-(2H-tetrazol-5-yl)-1H-indole

Example 874

1-Amino-3-(2H-tetrazol-5-yl)benzene

Example 875

1-Amino-4-(2H-tetrazol-5-yl)benzene

A mixture of 4-aminobenzonitrile (10 g, 84.6 mmol), sodium azide (16.5 g, 254 mmol) and ammonium chloride (13.6 g, 254 mmol) in DMF was heated at 125° C. for 16 hours. The cooled mixture was filtered and the filtrate was concentrated in vacuo. The residue was added water (200 mL) and diethyl ether (200 mL) which resulted in crystallisation. The mixture was filtered and the solid was dried in vacuo at 40° C. for 16 hours to afford 5-(4-aminophenyl)-2H-tetrazole.

¹H NMR DMSO-d₆): δ=5.7 (3H, bs), 6.69 (2H, d), 7.69 (2H, d).

HPLC-MS (Method C): m/z: 162 (M+1); Rt=0,55 min.

Example 876

1-Nitro-4-(2H-tetrazol-5-yl)benzene

Example 877

1-Bromo-4-(2H-tetrazol-5-yl)benzene

General Procedure (N) for Solution Phase Preparation of Amides of General Formula I₁₃: wherein Frag is any fragment carrying a carboxylic acid group, R is hydrogen, optionally substituted aryl or C_1-8-alkyl and R′ is hydrogen or C_1-4-alkyl.

Frag-CO₂H may be prepared eg by general procedure (D) or by other similar procedures described herein, or may be commercially available.

The procedure is further illustrated in the following example 878:

Example 878 (General Procedure (N))

N-(4-Chlorobenzyl)-2-[3-(2,4-dioxothiazolidin-5-ylidenemethyl)-1H-indol-1-yl]acetamide

[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)indol-1-yl]acetic acid (example 478, 90.7 mg, 0.3 mmol) was dissolved in NMP (1 mL) and added to a mixture of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, hydrochloride (86.4 mg, 0.45 mmol) and 1-hydroxybenzotriazol (68.8 mg, 0.45 mmol) in NMP (1 mL). The resulting mixture was shaken at RT for 2 h. 4-Chlorobenzylamine (51 mg, 0.36 mmol) and DIPEA (46.4 mg, 0.36 mmol) in NMP (1 mL) were added to the mixture and the resulting mixture shaken at RT for 2 days. Subsequently ethyl acetate (10 mL) was added and the resulting mixture washed with 2×10 mL waterfollowed by saturated ammonium chloride (5 mL). The organic phase was evaporated to dryness giving 75 mg (57%) of the title compound.

HPLC-MS (Method C): m/z: 426 (M+1); Rt. =3.79 min.

Example 879 (General Procedure (N))

N-(4-Chlorobenzyl)-4-[2-chloro-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]butyramide

HPLC-MS (Method A): m/z: 465 (M+1); Rt=4.35 min.

Example 880 (General Procedure (N))

N-(4-Chlorobenzyl)-4-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]butyramide

HPLC-MS (Method A): m/z: 431 (M+1); Rt=3.68 min.

Example 881 (General Procedure (N))

2-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]-N-(4-chlorobenzyl)acetamide

HPLC-MS (Method A): m/z: 483 (M+1); Rt=4.06 min.

Example 882 (General Procedure (N))

N-(4-Chlorobenzyl)-2-[3-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]acetamide

HPLC-MS (Method A): m/z: 403 (M+1); Rt=4.03 min.

Example 883 (General Procedure (N))

N-(4-Chlorobenzyl)-3-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenyl]acrylamide

HPLC-MS (Method A): m/z: 399 (M+1); Rt=3.82.

Example 884 (General Procedure (N))

N-(4-Chlorobenzyl)-4-[3-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]butyramide

HPLC-MS (Method A): m/z: 431 (M+1); Rt=3.84 min.

Example 885 (General Procedure (N))

4-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]-N-(4-chlorobenzyl)butyramide

HPLC-MS (Method A): m/z: 511 (M+1); Rt=4.05 min.

Example 886 (General Procedure (N))

4-[2-Bromo-4-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-phenoxy]-N-(4-chlorobenzyl)butyramide

HPLC-MS (Method A): m/z: 527 (M+1); Rt=4.77 min.

Example 887 (General Procedure (N))

N-(4-Chlorobenzyl)-2-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]acetamide

HPLC-MS (Method C): m/z: 431 (M+1); Rt. =4.03 min.

Example 888 (General Procedure (N))

N-(4-Chlorobenzyl)-3-[3-(2,4-dioxothiazolidin-5-ylidenemethyl)-1H-indol-1-yl]propionamide

HPLC-MS (Method C): m/z: 440 (M+1); Rt. =3.57 min.

Example 889 (General Procedure (N))

N-(4-Chlorobenzyl)-4-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyramide

HPLC-MS (Method C): m/z: 481 (M+1); Rt=4.08 min.

Example 890 (General Procedure (N))

4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)-naphthalen-1-yloxy]-N-hexylbutyramide

HPLC-MS (Method C): m/z: 441 (M+1); Rt=4.31 min.

Example 891 (General Procedure (N))

4-({[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)indole-7-carbonyl]amino}methyl)benzoic acid methyl ester

HPLC-MS (Method C): m/z: 436 (M+1); Rt.=3.55 min.

Example 892 (General Procedure (N))

N-(4-Chlorobenzyl)-4-[3-(2H-tetrazol-5-yl)carbazol-9-ylmethyl]benzamide

HPLC-MS (Method C): m/z:493 (M+1); Rt=4.19 min.

Example 893 (General Procedure (N))

N-(4-Chlorobenzyl)-3-[3-(2H-tetrazol-5-yl)carbazol-9-ylmethyl]benzamide

HPLC-MS (Method C): m/z: 493 (M+1); Rt=4.20 min.

Example 894 (General Procedure (N))

N-(4-Chlorobenzyl)-3-methyl-4-[3-(2H-tetrazol-5-yl)-carbazol-9-ylmethyl]benzamide

HPLC-MS (Method C): m/z: 507 (M+1); Rt=4.37 min.

Example 895 (General Procedure (N))

5-{2-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)-naphthalen-1-yloxy]-acetylamino}-isophthalic acid dimethyl ester

HPLC-MS (Method C): m/z=521 (M+1); Rt. =4.57 min.

Example 896 (General Procedure (N))

5-{2-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)-naphthalen-1-yloxy]-acetylamino}-isophthalic acid

HPLC-MS (Method C): m/z=515 (M+23); Rt. =3.09 min.

Example 897 (General Procedure (N))

5-(3-{2-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)-naphthalen-1-yloxy]-ethyl}-ureido)isophthalic acid monomethyl ester

HPLC-MS (Method C): m/z=536 (M+1); Rt=3,58 min.

Example 898 (General Procedure (N))

2-{4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoylamino}succinic acid dimethyl ester

4-[3-(1H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoic acid (2.00 g, 5.41 mmol), 1-hydroxybenzotriazole (1.46 g, 10.8 mmol) and N,N-di(2-propyl)ethylamine (4.72 mL, 3.50 g, 27.1 mmol) were dissolved in dry N,N-dimethylformamide (60 mL). The mixture was cooled in an ice-water bath, and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (1.45 g, 7.56 mmol) and (S)-aminosuccinic acid dimethyl ester hydrochloride (1.28 g, 6.48 mmol) were added. The cooling was discontinued, and the reaction mixture was stirred at room temperature for 18 hours before it was poured into hydrochloric acid (0.1N, 600 mL). The solid was collected by filtration and washed with water (2×25 mL) to furnish the title compound.

HPLC-MS (Method C): m/z: 513 (M+1); Rt=3.65 min.

¹H-NMR (DMSO-d₆): δ 8.90 (1H, d), 8.86 (1H, d), 8.29 (1H, d), 8.11 (1H, dd), 7.87 (1H, d), 7.75 (2H, d), 7.69 (1H, d), 7.51 (1H, t), 7.32 (1H, t), 7.28 (2H, d), 5.82 (2H, s), 4.79 (1H, m), 3.61 (3H, s), 3.58 (3H, s), 2.92 (1H, dd), 2.78 (1H, dd).

Example 899 (General Procedure (N))

2-{4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoylamino}succinic acid

2-{4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoylamino}succinic acid dim ethyl ester (1.20 g, 2.34 mmol) was dissolved in tetrahydrofuran (30 mL). Aqueous sodium hydroxide (1N, 14 mL) was added, and the resulting mixture was stirred at room temperature for 18 hours. The reaction mixture was poured into hydrochloric acid (0.1N, 500 mL). The solid was collected by filtration and washed with water (2×25 mL) and diethyl ether (2×25 mL) to furnish the title compound.

HPLC-MS (Method C): m/z: 485 (M+1); Rt=2.94 min.

¹H-NMR (DMSO-d₆): δ 12.44 (2H, s (br)), 8.90 (1H, d), 8.68 (1H, d), 8.29 (1H, d), 8.11 (1H, dd), 7.87 (1H, d), 7.75 (2H, d), 7.68 (1H, d), 7.52 (1H, t), 7.32 (1H, t), 7.27 (2H, d), 5.82 (2H, s), 4.70 (1H, m), 2.81 (1H, dd), 2.65 (1H, dd).

The compounds in the following examples were prepared in a similar fashion.

Example 900 (General Procedure (N))

2-{4-[3-(2H-Tetrazol-5-yl)-carbazol-9-ylmethyl]-benzoylamino}-succinic acid dimethyl ester

HPLC-MS (Method C): m/z=513 (M+1); Rt=3.65 min.

Example 901 (General Procedure (N))

2-{4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoylamino}pentanedioic acid dimethyl ester

HPLC-MS (Method C): m/z=527 (M+1); Rt=3.57 min.

Example 902 (General Procedure (N))

(Methoxycarbonylmethyl-4-[3-(2H-tetrazol-5-yl)-carbazol-9-ylmethyl]-benzoyl]-amino)-acetic acid methyl ester

HPLC-MS (Method C): m/z=513 (M+1); Rt=3,55 min.

Example 903 (General Procedure (N))

2-{4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoylamino}pentanedioic acid

HPLC-MS (Method C): m/z=499 (M+1); Rt=2.87 min.

Example 904 (General Procedure (N))

(Ethoxycarbonylmethyl-{4-[3-(2H-tetrazol-5-yl)-carbazol-9-ylmethyl]-benzoyl}-amino)-acetic acid ethyl ester

HPLC-MS (Method C): m/z=541 (M+1); Rt=3.91 min.

Example 905 (General Procedure (N))

3-(3-{4-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-naphthalen-1-yloxy]-butyrylamino}-propylamino)-hexanedioic acid dimethyl ester

HPLC-MS (Method C: m/z=585 (M+1); Rt=2,81 min.

Example 906 (General Procedure (N))

3-(3-{4-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-naphthalen-1-yloxy]-butyrylamino}-propylamino)-hexanedioic acid

HPLC-MS (Method C): m/z=554 (M-3); Rt=3,19 min.

Example 907 (General Procedure (N))

(Carboxymethyl-{4-[3-(2H-tetrazol-5-yl)-carbazol-9-ylmethyl]-benzoyl}-amino)-acetic acid

HPLC-MS (Method C): m/z=485 (M+1); Rt=3.04 min.

Example 908 (General Procedure (N))

4-(3-{4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)-naphthalen-1-yloxy]-butyrylamino}-propylamino)-cyclohexane-1,3-dicarboxylic acid dimethyl ester

HPLC-MS (Method C): m/z=612 (M+1); Rt=3,24 min.

Example 909 (General Procedure (N))

2-{3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoylamino}pentanedioic acid dimethyl ester

HPLC-MS (Method C): m/z=527 (M+1); Rt=3.65 min.

Example 910 (General Procedure (N))

2-{3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoylamino}pentanedioic acid dimethyl ester

HPLC-MS (Method C): m/z=527 (M+1); Rt=3.65 min.

Example 911 (General Procedure (N))

2-{3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoylamino}pentanedioic acid dimethyl ester

HPLC-MS (Method C): m/z=527 (M+1); Rt=3.65 min.

Example 912 (General Procedure (N))

2-{3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoylamino}pentanedioic acid

HPLC-MS (Method C): m/z=499 (M+1); Rt=3.00 min.

Example 913 (General Procedure (N))

(Methoxycarbonylmethyl-{3-[3-(2H-tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl}amino)acetic acid methyl ester

¹H-NMR (DMSO-d₆): δ 8.88 (1H, d), 8.29 (1H, d), 8.10 (1H, dd), 7.85 (1H, d), 7.67 (1H, d), 7.52 (1H, t), 7.39 (1H, t), 7.30 (2H, m), 7.17 (2H, m), 5.79 (2H, s), 4.17 (2H, s), 4.02 (2H, s), 3.62 (3H, s), 3.49 (3H, s).

Example 914 (General Procedure (N))

2-{3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoylamino}succinic acid dimethyl ester

HPLC-MS (Method C): m/z=513 (M+1); Rt=3.70 min.

Example 915 (General Procedure (N))

2-{3-[3-(2H-Tetrazol-5-yl)-carbazol-9-ylmethyl]-benzoylamino}-succinic acid

HPLC-MS (Method C): m/z=485 (M+1); Rt=2.96 min.

Example 916 (General Procedure (N))

(Carboxymethyl-{3-[3-(2H-tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl}amino)acetic acid

HPLC-MS (Method C): m/z=485 (M+1); Rt=2.87 min.

Example 917 (General Procedure (N))

δ 4-(4-(3-Carboxy-propylcarbamoyl)-4-{4-[3-(2H-tetrazol-5-yl)carbazol-9-ylmethyl]-benzoylamino}-butyrylamino)-butyric acid

The title compound was prepared by coupling of (S)-2{-4-[3-(2H-tetrazol-5-yl)carbazol-9-ylmethyl]benzoylamino}pentanedioic acid bis-(2,5-dioxopyrrolidin-1-yl) ester (prepared from (S)-2-{4-[3-(2H-tetrazol-5-yl)carbazol-9-ylmethyl]benzoylamino}pentanedioic acid by essentially the same procedure as described for the synthesis of 4-[3-(2H-tetrazol-5-yl)carbazol-9-ylmethyl]benzoic acid 2,5-dioxopyrrolidin-1-yl ester) with 4-aminobutyric acid according to the procedure described for the preparation of 4-{4-[3-(2H-tetrazol-5-yl)carbazol-9-ylmethyl]-benzoylamino}butyric acid.

HPLC-MS (Method C): m/z: 669 (M+1); Rt=2.84 min.

Example 918 (General Procedure (N))

[2-(2-{4-[3-(2H-Tetrazol-5-yl)-carbazol-9-ylmethyl]benzoylamino}ethoxy)ethoxy]acetic acid

HPLC-MS (Method C): m/z: 515 (M+1); Rt=3.10 min.

Example 919 (General Procedure (N))

2-{4-[3-(2H-Tetrazol-5-yl)-carbazol-9-ylmethyl]-benzoylamino}-pentanedioic acid di-tert-butyl ester

HPLC-MS (Method C): m/z=611 (M+1); Rt=4.64 min.

Example 920 (General Procedure (N))

4-{4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoylamino}butyric acid

HPLC-MS (Method C): m/z: 455 (M+1); Rt=3.13 min.

Example 921 (General Procedure (N))

[2-(2-{4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoylamino}ethoxy)ethoxy]acetic acid

The title compound was prepared by coupling of 4-[3-(2H-tetrazol-5-yl)carbazol-9-ylmethyl]benzoic acid 2,5-dioxopyrrolidin-1-yl ester with [2-(2-aminoethoxy)ethoxy]acetic acid (prepared from [2-[2-(Fmoc-amino)ethoxy]ethoxy]acetic acid by treatment with PS-Trisamine resin in DMF).

HPLC-MS (Method C): m/z: 515 (M+1); Rt=3.10 min.

The commercially available compounds in the following examples do all bind to the HisB10 Zn²⁺ site:

Example 922

1-(4-Bromo-3-methylphenyl)-1,4-dihydrotetrazole-5-thione

Example 923

1-(4-Iodophenyl)-1,4-dihydrotetrazole-5-thione

Example 924

1-(2,4,5-Trichlorophenyl)-1H-tetrazole-5-thiol

Example 925

1-(2,6-Dimethylphenyl)-1,4-dihydrotetrazole-5-thione

Example 926

1-(2,4,6-Trimethylphenyl)-1,4-dihydrotetrazole-5-thione

Example 927

1-(4-Dimethylaminophenyl)-1H-tetrazole-5-thiol

Example 928

1-(3,4-Dichlorophenyl)-1,4-dihydro-1H-tetrazole-5-thione

Example 929

1-(4-Propylphenyl)-1,4-dihydro-1H-tetrazole-5-thione

Example 930

1-(3-Chlorophenyl)-1,4-dihydro-1H-tetrazole-5-thione

Example 931

1-(2-Fluorophenyl)-1,4-dihydro-1H-tetrazole-5-thione

Example 932

1-(2,4-Dichlorophenyl)-1,4-dihydro-1H-tetrazole-5-thione

Example 933

1-(4-Trifluoromethoxyphenyl)-1,4-dihydro-1H-tetrazole-5-thione

Example 934

N-[4-(5-Mercaptotetrazol-1-yl)-phenyl]-acetamide

Example 935

1-(4-Chlorophenyl)-1,4-dihydrotetrazole-5-thione

Example 936

1-(4-Methoxyphenyl)-1,4-dihydrotetrazole-5-thione

Example 937

1-(3-Fluoro-4-pyrrolidin-1-ylphenyl)-1,4-dihydrotetrazole-5-thione

Example 938

N-[3-(5-Mercaptotetrazol-1-yl)phenyl]acetamide

Example 939

1-(4-Hydroxyphenyl)-5-mercaptotetrazole

Example 940

Preparation of 1-aryl-1,4-dihydrotetrazole-5-thiones (or the tautomeric 1-aryltetrazole-5-thiols) is described in the literature (eg. by Kauer & Sheppard, J. Org. Chem., 32, 3580-92 (1967)) and is generally performed eg. by reaction of aryl-isothiocyanates with sodium azide followed by acidification

1-Aryl-1,4-dihydrotetrazole-5-thiones with a carboxylic acid tethered to the aryl group may be prepared as shown in the following scheme:

Step 1 is a phenol alkylation and is very similar to steps 1 and 2 of general procedure (D) and may also be prepared similarly as described in example 481.

Step 2 is a reduction of the nitro group. SnCl₂, H₂ over Pd/C and many other procedures known to those skilled in the art may be utilised.

Step 3 is formation of an arylisothiocyanate from the corresponding aniline. As reagents CS₂, CSCl₂, or other reagents known to those skilled in the art, may be utilised.

Step 4 is a conversion to mercaptotetrazole as described above.

Compounds of the invention include:

Example 941
Example 942
Example 943
Example 944
Example 945
Example 946
Example 947

Example 948

4-(4-Hydroxyphenyl)-1H-[1,2,3]triazole-5-carbonitrile

Phenylsulphonyl acetonitrile (2.0 g, 11.04 mmol) was mixed with 4-hydroxybenzaldehyde (1.35 g, 11.04 mmol) in DMF (10 mL) and toluene (20 mL). The mixture was refluxed for 3 hours and subsequently evaporated to dryness in vacuo. The residue was treated with diethyl ether and toluene. The solid formed was filtered to afford 2.08 g (66%) of 2-benzenesulfonyl-3-(4-hydroxyphenyl)acrylonitrile.

HPLC-MS (Method C): m/z: 286 (M+1); Rt. =3.56 min.

A mixture of 2-benzenesulfonyl-3-(4-hydroxyphenyl)acrylonitrile (2.08 g, 7.3 mmol) and sodium azide (0.47 g, 7.3 mmol) in DMF (50 mL) was heated at reflux temperature 2 hours. After cooling, the mixture was poured on ice. The mixture was evaporated in vacuo to almost dryness and toluene was added. After filtration, the organic phase was evaporated in vacuo.

The residue was purified by silicagel chromatography eluting with a mixture of ethyl acetate and heptane (1:2). This afforded 1.2 g (76%) of the title compound.

¹H NMR (DMSO-d₆): 10.2 (broad, 1H); 7.74 (d, 2H); 6.99 (d, 2H); 3.6-3.2 (broad, 1H).

HPLC-MS (Method C) m/z: =187 (M+1); Rt. =1.93 min General Procedure (O) for Preparation of Compounds of General Formula I₁₄: wherein

• AA is as defined above,

Steps 1 and 2 are described in the literature (eg Beck & Gúnther, Chem. Ber., 106, 2758-66 (1973))

Step 1 is a Knoevenagel condensation of the aldehyde M-CHO with phenylsulfonylacetonitrile and step 2 is a reaction of the vinylsulfonyl compound obtained in step 1 with sodium azide. This reaction is usually performed in DMF at 90-110° C.

This general procedure is further illustrated in the following example 949:

Example 949 (General Procedure (O))

[4-(5-Cyano-1H-[1,2,3]triazol-4-yl)phenoxy]acetic acid

Phenylsulphonylacetonitrile (0.1 g, 0.55 mmol) was mixed with 4-formylphenoxyactic acid (0.099 g, 0.55 mmol) in DMF (3 mL) and heated to 110° C. for 3 h and subsequently cooled to RT. Sodium azide (0.036 g, 0.55 mmol) was added and the resulting mixture was heated to 110° C. for 3 h and cooled to RT. The mixture was poured into water (20 mL) and centrifuged.

The supernatant was discarded, ethanol (5 mL) was added and the mixture was centrifuged again. After discarding the supernatant, the residue was dried in vacuo to afford 50 mg (37%) of [4-(5-Cyano-1H-[1,2,3]triazol-4-yl)phenoxy]acetic acid.

HPLC-MS (Method C): m/z: 245 (M+1) Rt. 2.19 min.

Example 950 (General Procedure (O))

5-(Naphthalen-1-yl)-3H-[1,2,3]triazole-4-carbonitrile

HPLC-MS (Method C): m/z: 221 (M+1); Rt. 3.43 min.

Example 951 (General Procedure (O))

5-(Naphthalen-2-yl)-3H-[1,2,3]triazole-4-carbonitrile

HPLC-MS (Method C): m/z: 221 (M+1); Rt=3.66 min.

Example 952 (General Procedure (O))

4-[3-(5-Cyano-[1,2,3]triazol-4-yl)-1,4-dimethylcarbazol-9-ylmethyl]-benzoic acid

HPLC-MS (Method C): m/z=422 (M+1); Rt=3.85 min.

Preparation of Intermediary Aldehyde:

1,4 Dimethylcarbazol-3-carbaldehyde (0.68 g, 3.08 mmol) was dissolved in dry DMF (15 mL), NaH (diethyl ether washed) (0.162 g, 6.7 mol) was slowly added under nitrogen and the mixture was stirred for 1 hour at room temperature. 4-Bromomethylbenzoic acid (0.73 g, 3.4 mmol) was slowly added and the resulting slurry was heated to 40° C. for 16 hours. Water (5 mL) and hydrochloric acid (6N, 3 mL) were added. After stirring for 20 min at room temperature, the precipitate was filtered off and washed twice with acetone to afford after drying 0.38 g (34%) of 4-(3-formyl-1,4-dimethylcarbazol-9-ylmethyl)benzoic acid.

HPLC-MS (Method C): m/z=358 (M+1), RT. =4.15 min.

Example 953 (General Procedure (O))

5-(Anthracen-9-yl)-3H-[1,2,3]triazole-4-carbonitrile

HPLC-MS (Method C): m/z: 271 (M+1); Rt=3.87 min.

Example 954 (General Procedure (O))

5-(4-Methoxynaphthalen-1-yl)-3H-[1,2,3]triazole-4-carbonitrile

HPLC-MS (Method C): m/z: 251 (M+1); Rt=3.57 min.

Example 955 (General Procedure (O))

5-(1,4-Dimethyl-9H-carbazol-3-yl)-3H-[1,2,3]triazole-4-carbonitrile

HPLC-MS (Method C): m/z: 288 (M+1); Rt=3.67 min.

Example 956 (General Procedure (O))

5-(4′-Methoxybiphenyl-4-yl)-3H-[1,2,3]triazole-4-carbonitrile

HPLC-MS (Method C): m/z=277 (M+1); Rt=3.60 min.

Example 957 (General Procedure (O))

5-(4-Styrylphenyl)-3H-[1,2,3]triazole-4-carbonitrile

HPLC-MS (Method C): m/z=273 (M+1); Rt=4.12 min.

Example 958 (General Procedure (O))

5-(2,6-Dichloro-4-dibenzylaminophenyl)-3H-[1,2,3]triazole-4-carbonitrile

HPLC-MS (Method C): m/z=434 (M+1); Rt=4.64 min.

Example 959 (General Procedure (O))

5-(1-Bromonaphthalen-2-yl)-3H-[1,2, 3]triazole-4-carbonitrile

HPLC-MS (Method C: m/z=300 (M+1); Rt. =3.79 min.

Example 960

4-(4-Bromophenyl)-1H-[1,2,3]triazole-5-carbonitrile

This compound is commercially available (MENAI).

Example 961

N-[4-(5-Cyano-1H-[1,2,3]triazol-4-yl)-phenyl]-acetamide

This compound is commercially available (MENAI).

Example 962 (General Procedure (O))

5-(4′-Chlorobiphenyl-4-yl)-3H-[1,2,3]triazole-4-carbonitrile

HPLC-MS (Method C): m/z=281 (M+1); Rt=4.22 min.

The compounds in the following examples are commercially available and may be prepared using a similar methodology:

Example 963

4-(4-Trifluoromethoxyphenyl)-1H-[1,2,3]triazole-5-carbonitrile

Example 964

4-Benzo[1,3]dioxol-5-yl-1H-[1,2,3]triazole-5-carbonitrile

Example 965

4-(3-Trifluoromethylphenyl)-1H-[1,2,3]triazole-5-carbonitrile

Example 966

4-Pyridin-3-yl-1H-[1,2,3]triazole-5-carbonitrile

Example 967

4-(2,6-Dichlorophenyl)-1H-[1,2,3]triazole-5-carbonitrile

Example 968

4-Thiophen-2-yl-1H-[1,2,3]triazole-5-carbonitrile

Example 969

3,5-Dimethylisoxazole-4-carboxylic acid 4-(5-cyano-1H-[1,2,3]triazol-4-yl)phenyl ester

Example 970

3,3-Dimethyl-butyric acid 4-(5-cyano-1H-[1,2,3]triazol-4-yl)phenyl ester

Example 971

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid 4-(5-cyano-1H-[1,2,3]triazol-4-yl)phenyl ester

Example 972

4-Chlorobenzoic acid 4-(5-cyano-1H-[1,2,3]triazol-4-yl)phenyl ester

Example 973

4-(3-Phenoxyphenyl)-1H-[1,2,3]triazole-5-carbonitrile

Example 974

4-(5-Bromo-2-methoxyphenyl)-1H-[1,2,3]triazole-5-carbonitrile

Example 975

4-(2-Chloro-6-fluorophenyl)-1H-[1,2,3]triazole-5-carbonitrile

The following cyanotriazoles are also compounds of the invention:

• 4-(2-Chloro-6-fluorophenyl)-1H-[1,2,3]triazole-5-carbonitrile.
• Terephthalic acid mono[4-(5-cyano-1H-[1,2,3]triazol-4-yl)phenyl] ester.
• N-[4-(5-cyano-1H-[1,2,3]triazol-4-yl)-phenyl]terephthalamic acid
• 4-(4-Octyloxyphenyl)-1H-[1,2,3]triazole-5-carbonitrile
• 4-(4-Styrylphenyl)-1H-[1,2,3]triazole-5-carbonitrile.
• 4-(4′-Trifluoromethylbiphenyl-4-yl)-1H-[1,2,3]triazole-5-carbonitrile.
• 4-(4′-Chlorobiphenyl-4-yl)-1H-[1,2,3]triazole-5-carbonitrile.
• 4-(4′-Methoxybiphenyl-4-yl)-1H-[1,2,3]triazole-5-carbonitrile.
• 4-(1-Naphthyl)-1H-[1,2,3]triazole-5-carbonitrile.
• 4-(9-Anthranyl)-1H-[1,2,3]triazole-5-carbonitrile.
• 4-(4-Methoxy-1-naphthyl)-1H-[1,2,3]triazole-5-carbonitrile.
• 4-(4-Aminophenyl)-1H-[1,2,3]triazole-5-carbonitrile.
• 4-(2-Naphthyl)-1H-[1,2,3]triazole-5-carbonitrile. General Procedure (P) for Preparation of Compounds of General Formula I₁₅:
• wherein
• n is 1 or 3-20,
• AA is as defined above,
• R″ is a standard carboxylic acid protecting group, such as C₁-C₆-alkyl or benzyl and Lea is a leaving group, such as chloro, bromo, iodo, methanesulfonyloxy, toluenesulfonyloxy or the like.

This procedure is very similar to general procedure (D), steps 1 and 2 are identical.

Steps 3 and 4 are described in the literature (eg Beck & Gúnther, Chem. Ber., 106, 2758-66 (1973))

Step 3 is a Knoevenagel condensation of the aldehyde obtained in step 2 with phenylsulfonylacetonitrile and step 4 is a reaction of the vinylsulfonyl compound obtained in step 3 with sodium azide. This reaction is usually performed in DMF at 90-110° C.

This General procedure (P) is further illustrated in the following two examples

Example 976 (General Procedure (P))

5-[6-(5-Cyano-1H-[1,2,3]triazol-4-yl)-naphthalen-2-yloxy]-pentanoic acid ethyl ester

6-Hydroxynaphthalene-2-carbaldehyde (Syncom BV. NL, 15.5 g, 90 mmol) and K₂CO₃ (62.2 g, 450 mmol) were mixed in DMF (300 mL) and stirred at room temperature for 1 hour. Ethyl 5-bromovalerate (21.65 g, 103.5 mmol) was added and the mixture was stirred at room temperature for 16 hours. Activated carbon was added and the mixture was filtered. The filtrate was evaporated to dryness in vacuo to afford 28.4 g of crude 5-(6-formylnaphthalen-2-yloxy)pentanoic acid ethyl ester, which was used without further purification.

HPLC-MS (Method C): m/z=301 (M+1); Rt.=4.39 min.

5-(6-Formylnaphthalen-2-yloxy)pentanoic acid ethyl ester (28.4 g, 94.5 mmol), phenylsulfonylacetonitrile (20.6 g, 113.5 mmol), and piperidine (0.94 mL) were dissolved in DMF (200 mL) and the mixture was heated at 50° C. for 16 hours. The resulting mixture was evaporated to dryness in vacuo and the residue was dried for 16 hours at 40° C. in vacuo. The solid was recrystallised from 2-propanol (800 mL) and dried again as described above. This afforded 35 g (80%) of 5-[6-(2-benzenesulfonyl-2-cyanovinyl)naphthalen-2-yloxy]pentanoic acid ethyl ester.

HPLC-MS (Method C): m/z=486 (M+23); Rt.=5.09 min.

5-[6-(2-Benzenesulfonyl-2-cyanovinyl)naphthalen-2-yloxy]pentanoic acid ethyl ester (35 g, 74.6 mmol) and sodium azide (4.9 g, 75.6 mmol) were dissolved in DMF (100 mL) and stirred for 16 hours at 50° C. The mixture was evaporated to dryness in vacuo, redissolved in THF/ethanol and a small amount of precipitate was filtered off. The resulting filtrate was poured into water (2.5 L). Filtration afforded after drying 24.5 g (88%) of 5-[6-(5-cyano-1H-[1,2,3]triazol-4-yl)naphthalen-2-yloxy]pentanoic acid ethyl ester (24.5 g, 88%).

HPLC-MS (Method C): m/z=365 (M+1); Rt. =4.36 min.

Example 977 (General Procedure (B))

5-[6-(5-Cyano-1H-[1,2,3]triazol-4-yl)-naphthalen-2-yloxy]-pentanoic acid

5-[6-(5-Cyano-1H-[1,2,3]triazol-4-yl)naphthalen-2-yloxy]pentanoicacid ethyl ester (24.5 g, 67.4 mmol) was dissolved in THF (150 mL) and mixed with sodium hydroxide (8.1 g, 202 mmol) dissolved in water (50 mL). The mixture was stirred for 2 days and the volatiles were evaporated in vacuo. The resulting aqueous solution was poured into a mixture of water (1 L) and hydrochloric acid (1N, 250 mL). The solid was isolated by filtration, dissolved in sodium hydroxide (1N, 200 mL), and the solution was washed with DCM and then ethyl acetate, the aquous layer was acidified with hydrochloric acid (12N). The precipitate was isolated by filtration, dissolved in THF/diethyl ether, the solution was treated with MgSO₄ and activated carbon, filtrated and evaporated in vacuo to almost dryness followed by precipitation by addition of pentane (1 L). This afforded after drying in vacuo 17.2 g (76%) of the title compound.

HPLC-MS (Method C): m/z=337 (M+1); Rt. =3.49 min.

Example 978 (General Procedure (P))

6-[6-(5-Cyano-1H-[1,2,3]triazol-4-yl)naphthalen-2-yloxy]hexanoic acid

HPLC-MS (Method C): m/z=351 (M+1); Rt=3.68 min.

Example 979 (General Procedure (P))

11-[6-(5-Cyano-1H-[1,2,3]triazol-4-yl)-naphthalen-2-yloxy]-undecanoic acid

HPLC-MS (Method C): m/z=443 (M+23); Rt=4.92 min.

Example 980 (General Procedure (P))

2-{3-[6-(5-Cyano-1H-[1,2,3]triazol-4-yl)-naphthalen-2-yloxy]-propyl}-malonic acid diethyl ester

HPLC-MS (Method C): m/z=465 (M+1); Rt. =4.95 min.

Example 981 (General Procedure (P))

2-{5-[6-(5-Cyano-1H-[1,2,3]triazol-4-yl)-naphthalen-2-yloxy]-pentyl}-malonic acid diethyl ester

HPLC-MS (Method C): m/z=465 (M+1); Rt. =4.95 min.

Example 982 (General Procedure (P))

2-{3-[6-(5-Cyano-1H-[1,2,3]triazol-4-yl)-naphthalen-2-yloxy]-propyl}-malonic acid

HPLC-MS (Method C): m/z=381 (M+1); Rt. =3.12 min.

Example 983 (General Procedure (P))

2-{5-[6-(5-Cyano-1H-[1,2,3]triazol-4-yl)-naphthalen-2-yloxy]-pentyl}-malonic acid

HPLC-MS (Method C): m/z 0 409 (M+1); Rt. =3.51 min.

Example 984 (General Procedure (P))

4-[4-(5-Cyano-1H-[1,2,3]triazol-4-yl)-phenoxy]butyric acid

HPLC-MS (Method C): m/z=273 (M+1); Rt=2.44 min.

The following compounds may be prepared according to this general procedure (P):

• 4-(4-(5-Cyano-1H-[1,2,3]triazol-4-yl)phenoxy)butyric acid:
• 2-(4-(5-Cyano-1H-[1,2,3]triazol-4-yl)phenoxy)acetic acid:
• 4-(4-(5-Cyano-1H-[1,2,3]triazol-4-yl)phenoxy)butyric acid ethyl ester
• 5-(4-(5-Cyano-1H-[1,2,3]triazol-4-yl)phenoxy)pentanoic acid
• 8-(4-(5-Cyano-1H-[1,2,3]triazol-4-yl)phenoxy)octanoic acid
• 10-(4-(5-Cyano-1H-[1,2,3]triazol-4-yl)phenoxy)decanoic acid
• 12-(4-(5-Cyano-1H-[1,2,3]triazol-4-yl)phenoxy)dodecanoic acid General Procedure (R) for Preparation of Compounds of General Formula I₁₂: wherein T is as defined above and R² and R³ are hydrogen, aryl or lower alkyl, both optionally substituted.

The general procedure (R) is further illustrated by the following example:

Example 985 (General Procedure (R))

Phenyl-[3-(2H-tetrazol-5-yl)-carbazol-9-yl]-methanone

2-Chlorotritylchloride resin (100 mg, 0.114 mmol active chloride) was swelled in dichloromethane (4 mL) for 30 minutes. The solvent was drained, and a solution of 3-(2H-tetrazol-5-yl)-9H-carbazole (80 mg, 0.34 mmol) in a mixture of N,N-dimethylformamide/dichloromethane/N,N-di(2-propyl)ethylamine (5:5:1) (3 mL) was added. The reaction mixture was shaken at room temperature for 20 hours. The solvent was removed by filtration, and the resin was washed thoroughly with N,N-dimethylformamide (2×4 mL) and dichloromethane (6×4 mL). A solution of 4-(dimethylamino)pyridine (14 mg, 0.11 mmol) and N,N-di(2-propyl)ethylamine (0.23 mL, 171 mg, 1.32 mmol) in N,N-dimethylformamide (2 mL) was added followed by benzoyl chloride (0.13 mL, 157 mg, 1.12 mmol). The mixture was shaken for 48 hours at room temperature. The drained resin was washed consecutively with dichloromethane (2×4 mL), methanol (2×4 mL) and tetrahydrofuran (4 mL). The resin was treated for 2 hours at room temperature with a solution of dry hydrogen chloride in tetrahydrofuran/ethyl ether/ethanol=8:1:1 (0.1M, 3 mL). The reaction mixture was drained and concentrated. The crude product was stripped with dichloromethane (1.5 mL) three times to yield the title compound.

HPLC-MS (Method C): m/z: 340 (M+1); Rt=3.68 min.

¹H-NMR (DMSO-d₆): δ 8.91 (1H, s), 8.34 (1H, d), 8.05 (1H, d), 7.78 (3H, m), 7.63 (3H, m), 7.46 (2H, m), 7.33 (1H, dd).

The compounds in the following examples were prepared in a similar fashion.

Example 986 (General Procedure (R))

Phenyl-[5-(2H-tetrazol-5-yl)-indol-1-yl]-methanone

HPLC-MS (Method C): m/z: 290 (M+1); Rt=3.04 min.

¹H-NMR (DMSO-d₆): δ 8.46 (1H, d), 8.42 (1H, d), 8.08 (1H, dd), 7.82 (2H, d), 7.74 (1H, t), 7.64 (2H, t), 7.55 (1H, d), 6.93 (1H, d).

Example 987 (General Procedure (R))

(2,3-Difluorophenyl)-[5-(2H-tetrazol-5-yl)-indol-1-yl]-methanone

HPLC-MS (Method B): m/z =326 (M+1); Rt=3.85 min.

Example 988 (General Procedure (R))

(2-Fluoro-3-trifluoromethylphenyl)-[5-(2H-tetrazol-5-yl)-indol-1-yl]-methanone

HPLC-MS (Method B): m/z=376 (M+1); Rt=4.32 min.

Example 989 (General Procedure (R))

(3-Nitrophenyl)-[5-(2H-tetrazol-5-yl)-indol-1-yl]-methanone

HPLC-MS (Method B): m/z=335 (M+1); Rt=3.72 min.

Example 990 (General Procedure (R))

(4-Nitrophenyl)-[5-(2H-tetrazol-5-yl)-indol-1-yl]-methanone

HPLC-MS (Method B): m/z=335 (M+1); Rt=3.71 min.

Example 991 (General Procedure (R))

Naphthalen-2-yl-[5-(2H-tetrazol-5-yl)-indol-1-yl]-methanone

HPLC-MS (Method C): m/z=340 (M+1); Rt=4.25 min.

Example 992 (General Procedure (R))

HPLC-MS (Method C): m/z: 354 (M+1); Rt=3.91 min.

Example 993 (General Procedure (R))

HPLC-MS (Method C): m/z: 418 (M+1); Rt=4.39 min.

Example 994 (General Procedure (R))

HPLC-MS (Method C): m/z: 370 (M+1); Rt=4.01 min.

Example 995 (General Procedure (R))

HPLC-MS (Method C): m/z: 374 (M+1); Rt=4.28 min.

Example 996 (General Procedure (R))

HPLC-MS (Method C): m/z: 416 (M+1); Rt=4.55 min.

Example 997 (General Procedure (R))

HPLC-MS (Method C): m/z: 354 (M+1); Rt=4.22 min.

Example 998 (General Procedure (R))

HPLC-MS (Method C): m/z: 358 (M+1); Rt=3.91 min.

Example 999 (General Procedure (R))

HPLC-MS (Method C): m/z: 390 (M+1); Rt=4.38 min.

Example 1000 (General Procedure (R))

HPLC-MS (Method C): m/z: 418 (M+1); Rt=4.36 min.

Example 1001 (General Procedure (R))

HPLC-MS (Method C): m/z: 304 (M+1); Rt=3.32 min.

Example 1002 (General Procedure (R))

HPLC-MS (Method C): m/z: 368 (M+1); Rt=3.84 min.

Example 1003 (General Procedure (R))

HPLC-MS (Method C): m/z: 320 (M+1); Rt=3.44 min.

Example 1004 (General Procedure (R))

HPLC-MS (Method C): m/z: 324 (M+1); Rt=3.73 min.

Example 1005 (General Procedure (R))

HPLC-MS (Method C): m/z: 304 (M+1); Rt=3.64 min.

Example 1006 (General Procedure (R))

HPLC-MS (Method A): m/z: 308 (M+1); Rt=3.61 min.

Example 1007 (General Procedure (R))

HPLC-MS (Method C): m/z: 368 (M+1); Rt=3.77 min.

Example 1008 (General Procedure (R))

HPLC-MS (Method A): (sciex) m/z: 326 (M+1); Rt=3.73 min.

HPLC-MS (Method C): m/z: 326 (M+1); Rt=3.37 min.

Example 1009 (General Procedure (R))

HPLC-MS (Method C): m/z: 374 (M+1); Rt=4.03 min. General Procedure (Q) for Preparation of Compounds of General Formula I₁₆: wherein PS is polymeric support, a Tentagel S RAM resin, n is 1-20, m is 0-5, and p is 0 or 1.

The compounds of the invention of general formula (12) can be prepared by means of standard peptide chemistry (General Procedure H), e.g. in 0.5 mmol scale, using Fmoc strategy and HOAt or HOBT activated amino acids. The compounds prepared in the following examples according to General procedure (O) were all isolated as the TFA salts. This procedure is further illustrated in the following:

Typically, 2 gram of Fmoc Tentagel S RAM resin (Rapp Polymere, Tubingen) with substitution 0,25 mmol/g was washed with NMP then treated with 25% piperidine in NMP for 30 min followed by wash with NMP which renders the resin ready for coupling.

Step Wise Coupling of Fmoc-Arginine (Fmoc-Arg(Pmc)-OH), Fmoc-Glycine (Fmoc-Gly-OH) and Fmoc-4-aminobenzoic acid (Fmoc-4-Abz-OH):

To 2 mmol of Fmoc-L-Arg(Pmc)-OH (Novabiochem) was added 3,33 ml 0,6M HOAt in NMP (Perseptives) or 0,6M HOBT in NMP (Novabiochem) containing 0,2% bromphenolblue as indicator and added 330 μl of diisopropylcarbodiimide DIC (Fluka) and the solution was then added to the resin. After coupling for minimum 1 hour, or when the blue colour disappeared, the resin was washed with NMP and the Fmoc group was deprotected with 25% piperidine in NMP for 20 minutes followed by wash with NMP. This stepwise assembling of the arginine residues was repeated to give 3, 4, 5 or 6 arginines on the resin. The Fmoc-Glycine (Novabiochem) and Fmoc-4-aminobenzoic acid (Fluka and Neosystems) were coupled using the same procedure as described for Fmoc-Arg(Pmc)-OH.

Coupling of A-OH, e.g. 1H-benzotriazole-5-carboxylic Acid on Gly.

When A-OH, e.g. 1H-benzotriazole-5-carboxylic acid (Aldrich) was coupled on a glycine or arginine residue the coupling procedure was as described above.

Coupling of A-OH, e.g. 1H-benzotriazole-5-carboxylic acid on Abz or 4-Apac:

Due to the lower nucleophilicity of the amino group in Abz the following procedure was necessary.

To 4 mmol of A-OH, e.g. 1H-benzotriazole-5-carboxylic acid was added 6,66 ml of a solution of 0,6M HOAt, 0,2 mmol dimethylaminopyridine (DMAP) and 4 mmol DIC and was then added to the resin and allowed to react overnight.

Introduction of Fragment 4-Apac instead of 4-Abz:

4-Nitrophenoxyacetic acid may be coupled on a glycine or arginine residue using DIC and HOBT/HOAt as described above. Subsequent reduction of the nitro group may be done using SnCl₂ in NMP or DMF e.g. as described by Tumelty et al. (Tet. Lett., (1998) 7467-70).

Cleavage of the Peptides from the Resin.

After synthesis the resin was washed extensively with diethyl ether and dried. To 1 gram of the peptidyl resin was added 25 ml of a TFA solution containing 5% thioanisole, 5% ethanol, 5% phenol and 2% triisopropylsilane and allowed to react for 2 hours. The TFA solution was filtered and concentrated with argon flow for approximately 30 minutes. Then diethylether ca. 5-7 times the residual volume of TFA was added and the peptide precipitate was extracted in 10% AcOH and washed 5 times with diethyl ether and lyophilized.

RP-HPLC analysis and purification: The crude products were analysed on RP-HPLC C18 column (4,6×250 mm) using one of two gradients (see table 1 and 2), temperature 25° C., wavelength 214 nm and flow rate 1 ml/min with A-buffer 0,15% (w/w) TFA in H₂O and B-Buffer (87,5% (w/w) MeCN, 0,13% (w/w) TFA in H₂O).

The products were purified on preparative RP-HPLC C18 column (2×25 cm) using a gradient (variable, see e.g example 1013 and similar), temperature 25° C., wavelength 214 nm and flow rate

6 ml/min with A-buffer 0,15% (w/w) TFA in H₂O and B-Buffer (87,5% (w/w) MeCN, 0,13% (w/w) TFA in H₂O) and verified by mass spectrometry (MALDI).

	TABLE 1
	Time (min.)	Flow (ml/min) (	% A	% B
	0	1.00	95.0	5.0
	30.00	1.00	80.0	20.0
	35.00	1.00	0.0	100.0
	40.00	1.00	0.0	100.0
	45.00	1.00	95.0	5.0

	TABLE 2
	Time (min.)	Flow (ml/min)	% A	% B
	0	1.00	95.0	5.0
	30.00	1.00	40.0	60.0
	31.00	1.00	0.00	100.0
	35.00	1.00	0.00	100.0
	36.00	1.00	95.0	5.0

The following examples were prepared using this general procedure (O).

Example 1010 (General Procedure (O))

Benzotriazol-5-ylcarbonyl-Gly₂-Arg₃-NH₂ (BT-G₂R₃)

MS (MALDI): m/z: 746.7 g/mol; calculated: 744.2 g/mol.

HPLC gradient:

		Flow
	Time (min)	(ml/min)	% A	% B
	0.00	6.00	90.0	10.0
	120.00	6.00	90.0	10.0
	121.00	0.10	90.0	10.0

Example 1011 (General Procedure (O))

Benzotriazol-5-ylcarbonyl-Gly₂-Arg₄-NH₂ (BT-G₂R₄)

MS (MALDI): m/z: 903.0 g/mol; calculated: 900.6 g/mol.

HPLC gradient:

		Flow
	Time (min)	(ml/min)	% A	% B
	0.00	6.00	95.0	5.0
	30.00	6.00	80.0	20.0
	35.00	6.00	0.0	100.0
	40.00	6.00	0.0	100.0
	45.00	6.00	95.0	5.0
	64.00	6.00	95.0	5.0

Example 1012 (General Procedure (Q))

Benzotriazol-5-ylcarbonyl-Gly₂-Arg₅-NH₂ (BT-G₂R₅)

MS (MALDI): m/z: 1060.8 g/mol; calculated: 1057 g/mol.

HPLC gradient

		Flow
	Time (min)	(ml/min)	% A	% B
	0.00	6.00	88.0	12.0
	120.00	6.00	88.0	12.0
	121.00	0.10	88.0	12.0

Example 1013 (General Procedure (Q))

Benzotriazol-5-ylcarbonyl-Gly₂-Arg₆-NH₂ (BT-G₂R₆)

MS (MALDI): m/z: 1214.8 g/mol; calculated: 1213.4 g/mol.

HPLC gradient:

		Flow
	Time (min)	(ml/min)	% A	% B
	0.00	6.00	88.0	12.0
	120.00	6.00	88.0	12.0
	121.00	0.10	88.0	12.0

Example 1014 (General Procedure (Q))

Benzotriazol-5-ylcarbonyl-4-Abz-Gly₂-Arg₅-NH₂(BT-4-Abz-G₂R₅)

MS (MALDI): m/z: 1176.7 g/mol; calculated: 1177.9 g/mol.

HPLC gradient:

		Flow
	Time (min)	(ml/min)	% A	% B
	0.00	6.00	95.0	5.0
	40.00	6.00	60.0	40.0
	45.00	6.00	60.0	40.0
	50.00	6.00	0.0	100.0
	55.00	6.00	0.0	100.0
	60.00	6.00	95.0	5.0

Example 1015 (General Procedure (O))

Benzotriazol-5-ylcarbonyl-4-Abz-Gly-Arg₅-NH₂ (BT-4-Abz-G R₅)

MS (MALDI): m/z: 1122 g/mol; calculated: 1120.4 g/mol.

HPLC gradient:

		Flow
	Time (min)	(ml/min)	% A	% B
	0.00	6.00	95.0	5.0
	40.00	6.00	60.0	40.0
	45.00	6.00	60.0	40.0
	50.00	6.00	0.0	100.0
	55.00	6.00	0.0	100.0
	60.00	6.00	95.0	5.0

Example 1016 (General Procedure (Q))

Benzotriazol-5-ylcarbonyl-4-Abz-Arg₅-NH₂ (BT-4-Abz-R₅)

MS (MALDI): m/z: 1064.3 g/mol; calculated: 1063.2 g/mol.

HPLC gradient:

		Flow
	Time (min)	(ml/min)	% A	% B
	0.00	6.00	95.0	5.0
	40.00	6.00	60.0	40.0
	45.00	6.00	60.0	40.0
	50.00	6.00	0.0	100.0
	55.00	6.00	0.0	100.0
	60.00	6.00	95.0	5.0

General Procedure (R) for Preparation of Compounds of General Formula I₁₇: wherein X, Y, R¹⁰, E, B¹, B² are as defined above,

• p is 0 or 1,
• m is 0-5 and
• n is 1-20.

PS is a polymeric support, e.g. TentagenS RAM resin or a Rink amide resin.

This general procedure is very similar to General procedure (O), where benzotriazole-5-carboxylic acid in the last step before cleavage from the resin is replaced with compounds optionally prepared according to general procedure (D):

Example 1017 (General Procedure (R))

4-{2-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]acetylamino}benzoyl-Gly₂-Arg₅-NH₂

Example 1018 (General Procedure (R))

3-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenyl]acryloyl-Arg₅-NH₂

MS (MALDI): m/z: 1057.3 g/mol; calculated: 1055.3 g/mol.

Example 1019 (General Procedure (R))

3-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenyl]acryloyl-Arg₄-NH₂

MS (MALDI): m/z: 899.1 g/mol; calculated: 901.6 g/mol.

Example 1020 (General Procedure (R))

3-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenyl]acryloyl-Arg₃-NH₂

MS (MALDI): m/z: 746.2 g/mol; calculated: 742.9 g/mol.

Example 1021 (General Procedure (R))

4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₅-NH₂

MS (MALDI): m/z: 1088.7 g/mol; calculated: 1087 g/mol.

Example 1022 (General Procedure (R))

δ 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₄-NH₂

MS (MALDI): m/z: 933.0 g/mol; calculated: 931 g/mol.

Example 1023 (General Procedure (R))

4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₃-NH₂

MS (MALDI): m/z: 776.9 g/mol; calculated: 774.0 g/mol.

Example 1024 (General Procedure (R))

4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₁₂-NH₂

MS (MALDI): m/z: 2232.9.4 g/mol; calculated: 2230.3 g/mol.

Example 1025 (General Procedure (R))

4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₈-NH₂

MS (MALDI): m/z: 1607.4 g/mol; calculated: 1605.5 g/mol.

Example 1026 (General Procedure (R))

4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₅-NH₂

MS (MALDI): m/z: 1141.9 g/mol; calculated: 1137.4 g/mol.

Example 1027 (General Procedure (R))

δ 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₄-NH₂

MS (MALDI): m/z: 985.4 g/mol; calculated: 981.2 g/mol.

Example 1028 (General Procedure (R))

4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₃-NH₂

MS (MALDI): m/z: 828.5 g/mol; calculated: 825.0 g/mol.

The following compounds were prepared according to the methodology described in general procedure (Q) and (R):

Example 1029

4-(2H-Tetrazol-5-yl)benzoyl-4-Abz-Gly₂-Arg₅-NH₂

MS (MALDI): m/z: 1203.8 g/mol; calculated: 1203.8 g/mol.

Example 1030

4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₅-NH₂

MS (MALDI): m/z: 1152.5 g/mol; calculated: 1149.3 g/mol.

Example 1031

4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₈-NH₂

MS (MALDI): m/z: 1621.0 g/mol; calculated: 1617.5 g/mol.

Example 1032

4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₂-NH₂

MS (MALDI): m/z: 2247.9 g/mol; calculated: 2242.3 g/mol. General Procedure (S) for Preparation of Compounds of General Formula I₁₈:

Wherein PS is polymeric support, a Rink Amide AM resin, n is 0-20, m is 0-20, with the proviso that n+m≦20, wherein (Gly)_p is defined as in a broader sense as Frg1 above, p is 0-5, and furthermore the Frg2 (the Lys and Arg residues) may comprise one or more neutral amino acids independently selected from the group consisting of Gly, Ala, Thr, and Ser, and wherein CGr-Lnk-OH, CGr, and Lnk is as described above.

The compounds of the invention of general formula (I₁₈) can be prepared by means of standard peptide chemistry (as e.g. in General Procedure Q or R), e.g. in 7 mmol scale, using Fmoc strategy and HOAt or HOBt activated amino acids. The compounds prepared in the following examples according to General Procedure (S) were all isolated as the TFA salts. This procedure is further illustrated in the following:

• Typically, 10 gram (7 mmol) of Rink Amide AM resin (Novabiochem 200-400 mesh) with substitution 0,70 mmol/g was treated with NMP by shaking for 3 h or more -then treated with NMP/Piperidine/DBU (8012012) for (30-60 min)×2 followed by wash with NMP×6 which renders the resin ready for coupling. Step Wise Coupling of Fmoc-Arginine (Fmoc-Arg(Pbf)-OH).

21 mmol (13.6 g) of Fmoc-L-Arg(Pbf)-OH (MultiSyn Tech Gmbh., Germany) was dissolved in NMP (80 mL) together with HOBt-hydrate (21 mmol, 3.21 g). DIC (21 mmol, 3.27 mL) was added to the solution and the mixture kept for 2-5 min before it was added to the resin which was shaken for a minimum 3 h, the resin was washed with NMP (80 mL). After each coupling step a capping step was performed using 20× molar excess of Acetic acid/HOBt/DIC (8.4 g/21.4 g/21 mL) in NMP (80 mL) followed by washing with NMP (80 mL)×4 and the coupling was checked with TNBS (no red colour).The Fmoc group was deprotected with NMP/Piperidine/DBU (80/20/2) for (30-60 min)×2 followed by wash with NMP. Then another Fmoc-L-Arg(Pbf)-OH group was coupled as described above.

This stepwise assembling of the arginine residues was repeated to give the wanted number of arginines on the resin. When more than 6 residues were added double couplings were performed on each coupling step, one coupling carried out for 3 h or more- the other overnight.

When Lysine or Glycine were part of the synthesised molecules the same procedure as described above was used changing Fmoc-L-Arg(Pbf)-OH to Fmoc-L-Lys(Boc)-OH or Fmoc-Gly-OH, respectively.

Coupling of Ligand (CGr-Lnk-OH) to the Polymer Supported Amino Acid Chain.

The attachment of the ligand was carried out after deprotection of Fmoc as described above followed by coupling with the ligand containing a carboxylic acid using HOAt/DIC for activation using the same ratio as described above.

Double couplings and capping as described above were performed.

Cleavage from the Resin.

The resin was washed with DCM (80 mL)×4 followed by diethyl ether (80 mL)×4.

Subsequently the resin was dried well and then added to a 20 fold excess of a mixture of TFA/Thioanisol/Ethanol (90/5/5) and the mixture was stirred at RT overnight, evaporated to almost dryness and the residue was poured into a 20 fold excess of cold diethyl ether. The mixture was stirred for 30 min, filtered and the precipitate was washed with ether twice and dried. The dried compound was then dissolved in water and freeze dried, and the freeze dried material was then purified by HPLC.

RP-HPLC purification: The crude products were purified on RP-HPLC Kromasil RP18 100 Å50×350 mm, flow 10 mL/min; gradient: 0.0-2.0 min: 20% acetonotrile, 0.1% TFA; 2.0 17.0 min: 20% acetonitrile, 0.1% TFA to 28% acetonitrile, 0.1% TFA; 17.0-25.0 100% acetonitrile, 0.1% TFA. Alternatively other HPLC systems were used. The identity was verified by mass spectrometry (MALDI-TOF).

The following examples were prepared using this general procedure.

Example 1033 (General Procedure (S))

5-[6-(5-Cyano-1H-[1,2,3]triazol-4-yl)naphthalen-2-yloxy]pentanoyl-Arg₁₂-NH₂

MS (MALDI-TOF): m/z: 2210 g/mol; calculated: 2209.2 g/mol.

Example 1034 (General Procedure (S))

4′-[5-(2H-Tetrazol-5-yl)indol-1-ylmethyl]biphenyl-4-carbonyl-Arg₁₂-NH₂

MS (MALDI-TOF): m/z: 2268 g/mol; calculated: 2269 glmol.

Example 1035 (General Procedure (S))

4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₄-NH₂

MS (MALDI-TOF): m/z: 2553 g/mol; calculated: 2554 g/mol.

Example 1036 (General Procedure (S))

4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₂-Arg₁₂-NH₂

MS (MALDI-TOF): m/z: 2498 g/mol; calculated: 2499 g/mol.

Example 1037 (General Procedure (S))

δ 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Gly₄-Arg₈-NH₂

MS (MALDI-TOF): m/z: 1845 g/mol; calculated: 1846 g/mol.

Example 1038 (General Procedure (S))

3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₂-NH₂

MS (MALDI-TOF): m/z: 2242 g/mol; calculated: 2243 g/mol.

Example 1039 (General Procedure (S))

4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Gly₂-Arg₁₂-NH₂

MS (MALDI-TOF): m/z: 2497.5 g/mol; calculated: 2496 g/mol.

Example 1040 (General Procedure (S))

4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₆-NH₂

MS (MALDI-TOF): m/z: 2873 g/mol; calculated: 2864 g/mol.

Example 1041 (General Procedure (S))

4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₁₂-NH₂

MS (MALDI-TOF): m/z: 1905 g/mol; calculated: 1904 g/mol.

Example 1042 (General Procedure (S))

4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₆-NH₂

MS (MALDI-TOF): m/z: 1303 g/mol; calculated: 1304 g/mol.

Example 1043 (General Procedure (S))

4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₆-NH₂

MS (MALDI-TOF): m/z: 1293 g/mol; calculated: 1292 g/mol.

Other preferred compounds of the invention that may be prepared according to general procedures (O), (R) and/or general procedure (S) include:

Building Block from Example 469:

• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₁₀-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₉-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₇-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₁₁-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₁₃-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₁₄-NH₂ 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₁₅-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₁₆-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₁₇-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₁₈-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₁₉-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₂₀-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₆-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₅-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₄-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₃-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₇-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₈-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₉-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₁₀-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₁₁-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₁₂-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₁₃-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₁₄-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₁₅-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₁₆-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₁₇-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₁₈-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₁₉-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Lys₂₀-NH₂

Building Block from Example 470:

• 5-[4-(2,4-Dioxothiazolidin-5-yl idenemethyl)naphthalen-1-yloxy]pentanoyl-Arg₆-NH₂
• 5-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]pentanoyl-Arg₅-NH₂
• 5-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]pentanoyl-Arg₄-NH₂
• 5-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]pentanoyl-Arg₃-NH₂

Building Block from Page 232:

• 6-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]hexanoyl-Arg₃-NH₂
• 6-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]hexanoyl-Arg₄-NH₂
• 6-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]hexa noyl-Arg₅-NH₂

Building Block from Page 232:

• 7-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]heptanoyl-Arg₃-NH₂
• 7-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]heptanoyl-Arg₄-NH₂
• 7-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]heptanoyl-Arg₅-NH₂

Building Block from Page 232:

• 8-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]octanoyl-Arg₃-NH₂
• 8-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]octanoyl-Arg₄-NH₂
• 8-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]octanoyl-Arg₅-NH₂

Building Block from Page 232:

• 10-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]decanoyl-Arg₃-NH₂
• 10-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]decanoyl-Arg₄-NH₂
• 10-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]decanoyl-Arg₅-NH₂

Building Block from Page 232:

• 11-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]undecanoyl-Arg₃-NH₂
• 11-[4-(2,4-Dioxothiazolidi n-5-ylidenemethyl)naphthalen-1-yloxy]undecanoyl-Arg₄-NH₂
• 11-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]undecanoyl-Arg₅-NH₂

Building Block from Page 232:

• 12-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]dodecanoyl-Arg₃-NH₂
• 12-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]dodecanoyl-Arg₄-NH₂
• 12-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]dodecanoyl-Arg₅-NH₂

Building Block from Page 233:

• 15-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]pentadecanoyl-Arg₃-NH₂
• 15-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]pentadecanoyl-Arg₄-NH₂
• 15-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]pentadecanoyl-Arg₅-NH₂

Building Block from Example 283:

• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₁₀-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₉-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₈-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₇-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₆-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₅-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₄-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₃-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₁₁-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₁₂-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₁₃-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₁₄-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₁₅-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₁₆-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₁₇-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₁₈-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₁₉-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Arg₂₀-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₆-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₅-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₄-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₃-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₇-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₈-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₉-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₁₀-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₁₁-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₁₂-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₁₃-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₁₄-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₁₅-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₁₆-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₁₇-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₁₈-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₁₉-NH₂
• 4-[4-(2,4-Dioxothiazolidin-5-ylmethyl)naphthalen-1-yloxy]butyryl-Lys₂₀-NH₂

Building Block from Example 476:

• 2-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]acetyl-Arg₆-NH₂
• 2-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalene-1-yloxy]acetyl-Arg₅-NH₂
• 2-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalene-1-yloxy]acetyl-Arg₄-NH₂
• 2-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalene-1-yloxy]acetyl-Arg₃-NH₂

Building Block from Example 480:

• 2-{5-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)benzylidene]-4-oxo-2-thioxothiazolidin-3-yl}acetyl-Arg₆-NH₂
• 2-{5-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)benzylidene]-4-oxo-2-thioxothiazolidin-3-yl}acetyl-Arg₅-NH₂
• 2-{5-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)benzyidene-4-oxo-2-thioxothiazoidin-3-yl}acetyl-Arg₄-NH₂
• 2-{5-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)benzylidene]-4-oxo-2-thioxothiazolidin-3-yl}acetyl-Arg₃-NH₂
• 4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]butyryl-Arg₆-NH₂
• 4-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]butyryl-Arg₅-NH₂
• 4-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]butyryl-Arg₄-NH₂
• 4-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]butyryl-Arg₃-NH₂
• 15-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]pentadecanoyl-Arg₆-NH₂
• 15-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]pentadecanoyl-Arg₅-NH₂
• 15-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]pentadecanoyl-Arg₄-NH₂
• 15-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]pentadecanoyl-Arg₃-NH₂
• 5-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]pentanoyl-Arg₆-NH₂
• 5-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]pentanoyl-Arg₅-NH₂
• 5-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]pentanoyl-Arg₄-NH₂
• 5-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]pentanoyl-Arg₃-NH₂

Building Block from Example 462:

• 3-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenyl]acryloyl-Arg₆-NH₂

Building Block from Example 473:

• 2-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]acetyl-Arg₆-NH₂
• 2-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]acetyl-Arg₅-NH₂
• 2-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]acetyl-Arg₄-NH₂
• 2-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]acetyl-Arg₃-NH₂
• 8-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]octanoyl-Arg₆-NH₂
• 8-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]octanoyl-Arg₅-NH₂
• 8-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]octanoyl-Arg₄-NH₂
• 8-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]octanoyl-Arg₃-NH₂
• 6-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl) naphthalen-2-yloxy]hexanoyl-Arg₆-NH₂
• 6-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]hexanoyl-Arg₅-NH₂
• 6-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]hexanoyl-Arg₄-NH₂
• 6-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]hexanoyl-Arg₃-NH₂

Building Block from Example 466:

• 4-[2-Chloro-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₆-NH₂
• 4-[2-Chloro-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg-NH₂
• 4-[2-Chloro-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₄-NH₂
• 4-[2-Chloro-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₃-NH₂

Building Block from Example 460:

• 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₆-NH₂

Building Block from Example 467:

• 4-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₆-NH₂
• 4-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₅-NH₂
• 4-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₄-NH₂
• 4-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₃-NH₂
• 11-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]undecanoyl-Arg₆-NH₂
• 11-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]undecanoyl-Arg₅-NH₂
• 1-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]undecanoyl-Arg₄-NH₂
• 11-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-2-yloxy]undecanoyl-Arg₃-NH₂
• 4-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₆-NH₂
• 4-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₅-NH₂
• 4-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₄-NH₂
• 4-[2-Bromo-4-(2,4-dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₃-NH₂

Building Block from Example 464:

• 4-(2,4-Dioxothiazolidin-5-ylidenemethyl)benzoyl-Arg₆-NH₂
• 4-(2,4-Dioxothiazolidin-5-ylidenemethyl)benzoyl-Arg₅-NH₂
• 4-(2,4-Dioxothiazolidin-5-ylidenemethyl)benzoyl-Arg₄-NH₂
• 4-(2,4-Dioxothiazolidin-5-ylidenemethyl)benzoyl-Arg₃-NH₂

Building Block from Example 463:

• 2-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]acetyl-Arg₆-NH₂
• 2-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]acetyl-Arg₅-NH₂
• 2-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]acetyl-Arg₄-NH₂
• 2-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]acetyl-Arg₃-NH₂

Building Block from Example 461:

• 2-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]acetyl-Arg₆-NH₂
• 2-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]acetyl-Arg₅-NH₂
• 2-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]acetyl-Arg₄-NH₂
• 2-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]acetyl-Arg₃-NH₂

Building Block from Example 474:

• 4-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₆-NH₂
• 4-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₅-NH₂
• 4-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₄-NH₂
• 4-[3-(2,4-Dioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₃-NH₂

Building Block from Example 468:

• 4-[2-Bromo-4-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₆-NH₂
• 4-[2-Bromo-4-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)phenoxylbutyryl-Arg₅-NH₂
• 4-[2-Bromo-4-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₄-NH₂
• 4-[2-Bromo-4-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)phenoxy]butyryl-Arg₃-NH₂

Building Block from Example 738:

• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₄-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₃-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₇-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₉-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₀-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₁-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₃-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₅-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₇-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₈-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁ g-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₂₀-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₆-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₄-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₃-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₇-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₈-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₉-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₁₀-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₁₁-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₁₃-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₁₄-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₁₅-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₁₆-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₁₇-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₁₈-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₁₉-NH₂
• 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Lys₂₀-NH₂

Building Block from Page 322:

• 4′-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]biphenyl-4-carbonyl-Arg₆-NH₂
• 4′-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]biphenyl-4-carbonyl-Arg₅-NH₂
• 4′-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]biphenyl-4-carbonyl-Arg₄-NH₂
• 4′-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]biphenyl-4-carbonyl-Arg₃-NH₂

Building Block from Example 743:

• 3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₆-NH₂
• 3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₅-NH₂
• 3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₄-NH₂
• 3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₃-NH₂
• 3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₇-NH₂
• 3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₈-NH₂
• 3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₉-NH₂
• 3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₀-NH₂
• 3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁]-NH₂
• 3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₂-NH₂
• 3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₃-NH₂
• 3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₄-NH₂
• 3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₅-NH₂
• 3-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₆-NH₂

Example 1044

Equilibrium Solubility. For pH-solubility profiles, a 0.6 mM insulin stock solution containing 0.3 mM Zn²⁺, 30 mM phenol, 1.6% glycerol and Zn²⁺-binding ligand as required were prepared and the pH was adjusted to the desired value corresponding to the alkaline endpoint of the pH-solubility profile. From these stock solutions samples were withdrawn, the pH adjusted to the desired value in the pH 3-8 range, and samples were incubated at 23 C for 24 hours. After centrifugation (20,000 g in 20 min at 23° C.) of each sample, pH was measured and the solubility was determined by quantification of insulin contents in the supernatant by SEC HPLC analysis

The effect of various concentration of the ligand 4-[3-(2H-tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₂-NH₂ (Example 1032) on the pH-dependence of Gly^A21, Asp^B28 insulin solubility is illustrated in FIG. 1.

Example 1045

The effect of a high concentration of the ligand 4-[3-(2H-tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₂-NH₂ (Example 1032)on the pH-dependence of Gly^A21 insulin solubility is illustrated in FIG. 2. The solubility was determined as in example 1044. Solution conditions: 0.6 mM human insulin, 0.3 mM mM Zn²⁺, 30 mM phenol, 1.6% glycerol, 23° C.

Example 1046

The slow release (prolonged action) properties of certain formulations of the present invention was characterized by the disappearance rate from the subcutaneous depot following subcutaneous injections in pigs. T₅₀% is the time when 50% of the A14 Tyr(¹²⁵I) insulin has disappeared from the site of injection as measured with an external γ-counter (Ribel et al., The Pig as a Model for Subcutaneous Absorption in Man. In: M. Serrano-Rtios and P. J. Lefebre (Eds): Diabetes (1985) Proceedings of the 12^th congress of the International Diabetes Federation, Madrid, Spain, 1985 (Excerpta Medica, Amsterdam (1986), 891-896). The composition of a series of protracted formulations is given in the table below together with the T₅₀% values. The disappearance curves are illustrated in FIG. 3 a-c, e-f. For comparison, the T₅₀% for the corresponding insulin preparations formulated without the ligands would be about 2 hours. The disappearance curve for B29-N′-myristoyl-des(B30) human insulin (FIG. 3 d) is 11 hours.

The induction of slow release by addition of exogenous ligands of the invention affords further advantages in terms of versatility regarding the choice of insulin species and release patterns. Consequently, human or mutant insulins such as Gly^A21, Gly^A21Asp^B28 may be formulated as slow- or dual-release preparations by adding variable amounts of His^B10 Zn²⁺-site ligand. This is illustrated below for Gly^A21, Asp^B28 human insulin and Gly^A21 human insulin employing different Zn²⁺-site ligands. As shown in the table below and in FIG. 3 panels a-c and e-f, addition of ligand produces a slow release preparation with T₅₀% in the range of 5 to 16 hours.

	125I-Prep. 1	125I-Prep. 2	125I-Prep. 3	125I-Prep. 4	125I-Prep. 5	125I-Prep. 6
Insulin	0.6 GlyA21,	0.6 GlyA21,	0.6 GlyA21,	0.6 B29-Nε-	0.6 GlyA21	0.6 GlyA21
(mM)	AspB28	AspB28	AspB28	myristoyl-	insulin	insulin
	human insulin	human insulin	human insulin	des(B30)
				human
				insulin
Zn2+ (mM)	0.3	0.3	0.3	0.22	0.3	0.3
Phenolic	30 mM phenol	30 mM	30 mM phenol	16 mM	30 mM	30 mM
ligand		phenol		phenol,	phenol	phenol
				16 mM m-
				cresol
Zn2+ ligand	6 mM	6 mM	2 mM	20 mM NaCl	0.6 mM	1.2 mM
	1253R3	1253R5	1081AbzG2R5		1430R12	1430R12
	(Example	(Example	(Example		(Example	(Example
	781)	779)	782)		missing,	missing,
					PeM)	PeM)
Glycerol (%)	1.6	1.6	1.6	1.6	1.6	1.6
Phosphate	0	0	0	7	0	0
buffer (mM)
pH	4.0	4.0	4.0	7.5	4.0	4.0
T50% (hrs)	9.3	8.7	5.3	11.0	14.4	16.5

FIG. 3 shows the disappearance from the subcutaneous depot (pig model) of insulin preparations.

Curves a)-c) are Gly^A21, AsP^B28 human insulin formulated with an excess concentration compared to Zn²⁺ of a) 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₃-NH₂, b) 4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)naphthalen-1-yloxy]butyryl-Arg₅-NH₂ and c) 4-(2H-Tetrazol-5-yl)benzoyl-Abz-Gly₂-Arg₅-NH₂. Curve d) is B29-N^ε-myristoyl-des(B30) human insulin. Curves e) and f) are Gly^A21 human insulin formulated with two different excess concentrations compared to Zn²⁺ of 4-[3-(2H-Tetrazol-5-yl)carbazol-9-ylmethyl]benzoyl-Arg₁₂-NH₂.

Analytical Methods

Assays to Quantify the Binding Affinity of Ligands to the Metal Site of the Insulin R₆ Hexamers:

4H₃N-assay:

The binding affinity of ligands to the metal site of insulin R₆ hexamers are measured in a UV/vis based displacement assay. The UV/vis spectrum of 3-hydroxy-4-nitro benzoic acid (4H₃N) which is a known ligand for the metal site of insulin R₆ shows a shift in absorption maximum upon displacement from the metal site to the solution (Huang et al., 1997, Biochemistry 36, 9878-9888). Titration of a ligand to a solution of insulin R₆ hexamers with 4H₃N mounted in the metal site allows the binding affinity of these ligands to be determined following the reduction of absorption at 444 nm.

A stock solution with the following composition 0.2 mM human insulin, 0.067 mM Zn-acetate, 40 mM phenol, 0.101 mM 4H₃N is prepared in a 10 mL quantum as described below. Buffer is always 50 mM tris buffer adjusted to pH=8.0 with NaOH/ClO₄⁻.

• 1000 μL of 2.0 mM human insulin in buffer
• 66.7 μL of 10 mM Zn-acetate in buffer
• 800 μL of 500 mM phenol in H₂O
• 201 μL of 4H₃N in H₂O
• 7.93 ml buffer

The ligand is dissolved in DMSO to a concentration of 20 mM.

The ligand solution is titrated to a cuvette containing 2 mL stock solution and after each addition the UV/vis spectrum is measured. The titration points are listed in Table 3 below.

TABLE 3
ligand	ligand
addition	conc.	dilution
(μl)	(mM)	factor
1	0.010	1.0005
1	0.020	1.0010
1	0.030	1.0015
2	0.050	1.0025
5	0.100	1.0050
10	0.198	1.0100
20	0.392	1.0200
20	0.583	1.0300
20	0.769	1.0400
20	0.952	1.0500

The UV/vis spectra resulting from a titration of the compound 3-hydroxy-2-naphthoic acid is shown in FIG. 4. Inserted in the upper right corner is the absorbance at 444 nm vs. the concentration of ligand.

The following equation is fitted to these datapoints to determine the two parameters K_D(obs), the observed dissociation constant, and abs_max the absorbance at maximal ligand concentration. abs([ligand]_free)=(abs_max*[ligand]_free)/(K_D(obs)+[ligand]_free)

The observed dissociation constant is recalculated to obtain the apparent dissociation constant K_D(app)=K_D(obs)/(1+[4H₃N]/K_4H3N)

The value of K₄H₃N=50 μM is taken from Huang et al., 1997, Biochemistry 36, 9878-9888.

TZD-Assay:

The binding affinity of ligands to the metal site of insulin R₆ hexamers are measured in a fluorescense based displacement assay. The fluorescence of 5-(4-dimethylaminobenzylidene)thiazolidine-2,4-dione (TZD) which is a ligand for the metal site of insulin R₆ is quenched upon displacement from the metal site to the solution. Titration of a ligand to a stock solution of insulin R₆ hexamers with this compound mounted in the metal site allows the binding affinity of these ligands to be determined measuring the fluorescence at 455 nm upon excitation at 410 nm.

Preparation

Stock solution: 0.02 mM human insulin, 0.007 mM Zn-acetate, 40 mM phenol, 0.01 mM TZD in 50 mM tris buffer adjusted to pH=8.0 with NaOH/ClO₄⁻.

The ligand is dissolved in DMSO to a concentration of 5 mM and added in aliquots to the stock solution to final concentrations of 0-250 μM.

Measurements

Fluorescence measurements were carried out on a Perkin Elmer Spectrofluorometer LS50B. The main absorption band was excited at 410 nm and emission was detected at 455 nm. The resolution was 10 nm and 2.5 nm for excitation and emission, respectively.

The fluorescence spectra resulting from a titration of the compound 5-(4-dimethylaminobenzylidene)thiazolidine-2,4-dione (TZD) is shown in FIG. 5. Inserted in the upper right corner is the fluorescence at 455 nm upon exitation at 410 nM vs. the concentration of ligand.

Data Analysis

This equation is fitted to the datapoints ΔF(455 nm))=ΔF_max*[ligand]_free/(K_D(app)*(1+[TZD]/K_TZD)+[ligand]_free)) K_D(app) is the apparent dissociation constant and Fmax is the fluorescence at maximal ligand concentration. The value of KTZD is measured separately to 230 nM

Two different fitting-procedures can be used. One in which both parameters, K_D(app) and F_max, are adjusted to best fit the data and a second in which the value of F_max is fixed (F_max=1) and only K_D(app) is adjusted. The given data are from the second fitting procedure. The Solver module of Microsoft Excel can be used to generate the fits from the datapoints.

Claims

1. A pharmaceutical preparation comprising Acid-stabilised insulin Zinc ions A zinc-binding ligand of Formula (i): CGr-Lnk-Frg1-Frg2-X  Formula (I) wherein, CGr is a chemical group which reversibly binds to a HiSBIO Zn2+ site of an insulin hexamer; Lnk is a linker selected from a valence bond a chemical group GB of the formula —B1—B2—C(O)—, —B1—B2—SO2—, —B1—B2—CH2—, or —B1B2-NH—; wherein B1 is a valence bond, —O—, —S—, or —NR6B—, B2 is a valence bond, C1-C18-alkylene, C2-C18-alkenylene, C2-C18-alkynylene, arylene, heteroarylene, -C1-C18-alkyl-aryl-, —C2-C18-alkenyl-aryl-, —C2-C18-alkynyl-aryl-, —C(═O)—C1-C18-alkyl-C(═O)—, —C(═O)-C1-C18-alkenyl-C(═O)—, —C(═O)-C1-C18-alkyl-O-C1-C18-alkyl-C(═O)—, —C(═O)-C1-C18-alkyl-S-C1-C18-alkyl-C(═O)—, —C(═O)-C1-C18-alkyl-NR6-C1-C18-alkyl-C(═O)—, —C(═O)-aryl-C(═O)—, —C(═O)-heteroaryl-C(═O)—; wherein the alkylene, alkenylene, and alkynylene moieties are optionally substituted by —CN, —CF3, —OCF3, —OR6B, or NR6BR7B and the arylene and heteroarylene moieties are optionally substituted by halogen, —C(O)OR6B, —C(O)H, OCOR6B, —SO2, —CN, —CF3, —OCF3, —NO2, —OR6B, —NR6BR7B, C1-C18-alkyl, or C1-C18-alkanoyl; R6B and R7B are independently H, C1-C4-alkyl; Frg1 is a fragment consisting of 0 to 5 neutral α- or β-amino acids Frg2 is a fragment comprising 1 to 20 positively charged groups independently selected from amino or guanidino groups; and X is —OH, —NH2 or a diamino group, or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or any tautomeric forms:

2. A pharmaceutical preparation according to claim 1, wherein CGr is a chemical structure selected from the group consisting of carboxylates, dithiocarboxylates, phenolates, thiophenolates, alkylthiolates, sulfonamides, imidazoles, triazoles, 4-cyano-1,2,3-triazoles, benzimidazoles, benzotriazoles, purines, thiazolidinediones, tetrazoles, 5-mercaptotetrazoles, rhodanines, N-hydroxyazoles, hydantoines, thiohydantoines, barbiturates, naphthoic acids and salicylic acids.

3. A pharmaceutical preparation according to claim 2, wherein CGr is a chemical structure selected from the group consisting of benzotriazoles, 3-hydroxy 2-napthoic acids, salicylic acids, tetrazoles, thiazolidinediones, 5-mercaptotetrazoles, or 4-cyano-1,2,3-triazoles.

4. A pharmaceutical composition according to claim 1, wherein CGr is

5. A pharmaceutical composition according to claim 4, wherein K is a valence bond, C1-C6-alkylene, —NH—C(═O)—U—, -C1-C6-alkyl-S—, -C1-C6-alkyl-O—, or —C(═O)—, wherein any C1-C6-alkyl moiety is optionally substituted with R38.

6. A pharmaceutical composition according to claim 5, wherein K is a valence bond, C1-C6-alkylene, —NH—C(═O)—U—, -C1-C6-alkyl-S—, or -C1-C6-alkyl-O, wherein any C1-C6-alkyl moiety is optionally substituted with R38.

7. A pharmaceutical composition according to claim 6, wherein K is a valence bond, C1-C6-alkylene, or —NH—C(═O)—U, wherein any C1-C6-alkyl moiety is optionally substituted with R38.

8. A pharmaceutical composition according to claim 7, wherein K is a valence bond or C1-C6-alkylene, wherein any C1-C6-alkyl moiety is optionally substituted with R38.

9. A pharmaceutical composition according to claim 7, wherein K is a valence bond or —NH—C(═O)—U.

10. A pharmaceutical composition according to claim 8, wherein K is a valence bond.

11. A pharmaceutical composition according to claim 4, wherein U is a valence bond or C1-C6-alkyl-O—.

12. A pharmaceutical composition according to claim 11, wherein U is a valence bond.

13. A pharmaceutical composition according to claim 4, wherein M is arylene or heteroarylene, wherein the arylene or heteroarylene moieties are optionally substituted with one or more substituents independently selected from R40.

14. A pharmaceutical composition according to claim 13, wherein M is ArG1 or Het1, wherein the arylene or heteroarylene moieties are optionally substituted with one or more substituents independently selected from R40.

15. A pharmaceutical composition according to claim 14, wherein M is ArG1 or Het2, wherein the arylene or heteroarylene moieties are optionally substituted with one or more substituents independently selected from R40.

16. A pharmaceutical composition according to claim 15, wherein M is ArG1 or Het3, wherein the arylene or heteroarylene moieties are optionally substituted with one or more substituents independently selected from R40.

17. A pharmaceutical composition according to claim 16, wherein M is phenylene optionally substituted with one or more substituents independently selected from R40.

18. A pharmaceutical composition according to claim 16, wherein M is indolylene optionally substituted with one or more substituents independently selected from R40.

19. A pharmaceutical composition according to claim 18, wherein M is

20. A pharmaceutical composition according to claim 16, wherein M is carbazolylene optionally substituted with one or more substituents independently selected from R40.

21. A pharmaceutical composition according to claim 20, wherein M is

22. A pharmaceutical composition according to claim 4, wherein R40 is selected from hydrogen, halogen, —CN, —CF3, —OCF3, —NO2, —OR41, —NR41R42, —SR41, —S(O)2R41, —NR41C(O)R42, —OC1-C6-alkyl-C(O)NR41R42, —C2-C6-alkenyl-C(═O)OR41, —C(O)OR4, ═O, —NH—C(═O)—O-C1-C6-alkyl, or —NH—C(═O)—C(═O)—O-C1-C6-alkyl, C1-C6-alkyl or C2-C6— alkenyl which may each optionally be substituted with one or more substituents independently selected from R43, aryl, aryloxy, aryl-C1-C6-alkoxy, aryl-C1-C6-alkyl, aryl-C2-C6-alkenyl, heteroaryl, heteroaryl-C1-C6-alkyl, or heteroaryl-C2-C6-alkenyl, wherein the cyclic moieties optionally may be substituted with one or more substituents selected from R44.

23. A pharmaceutical composition according to claim 22, wherein R40 is selected from hydrogen, halogen, —CN, —CF3, —OCF3, —NO2, —OR4, —NR41R42, —SR41, —S(O)2R41, —NR41C(O)R42, —OC1-C6-alkyl-C(O)NR41R42, —C2-C6-alkenyl-C(═O)OR41, —C(O)OR41, ═O, —NH—C(═O)—O-C1-C6-alkyl, or —NH—C(═O)—C(═O)—O-C1-C6-alkyl, C1-C6-alkyl or C2-C6— alkenyl which may each optionally be substituted with one or more substituents independently selected from R43, ArG1, ArG1-O—, ArG1-C1-C6-alkoxy, ArG1-C1-C6-alkyl, ArG1-C2-C6-alkenyl, Het3, Het3-C1-C6-alkyl, or Het3-C2-C6-alkenyl, wherein the cyclic moieties optionally may be substituted with one or more substituents selected from R44.

24. A pharmaceutical composition according to claim 23, wherein R40 is selected from hydrogen, halogen, —CF3, —NO2, —OR4, —NR41R42, —C(O)OR41, ═O, or —NR41C(O)R42, C1-C6-alkyl, ArG1.

25. A pharmaceutical composition according to claim 24, wherein R40 is hydrogen.

26. A pharmaceutical composition according to claim 24, wherein R40 is selected from halogen, —NO2, —OR41, —NR41R42, —C(O)OR41, or —NR41C(O)R42, methyl, phenyl.

27. A pharmaceutical composition according to claim 4, wherein R41 and R42 are independently selected from hydrogen, C1-C6-alkyl, or aryl, wherein the aryl moieties may optionally be substituted with halogen or —COOH.

28. A pharmaceutical composition according to claim 27, wherein R41 and R42 are independently selected from hydrogen, methyl, ethyl, or phenyl, wherein the phenyl moieties may optionally be substituted with halogen or —COOH.

29. A pharmaceutical composition according to claim 4, wherein Q is a valence bond, C1-C6-alkylene, -C1-C6-alkyl-O—, -C1-C6-alkyl-NH—, —NH-C1-C6-alkyl, —NH—C(═O)—, —C(═O)—NH—, —O-C1-C6-alkyl, —C(═O)—, or -C1-C6-alkyl-C(═O)—N(R47)— wherein the alkyl moieties are optionally substituted with one or more substituents independently selected from R48.

30. A pharmaceutical composition according to claim 29, wherein Q is a valence bond, —CH2—, —CH2—CH2—, —CH2—O—, —CH2—CH2-O—, —CH2—NH—, —CH2—CH2-NH—, —NH—CH2—, —NH—CH2—CH2-, —NH—C(═O)—, —C(═O)—NH—, —O—CH2—, —O—CH2—CH2—, or —C(═O)—.

31. A pharmaceutical composition according to claim 4, wherein R47 and R48 are independently selected from hydrogen, methyl and phenyl.

32. A pharmaceutical composition according to claim 4, wherein T is hydrogen, C1-C6-alkyl optionally substituted with one or more substituents independently selected from R50, aryl, aryl-C1-C6-alkyl, heteroaryl, wherein the alkyl, aryl and heteroaryl moieties are optionally substituted with one or more substituents independently selected from R50.

33. A pharmaceutical composition according to claim 32, wherein T is hydrogen, C1-C6-alkyl optionally substituted with one or more substituents independently selected from R50, ArG1, ArG1-C1-C6-alkyl, Het3, wherein the alkyl, aryl and heteroaryl moieties are optionally substituted with one or more substituents independently selected from R50.

34. A pharmaceutical composition according to claim 33, wherein T is hydrogen, C1-C6-alkyl, optionally substituted with one or more substituents independently selected from R50, phenyl, phenyl-C1-C6-alkyl, wherein the alkyl and phenyl moieties are optionally substituted with one or more substituents independently selected from R50.

35. A pharmaceutical composition according to claim 34, wherein T is phenyl substituted with R50.

36. A pharmaceutical composition according to claim 4, wherein R50 is C1-C6-alkyl, C1-C6-alkoxy, aryl, aryloxy, aryl-C1-C6-alkoxy, —C(═O)—NH-C1-C6-alkyl-aryl, —C(═O)—NR50A-C1-C6-alkyl, —C(═O)—NH—(CH2CH2O)mC1-C6-alkyl-COOH, heteroaryl, -C1-C6-alkyl-COOH, —O-C1-C6-alkyl-COOH, —S(O)2R51, —C2-C6-alkenyl-COOH, —OR51, —NO2, halogen, —COOH, —CF3, —CN, ═O, —N(R51R52), wherein the aryl or heteroaryl moieties are optionally substituted with one or more R53.

37. A pharmaceutical composition according to claim 36, wherein R50 is C1-C6-alkyl, C1-C6-alkoxy, aryl, aryloxy, —C(═O )—N50A-C1-C6-alkyl, —C(═O)—NH—(CH2CH2O)mC1-C6-alkyl-COOH, aryl-C1-C6-alkoxy , —OR51, —NO2, halogen, —COOH, —CF3, wherein any aryl moiety is optionally substituted with one or more R53.

38. A pharmaceutical composition according to claim 37, wherein R50 is C1-C6-alkyl, aryloxy, —C(═O)—NR50A-C1-C6-alkyl, —C(═O)—NH—(CH2CH2O)mC1-C6-alkyl-COOH, aryl-C1-C6-alkoxy, —OR51, halogen, —COOH, —CF3, wherein any aryl moiety is optionally substituted with one or more R53.

39. A pharmaceutical composition according to claim 38, wherein R50 is C1-C6-alkyl, ArG1-O—, —C(═O)—NR50A-C1-C6-alkyl, —C(═O)—NH—(CH2CH2O)mC1-C6-alkyl-COOH, ArG1-C1-C6-alkoxy, —OR51, halogen, —COOH, —CF3, wherein any aryl moiety is optionally substituted with one or more R53.

40. A pharmaceutical composition according to claim 39, wherein R50 is —C(═O)—NR50ACH2, —C(═O)—NH—(CH2CH2O)2CH21—COOH, or —C(═O)—NR50ACH2CH2.

41. A pharmaceutical composition according to claim 39, wherein R50 is phenyl, methyl or ethyl.

42. A pharmaceutical composition according to claim 41, wherein R50 is methyl or ethyl.

43. A pharmaceutical composition according to claim 4, wherein m is 1 or 2.

44. A pharmaceutical composition according to claim 4, wherein R51 is methyl.

45. A pharmaceutical composition according to claim 4, wherein R53 is C1-C6-alkyl, C1-C6-alkoxy, —OR51, halogen, or —CF3.

46. A pharmaceutical composition according to claim 4, wherein R50A is —C(O)OCH3, —C(O)OCH2CH3—COOH, —CH2C(O)OCH3, —CH2C(O)OCH2CH3, —CH2CH2C(O)OCH3, —CH2CH2C(O)OCH2CH3, —CH2COOH, methyl, or ethyl.

47. A pharmaceutical composition according to claim 4, wherein R50B is —C(O)OCH3, —C(O)OCH2CH3—COOH, —CH2C(O)OCH3, —CH2C(O)OCH2CH3, —CH2CH2C(O)OCH3, —CH2CH2C(O)OCH2CH3, —CH2COOH, methyl, or ethyl.

48. A pharmaceutical preparation according to claim 1, wherein Frg1 consists of 0 to 5 neutral amino acids independently selected from the group consisting of Gly, Ala, Thr, and Ser.

49. A pharmaceutical preparation according to claim 48, wherein Frg1 consists of 0 to 5 Gly.

50. A pharmaceutical preparation according to claim 49, wherein Frg1 consists of 0 Gly.

51. A pharmaceutical preparation according to claim 49, wherein Frg1 consists of 1 Gly.

52. A pharmaceutical preparation according to claim 49, wherein Frg1 consists of 2 Gly.

53. A pharmaceutical preparation according to claim 49, wherein Frg1 consists of 3 Gly.

54. A pharmaceutical preparation according to claim 49, wherein Frg1 consists of 4 Gly.

55. A pharmaceutical preparation according to claim 49, wherein Frg1 consists of 5 Gly.

56. A pharmaceutical preparation according to claim 1, wherein GB is of the formula B1—B2-C(O)—, B1—B2—SO2— or B1—B2—CH2—, wherein B1 and B2 are as defined in claim 1.

57. A pharmaceutical preparation according to claim 1, wherein GB is of the formula B1—B2-C(O)—, B1—B2—SO2— or B1—B2—NH—, wherein B1 and B2 are as defined in claim 1.

58. A pharmaceutical preparation according to claim 1, wherein GB is of the formula B1—B2—C(O)—, B1—B2—CH2— or B1—B2—NH—, wherein B1 and B2 are as defined in claim 1.

59. A pharmaceutical preparation according to claim 1, wherein GB is of the formula B1—B2-CH2—, B1—B2—SO2— or B1—B2—NH—, wherein B1 and B2 are as defined in claim 1.

60. A pharmaceutical preparation according to any one of the claims 56 or 57, wherein GB is of the formula B1—B2—C(O)— or B1—B2—SO2—, wherein B1 and B2 are as defined in claim 1.

61. A pharmaceutical preparation according to any one of the claims 56 or 58, wherein GB is of the formula B1—B2—C(O)— or B1—B2—CH2—, wherein B1 and B2 are as defined in claim 1.

62. A pharmaceutical preparation according to any one of the claims 57 or 58, wherein GB is of the formula B1—B2—C(O)— or B1—B2—NH—, wherein B1 and B2 are as defined in claim 1.

63. A pharmaceutical preparation according to any one of the claims 56 or 59, wherein GB is of the formula B1—B2—CH2— or B1—B2—SO2—, wherein B1 and B2 are as defined in claim 1.

64. A pharmaceutical preparation according to any one of the claims 57 or 59, wherein GB is of the formula B1—B2—NH— or B1—B2—SO2—, wherein B1 and B2 are as defined in claim 1.

65. A pharmaceutical preparation according to any one of the claims 58 or 59, wherein GB is of the formula B1—B2—CH2— or B1—B2—NH—, wherein B1 and B2 are as defined in claim 1.

66. A pharmaceutical preparation according to any one of the claims 60, 61, or 62, wherein GB is of the formula B1—B2—C(O)—.

67. A pharmaceutical preparation according to any one of the claims 61, 63 or 65, wherein GB is of the formula B1—B2—CH2—.

68. A pharmaceutical preparation according to any one of the claims 61, 63 or 64, wherein GB is of the formula B1—B2—SO2—.

69. A pharmaceutical preparation according to any one of the claims 62, 64 or 65, wherein GB is of the formula B1—B2—NH—.

70. A pharmaceutical preparation according to claim 1, wherein B1 is a valence bond, —O—, or —S—.

71. A pharmaceutical preparation according to claim 1, wherein B1 is a valence bond, —O—, or —N(R6B)—.

72. A pharmaceutical preparation according to claim 1, wherein B1 is a valence bond, —S—, or —N(R6B)—.

73. A pharmaceutical preparation according to claim 1, wherein B1 is —O—, —S— or —N(R6B)—.

74. A pharmaceutical preparation according to any one of the claims 70 or 71, wherein B1 is a valence bond or —O—.

75. A pharmaceutical preparation according to any one of the claims 70 or 72, wherein B1 is a valence bond or —S—.

76. A pharmaceutical preparation according to any one of the claims 71 or 72, wherein B1 is a valence bond or —N(R6B)—.

77. A pharmaceutical preparation according to any one of the claims 70 or 73, wherein B1 is —O— or —S—.

78. A pharmaceutical preparation according to any one of the claims 71 or 73, wherein B1 is —O— or —N(R6B)—.

79. A pharmaceutical preparation according to any one of the claims 72 or 73, wherein B1 is —S— or —N(R6B)—.

80. A pharmaceutical preparation according to any one of the claims 74, 75 or 76, wherein B1 is a valence bond.

81. A pharmaceutical preparation according to any one of the claims 74, 77 or 78, wherein B1 is —O—.

82. A pharmaceutical preparation according to any one of the claims 75, 77 or 79, wherein B1 is —S—.

83. A pharmaceutical preparation according to any one of the claims 76, 78 or 79, wherein B1 is —N(R6B)—.

84. A pharmaceutical preparation according to claim 1, wherein B2 is a valence bond, C1-C18-alkylene, C2-C18-alkenylene, C2-C18-alkynylene, arylene, heteroarylene, -C1-C18-alkyl-aryl-, —C(═O)-C1-C18-alkyl-C(═O)—, —C(═O)-C1-C18-alkyl-O-C1-C18-alkyl-C(═O)—, —C(═O)-C1-C18-alkyl-S—C1-C18-alkyl-C(═O)—, —C(═O)-C1-C18-alkyl-NR6-C1-C18-alkyl-C(═O)—; and the alkylene and arylene moieties are optionally substituted as defined in claim 1.

85. A pharmaceutical preparation according to claim 84, wherein B2 is a valence bond, C1-C18-alkylene, C2-C18-alkenylene, C2-C18-alkynylene, arylene, heteroarylene, -C1-C18-alkyl-aryl, —C(═O)-C1-C18-alkyl-C(═O)—, —C(═O)-C1-C18-alkyl-O-C1-C18-alkyl-C(═O)—, and the alkylene and arylene moieties are optionally substituted as defined in claim 1.

86. A pharmaceutical preparation according to claim 85, wherein B2 is a valence bond, C1-C18-alkylene, C2-C18-alkenylene, C2-C18-alkynylene, arylene, heteroarylene, -C1-C18-alkyl-aryl, —C(═O)-C1-C18-alkyl-C(═O)—, and the alkylene and arylene moieties are optionally substituted as defined in claim 1.

87. A pharmaceutical preparation according to claim 86, wherein B2 is a valence bond, C1-C18-alkylene, arylene, heteroarylene, -C1-C18-alkyl-aryl-, —C(═O)-C1-C18-alkyl-C(═O)—, and the alkylene and arylene moieties are optionally substituted as defined in claim 1.

88. A pharmaceutical preparation according to claim 87, wherein B2 is a valence bond, C1-C18-alkylene, arylene, heteroarylene, -C1-C18-alkyl-aryl-, and the alkylene and arylene moieties are optionally substituted as defined in claim 1.

89. A pharmaceutical preparation according to claim 88, wherein B2 is a valence bond, C1-C18-alkylene, arylene, -C1-C18-alkyl-aryl-, and the alkylene and arylene moieties are optionally substituted as defined in claim 1.

90. A pharmaceutical preparation according to claim 89, wherein B2 is a valence bond or -C1-C18-alkylene, and the alkylene moieties are optionally substituted as defined in claim 1.

91. A pharmaceutical preparation according to claim 1, wherein Frg2 comprises 1 to 16 positively charged groups.

92. A pharmaceutical preparation according to claim 92, wherein Frg2 comprises 1 to 12 positively charged groups.

93. A pharmaceutical preparation according to claim 92, wherein Frg2 comprises 1 to 10 positively charged groups.

94. A pharmaceutical preparation according to claim 1, wherein Frg2 comprises 10 to 20 positively charged groups.

95. A pharmaceutical preparation according to claim 94, wherein Frg2 comprises 12 to 20 positively charged groups.

96. A pharmaceutical preparation according to claim 95, wherein Frg2 comprises 16 to 20 positively charged groups.

97. A pharmaceutical preparation according to any one of the claims 91 to 96, wherein the positively charged groups of Frg2 are basic amino acids independently selected from the group consisting of Lys and Arg and D-isomers of these.

98. A pharmaceutical preparation according to claim 97, wherein the basic amino acids are all Arg.

99. A pharmaceutical preparation according to any one of the claims 91 to 98, wherein Frg2 comprises one or more neutral amino acids independently selected from the group consisting of Gly, Ala, Thr, and Ser.

100. A pharmaceutical preparation according to claim 99, wherein Frg2 comprises one or more Gly.

101. A pharmaceutical preparation according to claim 1, wherein X is —OH or —NH2.

102. A pharmaceutical preparation according to claim 101, wherein X is —NH2.

103. A pharmaceutical preparation according to claim 1, which further comprises at least 3 phenolic molecules per putative insulin hexamer.

104. A pharmaceutical preparation according to claim 1, wherein the acid-stabilised insulin is an analogue of human insulin wherein A21 is Ala, Gln, Glu, Gly, His, Ile, Leu, Met, Phe, Ser, Thr, Trp, Tyr, Val, and hSer.

105. A pharmaceutical preparation according to claim 104, wherein the acid-stabilised insulin is an analogue of human insulin wherein A21 is Ala, Gly, Ile, Leu, Phe, Ser, Thr, Val, and hSer.

106. A pharmaceutical preparation according to claim 105, wherein the acid-stabilised insulin is an analogue of human insulin wherein A21 is Ala or Gly.

107. A pharmaceutical preparation according to claim 106, wherein the acid-stabilised insulin is an analogue of human insulin wherein A21 is Gly.

108. A pharmaceutical preparation according to any one of the claims 104 to 107, wherein the acid-stabilised insulin is an analogue of human insulin further modified by exchange or deletion of one or more amino acid residues according to the following: B3 is selected from Thr, Ser, Lys or Ala A18 is Gln B28 is Lys, Asp or Glu B29 is Pro or Glu B9 is Glu or Asp B10 is Glu B25 is deleted B30 is deleted.

109. A pharmaceutical preparation according to claim 108, wherein the acid-stabilised insulin is an analogue of human insulin further modified by exchange of B28 to Lys or Asp.

110. A pharmaceutical preparation according to claim 109, wherein the acid-stabilised insulin is an analogue of human insulin further modified by exchange of B28 to Asp.

111. A pharmaceutical preparation according to claim 109, wherein the acid-stabilised insulin is an analogue of human insulin further modified by exchange of B28 to Lys.

112. A pharmaceutical preparation according any one of the claims 104 to 111, wherein the acid-stabilised insulin is an analogue of human insulin further modified by exchange of B29 to Pro.

113. A pharmaceutical preparation according any one of the claims 104 to 112, wherein the acid-stabilised insulin is an analogue of human insulin further modified by exchange of B3 to Lys or Ala.

114. A pharmaceutical preparation according any one of the claims 104 to 113, wherein the acid-stabilised insulin is an analogue of human insulin further modified by exchange of A18 to Gin.

115. A pharmaceutical preparation according any one of the claims 104 to 114, wherein the acid-stabilised insulin is an analogue of human insulin further modified by deletion of B25.

116. A pharmaceutical preparation according any one of the claims 104 to 115, wherein the acid-stabilised insulin is an analogue of human insulin further modified by deletion of B30.

117. A pharmaceutical preparation according to claim 104, wherein the acid-stabilised insulin is selected from the group A21G A21G, B28K, B29P A21G, B28D A21G, B28E A21G, B3K, B29E A21G, desB27 A21G, B9E A21G, B9D A21G, B10E A21G, desB25 A21G, desB30 A21G, B28K, B29P, desB30 A21G, B28D, desB30 A21G, B28E, desB30 A21G, B3K, B29E, desB30 A21G, desB27, desB30 A21G, B9E, desB30 A21G, B9D, desB30 A21G, B10E, desB30 and A21G, desB25, desB30.

118. A pharmaceutical preparation according to claim 1, wherein zinc ions are present in an amount corresponding to 10 to 40 μg Zn/100 U insulin.

119. A pharmaceutical preparation according to claim 118, wherein zinc ions are present in an amount corresponding to 10 to 26 μg Zn/100 U insulin.

120. A pharmaceutical preparation according to claim 1, wherein the ratio between insulin and the zinc-binding ligand according to claim 1 is in the range from 99:1 to 1:99.

121. A pharmaceutical preparation according to claim 120, wherein the ratio between insulin and the zinc-binding ligand according to claim 1 is in the range from 95:5 to 5:95.

122. A pharmaceutical preparation according to claim 121, wherein the ratio between between insulin and the zinc-binding ligand according to claim 1 is in the range from 80:20 to 20:80.

123. A pharmaceutical preparation according to claim 122, wherein the ratio between between insulin and the zinc-binding ligand according to claim 1 is in the range from 70:30 to 30:70.

124. A pharmaceutical preparation according to claim 1, wherein the concentration of insulin is 60 to 3000 nmol/ml.

125. A pharmaceutical preparation according to claim 124, wherein the concentration of insulin is 240 to 1200 nmol/ml.

126. A pharmaceutical preparation according to claim 125, wherein the concentration of insulin is about 600 nmol/ml.

127. A method of preparing a zinc-binding ligand according to claim 1, comprising the steps of identifying starter compounds that binds to the R-state HisB10-Zn2+ site, optionally attaching a fragment consisting of 0 to 5 neutral α- or β-amino acids, and attaching a fragment comprising 1 to 20 positively charged groups independently selected from amino or guanidino groups.

128. Method of prolonging the action of an acid-stabilised insulin preparation which comprises adding a zinc-binding ligand according to claim 1 to the acid-stabilised insulin preparation.

129. A method of treating type 1 or type 2 diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical preparation according to claim 1.